0001437749-24-010308.txt : 20240401 0001437749-24-010308.hdr.sgml : 20240401 20240401152012 ACCESSION NUMBER: 0001437749-24-010308 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN SHARED HOSPITAL SERVICES CENTRAL INDEX KEY: 0000744825 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 942918118 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08789 FILM NUMBER: 24808619 BUSINESS ADDRESS: STREET 1: 601 MONTGOMERY STREET STREET 2: SUITE 1112 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 415-788-5300 MAIL ADDRESS: STREET 1: 601 MONTGOMERY STREET STREET 2: SUITE 1112 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 10-K 1 asha20231231_10k.htm FORM 10-K asha20231231_10k.htm
0000744825 AMERICAN SHARED HOSPITAL SERVICES false --12-31 FY 2023 false false false false 100,000 100,000 250,000 120,000 0 0 10,000,000 10,000,000 6,300,000 6,300,000 6,184,000 6,184,000 15 140,000 300,000 10 144,000 2 0 0 5 3 5 57,000 21 742,000 2.57 2.40 132,000 2.40 3,000 2.92 2.33 2.97 119,000 2.94 2.88 10,000 4 0 1 00007448252023-01-012023-12-31 iso4217:USD 00007448252023-03-30 xbrli:shares 00007448252024-03-22 thunderdome:item 00007448252023-12-31 00007448252022-12-31 0000744825us-gaap:RelatedPartyMember2023-12-31 0000744825us-gaap:RelatedPartyMember2022-12-31 iso4217:USDxbrli:shares 0000744825ams:RentalIncomeFromMedicalServicesMember2023-01-012023-12-31 0000744825ams:RentalIncomeFromMedicalServicesMember2022-01-012022-12-31 0000744825ams:PatientIncomeMember2023-01-012023-12-31 0000744825ams:PatientIncomeMember2022-01-012022-12-31 0000744825ams:EquipmentSalesMember2023-01-012023-12-31 0000744825ams:EquipmentSalesMember2022-01-012022-12-31 00007448252022-01-012022-12-31 0000744825us-gaap:CommonStockMember2021-12-31 0000744825us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000744825us-gaap:RetainedEarningsMember2021-12-31 0000744825us-gaap:ParentMember2021-12-31 0000744825us-gaap:NoncontrollingInterestMember2021-12-31 00007448252021-12-31 0000744825us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000744825us-gaap:ParentMember2022-01-012022-12-31 0000744825us-gaap:CommonStockMember2022-01-012022-12-31 0000744825us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2022-01-012022-12-31 0000744825us-gaap:RestrictedStockMember2022-01-012022-12-31 0000744825us-gaap:NoncontrollingInterestMember2022-01-012022-12-31 0000744825us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000744825us-gaap:CommonStockMember2022-12-31 0000744825us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000744825us-gaap:RetainedEarningsMember2022-12-31 0000744825us-gaap:ParentMember2022-12-31 0000744825us-gaap:NoncontrollingInterestMember2022-12-31 0000744825us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-31 0000744825us-gaap:ParentMember2023-01-012023-12-31 0000744825us-gaap:CommonStockMember2023-01-012023-12-31 0000744825us-gaap:RetainedEarningsMember2023-01-012023-12-31 0000744825us-gaap:NoncontrollingInterestMember2023-01-012023-12-31 0000744825us-gaap:CommonStockMember2023-12-31 0000744825us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000744825us-gaap:RetainedEarningsMember2023-12-31 0000744825us-gaap:ParentMember2023-12-31 0000744825us-gaap:NoncontrollingInterestMember2023-12-31 xbrli:pure 0000744825ams:NewcoMember2022-04-27 0000744825ams:GuadalupeMemberams:NewcoMember2022-04-27 0000744825ams:OR21LLCMember2023-12-31 0000744825ams:ArchitecturalDesignCompanyMemberams:OR21LLCMember2023-12-31 0000744825ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember2023-11-102023-11-10 0000744825ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember2023-11-10 0000744825ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember2023-12-31 0000744825us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31 0000744825us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0000744825us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberams:OneCustomerMember2023-01-012023-12-31 0000744825us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberams:OneCustomerMember2022-01-012022-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberams:CustomerOneMember2023-01-012023-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberams:CustomerTwoMember2023-01-012023-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberams:CustomerOneMember2022-01-012022-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberams:CustomerTwoMember2022-01-012022-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberams:CustomerThreeMember2022-01-012022-12-31 0000744825us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberams:CustomerFourMember2022-01-012022-12-31 utr:Y 0000744825us-gaap:OfficeEquipmentMembersrt:MinimumMember2023-12-31 0000744825us-gaap:OfficeEquipmentMembersrt:MaximumMember2023-12-31 0000744825us-gaap:BuildingMember2023-12-31 0000744825srt:MinimumMember2023-12-31 0000744825srt:MinimumMember2022-12-31 0000744825srt:MaximumMember2023-12-31 0000744825srt:MaximumMember2022-12-31 0000744825us-gaap:SalvageValueMember2023-01-012023-12-31 0000744825ams:ProtonBeamRadiationTherapyPBRTMember2023-12-31 0000744825ams:GammaKnifeAndRadiationTherapyEquipmentMember2023-12-31 0000744825ams:GammaKnifeAndRadiationTherapyEquipmentMember2022-12-31 0000744825ams:PbrtServicesMember2023-01-012023-12-31 0000744825ams:PbrtServicesMember2022-01-012022-12-31 0000744825ams:RevenueSharingArrangementsMember2023-01-012023-12-31 0000744825ams:RevenueSharingArrangementsMember2022-01-012022-12-31 0000744825ams:GKCEMember2023-12-31 0000744825ams:GKCEMember2022-01-01 0000744825ams:GKCEMember2022-12-31 0000744825ams:GammaKnifeUnitsMember2023-12-31 0000744825ams:OtherGammaKnifeUnitsMember2023-12-31 0000744825us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0000744825us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0000744825ams:MedicalEquipmentLeasingMember2023-01-012023-12-31 0000744825ams:MedicalEquipmentLeasingMember2022-01-012022-12-31 0000744825ams:DirectPatientServicesMember2023-01-012023-12-31 0000744825ams:DirectPatientServicesMember2022-01-012022-12-31 0000744825ams:MedicalEquipmentLeasingMember2023-12-31 0000744825ams:MedicalEquipmentLeasingMember2022-12-31 0000744825ams:DirectPatientServicesMember2023-12-31 0000744825ams:DirectPatientServicesMember2022-12-31 0000744825ams:GammaKnifeCenterEcuadorSAGKCEMember2020-06-122020-06-12 0000744825ams:GammaKnifeCenterEcuadorSAGKCEMemberus-gaap:TradeNamesMember2020-06-122020-06-12 0000744825ams:MedicalEquipmentAndFacilitiesMember2023-12-31 0000744825ams:MedicalEquipmentAndFacilitiesMember2022-12-31 0000744825us-gaap:OfficeEquipmentMember2023-12-31 0000744825us-gaap:OfficeEquipmentMember2022-12-31 0000744825us-gaap:ConstructionInProgressMember2023-12-31 0000744825us-gaap:ConstructionInProgressMember2022-12-31 0000744825us-gaap:NonUsMember2023-12-31 0000744825us-gaap:NonUsMember2022-12-31 0000744825ams:PBRTEquipmentMember2023-01-012023-12-31 0000744825ams:PBRTEquipmentMember2022-01-012022-12-31 0000744825ams:TheCreditAgreementMemberams:FifthThirdBankNAMember2021-04-092021-04-09 0000744825ams:TheCreditAgreementMemberams:FifthThirdBankNAMember2021-04-09 0000744825ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMemberams:FifthThirdBankNAMember2021-04-09 0000744825ams:TheCreditAgreementSecondLoanFacilityMemberams:FifthThirdBankNAMember2021-04-09 0000744825us-gaap:RevolvingCreditFacilityMemberams:TheCreditAgreementThirdLoanFacilityMemberams:FifthThirdBankNAMember2021-04-09 0000744825us-gaap:RevolvingCreditFacilityMemberams:TheCreditAgreementThirdLoanFacilityMemberams:FifthThirdBankNAMember2023-12-31 0000744825us-gaap:RevolvingCreditFacilityMemberams:TheCreditAgreementThirdLoanFacilityMemberams:FifthThirdBankNAMember2021-04-092021-04-09 0000744825us-gaap:RevolvingCreditFacilityMemberams:TheCreditAgreementThirdLoanFacilityMemberams:FifthThirdBankNAMemberams:LondonInterbankOfferedRateMember2021-04-092021-04-09 0000744825ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMemberams:FifthThirdBankNAMember2023-12-31 0000744825ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMemberams:FifthThirdBankNAMember2022-12-31 0000744825us-gaap:RevolvingCreditFacilityMemberams:TheCreditAgreementThirdLoanFacilityMemberams:FifthThirdBankNAMember2021-01-012021-12-31 0000744825ams:DfcLoanTrancheOneMember2023-12-31 0000744825ams:DfcLoanTrancheTwoMember2023-12-31 0000744825ams:DfcLoanMember2023-12-31 0000744825ams:DfcLoanMember2022-12-31 utr:sqft 0000744825ams:SubleaseOfficeInSanFranciscoCaliforniaMember2021-11-03 0000744825ams:SubleaseOfficeInSanFranciscoCaliforniaMember2021-11-032021-11-03 0000744825ams:LeaseAgreementForNewCorporateOfficeMember2021-11-03 0000744825ams:LeaseAgreementForNewCorporateOfficeMember2021-11-032021-11-03 utr:acre 0000744825ams:CorporateOfficeInSanFranciscoMember2023-12-31 0000744825ams:CorporateOfficeInSanFranciscoMember2023-01-012023-12-31 0000744825ams:SubleaseOfficeInSanFranciscoCaliforniaMember2023-12-31 0000744825ams:SubleaseOfficeInSanFranciscoCaliforniaMember2023-01-012023-12-31 0000744825ams:StandaloneFacilityInLimaPeruMember2023-12-31 0000744825ams:StandaloneFacilityInLimaPeruMember2023-01-012023-12-31 0000744825ams:CondominiumSpaceForGammaKnifeFacilityInGuayaquilEcuadorMember2023-12-31 0000744825ams:LandAndParkingSpacesForGammaKnifeFacilityInGuayaquilEcuadorMember2023-12-31 0000744825us-gaap:DomesticCountryMember2023-12-31 0000744825us-gaap:StateAndLocalJurisdictionMember2023-12-31 0000744825us-gaap:DomesticCountryMemberus-gaap:CapitalLossCarryforwardMember2023-12-31 0000744825us-gaap:StateAndLocalJurisdictionMemberus-gaap:CapitalLossCarryforwardMember2023-12-31 0000744825srt:MaximumMembersrt:ScenarioForecastMember2024-01-012024-12-31 0000744825ams:IncentiveCompensationPlanMember2021-06-30 0000744825ams:IncentiveCompensationPlanMember2023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:IncentiveCompensationPlanMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:IncentiveCompensationPlanMemberams:NonEmployeeDirectorsAndCorporateSecretaryMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:IncentiveCompensationPlanMemberams:NonEmployeeDirectorsMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:IncentiveCompensationPlanMemberams:EmployeesMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:IncentiveCompensationPlanMembersrt:ChiefExecutiveOfficerMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:IncentiveCompensationPlanMember2023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMember2023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:ExecutiveEquityAwardsMembersrt:ChiefExecutiveOfficerMember2020-05-042020-05-04 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:ExecutiveEquityAwardsMembersrt:ChiefExecutiveOfficerMember2020-08-032020-08-03 utr:D 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:ExecutiveEquityAwardsMembersrt:ChiefExecutiveOfficerMember2022-01-012022-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:ExecutiveEquityAwardsMember2022-01-012022-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:ExecutiveEquityAwardsMembersrt:ChiefExecutiveOfficerMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:ExecutiveEquityAwardsMember2023-01-012023-12-31 0000744825us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0000744825ams:ManagementBonusProgramMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberams:BoardMemberMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-31 0000744825us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-31 00007448252021-01-012021-12-31 00007448252022-01-01 0000744825srt:MinimumMember2022-01-012022-12-31 0000744825us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000744825ams:LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember2023-01-012023-12-31 0000744825ams:LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember2023-12-31 0000744825ams:MaintenanceAndSupportAgreementMevionServiceAgreementMemberams:MevionMedicalSystemsIncMember2022-09-04 0000744825ams:MaintenanceAndSupportAgreementMevionServiceAgreementMemberams:MevionMedicalSystemsIncMember2022-09-042022-09-04 0000744825srt:MaximumMemberams:LINACSystemMember2023-01-012023-12-31 0000744825srt:MinimumMemberams:LINACSystemMember2023-01-012023-12-31 0000744825ams:LINACSystemMember2023-12-31 0000744825ams:GKFSubsidiaryMember2023-12-31 0000744825ams:USSubsidiaryOfElektaMember2023-12-31 0000744825us-gaap:RelatedPartyMember2023-01-012023-12-31 0000744825us-gaap:RelatedPartyMember2022-01-012022-12-31 0000744825ams:USSubsidiaryOfElektaMember2023-12-31 0000744825ams:TheCreditAgreement2024SupplementalTermLoanMemberams:FifthThirdBankNAMemberus-gaap:SubsequentEventMember2024-01-25 0000744825ams:TheCreditAgreement2024SupplementalTermLoanMemberams:FifthThirdBankNAMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-01-252024-01-25
 

 Table of Contents



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 10-K

(Mark One)

 

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED December 31, 2023

 

or

 

 

TRANSITION REPORT PURSUANT To SECTION 13 or 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _______________TO_______________.

 

Commission file number 1-08789

 


 

American Shared Hospital Services

(Exact name of registrant as specified in its charter)

California

 

94-2918118

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

     

601 Montgomery

Suite 1112,

San Francisco,

California

94111-2619

(Address of Principal Executive Offices)

(Zip Code)

 

Registrants telephone number, including area code: (415) 788-5300

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock No Par Value

 

AMS

 

NYSEAMER

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large Accelerated Filer ☐       Accelerated Filer ☐        Non-Accelerated Filer ☒       Smaller reporting company

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by registered public accounting firm that prepared or issued its audit report. Yes No ☒

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

 

Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No ☒

 

As of June 30, 2023, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $11,205,000.

 

Number of shares of common stock of the registrant outstanding as of March 22, 2024: 6,330,000.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders are incorporated by reference into Part II, Item 5 and Part III of this report.

 



 

 

 

 

TABLE OF CONTENTS

Page

   

FORWARD-LOOKING STATEMENTS

 
   

PART I:

   
     

 

Item 1

Business

4

     

 

Item 1A

Risk Factors

11

     

 

Item 1B

Unresolved Staff Comments

16

     
  Item 1C Cybersecurity 16
     

 

Item 2

Properties

17

     

 

Item 3

Legal Proceedings

17

     

 

Item 4

Mine Safety Disclosures

17

     

PART II:

   
     

 

Item 5

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

18

     

 

Item 6

[Reserved]

18

     

 

Item 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

       
  Item 7A Quantitative And Qualitative Disclosures About Market Risk 26
     

 

Item 8

Financial Statements and Supplementary Data

26

     

 

Item 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

26

     

 

Item 9A

Controls and Procedures

26

     

 

Item 9B

Other Information

27

       
  Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 27
     

PART III:

   
     

 

Item 10

Directors, Executive Officers and Corporate Governance

27

     

 

Item 11

Executive Compensation

27

     

 

Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

27

     

 

Item 13

Certain Relationships and Related Transactions, and Director Independence

27

     

 

Item 14

Principal Accountant Fees and Services

27

     

PART IV:

   
     

 

Item 15

Exhibits and Financial Statement Schedules

27

     

 

Item 16

Form 10-K Summary

32

 

 

 

 

FORWARD-LOOKING STATEMENTS

 

Certain matters discussed in this Annual Report on Form 10-K other than statements of historical information are “forward-looking statements.” The Private Securities Litigation Reform Act of 1995 has established that these statements qualify for safe harbors from liability. Forward-looking statements may include words like we “believe”, “anticipate”, “target”, “expect”, “pro forma”, “estimate”, “intend”, “will”, “is designed to”, “plan” and words of similar meaning. Forward-looking statements describe our future plans, objectives, expectations or goals. Such statements address future events and conditions concerning and include, but are not limited to, such things as:

 

 

capital expenditures

 

earnings

 

liquidity and capital resources

 

financing of our business

 

government programs and regulations

 

legislation affecting the health care industry

 

the expansion of our proton beam radiation therapy business

 

accounting matters

 

compliance with debt covenants

  pending acquisitions
 

competition

 

customer concentration

 

contractual obligations

 

timing of payments

 

technology

 

interest rates

 

These forward-looking statements involve known and unknown risks that may cause our actual results in future periods to differ materially from those expressed in any forward-looking statement. Factors that could cause or contribute to such differences include, but are not limited to, such things as:

 

 

our level of debt

 

the limited market for our capital-intensive services

 

the impact of lowered federal reimbursement rates

 

the impact of U.S. health care reform legislation

 

competition and alternatives to our services

 

technological advances and the risk of equipment obsolescence

 

our significant investment in the proton beam radiation therapy business

  restrictions in our debt agreements that limit our flexibility to operate our business
  our ability to repay our indebtedness
  our ability to close the pending Rhode Island Acquisition and integrate the Rhode Island target companies with our existing business
  breaches in security of our information technology
 

the small and illiquid market for our stock

 

These lists are not all-inclusive because it is not possible to predict all factors. A discussion of some of these factors is included in this document under the headings “Item 1A. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” “–Application of Critical Accounting Policies and Estimates” and “–Liquidity and Capital Resources.” This report should be read in its entirety. No one section of this report deals with all aspects of the subject matter. Any forward-looking statement speaks only as of the date such statement was made, and we are not obligated to update any forward-looking statement to reflect events or circumstances after the date on which such statement was made, except as required by applicable laws or regulations.

 

 

PART I

 

ITEM 1. BUSINESS

 

GENERAL

 

American Shared Hospital Services (“ASHS” and, together with its subsidiaries, the “Company”) provides stereotactic radiosurgery equipment and advanced radiation therapy and related equipment. The Company provides Gamma Knife units to ten medical centers in ten states in the United States and two Gamma Knife units at stand-alone facilities in Lima, Peru and Guayaquil, Ecuador as of March 1, 2024. The Company provides Gamma Knife services through its 81% indirect interest in GK Financing, LLC, a California limited liability company (“GKF”). The remaining 19% of GKF is owned by GKV Investments, Inc. (“GKV Investments”), a wholly-owned U.S. subsidiary of Elekta AG, a Swedish company (“Elekta”). Elekta is the manufacturer of the Leksell Gamma Knife® (the “Gamma Knife”), which is a radiotherapy-treatment device that uses precise beams of gamma radiation to noninvasively target and remove lesions or tumors in the brain and treat various neurological disorders. GKF is a non-exclusive provider of alternative financing services for Leksell Gamma Knife units.

 

The Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), ASHS-Mexico, S.A. de C.V. (“ASHS-Mexico”), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC, ASHS-Bristol Radiation Therapy, LLC, OR21, Inc. and MedLeader.com, Inc. (“MedLeader”).

 

GKF has established the wholly-owned subsidiaries Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and HoldCo GKC S.A (“HoldCo”) for the purpose of providing similar Gamma Knife services in Peru and Ecuador, respectively.  HoldCo owns approximately 99.3% of the total outstanding shares of Gamma Knife Center Ecuador S.A. (“GKCE”).

 

ASRS is the majority-owner of GKF. GKF also owns a 51% interest in Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The remaining 49% in each of these two companies is owned by radiation oncologists.

 

The Company is also the sole owner of PBRT Orlando, LLC (“Orlando”) and the majority owner of Long Beach Equipment, LLC (“LBE”) which were formed to provide proton beam radiation therapy services in Orlando, Florida and Long Beach, California, respectively. A 40% minority ownership in LBE is owned by radiation oncologists.  LBE is not expected to generate revenue within the next two years.

 

MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses and other health care practitioners. MedLeader is not operational at this time and is not expected to generate significant revenue within the next two years. 

 

On April 27, 2022, the Company signed a Joint Venture Agreement (the “Agreement”) with the principal owners of Radioterapia Guadalupe Amor y Bien S.A. de C.V. (“Guadalupe”) to establish AB Radiocirugia Y Radioterapia de Puebla, S.A.P.I. de C.V. of Puebla (“Puebla”) to treat public- and private-paying cancer patients. The Company and Guadalupe will hold 85% and 15% ownership interests, respectively, in Puebla. Under the Agreement, the Company is responsible for providing a linear accelerator, an Elekta Versa HD, and Guadalupe is accountable for all site modification costs.  The Company formed ASHS-Mexico on October 3, 2022 to establish Puebla.  Puebla was formed on December 15, 2022 and the Company expects Puebla to begin treating patients in June 2024. Operating costs incurred for the twelve-month period ended December 31, 2023 by Puebla, are included in the consolidated statement of operations.

 

The Company continues to develop its design and business model for “The Operating Room for the 21st Century”SM through its 50% owned OR21, LLC (“OR21”). The remaining 50% of OR21 is owned by an architectural design company. OR21 is not expected to generate significant revenue within the next two years.

 

On November 10, 2023, the Company entered into an Investment Purchase Agreement (the “IPA”) with GenesisCare USA, Inc. (the “GenesisCare”) and GenesisCare USA Holdings, Inc. (“GC Holdings”), pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, (collectively, the “RI Target Companies”) together with the assignment of certain payor contacts for a purchase price of $2,850,000 (such transaction, the “RI Acquisition”).  The equity interests to be acquired by the Company under the IPA equates to a 60% interest in each RI Target Company. The RI Target Companies operate three functional radiation therapy cancer centers in Rhode Island. The RI Acquisition is contingent upon certain closing conditions, including GenesisCare and the Company entering into a consent agreement with the Rhode Island Department of Health and approval of all equity holders and managers of each RI Target Company. On March 1, 2024, the Company, GenesisCare and GC Holding entered into a First Amendment to the Investment Agreement pursuant to which the parties agreed to extend the date on which a party could terminate the IPA if the closing conditions had not been met from March 10, 2024 to April 30, 2024. The Company anticipates that the closing conditions will be met in April 2024.

 

The Company was incorporated in the State of California in 1983 and its predecessor, Ernest A. Bates, M.D., Ltd. (d/b/a American Shared Hospital Services), a California limited partnership, was formed in June 1980.

 

OPERATIONS

 

Gamma Knife Operations

 

Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. Compared to conventional surgery, Gamma Knife radiosurgery usually is an out-patient procedure with lower risk of complications and can be provided at a lower cost. Typically, Gamma Knife patients resume their pre-surgical activities one or two days after treatment. The Gamma Knife Perfexion unit, which was introduced by Elekta in 2006, treats patients with 192 single doses of gamma rays that are focused with great precision on small and medium sized, well circumscribed and critically located structures in the brain. The Cobalt-60 sources converge at the target area and deliver a dose that is high enough to destroy the diseased tissue without damaging the surrounding healthy tissue. In 2015, Elekta introduced an upgrade to the Gamma Knife Perfexion unit called Icon. In 2022, Elekta introduced an upgrade to the Icon, called the Esprit. As of March 1, 2024, eight of the Company’s ten Gamma Knife units in the United States are Gamma Knife Perfexion units and two of these Perfexion units have the Icon upgrade.  Two of the Company’s ten Gamma Knife units were upgraded to an Esprit in October 2023 and January 2024, respectively. The Company’s Gamma Knife unit in Ecuador was upgraded in November 2023 to a Perfexion with Icon. The Company’s Gamma Knife unit in Peru is Model 4(C).  The Company expects to replace the unit in Peru with an Esprit in late 2024.

 

 

The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain).

 

The Company, as of March 1, 2024, had ten operating Gamma Knife units located in the United States and two in South America in Lima, Peru and Guayaquil, Ecuador, respectively. The Company’s first Gamma Knife commenced operation in September 1991. The Company’s Gamma Knife units performed 1,195 procedures in 2023 for a cumulative total of approximately 47,400 procedures from commencement through December 31, 2023.

 

Revenue from Gamma Knife services for the Company during each of the last two years ended December 31, and the percentage of total revenue of the Company represented by the Gamma Knife for each of the last two years, are set forth below:

 

Year Ended

 

Total Gamma Knife

   

Gamma Knife % of

 

December 31,

 

Revenue (in thousands)

   

Total Revenue

 

2023

  $ 10,992       51.5 %

2022

  $ 10,794       54.7 %

 

The Company conducts its Gamma Knife business through its 81% indirect interest in GKF. The remaining 19% interest is indirectly owned by Elekta through its wholly-owned subsidiary, GKF Investments. GKF, formed in October 1995, is managed by its policy committee. The policy committee is composed of one representative from the Company, Raymond Stachowiak, ASHS’ Executive Chairman of the Board, and one representative from Elekta. The policy committee sets the operating policy for GKF. The policy committee may act only with the unanimous approval of both of its members. The policy committee selects a manager to handle GKF’s daily operations. Craig K. Tagawa, Chief Executive Officer of GKF and President of ASHS, serves as GKF’s manager.

 

GKF’s profits and/or losses and any cash distributions are allocated based on membership interests. GKF’s operating agreement requires that it have a cash reserve of at least $50,000 before cash distributions are made to its members. From inception to December 31, 2023, GKF has distributed $50,410,000 to the Company and $11,825,000 to Elekta.

 

Advanced Radiation Therapy Equipment and Services

 

The Company is continuing its efforts to contract new radiation therapy customers both domestically and internationally. The Company has increased its product offerings from standard linear accelerators to more advanced linear accelerators (“LINAC”) that incorporate Magnetic Resonance Imaging (“MRI”) and potentially Positron Emission Tomography (“PET”) imaging technologies. The Company believes that these more advanced technologies, with a higher capital cost component, may be potentially a more receptive market segment for its business model. The Company’s site in Puebla, Mexico will treat patients with a LINAC machine.

 

Additional information on our operations can be found in “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Note 1 - Business And Basis of Presentation” of the consolidated financial statements.

 

Proton Beam Radiation Therapy Operations (PBRT)

 

PBRT is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. PBRT, first clinically introduced in the 1950s, has physics advantages compared to photon-based systems which allow PBRT to deliver higher radiation doses to the tumor with less radiation to healthy tissue. PBRT currently treats prostate, brain, spine, head and neck, lung, breast, gastrointestinal tract and pediatric tumors. Approximately 280,000 patients have been treated with protons worldwide.

 

Introduction of PBRT in the United States, until recently, has been limited due to the high capital costs of these projects. The Company believes that the current development of one and two treatment room PBRT systems at lower capital costs and the level of reimbursement for PBRT from the Centers for Medicare & Medicaid Services (“CMS”) will help make this technology available to a larger segment of the market. 

 

Additional information on our operations can be found in “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Note 1 - Business And Basis of Presentation” of the consolidated financial statements.

 

 

CUSTOMERS

 

The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services either through medical equipment leasing or direct patient services. For medical equipment leasing, the Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services. The Company also owns and operates two single-unit facilities where it provides radiation therapy services directly to the patient. The Company has a third direct patient service facility in Puebla, Mexico, that the Company expects will begin treating patients in June 2024. The market for these services primarily consists of large and medium sized medical centers. The business is capital intensive; the total cost of a Gamma Knife facility usually ranges from $3.0 million to $4.5 million, including equipment, site construction and installation; the total cost of a single room PBRT system usually ranges from $30.0 million to $50.0 million, inclusive of equipment, site construction and installation. The Company pays for the equipment and the medical center generally pays for site and installation costs.

 

The following is a listing of the Company’s medical equipment leases as of March 1, 2024:

 

   

Original Term of

   

Year Contract

   

Customers (Gamma Knife except as noted)

 

Contract (in years)

   

Began

 

Basis of Payment

                   

Southwest Texas Methodist Hospital San Antonio, Texas

    10       1998  

Fee per use

Kettering Medical Center Kettering, Ohio

    10       1999  

Revenue sharing

Central Mississippi Medical Center Jackson, Mississippi

    10       2001  

Fee per use

OSF Saint Francis Medical Center Peoria, Illinois

    10       2001  

Fee per use

Albuquerque Regional Medical Center Albuquerque, New Mexico

    10       2003  

Fee per use

Northern Westchester Hospital Mt. Kisco, New York

    10       2005  

Fee per use

Sacred Heart Medical Center Pensacola, Florida

    10       2013  

Revenue Sharing

PeaceHealth Sacred Heart Medical Center at RiverBend Eugene, Oregon

    10       2014  

Revenue Sharing

Orlando Health Cancer Institute Orlando, Florida (PBRT)

    10       2016  

Revenue Sharing

Bryan Medical Center Lincoln, Nebraska

    10       2017  

Revenue Sharing

Methodist Hospital Merrillville, Indiana

    10       2019  

Revenue Sharing

 

The Company’s typical fee per use agreement is for a ten-year term. The fixed fee per use reimbursement amount that the Company receives from the customer is based on the Company’s cost to provide the service and the anticipated volume of the customer. The Gamma Knife contracts signed by the Company typically call for a fee ranging from $5,000 to $9,000 per procedure. There are no minimum volume guarantees required of the customer. In most cases, GKF is responsible for providing the Gamma Knife and related ongoing Gamma Knife equipment expenses (i.e., personal property taxes, insurance, and equipment maintenance) and helps fund the customer’s Gamma Knife marketing. The customer generally is obligated to pay site and installation costs and the costs of operating the Gamma Knife. The customer can either renew the agreement or terminate the agreement at the end of the contractual term. If the customer chooses to terminate the agreement, then GKF removes the equipment from the medical center for possible placement at another site.

 

The Company’s typical revenue sharing agreements are for a period of ten years. Instead of receiving a fixed fee, the Company receives all or a percentage of the reimbursement (exclusive of physician fees) received by the customer. The Company is at risk for any reimbursement rate changes for radiosurgery or radiation therapy services by the government or other third-party payors. There are no minimum volume guarantees required of the customer.

 

One customer accounted for approximately 48% and 45% of the Company’s total revenue in 2023 and 2022, respectively. At December 31, 2023, two customers each individually accounted for 30% and 31% of total accounts receivable, respectively. At December 31, 2022, four customers each individually accounted for 12%, 14%, 16% and 22% of total accounts receivable, respectively.

 

MARKETING

 

The Company markets financial and turn-key solutions to cancer treatment centers, hospitals, and large cancer networks worldwide.  The Company works closely with major global Original Equipment Manufacturers (“OEM’s”) that provide leading edge clinical treatment systems and software that treat cancer using radiation therapy and radiosurgery. The major products the Company is able to provide creative financial and turn-key services for are; MR Guided Radiation Therapy Linacs, Advanced Linear Accelerators, Proton Beam Therapy systems, Brachytherapy systems, and through our GK Financing partnership with Elekta, the Leksell Gamma Knife product and services.

 

The Company is product agnostic and works with all major OEMs to provide financial solutions to the end users for the products and services they desire.   The Company has enhanced and expanded its sales and marketing team and efforts to better provide sales and customer service to the healthcare community. The Company’s CEO manages directly the day to day operations as well as all sales, marketing, and customer service teams to ensure close contact with the Company’s customer installed base and management of the sales pipeline.

 

The major advantages to a health care provider in contracting with the Company for its financial and turn-key services include:

 

▪The cancer care center/medical center avoids the high cost of owning the equipment. By not acquiring the equipment supplied by the Company, the cancer care/medical center is able to allocate the funds otherwise required to purchase and/or finance the equipment to other projects within their facility.

 

▪The Company does not have minimum volume requirements, so the cancer care/medical center avoids the risk of equipment under-utilization. The cancer care/medical center pays the Company only for each procedure performed on a patient.

 

 

▪For contracts under revenue sharing arrangements, the Company assumes all or a portion of the risk of reimbursement rate changes. The cancer care/medical center pays the Company only the contracted portion of revenue received from each procedure.

 

▪The cancer care/medical center transfers the risk of technological obsolescence to the Company. The cancer care/medical center and its physicians are not under any obligation to utilize technologically obsolete cancer treatment equipment.

 

▪The Company provides planning, installation, operating and marketing assistance and support to its customers as well as providing turn-key solutions if room modifications, new vault, or even a new cancer care facility is needed by working with credible and reputable construction companies.

 

FINANCING

 

On April 9, 2021, the Company and certain of its domestic subsidiaries entered into a five year $22,000,000 credit agreement (the “Credit Agreement”) with Fifth Third Bank, N.A. (“Fifth Third”), which refinanced its existing domestic Gamma Knife portfolio.  The lease financing previously obtained by Orlando was also refinanced as long-term debt by the Credit Agreement. The Credit Agreement includes a $7,000,000 revolving line of credit (the “Revolving Line”) available for future projects and general corporate purposes. The Company borrowed $2,500,000 on the Revolving Line as of December 31, 2023, which was paid off in January 2024. The Credit Agreement is 48% amortized over a 58-month period with a balloon payment upon maturity and is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. 

 

On January 25, 2024 (the “First Amendment Effective Date”), the Company entered into a First Amendment to the Credit Agreement (the “First Amendment”) which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the “Supplemental Term Loan”). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and were used to finance capital expenditures that the Company paid cash for during 2023 towards its operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030 (the “Maturity Date’). Interest on the Supplemental Term Loan is payable monthly during the initial twelve-month period following the First Amendment Effective Date. Following such twelve-month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries.

 

The Company’s acquisition of GKCE and the Gamma Knife Esprit in Ecuador is financed by the United States International Development Finance Corporation (“DFC”). The loan entered into with DFC in connection with the acquisition of GKCE in June 2020 (the “DFC Loan”) is secured by a lien on GKCE’s assets. The first tranche of the DFC Loan was funded in June 2020. In October 2023, the second tranche of the DFC Loan was funded in the amount of $1,750,000 to finance its equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%. The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The maturity date for the first and second tranche of the DFC Loan is December 15, 2027. The DFC Loan also contains customary covenants and representations which the Company’s wholly-owned subsidiary, HoldCo, was not in compliance with as of  December 31, 2023.  On March 28, 2024, the Company obtained a waiver from DFC for the covenant noncompliance as of December 31, 2023. 

 

See Note 5 - Long Term Debt to the consolidated financial statements and Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Long-Term Debt for additional information.

 

COMPETITION

 

Conventional neurosurgery, radiation therapy and other radiosurgery devices are the primary competitors of Gamma Knife radiosurgery. Gamma Knife radiosurgery has gained acceptance as an alternative and/or adjunct to conventional surgery due to its more favorable morbidity outcomes for certain procedures as well as its non-invasiveness. Utilization of the Company’s Gamma Knife units is contingent on the acceptance of Gamma Knife radiosurgery by the customer’s neurosurgeons, radiation oncologists and referring physicians. In addition, the utilization of the Company’s Gamma Knife units is impacted by the proximity of competing Gamma Knife centers and providers using other radiosurgery devices.

 

Conventional linear accelerator-based radiation therapy is the primary competitor of the Company’s proton therapy system at Orlando Health Cancer Institute (“Orlando Health”). Although proton beam radiation therapy has been available for many years, it is only recently emerging as a more clinically beneficial alternative to conventional linear accelerators for certain tumors. Utilization of the Company’s proton therapy system is dependent on the acceptance of this technology by Orlando Health’s radiation oncologists and referring physicians, as well as patient self-referrals. There are currently no competing proton therapy facilities near the Company’s site.

 

There are several competing manufacturers of PBRT systems, including Mevion, IBA Particle Therapy Inc., Hitachi Ltd., ProNova Solutions, LLC, Sumitomo Heavy Industries, Ltd., ProTom International, Inc. and Mitsubishi Electric Corp. The Company has purchased one MEVION S250. The Mevion system, as well as single room proton therapy systems from other manufacturers, potentially provides cancer centers the opportunity to introduce single treatment room PBRT services with a cost in the range of approximately $30 to $50 million versus four and five PBRT treatment room programs costing in excess of $120 million including facility costs. The MEVION S250 system received FDA approval in the second quarter of 2012 and the first clinical treatment occurred in December 2013 at Barnes-Jewish Hospital. The MEVION S250i (Hyperscan) unit, which includes pencil beam scanning, was FDA approved in December 2017. The Company’s first MEVION S250 system in operation at Orlando Health treated its first patient in April 2016. 

 

The Company believes the business model it has developed for use in its stereotactic radiosurgery equipment and advanced radiation therapy placements can be tailored for the PBRT market segment. The Company is targeting large, hospital-based cancer programs. The Company’s ability to develop a successful PBRT financing entity depends on the decision of cancer centers to self-fund or to fund the PBRT through conventional financing vehicles rather than the Company, the Company’s ability to capture market share from competing alternative PBRT financing entities, and the Company’s ability to raise capital to fund PBRT projects.

 

The Company’s ability to secure additional customers for stereotactic radiosurgery equipment, advanced radiation therapy equipment and services and other proton beam radiation therapy services, or other equipment, is dependent on its ability to effectively compete against the manufacturers of these systems selling directly to potential customers and other companies that outsource these services. The Company does not have an exclusive relationship with any manufacturer and has previously lost sales to customers that chose to purchase equipment directly from manufacturers. The Company may continue to lose future sales to such customers and to the Company’s competitors.

 

 

GOVERNMENT PROGRAMS

 

The Medicare program is administered by CMS of the U.S. Department of Health and Human Services. Medicare is a health insurance program primarily for individuals 65 years of age and older, certain younger people with disabilities, and people with end-stage renal disease, and is provided without regard to income or assets.

 

The Medicare program is subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions, all of which could materially increase or decrease payments from these government programs in the future, as well as affect the cost of providing services to patients and the timing of payments to our client hospitals.

 

The Company’s Gamma Knife and PBRT customers receive payments for patient care from federal government and private insurer reimbursement programs. Currently in the United States, Gamma Knife and proton therapy services are performed primarily on an out-patient basis. Gamma Knife patients with Medicare as their primary insurer, treated on either an in-patient or out-patient basis, comprise an estimated 35%-45% of the total Gamma Knife patients treated nationwide. PBRT patients with Medicare as their primary insurer are treated primarily on an out-patient basis and comprise an estimated 45% of the total radiation therapy patients treated.

 

On September 29, 2020, CMS published a final rule that would have implemented a new mandatory payment model for radiation oncology services delivered to certain Medicare beneficiaries: the Radiation Oncology Alternative Payment Method (“RO APM”). On August 29, 2022, CMS published a final rule that delayed the start date of the RO APM to a date to be determined through future rulemaking and amended the definition of “model performance period” to provide that the start and end dates of the five-year model performance period will be established by CMS through future rulemaking.  If the RO APM had not been delayed, it would have significantly altered CMS’ payment methodology from a fee for service paradigm to a set reimbursement by cancer type methodology for radiation services provided within a 90 day episode of care. Under the RO APM, hospital based and free-standing radiation therapy providers would have been required to participate in the model based on whether the radiation therapy provider is located within a randomly selected core-based statistical area. At this time, it is not clear if the RO APM will be implemented and, if it is implemented, the timing for implementation and in what form it will be implemented.  If a start date for the RO APM is proposed, CMS will provide at least six months’ notice in advance of the proposed start date, and the proposed start date will be subject to public comment.

 

The average Medicare reimbursement delivery rate trends from 2022 to 2024 are outlined below:

 

Average Medicare Reimbursement Delivery Rate Trends - Gamma Knife

 

2022

   

2023

   

2024

 
$7,943     $7,691     $7,420  

 

The average Medicare reimbursement delivery rate trends for PBRT from 2022 to 2024 are outlined below. Patients typically undergo 25-40 delivery sessions.

 

 

Average Medicare Reimbursement Delivery Rate Trends - PBRT

 

   

2022

   

2023

   

2024

 

Simple without Compensation

  $ 554     $ 572     $ 561  

Simple with Compensation, Intermediate, or Complex

  $ 1,321     $ 1,323     $ 1,362  

 

We are unable to predict the effect of future government health care funding policy changes on operations. If the rates paid by governmental payers are reduced, if the scope of services covered by governmental payers is limited, or if one or more of our hospital clients are excluded from participation in the Medicare program or any other government health care program, there could be a material adverse effect on our business.

 

 

Affordable Care Act and Subsequent Regulation

In March 2010, the Patient Protection and Affordable Care Act was enacted, as amended by the Health Care and Education Reconciliation Act of 2010, (“Affordable Care Act”), which has resulted in significant changes to the health care industry. The primary goal of the legislation was to extend health care coverage to uninsured legal U.S. residents through both an expansion of public programs and reforms to private sector health insurance. The expansion of insurance coverage was expected to be funded in part by measures designed to promote quality and cost efficiency in health care delivery and by budgetary savings in the Medicare and Medicaid programs. Because the Company is not a health care provider, we were not directly affected by the law, but we could be indirectly affected principally as follows:

 

 

The repeal of the Affordable Care Act’s individual mandate requirement pursuant to the Tax Cuts and Jobs Act of 2017 could results in a decrease in the number of insured patients seeking Gamma Knife or radiation therapy treatment.

 

 

The Company’s revenue sharing contracts are subject to reimbursement rate changes for radiosurgery or radiation therapy services by the government or other third-party payors. Any changes to Medicare or Medicaid reimbursement through the repeal or modification of the Affordable Care Act could affect revenue generated from these sites.

 

Some of the provisions of the Affordable Care Act have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the Affordable Care Act such as removing penalties, starting January 1, 2019, for not complying with the Affordable Care Act’s individual mandate to carry health insurance and delaying the implementation of certain Affordable Care Act-mandated fees. Several states sought the repeal of the Affordable Care Act, arguing in part that the individual mandate is not severable from the Affordable Care Act, and that the removal of the individual mandate should invalidate the Affordable Care Act entirely. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the Affordable Care Act are invalid as well. On June 17, 2021, the Supreme Court of the United States ruled on appeal that the plaintiffs lacked standing to challenge the individual mandate and its severability from the Affordable Care Act. Notably, the Supreme Court’s ruling addressed standing and did not discuss the constitutionality of the individual mandate or its severability. The focus of the Supreme Court’s ruling on standing leaves open the opportunity for additional challenges on the same issues which may yet affect the validity of the Affordable Care Act.

 

In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, started in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act of 2020 subsequently extended Medicare sequestration cuts through fiscal year 2030. On January 2, 2013, the then-U.S. President signed into law the American Taxpayer Relief Act of 2012, which, among other things, also reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. It is unclear what effect, if any, the shifting legislative and other governmental proposals would have on our business.

 

GOVERNMENT REGULATION

 

The payment of remuneration to induce the referral of health care business has been a subject of increasing governmental and regulatory focus in recent years. Section 1128B(b) of the Social Security Act (sometimes referred to as the “federal anti-kickback statute”) provides criminal penalties and fines for individuals or entities that offer, pay, solicit or receive remuneration in order to induce referrals for items or services for which payment may be made under the Medicare and Medicaid programs and certain other government funded programs. The Affordable Care Act amended the anti-kickback statute to eliminate the requirement of actual knowledge, or specific intent to commit a violation, of the anti-kickback statute. The Social Security Act authorizes the Office of Inspector General through civil proceedings to exclude an individual or entity from participation in the Medicare and state health programs if it is determined any such party has violated Section 1128B(b) of the Social Security Act. However, the federal anti-kickback statute is subject to evolving interpretations. In the past, the government has enforced the federal anti-kickback statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The Company believes that it is in compliance with the federal anti-kickback statute. Additionally, the majority of states also have anti-kickback laws, which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers.

 

 

Additionally, the Omnibus Budget Reconciliation Act of 1993, often referred to as “Stark II”, bans physician self-referrals to providers of designated health services with which the physician has a financial relationship. On September 5, 2007, the third and final phase of the Stark regulations (Phase III) was published. The term “designated health services” includes, among others, radiation therapy services and in-patient and out-patient hospital services. On January 1, 1995, the Physician Ownership and Referral Act of 1993 became effective in California. This legislation prohibits physician self-referrals for covered goods and services, including radiation oncology, if the physician (or the physician's immediate family) concurrently has a financial interest in the entity receiving the referral. The Company believes that it is in compliance with these rules and regulations.

 

On August 19, 2008, the CMS published a final rule relating to inpatient hospital services paid under the Inpatient Prospective Payment System for discharges in the Fiscal Year 2009 (the “Final Rule”). Among other things, the Final Rule prohibits “per-click payments” to certain physician lessors for services rendered to patients who were referred by the physician lessor. This prohibition on per-click payments for leased equipment used in the treatment of a patient referred to a hospital lessee by a physician lessor applies regardless of whether the physician himself or herself is the lessor or whether the lessor is an entity in which the referring physician has an ownership or investment interest. The effective date of this prohibition was October 1, 2009. However, referrals made by a radiation oncologist for radiation therapy or ancillary services necessary for, and integral to, the provision of radiation therapy (such as Gamma Knife services) are not subject to this prohibition so long as certain conditions are met. GK Financing’s majority owned subsidiaries, AGKE and JGKE have minority ownership interests that are held solely by radiation oncologists, who are otherwise exempt from the referral prohibition under the Final Rule. The Company believes it is in compliance with the Final Rule.

 

A range of federal civil and criminal laws target false claims and fraudulent billing activities. One of the most significant is the Federal False Claims Act, which prohibits the submission of a false claim or the making of a false record or statement in order to secure a reimbursement from a government-sponsored program. In recent years, the federal government has launched several initiatives aimed at uncovering practices which violate false claims or fraudulent billing laws. Claims under these laws may be brought either by the government or by private individuals on behalf of the government, through a “whistleblower” or “qui tam” action. The Company believes that it is in compliance with the Federal False Claims Act; however, because such actions are filed under seal and may remain secret for years, there can be no assurance that the Company or one of its affiliates is not named in a material qui tam action.

 

Legislation in various jurisdictions requires that health facilities obtain a Certificate of Need (“CON”) prior to making expenditures for medical technology in excess of specified amounts. Four of the Company’s existing customers were required to obtain a CON or its equivalent. The CON procedure can be expensive and time consuming and may impact the length of time before Gamma Knife services commence. CON requirements vary from state to state in their application to the operations of both the Company and its customers. In some jurisdictions the Company is required to comply with CON procedures to provide its services and in other jurisdictions customers must comply with CON procedures before using the Company's services. The Company is unable to predict if any jurisdiction will eliminate or alter its CON requirements in a manner that will increase competition and, thereby, affect the Company's competitive position.

 

The Company’s Gamma Knife units contain Cobalt 60 radioactive sources. The medical centers that house the Company’s Gamma Knife units are responsible for obtaining possession and users licenses for the Cobalt 60 source from the Nuclear Regulatory Commission. Standard linear accelerator equipment utilized to treat patients is regulated by the FDA. The licensing is obtained by the individual medical center operating the equipment.

 

The Company’s Gamma Knife center in Peru was responsible for obtaining possession and user’s licenses for the Cobalt-60 sources from the Peruvian Regulatory Agencies.  The Company’s Gamma Knife center in Ecuador was responsible for obtaining possession and user’s licenses for the Cobalt-60 sources from the Subsecretaría de Control y Aplicaciones Nucleares (SCAN).  The Company’s stand-alone clinic in in Puebla, Mexico is in the process of obtaining its user license through the Comisión Nacional de Seguridad Nuclear y Salvaguardias (CNSNS). 

 

The Company believes it is in substantial compliance with the various rules and regulations that affect its businesses.

 

INSURANCE AND INDEMNIFICATION

 

The Company’s contracts with equipment vendors generally do not contain indemnification provisions. The Company maintains a comprehensive insurance program covering the value of its property and equipment, subject to deductibles, which the Company believes are reasonable.

 

The Company’s customer contracts generally contain mutual indemnification provisions. The Company maintains general and professional liability insurance in the United States. The Company is not involved in the practice of medicine and therefore believes its present insurance coverage and indemnification agreements are adequate for its business. The Company’s Peruvian and Ecuadorian Gamma Knife centers are free-standing facilities operated by GKPeru and GKCE, respectively. The treating physicians and clinical staff at these facilities are independent contractors. The Company maintains general and professional liability insurance consistent with the operations of these facilities and believes its present coverage is adequate for its business.

 

 

HUMAN CAPITAL RESOURCES

 

At December 31, 2023, the Company had a workforce of thirteen people on a full-time basis in the United States, thirteen people on a full-time basis in Lima, Peru, and five people on a full-time basis in Guayaquil, Ecuador. None of these employees are subject to a collective bargaining agreement and there is no union representation within the Company. The Company maintains various employee benefit plans and believes that its employee relations are good.

 

EXECUTIVE OFFICERS OF THE COMPANY

 

The following table provides current information concerning those persons who serve as executive officers of the Company. The executive officers were appointed by the Board of Directors and serve at the discretion of the Board of Directors.

 

Name:

 

Age:

 

Position:

Raymond C. Stachowiak

 

65

 

Executive Chairman of the Board

Peter Gaccione

 

65

 

Chief Executive Officer

Craig K. Tagawa   70   President
Robert Hiatt   58   Chief Financial Officer

 

Raymond C. Stachowiak was appointed the Executive Chairman of the Board of the Company on March 7, 2023.  Mr. Stachowiak previously served as Chief Executive Officer of the Company from October 1, 2020 to March 7, 2023 and as Interim President and Chief Executive Officer effective as of May 4, 2020 through September 30, 2020. Mr. Stachowiak joined the Board in 2009. Mr. Stachowiak previously served as President and Chief Executive Officer of Shared Imaging, a preferred independent provider of CT, MRI and PET/CT equipment and services, from its inception in December 1991 until his retirement in March 2013. In 2008, Mr. Stachowiak sold 50% of his interest in Shared Imaging to Lubar Equity Fund and remains a 50% owner of Shared Imaging. Mr. Stachowiak is the sole owner of RCS Investments, Inc., and owner-manager of Stachowiak Equity Fund, both of which are private equity funds. Mr. Stachowiak received a B.S. in Business and an M.B.A. from Indiana University. He is a Certified Public Accountant (inactive), Certified Internal Auditor (inactive) and holds a Certification in Production and Inventory Management.

 

Peter Gaccione was appointed the Chief Executive Officer of the Company on March 7, 2023.  Mr. Gaccione previously served as Chief Operating Officer of the Company from September 2022 through March 2023. He joined the Company in September 2022 and has over 40 years of experience in the global Radiation Oncology and Imaging business. Most recently, Mr. Gaccione served as President and a Member of the Executive Management Board of Myocardial Solutions Inc., a medical technology company in the cardiology and cardio-oncology field, where he led the product commercialization, sales, marketing development, and clinical teams. Prior to that, Mr. Gaccione held various positions within Elekta AB, a provider of precision radiation oncology treatment systems, brachytherapy, neuroscience, and software solutions from 1997 to 2020, that culminated with his position as President and Chief Executive Officer of Elekta Inc. and Elekta Medical S.A. de C.V. (Mexico), as well as Executive Vice President of Elekta North and Latin America Regions and a Member of the Elekta AB Global Executive Management team from June 2017 to February 2020.

 

Craig K. Tagawa has served as the President of the Company since October 1, 2020.  Mr. Tagawa was also Chief Operating Officer from February 1999 through September 2022. Mr. Tagawa also served as Chief Financial Officer from January 1992 through October 1995 and from May 1996 to April 2023. Previously a Vice President in such capacity, Mr. Tagawa became a Senior Vice President on February 28, 1993. He is also the Chief Executive Officer and manager of GKF. From September 1988 through January 1992, Mr. Tagawa served in various positions with the Company. Mr. Tagawa currently serves as Chief Financial Officer and Secretary of the Ernest A. Bates Foundation. He received his undergraduate degree from the University of California at Berkeley and his M.B.A. from Cornell University.

 

Robert Hiatt has served as the Chief Financial Officer of the Company since April 17, 2023. Mr. Hiatt was previously the Chief Financial Officer of AmeriCash Loans, a consumer finance company from October 2007 to December 2022. While at AmeriCash Loans, Mr. Hiatt was responsible for leading the finance team including internal financial reporting, external audit and tax coordination and debt management. From August 2003 to July 2007, Mr. Hiatt served as the Executive Vice President and Chief Financial Officer of United Financial Mortgage Corp, a provider of residential mortgages. Prior to that, Mr. Hiatt was Vice President Finance and Chief Accounting Officer of Novamed, Inc., an operator of ambulatory surgery centers, from September 1997 to August 2003. Mr. Hiatt received his Bachelor’s of Science in Accountancy from Miami University.

 

AVAILABLE INFORMATION

 

Our Internet address is www.ashs.com. We make available free of charge, through our Internet website under the “Investor Center” tab in the “Corporate” section, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, annual proxy reports, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (“Exchange Act”) as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The information contained on our Internet website is not part of this document.

 

ITEM 1A. RISK FACTORS

 

In addition to the other information in this report, the following factors could affect our future business, results of operations, cash flows or financial position, and could cause future results to differ materially from those expressed in any of the forward-looking statements contained in this report.

 

 

Company, Industry and Economic Risk

 

If the Company is not successful at diversifying its business model, its revenues and profitability may decline.

 

The Company has historically relied on Gamma Knife unit placement and a PBRT system to provide its revenues. Currently, there is a limited market for Gamma Knife equipment and PBRT systems. As a result, we plan to adapt our business model to place other types of stereotactic radiosurgery and advanced radiation therapy equipment in addition to Gamma Knife units and PBRT systems. This will constitute an expanded product mix for the Company and there can be no assurance that we can successfully adapt our historical business model to these new product offerings. If we are not successful, our revenues and profitability could decline substantially as existing contracts expire and are not renewed.

 

The Federal reimbursement rate for Gamma Knife treatments may not provide the Company with an adequate return on its investment.

 

Congress enacted legislation in 2013 that significantly reduced the Medicare reimbursement rate for outpatient Gamma Knife treatment by setting it at the same amount paid for linear accelerator-based radiosurgery treatment. Gamma Knife treatment has been relatively stable during the last five years. There can be no assurance that CMS reimbursement levels will be maintained at levels providing the Company an adequate return on its investment. Any future reductions in the reimbursement rate would adversely affect the Company’s revenues and financial results.

 

The Company's revenue sharing is subject to payor mix variability which could negatively impact the Company's revenue and financial results.

 

The Company’s average reimbursement rate for its revenue sharing and retail customers is dependent on the percentage mix of government associated payors and commercial managed care payors.  Commercial and managed care payors tend to reimburse at a higher level than government payors.  Therefore, a shift in payor mix to a higher level of government payors will reduce the Company’s average reimbursement rate per treatment. 

 

The Companys capital investment at each site is substantial and the Company may not be able to fully recover its costs or capital investment which could have a material negative impact on its revenues and financial results.

 

Each Gamma Knife, PBRT or advanced LINEAR accelerator device requires a substantial capital investment. In some cases, we contribute additional funds for capital costs and/or annual operating and equipment related costs such as marketing, maintenance, insurance and property taxes. Due to the structure of our contracts with medical centers, there can be no assurance that these costs will be fully recovered or that we will earn a satisfactory return on our investment, which could have a material negative impact on our revenues and financial results.  Additionally, the Company is obligated to remove the equipment at the end of the lease term. In the event the customer does not purchase the equipment from the Company or the Company is not able to trade in the equipment, the Company is required to remove the equipment and record an ARO.

 

The market for the Gamma Knife is limited and the Company may not be able to place additional Gamma Knife units which could negatively impact the Company's revenue and financial results.

 

There is a limited market for the Gamma Knife, and the market in the United States may be mature. The Company has begun and continued operation at only five new Gamma Knife sites in the United States since 2011. Due to the substantial costs of acquiring a Gamma Knife unit, we must identify medical centers that possess neurosurgery and radiation oncology departments capable of performing a large number of Gamma Knife procedures. There can be no assurance that we will be successful in placing additional units at any sites in the future. In recognition of the Gamma Knife's limited growth opportunity, the Company has expanded its product mix to include LINACs, MR LINACs, PET LINACs and is continuing to market PBRT units, but there can be no assurance that the Company will be successful in placing these products with customers. The Company’s existing contracts with its customers are fixed in length and there can be no assurance that the customers will wish to extend the contract beyond the end of the term.

 

The Company has incurred debt and may incur additional debt to finance its operations and if the Company is unable to secure additional credit in the future its operations and profits will be negatively impacted.

 

The Company’s business is capital intensive. On April 9, 2021, the Company and certain of its domestic subsidiaries entered into a five year $22,000,000 credit agreement with Fifth Third, which refinanced its existing domestic Gamma Knife portfolio.  The lease financing previously obtained by Orlando was also refinanced as long-term debt by the Credit Agreement. On January 25, 2024, the Company and Fifth Third entered into the First Amendment which added an additional $2,700,000 term loan. In June 2020, the Company’s wholly-owned subsidiary, HoldCo, entered into the DFC Loan in connection with the acquisition of GKCE. The first tranche of the DFC Loan was funded in June 2020. In October 2023, the second tranche of the DFC Loan was funded in the amount of $1,750,000 to finance its equipment upgrade in Ecuador. The Company’s combined long-term debt, net, totaled $13,125,000 as of December 31, 2023. The Credit Agreement is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries and the DFC Loan is secured by a lien on GKCE’s assets. The Credit Agreement includes a $7,000,000 Revolving Line available for future projects and general corporate purposes. The Company borrowed $2,500,000 on the Revolving Line as of December 31, 2023, which was paid off in January 2024. Depending on the Company’s financing requirements and market conditions, the Company may seek to finance its operations by incurring additional long-term debt in the future. The Company’s current level of debt may adversely affect the Company’s ability to secure additional credit in the future, and as a result may affect operations and profitability. If a default on debt occurs in the future, the Company’s creditors would have the ability to accelerate the defaulted loan, to seize the Company’s assets with respect to which default has occurred, and to apply any collateral they may have at the time to cure the default.

 

 

The Companys debt agreements contain restrictions that limit its flexibility in operating its business, and the Company may be required to repay the outstanding indebtedness in an event of default, which would have an adverse effect on our business.

 

The Credit Agreement and the DFC Loan contain various covenants that limit the Company’s ability to engage in specified types of transactions. These covenants subject the Company to various restrictions that limit the Company from, among other activities, creating any unpermitted liens to exist on its assets, incurring additional indebtedness, causing a sale of all or substantially all of its assets, effecting a merger, paying dividends or other distributions on capital stock, redeeming shares of capital stock, engaging in transactions with affiliates, or undertaking lease obligations above certain thresholds

 

In addition, the Company is obligated to comply with certain financial-reporting requirements, financial ratios, and liquidity and leverage thresholds under certain covenants in its Credit Agreement and DFC Loan. The Company’s ability to meet those financial ratios and tests can be affected by events beyond our control, including prevailing economic, financial market and industry conditions and the Company cannot give assurance that it will be able to satisfy such ratios and tests when required.

 

A breach of any of these covenants could result in a default under the Credit Agreement and the DFC Loan. Upon the occurrence of an event of default, the lenders could elect to declare the amount outstanding under the Credit Agreement or DFC Loan immediately due and payable. The lenders under the Credit Agreement and the DFC Loan could also exercise their rights to take possession of, and to dispose of, the collateral securing the credit facilities and loans. The Company’s business, financial condition, and results of operations could be materially adversely affected as a result of any of those events. The Company may seek to enter into an extension of the credit and loan agreements or to enter into a new facility or loan agreement with another lender. However, the Company may not be able to extend the term or obtain other debt financing on terms that are favorable to the Company, if at all, and the Company could be subject to additional restrictions on its business operations. If the Company is unable to obtain adequate financing or financing on satisfactory terms when required, the Company’s ability to support its business growth and to respond to business challenges could be significantly impaired, and its business may be harmed.

 

As of December 31, 2023, HoldCo was not in compliance with all of its debt covenants then in effect pursuant to the DFC Loan. However, on March 28, 2024, the Company obtained a waiver for the covenant non-compliance as of December 31, 2023 (the “DFC Waiver”). The Company expects to be compliant with all of its debt covenants by the end of the fiscal quarter ended March 31, 2024. However, if a waiver from DFC is required in the future for potential non-compliance, DFC may be unwilling to provide a waiver and could, as a result, among other remedies, accelerate the repayment of the debt obligations oustanding under the DFC Loan, which could have a material adverse effect on the Company’s financial condition.

 

The Company may fail to successfully integrate the interests to be acquired in the RI Acquisition with its existing business in a timely manner, which could have a material adverse effect on the Companys business, financial condition, results of operations, or cash flows, or the Company may fail to realize all of the expected benefits of the RI Acquisition, which could negatively impact the Companys future results of operations.

 

The integration of any acquisitions, including the Company’s planned RI Acquisition, requires significant time and resources. A failure by the Company to successfully integrate the businesses, operations, and contractual obligations of the RI Target Companies with the Company’s existing business in a timely manner could have a material adverse effect on the Company’s business, financial condition, cash flows, or results of operations. Acquiring majority interests in the RI Target Companies, assuming obligations under the commercial payor contracts set forth in the IPA, and integrating the businesses of the three turn-key radiation therapy cancer centers that the RI Target Companies operate in Rhode Island involves several risks that could undermine the success and expected benefits of the RI Acquisition. Such risks include but are not limited to the following:

 

 

the potential difficulty of assimilating the businesses and operations of the RI Target Companies with our existing business and operations;

 

 

the added costs that could be incurred from coordinating the integration of personnel from diverse business backgrounds and consolidating the corporate and administrative functions of the Company and the RI Target Companies;

 

 

the potential disruption to our existing operations that could result from the Company expanding into another state and expending time and resources to oversee the RI Target Companies’ operation of their three radiation oncology centers;

 

 

the added costs and burdens that the Company will incur in connection with obtaining the governmental and regulatory approvals that are necessary to effect the RI Acquisition and to stay regulatorily compliant under Rhode Island law if the RI Acquisition is effected;

 

 

the diversion of the resources of the Company and the attention of the Company’s management from the Company’s existing operations and business ventures to the operations of the RI Target Companies, which could hinder the performance of the Company and its subsidiaries;

 

 

the potential management differences that could result from the Company gaining majority interests in the RI Target Companies and taking control from GenesisCare; and

 

 

the risk of financial loss due to the existing debts and liabilities of the RI Target Companies and the potential need for the Company to expend substantial capital to stabilize the businesses of the RI Target Companies due to any instability created by the GenesisCare bankruptcy, with no guarantee of return on investment.

 

If the Company is not successful in addressing these risks effectively, the Company’s business and operations could be impaired.

 

 

The Companys cash flow could become insufficient to service its debt due to financial, business, and other factors.

 

The Company’s ability to make scheduled payments of the principal and interest on its indebtedness depends on the Company’s financial condition and operating performance, which is subject to economic and competitive conditions and to certain financial, business, and other factors. There can be no assurance that the Company will maintain a level of cash flow from operating activities sufficient to permit it to pay the principal of and any interest on its indebtedness. If the Company’s cash flow and capital resources are insufficient to fund its debt obligations, the Company may be forced to delay investments and capital expenditures, to seek additional capital, or to restructure or refinance its indebtedness. There can be no guarantee that those alternative measures will be available, either at all or on terms that are favorable to the Company, or that they will be successful even if available in allowing the Company to meet its debt-service obligations. In the absence of such operating results and resources, the Company could experience liquidity issues, which could force the Company to take alternative measures to satisfy its debt obligations, such as selling assets, restructuring debt, or obtaining additional equity capital on potentially onerous or highly dilutive terms. The Credit Agreement and DFC Loan restrict the Company’s ability to dispose of assets and to use the proceeds from such dispositions, so the Company may be restricted from taking certain measures, such as conducting an asset sale, to meet its debt-service obligations. The ability to refinance indebtedness would also depend on the general state of capital markets and on the Company’s financial condition, neither of which can be predicted at this time.

 

A small number of customers account for a major portion of our revenues and the loss of any one of these significant customers could have a material adverse effect on the Company's business and results of operations.

 

A limited number of customers have historically accounted for a substantial portion of the Company’s total revenue, and the Company expects such customer concentration to continue for the foreseeable future. For example, in 2023, one customer in total accounted for approximately 48% of the Company’s revenue. The loss of a significant customer or a significant decline in the business from the Company’s largest customers could have a material adverse effect on the Company’s business and results of operations.

 

The Company occupies many of its facilities under long-term leases and the Company may not be able to renew its leases at the end of their terms.

 

The Company leases many of the facilities where it holds its equipment. At the end of the lease term for a facility, the Company may be unable to renew the lease without substantial additional costs, if at all. If we are unable to renew our facility leases, we may be required to relocate or close a facility. Additionally, due to the nature of its radiation equipment, there can be a long lead time to prepare space for holding its equipment and substantial cost involved in moving the equipment should the Company need to change locations.  The failure to be able to obtain leased space when required or the costs of relocation could have a material adverse effect on our business and results of operations.

 

The market for the Companys services is competitive and if the Company is not able to compete its business and results of operations could be negatively impacted.

 

The Company estimates that there are two other companies that actively provide alternative, non-conventional Gamma Knife financing to potential customers. The Company’s relationship with Elekta, the manufacturer of the Leksell Gamma Knife unit, is non-exclusive, and the Company has lost sales to customers that chose to purchase a Gamma Knife unit directly from Elekta. The Company also has several competitors in the financing of proton therapy projects. The Company’s business model differs from its competitors, but there can be no assurances that the Company will not lose placements to its competitors. In addition, the Company may continue to lose future sales to customers purchasing equipment directly from manufacturers. There can be no assurance that the Company will be able to successfully compete against others in placing future units and if the Company is not able to compete its business and results of operations could be negatively impacted.

 

There are alternatives to the Gamma Knife and medical centers could choose to use other radiosurgery devices instead of the Gamma Knife.

 

Other radiosurgery devices and conventional neurosurgery compete against the Gamma Knife. Each of the medical centers targeted by the Company could decide to acquire another radiosurgery device instead of a Gamma Knife to perform cranial radiosurgery. In addition, neurosurgeons who are responsible for referring patients for Gamma Knife surgery may not be willing to make such referrals for various reasons, instead opting for invasive surgery. Because of these competing alternatives, there can be no assurance that the Company will be able to secure a sufficient number of future sites or Gamma Knife procedures to sustain its profitability and growth and accordingly there may be a material negative impact on the business and results of operations of the Company.

 

International operations make the Company vulnerable to risks associated with doing business in foreign countries that can affect its business, financial condition, results of operations and cash flows.

 

The Company installed a Gamma Knife unit in Lima, Peru in 2017 and acquired a Gamma Knife unit operation in Guayaquil, Ecuador in 2020. The Company’s third international site in Puebla, Mexico is expected to begin treating patients in June 2024. International operations can be subject to exchange rate volatility, which could have an adverse effect on our financial results and cash flows. In addition, international operations can be subject to legal and regulatory uncertainty and political and economic instability, which could result in problems asserting property or contractual rights, potential tariffs, increased compliance costs, increased regulatory scrutiny, foreign customers with longer payment cycles than customers in the United States, potential adverse tax consequences, the inability to repatriate funds to the United States, and the Company’s inability to operate in those locations.

 

There can be no assurance that the Companys pending RI Acquisition will close as anticipated, as the closing of the transactions provided for in the IPA are subject to various judicial, regulatory, and contractual contingencies over which the Company has little to no control

 

The closing of the pending RI Acquisition is contingent upon certain closing conditions, including GenesisCare and the Company entering into a consent agreement with the Rhode Island Department of Health and approval of all equity holders and managers of each RI Target Company. There can be no assurance that the Company and GenesisCare will receive the necessary approvals and consents to effect the RI Acquisition or that such approvals and consents will be delivered. Furthermore, if all of the closing conditions to the RI Acquisition are not met by April 30, 2024, both the Company and GenesisCare have the right to terminate the IPA without completing the RI Acquisition. The Company cannot assure that the pending RI Acquisition will close on our anticipated timeline or at all, or without material adjustment.

 

 

Flaws in the Companys ongoing due-diligence assessment in connection with the equity interests and payor contracts to be acquired in the RI Acquisition could have a significant negative effect on the Companys financial condition and results of operations.

 

The Company conducted due diligence when evaluating the RI Acquisition prior to executing the IPA and continues to complete due diligence during the interim period between signing the IPA and closing the RI Acquisition. The process of completing due diligence is expensive and time consuming due to the operations, accounting, finance, and legal professionals who must be involved in the due-diligence process and the fact that such efforts do not always lead to a consummated transaction. The time and costs of the due-diligence process were amplified with respect to the Company’s evaluation of the potential costs and benefits of the RI Acquisition due to the distressed state and bankruptcy of GenesisCare. Despite the thoroughness of the Company’s review, diligence may not reveal all material issues that could affect the Company’s interests in the RI Target Companies if the RI Acquisition is consummated. In addition, factors outside of the Company’s control could later arise. The Company’s failure to identify material issues specific to the business and operations of the RI Target Companies and the liabilities and obligations the Company is assuming upon the assignment of the payor contracts during the Company’s ongoing due-diligence process could negatively impact the Company’s financial condition and results of operations after the closing of the RI Acquisition.

 

The impact of a pandemic, epidemic, or outbreak of an infection disease, such as COVID-19 and associated economic disruptions, has and may in the future adversely affect the Companys business operations and financial condition. 

 

The magnitude of the continued impact of COVID-19 on our business and operations are largely dependent on external factors and future developments that are beyond our control, such as the extent and duration of any COVID-19 resurgence, the spread of new variants, the occurrence of other severe health events or similar unprecedented outbreaks, the response to any such resurgence, new variant, or outbreak by government and regulatory agencies, such as the potential reinstatement of “shelter-in-place” lockdown orders, the efficacy and implementation of vaccinations and boosters to counter the virus, the availability of Gamma Knife and PBRT treatments, patients’ assessment of the risks of prioritizing rather than delaying such treatments in the event of any COVID-19 resurgence, new variant, or outbreak, the worsening of current economic conditions, and the severity of ongoing supply-chain disruptions. If there are regressions in our global progress to combat the COVID-19 pandemic or if any similar global public-health events develop, the scope and nature of the impact on our business, results of operations, financial condition, liquidity and cash flows would be uncertain and potentially materially adverse.

 

New technology and products could result in making the Company's equipment obsolete which could have a material adverse impact on its business and results of operations.

 

There is constant change and innovation in the market for highly sophisticated medical equipment. New and improved medical equipment can be introduced that could make the Gamma Knife technology obsolete and that would make it uneconomical to operate. In 2006, Elekta introduced a new model of the Gamma Knife, the Perfexion, which the Company has implemented at all of its domestic sites. The Perfexion can perform procedures faster than previous Gamma Knife models and it involves less health care personnel intervention. In 2015, Elekta introduced the Leksell Gamma Knife Icon ™. The Perfexion is upgradeable to the Icon platforms which has enhanced imaging capabilities allowing for treatment without a head frame and the treatment of larger tumors. In 2022, Elekta introduced an upgrade to the Icon, called the Esprit. Existing model 4(C)s of the Gamma Knife are not upgradeable to the Perfexion model. As of March 1, 2024, two of the Company’s ten Gamma Knife units in the United States are Esprits and eight of the Company’s ten Gamma Knife units are Perfexion models, two of which have the Icon upgrade. The Company’s equipment in Ecuador was upgraded to a Perfexion with Icon in November 2023. The Company’s equipment in Peru is a Model 4(C). The failure to acquire or use new technology and products could have a material adverse effect on our business and results of operations.

 

Any failure, interruption, or breach in security of the Companys information technology (IT) infrastructure due to a cyber-attack or other security incident could cause the Company to incur financial penalties and losses, reputational damage, and legal liability, which could have a material adverse effect on the Companys business, financial condition, and results of operations.

 

The Company’s ability to carry out its internal and external business operations depends in part on an IT infrastructure that includes computer systems, hardware, software, online sites, servers, networks, and other IT products and services, some of which are owned and managed by third-party service providers and suppliers. Although the Company takes steps to safeguard its IT infrastructure, cybersecurity risks are an evolving and pervasive threat to the Company’s business, operations, and financial performance. Security incidents that the Company must protect against include unauthorized access of the Company’s IT systems, breaches of the Company’s data and confidential information, sophisticated malware, advanced phishing and social-engineering ploys, cyber-attacks, and commercial-software vulnerabilities that are integrated into the Company’s or any of its suppliers’ or service providers’ IT systems. While the Company strives to maintain the integrity and confidentiality of its data, systems, and information and to protect it from internal and external cybersecurity threats by taking the preventative measures and abiding by the security protocols identified in “Item 1C. Cybersecurity” below, there is no guarantee that the IT infrastructure developed by the Company and the cybersecurity measures implemented by the Company will be successful in preventing and defending against the evolving and increasingly sophisticated range of cyber incidents that the Company could be exposed to. Furthermore, there can be no assurance that the Company’s cybersecurity risk management strategy and processes will be fully implemented, complied with, or effective in safeguarding the Company’s data, systems, and information.

 

Any actual compromise of or perceived threat to the Company’s IT systems and infrastructure could cause significant legal and financial exposure for the Company, damage the Company’s reputation, and create adverse publicity, which could adversely affect the Company’s business, operations, and financial condition. Any necessary response to a cyber-attack, which could include analyzing a security incident, patching up security vulnerabilities, notifying individuals affected by the incident, determining the materiality of the incident, disclosing the incident in accordance with any applicable legal and regulatory requirements, and responding to any resulting litigation, could also divert the Company’s resources and attention from its growth operations and business objectives, which could further hinder its operational and financial performance.

 

Stock Ownership Risk

 

The trading volume of the Companys common stock is low

 

Although the Company’s common stock is listed on the NYSE American, the Company’s common stock has historically experienced low trading volume. Reported average daily trading volume in our common stock for the three-month period ended December 31, 2023 was approximately 10,000 shares. There is no reason to think that a further increase in an active trading market in the Company’s common stock will develop in the future. Limited trading volume subjects the Company’s common stock to greater price volatility and may make it difficult for shareholders to sell their shares in a quantity or at a price that is attractive.

 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 1C. CYBERSECURITY

 

The Company recognizes the importance of securing its information, devices, and data and the IT systems it relies on to conduct its business. The Company has established its Network, Information, and Data Security Policy Guidelines (the “NIDSP Guidelines”) designed to protect the integrity and confidentiality of data and information belonging to or being exchanged by the Company and its employees, partners, customers, service providers, and suppliers and to safeguard that information and the Company’s IT infrastructure from unauthorized access, use, disclosure, alteration, and destruction.

 

Risk Management and Strategy

 

The protections, procedures, and controls set forth in the NIDSP Guidelines demonstrate the Company’s attention to and prioritization of cybersecurity as a component of its overall strategy and system for managing risks. The NIDSP Guidelines include five policies described below, that together define the Company’s strategy and practices for managing cybersecurity threats and mitigating cybersecurity risks.

 

 

Physical Security Policy (the PSP).   The PSP establishes guidelines related to selecting IT operation sites, designating security zones, using, inspecting, and storing IT Assets, designing restricted-access and security controls, and monitoring compliance with safety and security standards. The goal of the PSP is to minimize risks of damage, destruction, unauthorized access, inadvertent disclosure, misuse, loss, or theft of the Company’s IT Assets. In accordance with the PSP, the Company: (i) evaluates IT operation sites based on their susceptibility to natural disasters, crime and theft, and unauthorized access; (ii) requires the use of keycards or biometrics in order to enforce security zones and give users the least amount of access required to do their jobs; (iii) requires systems and devices that store confidential data to be maintained and protected in accordance with the Company’s Confidential Data Policy; and (iv) requires visitors at the Company’s office to complete a sign-in log, wear a visitor badge, and be escorted by a designated employee at all times.

 

 

Network Security Policy (the NSP).  The NSP aims to protect the integrity of the Company’s data by securing the systems and devices that make up the Company’s network infrastructure. Pursuant to the NSP, the Company: (i) enforces strict password-construction criteria for network devices; (ii) requires employees to verify their identities using multi-factor authentication to access internal resources; (iii) maintains and reviews logs from application services, network devices, and critical devices and requires the retention of logs in accordance with the Company’s Retention Policy; (iv) implements and configures firewall technology to filter both inbound and outbound network connections; (v) authorizes the IT Manager to determine the extent and scope of external security testing to be performed; (vi) establishes a software-use policy; and (vii) requires antivirus and anti-malware software to be used and timely patched and updated on any Company-provided devices.

 

 

Backup Policy.  The Company’s Backup Policy applies to all data stored on Company systems. The Backup Policy specifies the types of data and information considered to be critical to the Company’s operations and thus required to be backed up, establishes a backup schedule that is necessary for successful data recovery, and implements procedures for the off-site rotation, storage, and retention of backups. The Backup Policy also establishes the Company’s data-restoration procedures and mandates the periodic testing of those procedures.

 

 

Remote Access Policy (the RAP).  The RAP defines the Company’s standards for accessing IT resources from outside the Company’s network, such as when an employee is working remotely. Pursuant to the RAP, remote access is only permitted if accomplished through secure, Company-provided means. The Company’s uses remote-access software designed to guard against unauthorized access using traffic encryption during transmission and firewall protections.

 

 

Confidential Data Policy (the CDP).  The CDP governs the handling, storage, transmission, destruction, and protection of confidential data. Pursuant to the CDP, confidential data must be securely stored, removed from common areas, properly marked as confidential data, protected with strong encryption if being transmitted, and destroyed by means that make recovery impossible. Employees who are given access to confidential data are required to immediately notify their supervisor if they suspect any misuse or unauthorized disclosure of confidential information.

 

The Company’s NIDSP Guidelines and policies apply not only to the Company’s employees and consultants but also to any third parties that access or utilize the Company’s information and systems. Such third parties may include the Company’s service providers, customers, suppliers, contractors, consultants, and any other individuals the Company conducts business with. The IT infrastructure that the Company has developed in accordance with the NIDSP Guidelines is designed to monitor both internal and external cybersecurity risks. The NIDSP Guidelines equip the Company with the tools and systems necessary to recognize, address, and protect against risks associated with its third-party interactions.

 

 

Cybersecurity Governance

 

The Company’s IT Manager and executive team is responsible for the day-to-day management of cybersecurity risks, while the Company’s Board of Directors has responsibility for oversight of risk management.  

 

As part of the Company’s framework for cybersecurity risk oversight and governance, the Company’s network, information, and data-security policies set forth in the NIDSP Guidelines are enforced by the Company’s IT Manager and/or its executive team. The IT Manager is an employee designated by the Company to manage the Company’s security policies and program. The IT Manager is tasked with ensuring that the Company maintains compliance with the Company’s security policies and any applicable security regulations. The IT Manager is responsible for: (i) implementing the Company’s security policies; (ii) disseminating the Company’s security policies to all employees; (iii) establishing a training program for all employees and users covered by the Company’s IT security policy to notify them of the Company’s security policies, train and re-train them to comply with the Company’s IT security program, and educate them on the importance of data security; (iv) performing any ongoing testing or analysis of the Company’s security infrastructure, policies, and procedures; and (v) updating the NSP and any other policies and guidelines as needed to comply with applicable regulations and to stay up to date with the changing IT security landscape.

 

The IT Manager works closely with the Company’s management and executive team to determine the Company’s IT-related needs, to evaluate the sufficiency of the Company’s data-governance policies and practices, to keep the Company’s management informed of notable cybersecurity-related updates, to review its security-related policies, and to identify ways to strengthen the systems and procedures implemented by the Company to detect, assess, and manage data risks.

 

In the event of the detection of an actual or suspected cybersecurity incident, the Company's IT Team, lead by the IT Manager, assesses the incident as “minimal”, “low", “moderate” or “high”.  Incidents assessed at a minimal or low risk are reported to Company’s management and the Executive Chairman of the Board and the Executive Chairman of the Board may share this information with the Board. Incidents assessed at a moderate or high risk are reported to Company’s management, the Executive Chairman of the Board, and the Company’s Board of Directors.

 

Notwithstanding the Company’s cybersecurity-related policies, procedures, and governance framework, the ever-present threat of a cyber-attack, data breach, or other security incident is pervasive. The increasingly sophisticated nature of the tactics used to circumvent IT security safeguards makes cybersecurity threats increasingly difficult to detect and respond to. While the Company does not believe its business strategy, results of operations, or financial condition have been materially adversely affected by any cybersecurity threats or incidents, there is no assurance that the Company will not be materially affected by such threats or incidents in the future. Accordingly, the Company will continue to monitor cybersecurity risks and strive to invest in and strengthen its cybersecurity infrastructure.

 

ITEM 2. PROPERTIES

 

The Company’s corporate offices are located at 601 Montgomery Street, Suite 1112, San Francisco, California, where it leases approximately 900 square feet for $4,500 per month with a lease expiration date in November 2024. The Company subleased its prior corporate offices located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month. This lease expired in August 2023. The monthly lease expense was offset by sublease income of $16,195. The sublease term was consistent with the existing lease term. The Company owns and operates a stand-alone Gamma Knife facility in Lima, Peru where it leases approximately 1,600 square feet for approximately $8,850 per month on a month-to-month basis. The Company also owns and operates a stand-alone Gamma Knife facility in Guayaquil, Ecuador where it owns 864 square feet of condominium space in an office building and approximately 10,135 of related land and parking spaces.

 

ITEM 3. LEGAL PROCEEDINGS

 

There are no material pending legal proceedings involving the Company or any of its property. The Company knows of no legal or administrative proceedings against the Company contemplated by governmental authorities.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information and Dividend Policy

 

The Company’s common shares, no par value (the “Common Shares”), are currently traded on the NYSE American. At December 31, 2023, the Company had 6,300,000 issued and outstanding common shares, 146,000 common shares reserved for options, 33,000 unvested restricted stock units, and 123,000 vested, but not issued restricted stock units.

 

The Company estimates that there were approximately 1,100 beneficial holders of its Common Shares at December 31, 2023.

 

There were no dividends declared or paid during 2023 and 2022.

 

Stock Repurchase Program

 

In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its common stock on the open market from time to time at prevailing prices, and in 2008 the Board of Directors reaffirmed these authorizations. In 2023 and 2022, there were no shares repurchased by the Company. A total of approximately 928,000 shares have been repurchased in the open market pursuant to these authorizations at a cost of approximately $1,957,000.  As of December 31, 2023, there were approximately 72,000 shares remaining under the repurchase authorizations.

 

Equity Compensation Plans

 

During 2023, 26,000 restricted stock units, 120,000 shares for executive compensation, and 70,000 options were granted. Additional information regarding our equity compensation plans is incorporated herein by reference from the 2024 Proxy Statement. Also, see Note 8 - Stock-Based Compensation Expense to the consolidated financial statements for additional information.

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

American Shared Hospital Services is a leading provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The main drivers of the Company’s revenue are numbers of sites, procedure volume, and reimbursement. The Company delivers radiation therapy through medical equipment leasing and direct patient services, its two reportable segments. The medical equipment leasing segment, which we also refer to as the Company’s leasing segment, operates by fee-per-use contracts or revenue sharing contracts where the Company shares in the revenue and operating costs of the equipment.  The Company leases ten Gamma Knife systems and one PBRT system as of December 31, 2023, where a contract exists between the hospital and the Company.  The Company, through GKF, also owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company’s facilities in Peru and Ecuador are considered direct patient services, which we also refer to as the Company’s retail segment, where a contract exists between the Company's facilities and the individual treated at the facility. A summary of the Company’s medical equipment leases and direct patient service sites is set forth in the table below:

 

Number of Sites

 

   

12/31/2023

   

12/31/2022

 

Revenue Sharing

    5       6  

Fee Per Use

    5       6  

Medical Equipment Leasing - Gamma Knife

    10       12  
                 

Medical Equipment Leasing - Proton Bream Radiation Therapy

    1       1  
                 

Medical Equipment Leasing - Total

    11       13  
                 

Direct Patient Services ("Retail") - Gamma Knife

    2       2  

 

The Company had two contracts expire in the second and third quarters of 2023, respectively.  The Company had a third contract up for renewal in 2023. This lease was extended and the equipment was upgraded to an Esprit during the fourth quarter.  The Company has one customer contract that will expire in November 2024. A summary of the Company’s procedure volumes for fiscal years 2023 and 2022 are set forth in the table below.

 

 

Volume

 

                      Increase       Increase  

Gamma Knife

    12/31/2023       12/31/2022       (Decrease)       (Decrease)  

Medical Equipment Leasing - Gamma Knife

    824       954       (130 )     (13.6 )%

Direct Patient Services ("retail") - Gamma Knife

    371       332       39       11.7 %

Gamma Knife - Total

    1,195       1,286       (91 )     (7.1 )%
                                 

PBRT Procedures (medical equipment leasing)

    5,369       5,296       73       1.4 %

 

The decrease in Gamma Knife volume, under medical equipment lease, during 2023 was primarily due to the expiration of two contracts in the second and third quarters of 2023, respectively. Same center procedures decreased 4% compared to 2022 due to downtime for the upgrade of two Gamma Knife systems to the Esprit during the third and fourth quarters of 2023. The increase in Gamma Knife volume, under direct patient services, during 2023 was due to improved marketing and physician outreach at the Company’s international locations, offset by downtime to upgrade the Gamma Knife equipment in Ecuador to the Icon. The increase in PBRT volume was due to normal, cyclical fluctuations.

 

Reimbursement

 

CMS established a 2024 delivery code reimbursement rate of approximately $7,420 ($7,691 in 2023) for a Medicare Gamma Knife treatment. The approximate CMS reimbursement rates for delivery of PBRT for a simple treatment without compensation for 2024 is $561 ($572 in 2023) and $1,362 ($1,323 in 2023) for simple with compensation, intermediate and complex treatments, respectively.

 

On September 29, 2020, CMS published a final rule that would have implemented a new mandatory payment model for radiation oncology services delivered to certain Medicare beneficiaries: the RO APM. On August 29, 2022, CMS published a final rule that delayed the start date of the RO APM to a date to be determined through future rulemaking and amended the definition of “model performance period” to provide that the start and end dates of the five-year model performance period will be established by CMS through future rulemaking. If the RO APM had not been delayed, it would have significantly altered CMS’ payment methodology from a fee for service paradigm to a set reimbursement by cancer type methodology for radiation services provided within a 90 day episode of care. Under the RO APM, hospital based and free-standing radiation therapy providers would have been required to participate in the model based on whether the radiation therapy provider is located within a randomly selected core-based statistical area. At this time, it is not clear if the RO APM will be implemented and, if it is implemented, the timing for implementation and in what form it will be implemented.  If a start date for the RO APM is proposed, CMS will provide at least six months’ notice in advance of the proposed start date, and the proposed start date will be subject to public comment.

 

Pending Acquisition

 

On November 10, 2023, the Company entered into the IPA with GenesisCare and GC Holdings pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of RI Target Companies together with the assignment of certain payor contacts for a purchase price of $2,850,000.  The equity interests to be acquired by the Company under the IPA equates to a 60% interest in each RI Target Company. The RI Target Companies operate three functional radiation therapy cancer centers in Rhode Island. The RI Acquisition is contingent upon certain closing conditions, including Genesis Care and the Company entering into a consent agreement with the Rhode Island Department of Health and approval of all equity holders and managers of each RI Target Company. On March 1, 2024, the Company, GenesisCare and GC Holding entered to a First Amendment to Investment Agreement pursuant to which the parties agreed to extend the date on which a party could terminate the IPA if the closing conditions had not been met from March 10, 2024 to April 30, 2024. The Company anticipates that the closing conditions will be met in April 2024.

 

 

APPLICATION OF CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

The Company’s consolidated financial statements are prepared in accordance with generally accepted accounting principles and follow general practices within the industry in which it operates. Application of these principles requires management to make estimates, assumptions and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates, assumptions and judgments are based on information available as of the date of the consolidated financial statements; accordingly, as this information changes, consolidated the financial statements could reflect different estimates, assumptions and judgments. Certain policies inherently have a greater reliance on the use of estimates, assumptions and judgments and as such have a greater possibility of producing results that could be materially different than originally reported.

 

The most significant accounting policies followed by the Company are presented in Note 2 – Accounting Policies to the consolidated financial statements. These policies along with the disclosures presented in the other consolidated financial statement notes and, in this discussion, and analysis, provide information on how significant assets and liabilities are valued in the consolidated financial statements and how those values are determined. Based on the valuation techniques used and the sensitivity of the consolidated financial statement amounts, and the methods, assumptions and estimates underlying those amounts, management has identified revenue recognition and costs of sales for revenue sharing customers, and the salvage value of equipment, and as such the aforementioned could be most subject to revision as new information becomes available. The following are our critical accounting policies in which management’s estimates, assumptions and judgments most directly and materially affect the consolidated financial statements:

 

Revenue Recognition

 

The Company recognizes revenues under Accounting Standards Codification (“ASC”) 842 Leases (“ASC 842”) and ASC 606 Revenue from Contracts with Customers (“ASC 606”). The Company delivers radiation therapy through medical equipment leasing (“leasing”) and direct patient services (“retail”). The Company leased ten Gamma Knife systems and one PBRT system as of December 31, 2023. The leasing business operates by fee-per-use contracts or revenue sharing, where the Company shares in the revenue and operating costs of the equipment.  The Company, through GKF, also owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador, which provide radiation therapy services directly to the patient, or, retail.

 

Rental Revenue from Medical Equipment Leasing (“Leasing”)

 

The Company recognizes leasing revenue under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s lease contracts are typically for a ten-year term and are classified as either fee per use or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s lease agreement with the Company. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from third party payors, and the Company is responsible for paying operating costs of the equipment determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the years ended, December 31, 2023 and 2022, the Company recognized leasing revenue of approximately $17,772,000 and $16,655,000 under ASC 842, respectively, of which approximately $10,133,000 and $8,952,000 were for PBRT services, respectively.

 

Revenue sharing arrangements amounted to approximately 70% and 67% of total revenue for the years ended December 31, 2023 and 2022, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.  Payor mix is a significant variable in the Company’s estimate for revenue sharing revenues. Fluctuations in payor mix that may result in a 5% to 10% change in the estimate could increase or decrease revenues as of December 31, 2023, by approximately $113,000 to $226,000.  

 

Direct Patient Services Revenue (“Retail”)

 

The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid between three and six months, following issuance of invoice. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts.  Accounts receivable under ASC 606 at December 31, 2023 was $1,626,000. Accounts receivable under ASC 606 at January 1, 2022 and December 31, 2022 was $668,000 and $1,119,000. For the years ended December 31, 2023 and 2022, the Company recognized retail revenues of approximately $3,553,000 and $3,091,000 under ASC 606, respectively.

 

Equipment Sales

 

During the year-ended December 31, 2023, the Company completed a sale of equipment to a new customer.  The Company assessed this transaction under ASC 606 and concluded the Company acted as the agent in this transaction and provided, at a point in time, two performance obligations, in the form of an equipment sale of an Icon and Cobalt-60 reload.  The performance obligation to sell, assign, transfer and deliver the equipment to the customer was carried out via Elekta.  Revenue related to the equipment sale is recognized on a net basis when the sale is complete.  The Company recognized net revenue of $200,000 on the sale of equipment for the year-ended December 31, 2023.

 

 

Salvage Value on Equipment

 

Salvage value is based on the estimated fair value of the equipment at the end of its useful life. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. There is no active resale market of Gamma Knife or PBRT equipment, but the Company believes its salvage value estimates were a reasonable assessment of the economic value of the equipment when the contract ends. There is no salvage value assigned to the two Gamma Knife units in Peru or Ecuador.  The Company has not assigned salvage value to its PBRT equipment.  

 

As of April 1, 2021, the Company reduced its estimate for salvage value for nine of its domestic Gamma Knife Perfexion units. As of October 1, 2022, the Company further reduced its estimate for salvage value for one of its domestic Gamma Knife Perfexion units. See Note 3 - Property and Equipment to the consolidated financial statements for further discussion on salvage value.  As of December 31, 2023, the Company had seven domestic Gamma Knife units with salvage value ranging from $140,000 to $300,000. A further change in estimate for salvage value could have an impact on future earnings of the Company.  For example, if the Company determined the salvage value of the existing seven domestic Gamma Knife units should be $0, there could be an annual increase to depreciation expense of approximately $676,000.    

 

Accounting pronouncements issued and not yet adopted - In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses.  The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-07 to determine the impact it may have on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign.  ASU 2023-09 is effective for annual periods beginning after December 31, 2024.  The Company is currently evaluating ASU 2023-09 to determine the impact it may have on its consolidated financial statements. 

 

2023 Results

 

For each of the years ended December 31, 2023 and 2022, 84% and 16% of the Company’s revenue was derived from the leasing segment versus the retail segment, respectively.  For the year ended December 31, 2023, 51% of the Company’s revenue was derived from its Gamma Knife business, 48% was derived from its PBRT business and 1% was derived from equipment sales. For the year ended December 31, 2022, 55% of the Company’s revenue was derived from its Gamma Knife business and 45% was derived from its PBRT business.

 

TOTAL REVENUE

 

           

Increase

         

(in thousands)

 

2023

   

(Decrease)

   

2022

 

Total revenue

  $ 21,325       8.0 %   $ 19,746  

 

Total revenue in 2023 increased 8.0% compared to 2022 primarily due to an increase in PBRT revenues and equipment sales during the current year.  Revenues from the Company’s leasing segment increased $1,117,000 in 2023 compared to 2022 due to an increase in PBRT volumes and PBRT average reimbursement, offset slightly by lower Gamma Knife revenues.  Revenues from the Company’s retail segment increased by $462,000 in 2023 compared to 2022 primarily due to an increase in volume.  

 

Gamma Knife Revenue

           

Increase

         
   

2023

   

(Decrease)

   

2022

 

Revenue from Gamma Knife (in thousands)

  $ 10,992       1.8 %   $ 10,794  

Number of Gamma Knife procedures

    1,195       (7.1 )%     1,286  

Average revenue per procedure

  $ 9,198       9.6 %   $ 8,393  

 

Gamma Knife revenue for 2023 was $10,992,000 compared to $10,794,000 in 2022. Gamma Knife revenue for 2023 increased $198,000 compared to 2022 due to an increase in average reimbursement, offset by lower procedure volume. 

 

The number of Gamma Knife procedures performed in 2023 decreased by 91 compared to 2022 primarily due to the expiration of two contracts in the second and third quarters of 2023. Excluding the two Gamma Knife contracts that expired, Gamma Knife procedures for existing sites increased 1% in 2023 compared to the prior year. The increase in Gamma Knife procedures for existing customer sites was driven by a 12% increase in the Company’s retail segment, partially offset by a 4% decrease in the Company’s Gamma Knife leasing segment in 2023 compared to 2022, respectively.  The increase in Gamma Knife volumes from retail sites was due to improved marketing and physician outreach at the Company’s international locations, partially offset by downtime due to upgrade the Gamma Knife equipment in Ecuador to the Icon.  

 

Revenue per procedure increased by $805 in 2023 compared to 2022. This increase was due to higher reimbursement at the Company’s retail sites, driven by several large reimbursements from commercial payors at a few of the customer sites.

 

Proton Therapy Revenue

           

Increase

         
   

2023

   

(Decrease)

   

2022

 

Revenue from PBRT (in thousands)

  $ 10,133       13.2 %   $ 8,952  

Number of PBRT fractions

    5,369       1.4 %     5,296  

Average revenue per fraction

  $ 1,887       11.7 %   $ 1,690  

 

 

PBRT revenue for 2023 was $10,133,000 compared to $8,952,000 in 2022. The number of PBRT fractions performed in 2023 was 5,369 compared to 5,296 in 2022. Revenue per fraction in 2023 was $1,887 compared to $1,690 in 2022. The increase in PBRT volume was due to the higher utilization of the equipment by the customer. The average reimbursement increased due to a shift in payor mix from Medicare to commercial or other payors, which are reimbursed at a higher amount.

 

COSTS OF REVENUE

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 

Total costs of revenue

  $ 11,981       5.4 %   $ 11,364  

Percentage of total revenue

    56.2 %             57.6 %

 

The Company’s costs of revenue, consisting of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s revenue sharing and international sites) increased by $617,000 in 2023 compared to 2022.

 

Maintenance and supplies and other direct operating costs, related party, as a percentage of total revenue were 13.5% and 15.1% in 2023 and 2022, respectively. Maintenance and supplies and other direct operating costs, related party decreased by $89,000 in 2023 compared to 2022. The decrease in 2023 compared to 2022was primarily due to maintenance for one of the Company’s Gamma Knife contracts that expired in June 2023.

 

Depreciation and amortization costs as a percentage of total revenue were 23.8% and 23.9% in 2023 and 2022. Depreciation and amortization costs increased $347,000 in 2023 compared to 2022. The increase in 2023 compared to 2022was due to a change in estimate for useful life for one of the Company’s Gamma Knife units.  As of January 1, 2023, the Company reduced its estimated useful life for one of its retail Gamma Knife units. The net effect of the change in estimate made January 1, 2023, for the year ended December 31, 2023, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.

 

Other direct operating costs as a percentage of total revenue were 18.9% and 18.6% in 2023 and 2022, respectively. Other direct operating costs increased by $359,000 in 2023 compared to 2022. The increase in 2023 was primarily due to increased volume and therefore increased operating costs from the retail segment.

 

SELLING AND ADMINISTRATIVE EXPENSE

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 
                         

Selling and administrative expense

  $ 7,022       36.5 %   $ 5,145  

Percentage of total revenue

    32.9 %             26.1 %

 

The Company’s selling and administrative costs increased $1,877,000 in 2023 compared to 2022. The increase in 2023 was due to increased staffing in the sales, finance and customer retention areas and approximately $919,000 in fees associated with new business opportunities, including the Company’s pending RI Acquisition.

 

INTEREST EXPENSE

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 
                         

Interest expense

  $ 1,112       38.0 %   $ 806  

Percentage of total revenue

    5.2 %             4.1 %

 

The Company’s interest expense increased $306,000 in 2023 compared to 2022. The debt under the Credit Agreement carries a floating interest rate of LIBOR plus 3%.  The increase for the year ended December 31, 2023 was due to an increase in LIBOR compared to the same period of the prior year.

 

 

(LOSS) ON WRITE DOWN OF IMPAIRED ASSETS AND ASSOCIATED REMOVAL COSTS

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 
                         

Loss on write down of impaired assets

  $ 940       *     $  
                         

Percentage of total revenue

    4.4 %             0.0 %

 

As of December 31, 2023 and 2022, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively.  During the year ended December 31, 2023, the Company recorded an asset removal obligation (“ARO”) for one of the customer contracts that expired during 2023.  An ARO for the second contract that expired during 2023 was recorded and impaired in a prior period. For the ARO recorded during 2023, the Company concluded the related increase to the underlying assets could not be supported by the cash flows of the equipment and therefore the Company recorded a loss on the write-down of the ARO during the three-month period ended June 30, 2023. The Company also reviewed its long-lived assets during the fourth quarter of 2023 and concluded events and circumstances existed that indicated additional impairment existed at a third Gamma Knife site related to the existing equipment. See Note 3 - Property and Equipment to the consolidated financial statements for further discussion on impairment.   

 

INTEREST AND OTHER INCOME

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 
                         

Interest and other income (loss)

  $ 422       385.1 %   $ 87  
                         

Percentage of total revenue

    2.0 %             0.4 %

 

Interest and other income increased $422,000 in 2023 compared to 2022.  The increases are primarily due to increases in the interest paid on the Company’s cash in 2023 compared to 2022.

 

INCOME TAX EXPENSE

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 
                         

Income tax expense

  $ 431       (55.2 )%   $ 963  

Percentage of total revenue

    2.0 %             4.9 %

Percentage of income, after net income attributable to non-controlling interests, and before income taxes

    41.4 %             42.0 %

 

Income tax expense decreased $532,000 in 2023 compared to 2022. The decrease in income tax expense in 2023 was due to lower earnings during 2023, and return-to-provision adjustments arising from foreign tax returns filed during 2022, as well as permanent domestic tax differences recorded in the prior year.

 

The Company anticipates that it will continue to record income tax expense if it operates profitably in the future. Currently there are state income tax payments required for most states in which the Company operates. At December 31, 2022, the Company exhausted the remainder of its net operating loss carryforward for federal income tax return purposes. The Company has net operating loss carryforwards for state income tax purposes.

 

 

NET (LOSS) INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS

 

           

Increase

         

(In thousands)

 

2023

   

(Decrease)

   

2022

 
                         

Net (loss) income attributable to non-controlling interests

  $ (345 )     (252.0 )%   $ 227  
                         

Percentage of total revenue

    (1.6 )%             1.1 %

 

Net income attributable to non-controlling interests decreased $572,000 in 2023 compared to 2022. Net income attributable to non-controlling interests represents the pre-tax income earned by the 19% non-controlling interest in GKF, and the pre-tax income or losses of the non-controlling interests in various subsidiaries controlled by GKF. The decrease or increase in net income attributable to non-controlling interests reflects the relative profitability of GKF. The decrease in 2023 compared to 2022 was due to lower pre-tax income for GKF stand-alone operations.

 

NET INCOME ATTRIBUTABLE TO AMERICAN SHARED HOSPITAL SERVICES

 

(In thousands,

         

Increase

         

except per share amounts)

 

2023

   

(Decrease)

   

2022

 
                         

Net income attributable to ASHS

  $ 610       (54.1 )%   $ 1,328  

Net income per share attributable to ASHS, diluted

  $ 0.10       (52.4 )%   $ 0.21  

 

Net income attributable to American Shared Hospital Services decreased $718,000 in 2023 compared to 2022. Net income for the Company’s retail segment decreased $49,000 in 2023 compared to 2022. The decrease in 2023 compared to 2022 was primarily due to down time for the upgrade of the equipment in Ecuador. Net income for the Company’s leasing segment decreased $669,000 in 2023 compared to 2022. The decrease in 2023 compared to 2022 was due to higher selling and administrative expense to support the Company’s pursuit of new business opportunities as well as higher interest expense, losses on the write-down of impaired equipment and associated removal costs, and the Company’s change in estimate for depreciation.

 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company’s primary liquidity needs are to fund capital expenditures as well as support working capital requirements. In general, the Company’s principal sources of liquidity are cash and cash equivalents on hand and a $7,000,000 revolving line of credit.  As of December 31, 2023, the Company borrowed $2,500,000 on its line of credit, which was paid off in January 2024. The Company had cash and cash equivalents, including restricted cash, of $13,808,000 at December 31, 2023 compared to $12,453,000 at December 31, 2022, an increase of $1,355,000. The Company’s expected primary cash needs on both a short and long-term basis are for capital expenditures, business expansion (including the payment of the purchase price in connection with the RI acquisition), working capital, and other general corporate purposes. The Company believes that its borrowing capacity under its Revolving Line and its access to capital resources are sufficient to continue funding its present operations, to meet its commitments on its existing debt, and to meet its operating capital and funding requirements for the next 12 months from the date of this Annual Report.

 

Cash Flows

 

Cash Flows Provided by Operating Activities

 

Operating activities provided $5,718,000 of cash in 2023, which was driven by net income of $265,000, non-cash charges for depreciation and amortization of $5,165,000, a loss on the write down of impaired assets of $940,000, stock-based compensation expense of $389,000, accretion of deferred issuance costs of $46,000, income taxes payable of $974,000, and changes in prepaids and other assets of $21,000. These increases were offset by net changes in Right-of-Use assets and lease liabilities of $34,000, deferred income taxes of $759,000, changes in payables and other accrued liabilities of $79,000, changes in receivables of $719,000, and changes in related party liabilities of $491,000.

 

The Company’s trade accounts receivable increased by $542,000 to $4,343,000 at December 31, 2023 from $3,801,000 at December 31, 2022. The number of days revenue (sales) outstanding (“DSO”) in accounts receivable as of December 31, 2023 was 74 days compared to 70 days at December 31, 2022. DSO fluctuates depending on timing of customer payments received and the mix of fee per use versus revenue sharing and retail customers. The revenue sharing and retail sites generally have longer collection periods than fee per use sites.

 

Cash Flows Used in Investing Activities

 

Investing activities used $6,273,000 of cash in 2023, due to payments made towards the purchase of property and equipment.  During 2023, the Company completed one Esprit upgrade and began a second Esprit upgrade at existing customer sites, and predominantly completed the installation of a LINAC at it’s new site in Puebla, Mexico.  The Company amended its Credit Agreement to include financing for the LINAC equipment in in January 2024.

 

Cash Flows Provided by (Used in) Financing Activities

 

Financing activities provided $1,910,000 of cash during 2023, which was driven by long-term debt financing from the second tranche of the DFC Loan of $1,750,000 and net borrowings on the Revolving Line of $2,500,000.  These increases were offset by payments on long-term debt of $2,129,000, debt issuance costs of $9,000 and payments on short-term financing of insurance premiums of $202,000. 

 

Working Capital

 

The Company had working capital at December 31, 2023 of $9,677,000 compared to working capital of $13,548,000 at December 31, 2022. The $3,871,000 decrease in net working capital was primarily due to a decrease in cash driven by payments for equipment that the Company financed subsequent to year-end. The Company paid substantially all of the project invoices for the Puebla equipment during 2023. On January 25, 2024, the Company amended the Credit Agreement to include financing for the LINAC equipment in Puebla totaling $2,700,000. See Note 5 - Long-Term Debt to the consolidated financial statements for more information.

 

 

The Company, in the past, has secured financing for its Gamma Knife and radiation therapy units. The Company has secured financing for its projects from several lenders and anticipates that it will be able to secure financing on future projects from these or other lending sources, but there can be no assurance that financing will continue to be available on acceptable terms.

 

Long-Term Debt

 

On April 9, 2021, the Company and certain of its domestic subsidiaries entered into a five year $22,000,000 credit agreement with Fifth Third Bank, N.A., which refinanced its existing domestic Gamma Knife portfolio.  The lease financing previously obtained by Orlando was also refinanced as long-term debt by the Credit Agreement. The Credit Agreement includes three loan facilities: (1) a $9,500,000 term loan (the “Term Loan”), which was used to refinance the domestic Gamma Knife debt and finance leases and the associated closing costs; (2) a $5,500,000 delayed draw term loan (the “DDTL”), which was used to refinance the Company’s PBRT finance leases and associated closing costs and to provide additional working capital for the Company; and (3) a $7,000,000 revolving line of credit (the “Revolving Line”), which is available for the Company’s future projects and general corporate purposes. The Company borrowed $2,500,000 under the Revolving Line as of December 31, 2023, which the Company repaid in January 2024. The Credit Agreement is 48% amortized over a 58-month period with a balloon payment upon maturity and is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The Revolving Loan, the Term Loan, and the DDTL will mature on April 9, 2026 unless accelerated due to the occurrence of certain events specified in the Credit Agreement. The Revolving Line is charged an unused line fee of 0.25% per annum. The Term Loan and DDTL have interest and principal payments due quarterly. Principal amortization on an annual basis for the Term Loan and DDTL equates to 48% of the original principal loan commitments in years one through five and an end of term payment of the remaining principal balance. 

 

On January 25, 2024, the, the Company entered into a First Amendment to Credit Agreement with Fifth Third which amended the Credit Agreement to add the Supplemental Term Loan, a new term loan in the aggregate principal amount of $2,700,000. The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and were used to finance capital expenditures that the Company paid cash for during 2023 for its operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030, unless accelerated due to the occurrence of certain events specified in the Credit Agreement. Interest on the Supplemental Term Loan is payable monthly during the initial twelve month period following the First Amendment Effective Date. Following such twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The First Amendment also replaces the LIBOR-based rates in the Credit Agreement with SOFR-based rates. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

 

As of December 31, 2023, the Company was subject to customary covenants under the Credit Agreement which included, among other covenants and obligations, a minimum fixed charge coverage ratio of 1.25 to 1.0 and a total funded debt to EBITDA ratio of 3.0 to 1.0 (tested on a trailing twelve-month basis at the end of each fiscal quarter), along with an annual clean-up covenant that requires the Company to cause the outstanding principal balance under the Revolving Loan to be less than $3,500,000 for at least 30 consecutive days during each calendar year (the “Credit Agreement Covenants”). The Company was in compliance with the Credit Agreement Covenants as of December 31, 2023.

 

The Company’s acquisition of GKCE and the Gamma Knife Esprit in Ecuador is financed with DFC. The loan entered into with DFC in June 2020 was obtained through the Company's wholly-owned subsidiary, HoldCo, and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE’s assets. The first tranche of the DFC Loan was funded in June 2020. In October 2023, the second tranche of the DFC Loan was funded in the amount of $1,750,000 to finance its equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%. The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The Company’s loan with DFC also contains customary covenants and representations, which, following the funding of the second Tranche, the Company was not in compliance with as of  December 31, 2023.  The Company obtained a waiver for the covenants for December 31, 2023. 

 

The DFC Loan contains customary covenants among other covenants and obligations, requirements that the Company maintain certain financial ratios related to liquidity and cash flow as well as depository requirements.  On March 28, 2024 the Company received a waiver and amendment from DFC for certain covenants as of December 31, 2023 and through December 31, 2024 and amended other covenants and definitions permanently. The Company expects to be in compliance with all debt covenants pursuant to the DFC Loan as amended and waived at March 31, 2024.

 

If the Company fails to comply with the Credit Agreement Covenants or the DFC Loan Covenants, the Company’s credit commitments could be terminated and the principal of any outstanding borrowings, together with any accrued but unpaid interest, under the Credit Agreement or the DFC Loan could be declared immediately due and payable. Furthermore, The lenders under the Credit Agreement and the DFC Loan could also exercise their rights to take possession of, and to dispose of, the collateral securing the credit facilities and loans and could take any additional remedies upon default as set forth in each such agreement.

 

The Company’s combined long-term debt, net, totaled $13,125,000 as of December 31, 2023. See Note 5 - Long Term Debt to the consolidated financial statements for additional information.

 

Commitments

 

As of December 31, 2023, the Company had commitments to purchase and install Gamma Knife and LINAC equipment totaling $15,925,000. There are no significant cash requirements, pending financing, for these commitments in the next 12 months. There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company.  However, the Company currently has cash on hand of $13,808,000 and a line of credit of $7,000,000 to fund these projects.

 

The Company also had commitments to service these various equipment commitments totaling $14,805,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from operations, cash on hand and its line of credit will be sufficient to cover these payments.  See Note 10 - Commitments and Contingencies to the consolidated financial statements for further discussion on commitments.

 

The Company’s commitments to purchase a second and third PBRT unit expired in January 2024.

 

 

Related Party Transactions

 

The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife. Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta such as equipment purchases, commitments to purchase and service equipment, and costs to de-install and maintain the equipment

 

The following summarizes related party activity for the years ended December 31, 2023 and 2022:

   

December 31,

 
   

2023

   

2022

 

Equipment purchases and de-install costs

  $ 6,918,000     $ 1,844,000  

Costs incurred to maintain equipment

    851,000       1,094,000  

Total related party transactions

  $ 7,769,000     $ 2,938,000  

 

The Company also had related party commitments to install three Esprit upgrades, one Cobalt-60 reload, purchase one MR LINAC, purchase one Gamma Plan workstation, and service the related equipment. The Company also has two commitments to de-install Gamma Knife units at existing customer sites. Total related party commitments were $18,968,000 as of December 31, 2023.

 

Related party liabilities on the consolidated balance sheets consist of the following as of December 31, 2023 and 2022:

 

   

December 31,

 
   

2023

   

2022

 

Accounts payable and other accrued liabilities

  $ 1,961,000     $ 497,000  

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined in Rule 10(f)(1) of Regulation S-K under the Exchange Act, the Company is not required to provide the information required by this item.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See the Index to Consolidated Financial Statements and Financial Statement Schedules included at page F-1 of this report.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

(a)

Evaluation of disclosure controls and procedures.

   
  Our Executive Chairman of the Board and our Chief Financial Officer, after evaluating the effectiveness of the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e)) of the Exchange Act) as of the end of the period covered by this annual report, have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.
   
(b) Managements report on internal control over financial reporting.
   
  The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control system was designed to provide reasonable assurance to its management and Board of Directors regarding the preparation and fair presentation of published financial statements.
   
  All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.
   
  Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control – Integrated Framework (2013). Based on this assessment management believes that, as of December 31, 2023, the Company’s internal control over financial reporting is effective based on those criteria.

 

 

(c)

Changes in internal controls over financial reporting.

   
  Our Executive Chairman of the Board and our Chief Financial Officer have evaluated the changes to the Company’s internal control over financial reporting that occurred during our last fiscal quarter ended December 31, 2023, as required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15, and have concluded that there were no such changes that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

ITEM 9B. OTHER INFORMATION

 

None.

 

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Information regarding directors is incorporated herein by reference from the Company’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders (the “2024 Proxy Statement”). Information regarding executive officers of the Company, included herein under the caption “Executive Officers of the Company” in “Part I, Item 1. Business” above, is incorporated herein by reference.

 

Information concerning the identification of our standing audit committee required by this Item is incorporated by reference from the 2024 Proxy Statement.

 

Information concerning our audit committee financial experts required by this Item is incorporated by reference from the 2024 Proxy Statement.

 

Information concerning compliance with Section 16(a) of the Exchange Act required by this Item is incorporated by reference from the 2024 Proxy Statement.

 

We have adopted a Code of Ethics that is available on our website at www.ashs.com. The information on our website is not part of this report. You may also request a copy of this document free of charge by writing our Corporate Secretary.

 

ITEM 11. EXECUTIVE COMPENSATION

 

Information required by this Item is incorporated herein by reference from the 2024 Proxy Statement.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Information required by this Item is incorporated herein by reference from the 2024 Proxy Statement.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Information required by this Item is incorporated herein by reference from the 2024 Proxy Statement.

 

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required by this item is incorporated by reference to the section entitled “Ratification of the Appointment of Our Independent Registered Public Accounting Firm” in our Proxy Statement for the 2024 Annual Meeting of Stockholders.

 

Auditor Firm Id:

659

Auditor Name:

Moss Adams LLP

Auditor Location:

Seattle, WA United States

 

 

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)

Financial Statements and Schedules.

   
  The following Financial Statements and Schedules are filed with this Report:
    Report of Independent Registered Public Accounting Firm
    Audited Consolidated Financial Statements
    Consolidated Balance Sheets
    Consolidated Statements of Operations
    Consolidated Statement of Shareholders' Equity
    Consolidated Statements of Cash Flows
    Notes to Consolidated Financial Statements
    Financial Statement Schedules- no schedules are included since the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the financial statements and notes thereto.

 

 

(b)

Exhibits.

   
  The following Exhibits are filed with this Report.

 

Exhibit

     

Incorporated by reference herein

Number  

Description

 

Form

 

Exhibit

 

Date

3.1

 

Articles of Incorporation of the Company.

 

10-Q

001-08789

 

3.1

 

5/15/2017

                 

3.1a

 

Certificate of Amendment to Articles of Incorporation of the Company.

 

10-K

001-08789

 

3.1

 

3/27/2017

                 

3.2

 

By-laws of the Company, as amended to date.

 

10-Q
001-08789

 

3.2

 

8/15/2022

                 

4.1

 

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

 

10-K
001-08789

 

4.1

 

4/6/2021

                 

10.1

 

Operating Agreement for GK Financing, LLC dated as of October 17, 1995 between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

S-1

033-63721

 

10.12

 

10/26/1995

                 

10.1a

 

Amendment Agreement dated as of October 26, 1995 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

S-1/A

033-63721

 

10.13

 

3/29/1996

                 

10.1b

 

Second Amendment Agreement dated as of December 20, 1995 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

S-1/A

033-63721

 

10.13

 

3/29/1996

                 

10.1c

 

Third Amendment Agreement dated as of October 16, 1996 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.13b

 

3/31/1998

                 

10.1d

 

Amendment Four Agreement dated as of March 31, 1998 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.8

 

3/31/1999

                 

10.1e

 

Fifth Amendment Agreement dated as of March 31, 1998 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.9

 

3/31/1999

                 

10.1f

 

Sixth Amendment Agreement dated as of June 5, 1998 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.10

 

3/31/1999

                 

10.1g

 

Seventh Amendment Agreement dated as of October 18, 2006 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.52

 

4/2/2007

                 

10.1h

 

Eighth Amendment Agreement dated as of April 28, 2010 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.1h

 

3/30/2016

                 

10.1i

 

Ninth Amendment Agreement dated as of May 16, 2011 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.

 

10-K

001-08789

 

10.1i

 

3/30/2016

                 
10.1j   Tenth Amendment Agreement dated as of March 25, 2021 to the GK Financing, LLC Operating Agreement between American Shared Radiosurgery Services, Inc. and GKV Investments, Inc.  

10-K

001-08789

  10.1j   3/30/2022

 

 

10.2

 

Lease Agreement for a Gamma Knife Unit dated as of October 29, 1996 between GK Financing, LLC and Methodist Healthcare Systems of San Antonio, Ltd., dba Southwest Texas Methodist Hospital.

 

10-K

001-08789

 

10.2

 

3/30/2016

                 

10.2a

 

Addendum to Lease Agreement for a Gamma Knife Unit dated as of October 31, 1996 between GK Financing, LLC and Methodist Healthcare System of San Antonio, Ltd., dba Southwest Texas Methodist Hospital.  

 

10-K

001-08789

 

10.2a

 

3/30/2016

                 

10.2b

 

Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of October 16, 1997 between Methodist Healthcare System of San Antonio, Ltd., d.b.a. Southwest Texas Methodist Hospital and GK Financing, LLC.

 

10-K

001-08789

 

10.2b

 

3/30/2016

                 

10.2c

 

Amendment to Lease Agreement for a Gamma Knife Unit dated as of December 13, 2003 between Methodist Healthcare Systems of San Antonio, Ltd., d/b/a Southwest Texas Methodist Hospital and GK Financing, LLC.

 

10-K

001-08789

 

10.2c

 

3/30/2016

                 

10.2d

#

Second Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) dated as of December 23, 2009 between GK Financing, LLC and Methodist Healthcare Systems of San Antonio, Ltd., d/b/a Southwest Texas Methodist Hospital.  

 

10-Q

001-08789

 

10.18b

 

11/15/2010

                 
10.2e   Third Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) dated June 1, 2020 between GK Financing, LLC and Methodist Healthcare System of San Antonio, Ltd., d/b/a Southwest Texas Methodist Hospital  

10-Q

001-08789

  10.4   5/12/2023
                 
10.2f * Fourth Amendment to Lease Agreement for a Gamma Knife Unit (Esprit Upgrade) dated July 28, 2023 between GK Financing, LLC and Methodist Healthcare System of San Antonio, Ltd., L.L.P. (f/k/a Methodist Healthcare System of San Antonio, Ltd.) d/b/a Southwest Texas Methodist Hospital.  

 

       
                 

10.4

 

Purchased Services Agreement (for a Gamma Knife Unit) dated as of November 19, 2008 between GK Financing, LLC and Kettering Medical Center.

 

10-Q

001-08789

 

10.1

 

8/11/2016

                 

10.4a

 

First Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of June 11, 2009 between GK Financing, LLC and Kettering Medical Center.  

 

10-Q

001-08789

 

10.1a

 

8/11/2016

                 

10.4b

#

Second Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of February 27, 2014 between GK Financing, LLC and Kettering Medical Center.

 

10-K

001-08789

 

10.21c

 

4/1/2015

                 

10.4c

#

Third Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of March 28, 2019 between GK Financing, LLC and Kettering Medical Center

 

10-Q
001-08789

 

10.1

 

11/7/2019

                 
10.4d # Fourth Amendment to Purchased Services Agreement dated April 20, 2021 between GK Financing, LLC and Kettering Medical Center.   10-Q
001-08789
  10.1   8/14/2023
                 
10.4e   Fifth Amendment to Purchased Services Agreement dated May 1, 2023 between GK Financing, LLC and Kettering Medical Center.   10-Q
001-08789
  10.2   8/14/2023
                 

10.10

 

Lease Agreement for a Gamma Knife Unit dated as of November 1, 1999 between GK Financing, LLC and Jackson HMA, Inc. d/b/a Central Mississippi Medical Center.  

 

10-K

001-08789

 

10.10

 

3/30/2016

                 

10.10a

 

Addendum to Lease Agreement for a Gamma Knife Unit dated as of November 1, 1999 between Jackson HMA, Inc. dba Central Mississippi Medical Center and GK Financing, LLC.

 

10-Q

001-08789

 

10.34

 

8/10/2001

                 

10.10b

#

Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of November 6, 2006 between GK Financing, LLC and Jackson HMA, Inc. d/b/a Central Mississippi Medical Center.

 

10-K

001-08789

 

10.51

 

4/2/2007

 

 

10.10c

 

Amendment Three to Lease Agreement for a Gamma Knife Unit dated as of February 23, 2010 between GK Financing, LLC and Jackson HMA, LLC d/b/a Central Mississippi Medical Center.

 

10-K

001-08789

 

10.10c

 

3/30/2016

                 

10.10d

 

Amendment Four to Lease Agreement for a Gamma Knife Unit dated as of May 1, 2019 between GK Financing, LLC and Jackson HMA, LLC d/b/a Central Mississippi Medical Center.

 

10-Q

001-08789

 

10.1

 

5/11/2020

                 

10.11

 

Lease Agreement for a Gamma Knife Unit dated as of February 18, 2000 between GK Financing, LLC and OSF HealthCare System.

 

10-K

001-08789

 

10.11

 

3/30/2016

                 

10.11a

 

Addendum to Lease Agreement for a Gamma Knife Unit dated as of April 13, 2007, between GK Financing, LLC and OSF Healthcare System.

 

10-Q

001-08789

 

10.2

 

8/11/2016

                 

10.11b

 

Addendum Two to Lease Agreement for a Gamma Knife Unit dated as of October 31, 2012 between GK Financing, LLC and OSF Healthcare System.

 

10-Q

001-08789

 

10.2a

 

8/11/2016

                 

10.11c

#

Addendum Three to Lease Agreement for a Gamma Knife Unit dated as of June 7, 2016 between GK Financing, LLC and OSF Healthcare System.

 

10-Q

001-08789

 

10.2b

 

8/11/2016

                 

10.11d

 

Addendum Four to Lease Agreement for a Gamma Knife Unit dated as of February 6, 2020 between GK Financing, LLC and OSF Healthcare System.

 

10-K
001-08789

 

10.11d

 

4/6/2021

                 
10.11e # Addendum Five to Lease Agreement for a Gamma Knife Unit dated as of  April 28, 2021 between GK Financing, LLC and OSF Healthcare System.   10-K
001-08789
  10.11e   3/30/2022
                 

10.13

 

Equipment Lease Agreement (for a Gamma Knife Unit) dated as of February 13, 2003 between GK Financing, LLC and AHS Albuquerque Regional Medical Center, LLC.

 

10-K

001-08789

 

10.13

 

3/30/2016

                 

10.13a

#

Amendment to Equipment Lease Agreement (Perfexion Upgrade) dated as of April 8, 2011 between GK Financing, LLC and Lovelace Health System, Inc., d/b/a Lovelace Medical Center.  

 

10-Q

001-08789

 

10.62

 

8/15/2011

                 

10.13b

 

Assignment and Assumption of Purchase and License Agreement dated as of February 2, 2011 between Elekta, Inc., GK Financing, LLC and Albuquerque GK Equipment, LLC.

 

10-Q

001-08789

 

10.62a

 

8/15/2011

                 

10.13c

#

Icon Upgrade and Amendment Two to Equipment Lease Agreement for a Gamma Knife Unit dated as of October 15, 2019 between GK Financing, LLC and Lovelace Health System, Inc., d/b/a Lovelace Medical Center.  

 

10-Q

001-08789

 

10.1

 

11/13/2020

                 
10.13d * Amendment Three to Equipment Lease Agreement dated as of November 9, 2023 between GK Financing, LLC and Lovelace Health System, LLC d/b/a Lovelace Medical Center.            
                 

10.14

 

Equipment Lease Agreement (for a Gamma Knife Unit) dated as of March 21, 2003 between GK Financing, LLC and Northern Westchester Hospital Center.

 

10-K

001-08789

 

10.14

 

3/30/2016

                 

10.14a

#

Amendment to Equipment Lease Agreement (Perfexion Upgrade) dated as of June 8, 2012 between GK Financing, LLC and Northern Westchester Hospital Center.

 

10-Q

001-08789

 

10.46a

 

8/14/2013

                 
10.14b # Amendment Two to Equipment Lease Agreement (Reload) dated as of October 7, 2020 between GK Financing, LLC and Northern Westchester Hospital Association.  

10-Q

001-08789

  10.1   5/13/2021
                 

10.16

#

Purchased Services Agreement (for a Gamma Knife Unit) dated as of March 5, 2008 between GK Financing, LLC and USC University Hospital, Inc.

 

10-Q

001-08789

 

10.57

 

5/14/2008

                 

10.16a

#

First Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of April 1, 2009 between GK Financing, LLC and University of Southern California.

 

10-Q

001-08789

 

10.57a

 

8/14/2009

                 

10.16b

#

Second Amendment to Purchased Services Agreement (for a Gamma Knife Unit) dated as of October 1, 2013 between GK Financing, LLC and University of Southern California.

 

10-Q

001-08789

 

10.57b

 

8/14/2014

 

 

10.16c

 

Third Amendment to Purchased Services Agreement dated as June 30, 2020 between GK Financing, LLC and University of Southern California.

 

10-Q

001-08789

 

10.2

 

11/13/2020

                 
10.16d   Fourth Amendment to Purchased Services Agreement dated as of July 28, 2021 between GK Financing, LLC and University of Southern California.  

10-Q

001-08789

  10.1   11/10/2021
                 

10.18

#

Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of August 5, 2011 between Jacksonville GK Equipment, LLC and St. Vincent’s Medical Center, Inc.

 

10-K

001-08789

 

10.63

 

3/30/2012

                 

10.18a

#

First Amendment to the Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of October 10, 2011 between Jacksonville GK Equipment, LLC and St. Vincent’s Medical Center, Inc.

 

10-K

001-08789

 

10.63a

 

3/30/2012

                 

10.19

#

Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of January 19, 2012 between GK Financing, LLC and Sacred Heart Health System, Inc.

 

10-Q

001-08789

 

10.65

 

5/15/2013

                 

10.20

#

Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of March 27, 2014 between GK Financing, LLC and PeaceHealth doing business through its operating division PeaceHealth Sacred Heart Medical Center at RiverBend.

 

10-K

001-08789

 

10.67

 

4/1/2015

                 
10.20a   Amendment One to Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of March 27, 2014 between GKF Financing, LLC and PeaceHealth Sacred Heart Medical Center at Riverbend.  

10-Q

001-08789

  10.2   5/13/2021
                 
10.20b * Amendment Two to Leksell Gamma Knife Perfexion Purchased Services Agreement dated as of January 19, 2024 between GKF Financing, LLC and PeaceHealth Sacred Heart Medical Center at RiverBend,            
                 

10.21

#

Equipment Lease Agreement (for a Gamma Knife Unit) dated as of February 21, 2017 between Bryan Medical Center, and GK Financing, LLC.

 

10-Q

001-08789

 

10.1

 

11/13/2017

                 

10.21a

#

First Amendment to Equipment Lease Agreement (for a Gamma Knife unit) dated as of February 14, 2018 between Bryan Medical Center and GK Financing, LLC

 

10-Q

001-08789

 

10.1

 

5/10/2018

                 

10.22

#

Proton Beam Radiation Therapy Lease Agreement dated as of October 18, 2006 between American Shared Hospital Services and Orlando Regional Healthcare System, Inc.

 

10-Q

001-08789

 

10.3

 

8/11/2016

                 

10.22a

#

Amendment One to Proton Beam Radiation Therapy Lease Agreement dated as of August 12, 2012 between American Shared Hospital Services and Orlando Health, Inc., formerly known as Orlando Regional Healthcare System, Inc.

 

10-Q

001-08789

 

10.3a

 

8/11/2016

                 

10.23a

#

Equipment Lease Agreement (for a Gamma Knife Unit) dated as of May 8, 2018 between The Methodist Hospitals, Inc. and GK Financing, LLC

 

10-Q
001-08789

 

10.1

 

5/13/2019

                 
10.23b * First Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion on site upgrade to Elekta Esprit) dated as of April 18, 2023 between The Methodist Hospitals, Inc. and GK Financing, LLC.            
                 
10.23c * Second Amendment to Lease Agreement for a Gamma Knife Unit (Cobalt-60 Reload) dated as of June 13, 2023 between The Methodist Hospitals, Inc. and GK Financing, LLC.            
                 

10.24

American Shared Hospital Services Incentive Compensation Plan as Amended and Restated effective June 25, 2021

  8-K 001-08789  

10.1

 

7/1/2021

                 

10.25

Form of Indemnification Agreement between American Shared Hospital Services and members of its Board of Directors.

 

10-K

001-08789

 

10.26

 

3/30/2016

                 

10.26

Form of American Shared Hospital Services Incentive Compensation Plan Performance Share Award Agreement.

 

10-K

001-08789

 

10.25

 

3/27/2017

                 
10.27 Form of American Shared Hospital Services Incentive Compensation Plan Restricted Stock Unit Issuance Agreement.   10-Q
001-08789
  10.2   5/12/2023
                 
10.28 Form of American Shared Hospital Services Incentive Compensation Plan Notice of Grant of Incentive Stock Option.   10-Q
001-08789
  10.3   5/12/2023
                 

10.29

Offer Letter between the Company and Mr. Raymond C. Stachowiak dated April 22, 2020

 

8-K

001-08789

 

99.1

 

4/22/2020

                 
10.30 Offer Letter between the Company and Peter Gaccione dated August 26, 2022.  

8-K

001-08789

  10.1   9/1/2022
                 
10.31 Offer Letter between the Company and Robert Hiatt dated April 12, 2023.  

8-K

001-08789

  10.1   4/18/2023
                 
10.32a   Credit Agreement dated as of April 9, 2021 among the Company, PBRT Orlando, LLC and GK Financing, LLC as the initial co-Borrowers, and American Shared Radiosurgery Services as the initial additional Loan Party and Fifth Third Bank, National Association, as Lender.  

8-K

001-08789

  10.1   4/15/2021
                 
10.32b   First Amendment to Credit Agreement dated as of January 25, 2024 among the Company, PBRT Orlando, LLC and GK Financing, LLC as the Borrowers, American Shared Radiosurgery Services as a Loan Party and Fifth Third Bank, National Association, as Lender.  

8-K

001-08789

  10.1   1/31/2024
                 
10.33a   Investment Agreement dated as of November 10, 2023 between GenesisCare USA, Inc., GenesisCare USA Holdings, Inc., and the Company.  

8-K

001-08789

  10.1   11/16/2023
                 
10.33b * First Amendment to Investment Agreement dated as of March 1, 2024 between the Company, GenesisCare USA, Inc., and GenesisCare USA Holdings, Inc.            
                 

21.1

*

Subsidiaries of the Company

           
                 

23.1

*

Consent of Independent Registered Public Accounting Firm

           

 

 

31.1

*

Certification of Principal Executive Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

           
                 

31.2

*

Certification of Principal Financial Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

           
                 

32.1

ǂ

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

           
                 
97 * American Shared Hospital Services Compensation Recoupment Policy, effective October 2, 2023.            
                 

101.INS

*

Inline XBRL Instance Document

           

101.SCH

*

Inline XBRL Taxonomy Extension Schema Document

           

101.CAL

*

Inline XBRL Taxonomy Calculation Linkbase Document

           

101.DEF

*

Inline XBRL Taxonomy Definition Linkbase Document

           

101.LAB

*

Inline XBRL Taxonomy Label Linkbase Document

           

101.PRE

*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

           

104

*

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline Instance XBRL contained in Exhibit 101            
                 
 

*

Filed herewith.

           
 

ǂ

Furnished herewith.

           
 

#

As permitted by Regulation S-K, Item 601(b)(10)(iv) of the Securities Exchange Act of 1934, as amended, certain confidential portions of this exhibit have been redacted from the publicly filed document. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request. Omitted information has been replaced with asterisks.

 

Indicates management compensatory plan, contract, or arrangement.

 

ITEM 16. FORM 10-K SUMMARY

 

The optional summary in Item 16 has not been included in this Form 10-K.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

AMERICAN SHARED HOSPITAL SERVICES

 

(Registrant)

     

April 1, 2024

By:

/s/ Raymond C. Stachowiak

   

Raymond C. Stachowiak

   

Executive Chairman of the Board

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

         

/s/ Raymond C. Stachowiak

 

Executive Chairman of the Board (principal executive officer)

 

April 1, 2024

Raymond C. Stachowiak

       
         

/s/ Daniel G. Kelly Jr.

 

Director

 

April 1, 2024

Daniel G. Kelly JR.

       
         

/s/ Kathleen Miles

 

Director

 

April 1, 2024

Kathleen Miles

       
         

/s/ Vicki L. Wilson

 

Director

 

April 1, 2024

Vicki L. Wilson

       
         

/s/ Robert L. Hiatt

 

Chief Financial Officer

 

April 1, 2024

Robert L. Hiatt

  (principal financial officer and principal accounting officer)    

 

 

AMERICAN SHARED HOSPITAL SERVICES

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

and

CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF December 31, 2023 and 2022,

and

FOR THE YEARS THEN ENDED

   

CONTENTS

 
   
 

PAGE

   

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

F- 1

   

CONSOLIDATED FINANCIAL STATEMENTS

 

Balance sheets

F- 2

Statements of operations

F- 3

Statement of shareholders’ equity

F- 4

Statements of cash flows

F- 5

Notes to financial statements

F- 7

 

 
 

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and the Board of Directors of

American Shared Hospital Services, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of American Shared Hospital Services, Inc. (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations, shareholders’ equity and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.

 

Rental Revenue from Medical Equipment Leasing  Estimates of Reimbursement Rates 

 

As described in Note 2 in the Company’s consolidated financial statements, the Company has rental revenue from medical equipment leasing on either a fee per use or revenue sharing basis that are recognized under Accounting Standards Codification 842, Leases. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. Under fee per use arrangements, the Company receives payment from the hospital as determined by each hospital’s lease agreement with the Company.

 

We identified management’s estimates of reimbursement rates to record rental revenue from medical equipment leasing and related accounts receivable, as a critical audit matter.  Rental revenue from medical equipment leasing and related accounts receivable involves significant judgment and estimation, including measurement uncertainty, by management based on the estimates and assumptions used and are subject to adjustments based on actual reimbursements received by the Company. In turn, auditing management’s judgments and estimates related to rental revenue from medical equipment leasing and related accounts receivable involved a high degree of subjectivity, as they are based on estimates of reimbursement rates.

 

The primary procedures we performed to address this critical audit matter included:

 

 

Obtaining management’s reconciliation of rental revenue from medical equipment leasing and accounts receivable by site and agreeing management’s reconciliation to supporting documentation related to the estimated reimbursement rates used in the calculation.

 

 

Testing the completeness, accuracy, and relevance of the underlying data of the system-generated reports used by management.

 

 

Obtaining third party confirmations, confirming the number of procedures, payment dates and amounts paid, and reconciling confirmed amounts to management’s reconciliation, to validate the approximate rate per procedure.

 

 

Testing subsequent cash receipts and evaluating the reasonableness of management’s estimates through a look-back analysis over rental revenue from medical equipment leasing as compared to accounts receivable balances previously recognized.

 

 

Developing an independent expectation of reimbursement rates per procedure based on historical trends, procedures, and payment amounts received through confirmation directly with the hospital and comparing to management’s estimates.

 

/s/ Moss Adams LLP

 

San Francisco, California

April 1, 2024

 

We have served as the Company’s auditor since 2000.

 

  

 

AMERICAN SHARED HOSPITAL SERVICES

CONSOLIDATED BALANCE SHEETS

 

  

December 31,

 
  

2023

  

2022

 

ASSETS

        

CURRENT ASSETS

        

Cash and cash equivalents

 $13,690,000  $12,335,000 

Restricted cash

  118,000   118,000 

Accounts receivable, net of allowance for credit losses of $100,000 At December 31, 2023 and December 31, 2022

  4,343,000   3,801,000 

Other receivables

  504,000   327,000 

Prepaid maintenance

  1,275,000   1,245,000 

Prepaid expenses and other current assets

  526,000   897,000 
         

Total current assets

  20,456,000   18,723,000 
         

PROPERTY AND EQUIPMENT, net

  25,844,000   23,467,000 

LAND

  19,000   19,000 

GOODWILL

  1,265,000   1,265,000 

INTANGIBLE ASSETS

  78,000   78,000 

RIGHT OF USE ASSETS, net

  57,000   317,000 

OTHER ASSETS

  443,000   87,000 

TOTAL ASSETS

 $48,162,000  $43,956,000 

LIABILITIES AND SHAREHOLDERS’ EQUITY

        

CURRENT LIABILITIES

        

Accounts payable

 $315,000  $230,000 

Employee compensation and benefits

  757,000   735,000 

Other accrued liabilities

  1,226,000   1,544,000 

Related party liabilities

  1,961,000   497,000 

Asset retirement obligations, related party (includes $250,000 and $120,000 non-related party at December 31, 2023 and 2022, respectively)

  650,000   360,000 

Income taxes payable

  1,229,000   255,000 

Current portion of lease liabilities

  57,000   292,000 

Line of credit

  2,500,000    

Current portion of long-term debt, net

  2,084,000   1,262,000 
         

Total current liabilities

  10,779,000   5,175,000 
         

LONG-TERM LEASE LIABILITIES, less current portion

     59,000 

LONG-TERM DEBT, net, less current portion

  11,041,000   12,205,000 

DEFERRED REVENUE, less current portion

     70,000 

DEFERRED INCOME TAXES

  63,000   822,000 
         

TOTAL LIABILITIES

  21,883,000   18,331,000 

COMMITMENTS AND CONTINGENCIES (See Note 10)

          

SHAREHOLDERS’ EQUITY

        

Common stock

        

Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares – 6,300,000 at December 31, 2023 and 6,184,000 at December 31, 2022

  10,763,000   10,763,000 

Additional paid-in capital

  8,232,000   7,843,000 

Retained earnings

  3,629,000   3,019,000 

Total equity- American Shared Hospital Services

  22,624,000   21,625,000 

Non-controlling interests in subsidiaries

  3,655,000   4,000,000 

Total shareholders’ equity

  26,279,000   25,625,000 
         

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

 $48,162,000  $43,956,000 

 

See accompanying notes

 

 

 

AMERICAN SHARED HOSPITAL SERVICES

CONSOLIDATED STATEMENTS OF OPERATIONS

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 
         

Revenues:

        

Rental revenue from medical equipment leasing

 $17,772,000  $16,655,000 

Direct patient services revenue

  3,353,000   3,091,000 

Equipment sales, net

  200,000    
   21,325,000   19,746,000 

Costs of revenue:

        

Maintenance and supplies

  2,032,000   1,878,000 

Depreciation and amortization

  5,073,000   4,726,000 

Other direct operating costs

  4,025,000   3,666,000 

Other direct operating costs, related party

  851,000   1,094,000 
   11,981,000   11,364,000 

Gross margin

  9,344,000   8,382,000 
         

Selling and administrative expense

  7,022,000   5,145,000 

Interest expense

  1,112,000   806,000 

Loss on write down of impaired assets and associated removal costs

  940,000    
         

Operating income

  270,000   2,431,000 
         

Interest and other income, net

  426,000   87,000 

Income before income taxes

  696,000   2,518,000 

Income tax expense

  431,000   963,000 
         

Net income

  265,000   1,555,000 
         

Less (plus): net loss (income) attributable to non-controlling interests

  345,000   (227,000)

Net income attributable to American Shared Hospital Services

 $610,000  $1,328,000 
         

Net income per share attributable to American Shared Hospital Services:

        

Earnings per common share - basic

 $0.10  $0.21 

Earnings per common share - diluted

 $0.10  $0.21 
         

Weighted average common shares for basic earnings per share

  6,358,000   6,297,000 

Weighted average common shares for diluted earnings per share

  6,393,000   6,303,000 

 

See accompanying notes

 

 

 

AMERICAN SHARED HOSPITAL SERVICES

CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY

 

  

YEARS ENDED December 31, 2023 and 2022

 
  

Common Shares

  

Common Stock

  

Additional Paid-in Capital

  

Retained Earnings

  

Sub-Total ASHS

  

Non-controlling Interests in Subsidiaries

  

Total

 

Balances at December 31, 2021

  6,049,000  $10,758,000  $7,444,000  $1,691,000  $19,893,000  $4,346,000  $24,239,000 

Stock-based compensation expense

        399,000      399,000      399,000 

Options exercised

  3,000   5,000         5,000      5,000 

Vested restricted stock awards

  132,000                    

Cash distributions to non-controlling interests

                 (573,000)  (573,000)

Net income

           1,328,000   1,328,000   227,000   1,555,000 

Balances at December 31, 2022

  6,184,000   10,763,000   7,843,000   3,019,000   21,625,000   4,000,000   25,625,000 

Stock-based compensation expense

        389,000      389,000      389,000 

Vested restricted stock awards

  116,000                   

Net income

           610,000   610,000   (345,000)  265,000 

Balances at December 31, 2023

  6,300,000  $10,763,000  $8,232,000  $3,629,000  $22,624,000  $3,655,000  $26,279,000 

 

See accompanying notes

 

 

 

AMERICAN SHARED HOSPITAL SERVICES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

OPERATING ACTIVITIES

        

Net income

 $265,000  $1,555,000 

Adjustments to reconcile net income to net cash from operating activities:

        

Depreciation and amortization

  5,165,000   4,783,000 

Non cash lease expense

  (34,000)  (40,000)

Accretion of deferred issuance costs

  46,000   84,000 

Loss on write down of impaired assets

  940,000    

Deferred income taxes

  (759,000)  344,000 

Stock-based compensation

  389,000   399,000 

Changes in operating assets and liabilities:

        

Receivables

  (719,000)  696,000 

Prepaid expenses and other assets

  21,000   (111,000)

Asset retirement obligations, related party

     (397,000)

Related party liabilities

  (491,000)  (845,000)

Accounts payable, accrued liabilities and deferred revenue

  (79,000)  608,000 

Income taxes payable

  974,000   159,000 

Net cash provided by operating activities

  5,718,000   7,235,000 

INVESTING ACTIVITIES

        

Payment for purchases of property and equipment

  (6,273,000)  (388,000)

Net cash (used in) investing activities

  (6,273,000)  (388,000)

FINANCING ACTIVITIES

        

Principal payments on long-term debt

  (2,129,000)  (2,032,000)

Principal payments on line of credit

  (1,400,000)   

Long-term debt financing on purchase of property and equipment

  1,750,000    

Advances on line of credit

  3,900,000    

Distributions to non-controlling interests

     (573,000)

Debt issuance costs long-term debt

  (9,000)  (9,000)

Proceeds from options exercised

     5,000 

Principal payments on short-term financing prepaid insurance

  (202,000)  (48,000)

Net cash provided by (used in) financing activities

  1,910,000   (2,657,000)

Net change in cash and cash equivalents

  1,355,000   4,190,000 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year

  12,453,000   8,263,000 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year

 $13,808,000  $12,453,000 

 

See accompanying notes

 

 

SUPPLEMENTAL CASH FLOW DISCLOSURE

        

Cash paid for interest

 $1,066,000  $722,000 

Cash paid for income taxes

 $297,000  $169,000 
         

SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES

        

Equipment included in accounts payable and accrued liabilities

 $1,955,000  $ 
         

DETAIL OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD

        

Cash and cash equivalents

 $13,690,000  $12,335,000 

Restricted cash

  118,000   118,000 

Cash, cash equivalents, and restricted cash at end of period

 $13,808,000  $12,453,000 

 

 

See accompanying notes

 

F- 6

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 BUSINESS AND BASIS OF PRESENTATION

 

Business – These consolidated financial statements include the accounts of American Shared Hospital Services (“ASHS”) and its subsidiaries (the “Company”) as follows: ASHS wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), ASHS-Mexico, S.A. de C.V. (“ASHS-Mexico”), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC, ASHS-Bristol Radiation Therapy, LLC, OR21, Inc., and MedLeader.com, Inc. (“MedLeader”); ASHS is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and HoldCo GKC S.A. (“HoldCo”). HoldCo wholly owns the subsidiary Gamma Knife Center Ecuador S.A. (“GKCE”). GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). 

 

The Company (through ASRS) and Elekta AG (“Elekta”), the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. During 2023, GKF leased Gamma Knife units to twelve medical centers in the United States in the states of California, Florida, Illinois, Indiana, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, and Texas. GKF also owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States.

 

The Company formed the subsidiary GKPeru and acquired GKCE for the purposes of expanding its business internationally; Orlando and LBE to provide PBRT equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. LBE is not expected to generate revenue within the next two years.

 

On  April 27, 2022, the Company signed a Joint Venture Agreement (the “Agreement”) with the principal owners of Radioterapia Guadalupe Amor y Bien S.A. de C.V. (“Guadalupe”) to establish AB Radiocirugia y Radioterapia de Puebla, S.A.P.I. de C.V. of Puebla (“Puebla”) to treat public- and private-paying cancer patients and provide radiation therapy and radiosurgery services locally in Mexico. The Company and Guadalupe hold 85% and 15% ownership interests, respectively, in Puebla. Under the Agreement, the Company is responsible for providing a linear accelerator and Guadalupe will be accountable for all site modification costs.  The Company formed ASHS-Mexico on October 3, 2022 to establish Puebla.  Puebla was formed on December 15, 2022 and the Company expects Puebla to begin treating patients in June 2024.  Operating costs incurred during the year ended  December 31, 2023 by Puebla, are included in the consolidated statement of operations.

 

The Company continues to develop its design and business model for The Operating Room for the 21st CenturySM through its 50% owned OR21, LLC (“OR21”). The remaining 50% of OR21 is owned by an architectural design company. OR21 is not expected to generate significant revenue within the next two years.

 

MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time.

 

On November 10, 2023, the Company entered into an Investment Purchase Agreement (the “IPA”) with GenesisCare USA, Inc. (the “GenesisCare”) and GenesisCare USA Holdings, Inc. (“GC Holdings”), pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, (collectively, the “RI Target Companies”) together with the assignment of certain payor contacts for a purchase price of $2,850,000 (such transaction, the “RI Acquisition”).  The equity interests to be acquired by the Company under the IPA equates to a 60% interest in each RI Target Company. The RI Target Companies operate three functional radiation therapy cancer centers in Rhode Island. The RI Acquisition is contingent upon certain closing conditions, including GenesisCare and the Company entering into a consent agreement with the Rhode Island Department of Health and approval of all equity holders and managers of each RI Target Company. On March 1, 2024, the Company, GenesisCare and GC Holding entered into a First Amendment to the Investment Agreement pursuant to which the parties agreed to extend the date on which a party could terminate the IPA if the closing conditions had not been met from March 10, 2024 to April 30, 2024. The Company anticipates that these conditions will be met in April 2024.

 

The transaction will be accounted for as a business combination under ASC 805 Business Combinations, which requires, among other things, that purchase consideration, assets acquired, and liabilities assumed be measured at their fair values as of the acquisition date. The initial purchase allocation for the business combination is incomplete at this time, subject to finalizing the IPA. After closing, disclosures regarding amounts recognized for major classes of assets acquired and liabilities assumed will be provided once the initial accounting is completed. 

 

Costs related to legal, financial and due diligence services performed in connection with this transaction recorded in the consolidated statement of operations were $432,000 for the year ended  December 31, 2023.

 

All intercompany accounts and transactions have been eliminated in consolidation.

 

 

NOTE 2 ACCOUNTING POLICIES

 

Use of estimates in the preparation of financial statements – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the estimated useful lives of property and equipment and its salvage values, revenues and costs of sales for revenue sharing customers.  Actual results could differ from those estimates.

 

Advertising and marketing – The Company expenses advertising and marketing costs as incurred (collectively, marketing costs”). Marketing costs were $165,000 and $233,000 during the years ended December 31, 2023 and 2022, respectively. Marketing costs include joint marketing with customers and corporate advertising costs. Marketing costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of income. 

 

Sales and Service – The Company markets its financial and turn-key solutions directly to cancer treatment centers, hospitals, and large cancer networks worldwide through its sales staff.  Sales expense includes payroll and travel costs for the Company’s sales staff. The Company also typically provides the equipment, as well as planning, installation, reimbursement and marketing support services to its customers.

 

Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.

 

F- 7

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement and the minimum cash that must be maintained by GKF per it’s financing agreement with the United States International Development Finance Corporation (“DFC”).  See further discussion at Note 5 - Long Term Debt.

 

Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. The Company monitors the financial condition of the financial institutions it uses on a regular basis.

 

All of the Company’s revenue was provided by 15 locations or 1 PBRT unit and 14 Gamma Knife units in each of 2023 and 2022. One location accounted for approximately 48% and 45% of the Company’s total revenue in 2023 and 2022, respectively. At December 31, 2023two locations each individually accounted for 30% and 31% of total accounts receivable, respectively. At December 31, 2022, four locations each individually accounted for 12%, 14%, 16% and 22% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.

 

All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.

 

Accounts receivable and allowance for credit losses – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for expected losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are offset against bad debt expense when received.

 

Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. Non-controlling interest is determined by the income (loss) multiplied by the non-controlling interest in subsidiaries, and the income or losses of the non-controlling interests in various subsidiaries controlled by GKF.  The Company also presents the consolidated net income and the portion of the consolidated net income (loss) allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations.

 

Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 310 years, and after accounting for salvage value on the equipment where applicable. The Company acquired a building as part of the acquisition of GKCE in June 2020. Depreciation for buildings is determined using the straight-line method over 20 years. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. As of October 1, 2022, the Company reduced its estimate for salvage value for one of its domestic Gamma Knife Perfexion units. As of December 31, 2023 and 2022, the Company had seven domestic Gamma Knife units with salvage value ranging from $140,000 to $300,000

 

As of January 1, 2023, the Company reduced its estimated useful life for one of its direct patient services Gamma Knife units. The net effect of the change in estimate made January 1, 2023, for the year ended  December 31, 2023, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.

 

Depreciation for PBRT and related equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.

 

The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements accounted for as operating leases. At December 31, 2023, the Company held equipment under operating lease contracts with customers with an original cost of $70,635,000 and accumulated depreciation of $52,302,000. At December 31, 2022, the Company held equipment under operating lease contracts with customers with an original cost of $69,306,000 and accumulated depreciation of $47,992,000

 

As of December 31, 2023 and 2022, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. During the year ended December 31, 2023, the Company recorded an asset removal obligation (“ARO”) for one of the customer contracts that expired during 2023.  An ARO for the second contract that expired during 2023 was recorded and impaired in a prior period. For the ARO recorded during 2023, the Company concluded the related increase to the underlying assets could not be supported by the cash flows of the equipment and therefore the Company recorded a loss on the write-down of the ARO in June 2023. The Company’s estimate for the ARO liability was subsequently adjusted during the fourth quarter of 2023 based on new information. Total ARO impairment for the year ended  December 31, 2023 was $290,000. The Company also reviewed its long-lived assets during the fourth quarter of 2023 and concluded events and circumstances existed that indicated additional impairment existed at a third Gamma Knife site related to the existing equipment.  Total equipment impairment for the year ended  December 31, 2023 was $650,000See further discussion under Note 2 - Long-lived asset impairment and Note 3 - Property and Equipment.

 

F- 8

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 ACCOUNTING POLICIES (CONTINUED)

 

Revenue recognition - The Company recognizes revenues under ASC 842 Leases (“ASC 842”) and ASC 606 Revenue from Contracts with Customers (“ASC 606”).

 

Rental income from medical equipment leasing (leasing) – The Company recognizes leasing revenue under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s lease contracts are typically for a ten-year term and are classified as either fee per use or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s lease agreement with the Company. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from third party payors, and the Company is responsible for paying operating costs of the equipment determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the years ended,  December 31, 2023 and 2022, the Company recognized leasing revenue of approximately $17,772,000 and $16,655,000 under ASC 842, respectively, of which approximately $10,133,000 and $8,952,000 were for PBRT services, respectively.

 

Revenue sharing arrangements amounted to approximately 70 % and 67% of total revenue for the years ended December 31, 2023 and 2022, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.  Payor mix is a significant variable in the Company’s estimate for revenue sharing revenues.  

 

Direct patient services income (retail) – The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid between three and six months, following issuance of invoice. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. Accounts receivable under ASC 606 at December 31, 2023 was $1,626,000. Accounts receivable under ASC 606 at January 1, 2022 and  December 31, 2022 was $668,000 and $1,119,000. For the years ended  December 31, 2023 and 2022, the Company recognized retail revenues of approximately $3,553,000 and $3,091,000 under ASC 606, respectively.

 

Equipment sales – During the year-ended December 31, 2023, the Company completed a sale of equipment to a new customer.  The Company assessed this transaction under ASC 606 and concluded the Company acted as the agent in this transaction and provided, at a point in time, two performance obligations, in the form of an equipment sale of an Icon and Cobalt-60 reload.  The performance obligation to sell, assign, transfer and deliver the equipment to the customer was carried out via Elekta.  Revenue related to the equipment sale is recognized on a net basis when the sale is complete.  The Company recognized net revenue of $200,000 on the sale of equipment for the year-ended December 31, 2023.

 

Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 8 - Stock-Based Compensation Expense for additional information on the Company’s stock-based compensation programs.

 

Costs of revenue – The Company’s costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s revenue sharing and retail sites). Costs of revenue are recognized as incurred.

 

Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

 

F- 9

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 ACCOUNTING POLICIES (CONTINUED)

 

The Company accounts for uncertainty in income taxes as required by the provisions of ASC 740 Income taxes (“ASC 740”), which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires the Company to determine the probability of various possible outcomes. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.

 

See Note 7 - Income Taxes for further discussion on income taxes.

 

Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will reassess its accounting for the operation to the local currency from the U.S. dollar. The Company analyzed it’s Gamma Knife site in Peru and its startup operations in Mexico for Puebla under ASC 830 as of December 31, 2023 and 2022 and concluded the functional currency was the U.S. dollar. As facts and circumstances change, the Company will revisit this conclusion.  The functional currency of the Company’s Gamma Knife site in Ecuador is the U.S. dollar because that is the local currency of Ecuador. 

 

Asset Retirement Obligations – Based on the guidance provided in ASC 410, Asset Retirement Obligations (“ASC 410”), the Company analyzed its existing lease agreements and determined whether an ARO exists to remove the respective units at the end of the lease terms. As of December 31, 2023, the Company has two AROs recorded for the two customer sites that expired during the year, totaling $650,000.  One ARO was recorded and impaired in a prior period.  The Company recorded and impaired an ARO for the second customer site during 2023. No liability has been recorded as of December 31, 2023 for the remaining Gamma Knife or PBRT locations, because it is uncertain these units will be removed and the Company historically has not removed the equipment at the end of the lease term. The Company will re-evaluate the need to record additional ARO liabilities on a periodic basis when facts and circumstances change that could affect this conclusion.

 

Earnings per share – The Company calculates diluted shares using the treasury stock method. Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding and unvested restricted stock units, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options and from unvested restricted stock units. The computation for the years ended  December 31, 2023 and 2022 excluded approximately 144,000 and 20,000, respectively, of the Company’s stock options because the exercise price of the options was higher than the average market price during the period. The weighted average common shares outstanding for the years ended  December 31, 2023 and 2022, included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance. 


The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2023 and 2022.

 

  

2023

  

2022

 

Numerator for basic and diluted earnings per share

 $610,000  $1,328,000 

Denominator:

        

Denominator for basic earnings per share – weighted-average shares

  6,358,000   6,297,000 

Effect of dilutive securities employee stock options and restricted stock

  35,000   6,000 

Denominator for diluted earnings per share – adjusted weighted-average shares

  6,393,000   6,303,000 

Earnings per common share- basic

 $0.10  $0.21 

Earnings per common share- diluted

 $0.10  $0.21 

 

F- 10

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 ACCOUNTING POLICIES (CONTINUED)

 

Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting (“ASC 280”), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are two reportable segments, leasing and retail. During 2023, the Company provided Gamma Knife and PBRT equipment to thirteen hospitals in the United States and owns and operates two single-unit facilities in Lima, Peru and Guayaquil, Ecuador as of December 31, 2023. An operating segment is defined by ASC 280 as it engages in business activities in which it may recognize revenues and incur expenses, its operating results are regularly reviewed by the Company’s Chief Operating Decision Maker (“CODM”), and its discrete financial information is available. The Company determined two reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the two reportable segments are reviewed by the Company’s Executive Chairman of the Board, who is also the CODM.

 

For the years ended  December 31, 2023 and 2022, the Company’s PBRT operations represented a significant majority of the net income attributable to American Shared Hospital Services from the leasing segment, disclosed below. The revenues, depreciation, interest expense, interest income, tax expense, and net income attributable to American Shared Hospital Services, and total asset allocations for the Company’s two reportable segments as of December 31, 2023 and 2022 consists of the following:

 

  

2023

  

2022

 

Revenues

        

Leasing

 $17,772,000  $16,655,000 

Retail

  3,553,000   3,091,000 

Total

 $21,325,000  $19,746,000 

 

  

2023

  

2022

 

Depreciation expense

        

Leasing

 $4,429,000  $4,268,000 

Retail

  736,000   515,000 

Total

 $5,165,000  $4,783,000 

 

  

2023

  

2022

 

Interest expense

        

Leasing

 $1,087,000  $806,000 

Retail

  25,000    

Total

 $1,112,000  $806,000 

 

  

2023

  

2022

 

Interest income

        

Leasing

 $458,000  $103,000 

Retail

      

Total

 $458,000  $103,000 

 

  

2023

  

2022

 

Income tax expense

        

Leasing

 $306,000  $753,000 

Retail

  125,000   210,000 

Total

 $431,000  $963,000 

 

  

2023

  

2022

 

Net income attributable to American Shared Hospital Services

        

Leasing

 $518,000  $1,187,000 

Retail

  92,000   141,000 

Total

 $610,000  $1,328,000 

 

  

2023

  

2022

 

Total assets

        

Leasing

 $39,854,000  $37,575,000 

Retail

  8,308,000   6,381,000 

Total

 $48,162,000  $43,956,000 

 

F- 11

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 ACCOUNTING POLICIES (CONTINUED)

 

Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. As of December 31, 2023, impairment of $650,000 was recorded related to cash flow losses of one of the Company’s Gamma Knife units.  No impairment was recorded as of December 31, 2022. See Note 3 - Property and Equipment for further discussion.

 

Goodwill and intangible assets - The Company recorded goodwill of $1,265,000 and an intangible asset with a fair value of $78,000 as part of the acquisition of GKCE in June 2020. The intangible asset identified was GKCE’s trade name and the Company assigned an indefinite useful life to the asset. Based on the guidance provided in accordance with ASC 350 Intangibles-Goodwill and Other (“ASC 350”), the Company does not amortize the intangible asset because it has an indefinite life. The Company assesses goodwill at the reporting unit level, which has been determined to be GKCE. Each reporting period, the Company assesses whether events or circumstances continue to support an indefinite useful life for the intangible asset. Per ASC 350, the Company tests goodwill and intangibles for impairment annually or as events or circumstances change that indicate the fair value may be below the carrying amount. As of December 31, 2023 and 2022, there has been no change to the Company's assessment of the value of intangible assets or goodwill.

 

Accounting pronouncements issued and not yet adopted - In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses.  The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-07 to determine the impact it may have on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign.  ASU 2023-09 is effective for annual periods beginning after December 31, 2024.  The Company is currently evaluating ASU 2023-09 to determine the impact it may have on its consolidated financial statements. 

 

Reclassifications - Certain comparative balances as of and for the year ended have been reclassified to make them consistent with the current year presentation.

 

NOTE 3 PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following:

 

  

December 31,

 
  

2023

  

2022

 

Medical equipment and facilities

 $77,150,000  $73,709,000 

Office equipment

  306,000   422,000 

Construction in progress

  3,771,000   106,000 
   81,227,000   74,237,000 

Accumulated depreciation

  (55,383,000)  (50,770,000)

Net property and equipment

 $25,844,000  $23,467,000 

 

As of December 31, 2023 and 2022, approximately $3,966,000 and $2,201,000, respectively, of the net property and equipment balance is outside of the United States.  Depreciation expense recorded in costs of revenue and selling and administrative expense in the consolidated statements of income for the years ended  December 31, 2023 and 2022, was $5,165,000 and $4,783,000, respectively.

 

As of October 1, 2022, the Company reduced its estimate for salvage value for one of its domestic Gamma Knife Perfexion units.  As of January 1, 2023, the Company reduced its estimated useful life for one of its direct patient services Gamma Knife units. The net effect of the change in estimate made January 1, 2023, for the year ended  December 31, 2023, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.

 

As of December 31, 2023 and 2022, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. The impairment as of  December 31, 2023 was related to cash flow impairment for one of the Company’s Gamma Knife units and estimated removal costs of the two Gamma Knife contracts that expired during the year. The Company reviewed its Gamma Knife equipment, in light of available information as of December 31, 2022 and concluded no impairment existed. The Company reviewed it’s PBRT equipment, in light of available information as of December 31, 2023 and 2022 and concluded no impairment exists.

 

F- 12

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 4 - OTHER ACCRUED LIABILITIES

 

Other accrued liabilities consists of the following:

 

  

December 31,

 
  

2023

  

2022

 

Insurance financing

 $  $591,000 

Professional services

  472,000   92,000 

Operating costs

  450,000   539,000 

Other

  304,000   322,000 

Total other accrued liabilities

 $1,226,000  $1,544,000 

 

 

NOTE 5 - LONG TERM DEBT

 

On  April 9, 2021 the Company along with certain of its domestic subsidiaries (collectively, the “Loan Parties”) entered into a five year $22,000,000 credit agreement with Fifth Third Bank, N.A. (“the Credit Agreement”). The Credit Agreement includes three loan facilities. The first loan facility is a $9,500,000 term loan (the “Term Loan”) which was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs. The second loan facility is a $5,500,000 delayed draw term loan (the “DDTL”) which was used to refinance the Company’s PBRT finance leases and associated closing costs, as well as to provide additional working capital. The third loan facility provides for a $7,000,000 revolving line of credit (the “Revolving Line”) available for future projects and general corporate purposes. The Company borrowed $2,500,000 on the Revolving Line as of  December 31, 2023, which was paid off in January 2024.  The facilities have a five-year maturity, carry a floating interest of LIBOR plus 3.0% and are secured by a lien on substantially all of the assets of the Loan Parties and guaranteed by ASHS.  The long-term debt on the consolidated balance sheets related to the Term Loan and DDTL was $10,825,000 and $12,624,000 as of December 31, 2023 and 2022, respectively.

 

The Revolving Line is charged an unused line fee of 0.25% per annum. The Term Loan and DDTL have interest and principal payments due quarterly. Principal amortization on an annual basis for the Term Loan and DDTL equates to 48% of the original principal loan commitments in years one through five and an end of term payment of the remaining principal balance.

 

The Credit Agreement contains customary covenants and representations, including without limitation, a minimum fixed charge coverage ratio of 1.25 and maximum funded debt to EBITDA ratio of 3.0 to 1.0 (tested on a trailing twelve-month basis at the end of each fiscal quarter), reporting obligations, limitations on dispositions, changes in ownership, mergers and acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and capital expenditures.  The Loan Parties are in compliance with the Credit Agreement covenants as of  December 31, 2023On January 25, 2024, the Company amended its Credit Agreement to include financing for the equipment in Puebla, see Note 12 - Subsequent Event for further information.

 

The loan entered into with DFC in connection with the acquisition of GKCE in  June 2020 (the “DFC Loan”) was obtained through the Company’s wholly-owned subsidiary, HoldCo, and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE’s assets. The first tranche of the DFC Loan was funded in June 2020. During the fourth quarter of 2023, the second tranche of the DFC loan was funded to finance the equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%.  The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The long-term debt on the consolidated balance sheets related to the DFC loan was $2,464,000 and $1,041,000 as of  December 31, 2023 and 2022, respectively.  The Company capitalized debt issuance costs of $9,000 and $9,000 as of  December 31, 2023 and 2022, respectively, related to maintenance and administrative fees on the DFC Loan.  

 

The DFC Loan contains customary covenants among other covenants and obligations, requirements that the Company maintain certain financial ratios related to liquidity and cash flow as well as depository requirements.  On March 28, 2024 the Company received a waiver and amendment from DFC for certain covenants as of December 31, 2023 and through December 31, 2024 and amended other covenants and definitions permanently. The Company expects to be in compliance with all debt covenants pursuant to the DFC Loan as amended and waived at  March 31, 2024.

 

The accretion of debt issuance costs for the years ended  December 31, 2023 and 2022, was $46,000 and $84,000, respectively. As of  December 31, 2023 and 2022, the unamortized debt issuance costs on the consolidated balances sheets were $164,000 and $198,000.  

 

The following are contractual maturities of long-term debt by year at December 31, 2023, excluding debt issuance costs of $164,000:

 

Year ending December 31,

 

Principal

 

2024

 $2,157,000 

2025

  2,907,000 

2026

  7,732,000 

2027

  493,000 
  $13,289,000 

 

F- 13

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 6 - LEASES

 

The Company determines if a contract is a lease at inception. Under ASC 842, the Company is a lessor of equipment to various customers. Leases that commenced prior to ASC 842 adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. All of the Company’s lessor arrangements entered into after ASC 842 adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do not contain the option to terminate early or purchase the asset at the end of the term. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset.

 

The Company’s Gamma Knife and PBRT contracts with hospitals are classified as operating leases under ASC 842. The related equipment is included in medical equipment and facilities on the Company’s consolidated balance sheets (see further discussion at Note 2). As all income from the Company’s lessor arrangements is solely based on procedure volume, all income is considered variable payments not dependent on an index or a rate. As such, the Company does not measure future operating lease receivables.

 

On November 3, 2021, the Company entered into an agreement to sublease (the “Sublease”) its corporate office located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month. The lease expired in August 2023. The Sublease was for $16,195 per month through the existing contract expiration date. The Company also entered into a lease (the “Lease”) agreement for new corporate office space at 601 Montgomery, Suite 1112, San Francisco, CA for approximately 900 square feet for $4,500 per month with a lease expiration date in November 2024.  The Company assessed the Lease under ASC 842 and concluded the Lease should be classified as an operating lease. 

 

The Company’s lessee operating leases are accounted for as ROU assets, current portion of lease liabilities, and lease liabilities on the consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s operating lease contracts do not provide an implicit rate for calculating the present value of future lease payments, so the Company determined its incremental borrowing rate to be in the range of approximately 4.0% and 6.0% by using available market rates and expected lease terms. The operating lease ROU assets and liabilities also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company’s lessee operating lease agreements are for administrative office space and related equipment, and the agreement to lease clinic space for its stand-alone facility in Lima, Peru. These leases have remaining lease terms of approximately 1 year, some of which include options to renew or extend the lease. As of December 31, 2023, operating ROU assets and lease liabilities were $57,000.

 

The following table summarizes maturities of lessee operating lease liabilities as of December 31, 2023:

 

Year ending December 31,

 

Operating Leases

 
     

2024

 $58,000 

Total lease payments

  58,000 

Less imputed interest

  (1,000)

Total

 $57,000 

 

  

Year Ended December 31,

 
  

2023

  

2022

 

Lease cost

        

Operating lease cost, net of impairment

 $302,000  $406,000 

Sublease income

  (129,000)  (174,000)

Total lease cost

 $173,000  $232,000 
         

Other information

        

Cash paid for amounts included in the measurement of lease liabilities - Operating leases

 $302,000  $406,000 

Weighted-average remaining lease term - Operating leases in years

  0.80   1.11 

Weighted-average discount rate - Operating leases

  4.65%  5.65%

 

The Company’s corporate offices are located at 601 Montgomery Street, Suite 1112, San Francisco, California, where it leases approximately 900 square feet for $4,500 per month with a lease expiration date in November 2024. The Company subleased its existing corporate offices located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month.  This lease expired in August 2023. The monthly lease expense was offset by sublease income of $16,195. The sublease term was consistent with the existing lease term. The Company owns and operates a stand-alone Gamma Knife facility in Lima, Peru where it leases approximately 1,600 square feet for approximately $8,850 per month with a lease expiration date in January 2024. The lease in Peru is currently on a month-to-month basis. The Company also owns and operates a stand-alone Gamma Knife facility in Guayaquil, Ecuador where it owns 864 square feet of condominium space in an office building and approximately 10,135 of related land and parking spaces.

 

Net rent expense was $234,000 and $290,000 for the years ended December 31, 2023 and 2022, respectively, and includes the above operating leases as well as month-to-month rental and certain executory costs. 

 

F- 14

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 7  INCOME TAXES

 

The components of income before income taxes for the years ended  December 31, 2023 and 2022 are as follows:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 
         

Domestic

 $666,000  $2,350,000 

Foreign

  30,000   168,000 

Income before income taxes

 $696,000  $2,518,000 

 

For the year ended  December 31, 2023 and 2022, the Company recorded an income tax expense of $431,000 and $963,000, respectively. 

 

The components of the provision for income taxes for the years ended  December 31, 2023 and 2022 consists of the following:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Current:

        

Federal

 $940,000  $355,000 

State

  115,000   60,000 

Foreign

  135,000   204,000 

Total current

  1,190,000   619,000 
         

Deferred:

        

Federal

  (672,000)  290,000 

State

  (77,000)  48,000 

Foreign

  (10,000)  6,000 

Total deferred

  (759,000)  344,000 
  $431,000  $963,000 

 

Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2023 and 2022 are as follows:

 

  

December 31,

 
  

2023

  

2022

 

Deferred tax liabilities:

        

Property and equipment

 $(323,000) $(708,000)

Prepaid expenses

  (409,000)  (493,000)

ROU asset

  (12,000)  (54,000)
         

Total deferred tax liabilities

  (744,000)  (1,255,000)
         

Deferred tax assets:

        

Net operating loss carryforwards

  155,000   139,000 

Accruals and allowances

  438,000   167,000 

Lease liabilities

  12,000   61,000 

Tax credits

  4,000   3,000 

Other

  140,000   114,000 

Capital loss carryover

  646,000   646,000 
         

Total deferred tax assets

  1,395,000   1,130,000 
         

Valuation allowance

  (714,000)  (697,000)
         

Deferred tax assets net of valuation allowance

  681,000   433,000 
         

Net deferred tax liabilities

 $(63,000) $(822,000)

 

F- 15

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 7  INCOME TAXES (CONTINUED)

 

The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in 2023 and 2022) to income before taxes as follows:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Computed expected federal income tax

 $218,000  $477,000 

State income taxes, net of federal benefit

  12,000   100,000 

Foreign rate differential

  38,000    

Stock compensation

  7,000    

Non-deductible expenses

  6,000   (25,000)

Return to provision true-up

  18,000   52,000 

Uncertain tax positions

  9,000   (17,000)

Alternative minimum tax payable adjustment

     208,000 

Change in valuation allowance

  17,000    

Other deferred tax adjustments

  106,000   168,000 
         
  $431,000  $963,000 

 

As of  December 31, 2023, the Company has net operating loss carryforwards for federal and state income tax return purposes of approximately $0 and $2,586,000 that begin to expire in 2029. 

 

Utilization of the net operating loss and credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended (the “Code”), and similar state provisions. Any annual limitation may result in the expiration of net operating losses and credits before utilization.

 

At December 31, 2023, the Company has a capital loss carryforward for federal income tax return purposes of approximately $2,679,000,which start to expire in 2024. The Company has capital loss carryforwards for state income tax purposes of approximately $129,000, which starts to expire in 2024.

 

Due to uncertainty surrounding the realization of impairment losses, capital losses and foreign operating losses in future years, the Company has placed a valuation allowance against a portion of its net domestic and foreign deferred tax assets. The net valuation allowance increased by $17,000 and $0 for the years ended December 31, 2023 and 2022, respectively.

 

The tax return years 2019 through 2022 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for calendar years 1999 through 2004, 2009, 2010, 2012, 2014, 2015, 2016, 2017 and 2018 remain open to examination by the major domestic taxing jurisdictions.

 

F- 16

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 7  INCOME TAXES (CONTINUED)

 

The Company has adopted accounting standards which prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a companys income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Additionally, these accounting standards specify that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company has made no reclassifications between current taxes payable and long term taxes payable under this guidance.

 

As of December 31, 2023, the unrecognized tax benefit was $287,000 which, if recognized, will not affect the annual effective tax rate as these unrecognized tax benefits would increase deferred tax assets, which would be subject to a full valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Balance at beginning of year

 $278,000  $295,000 

Additions based on tax positions of prior years

  9,000   (17,000)
         

Balance at end of year

 $287,000  $278,000 

 

The Company’s policy for deducting interest and penalties is to treat interest as interest expense and penalties as income taxes. As of December 31, 2023, the Company had $58,000 accrued for the payment of penalties and zero interest related to unrecognized tax benefits. The Company does not expect any material changes to our uncertain tax positions within the next 12 months. The Company believes that it is reasonably possible that a decrease of up to $100,000 in unrecognized tax benefits related to foreign taxes may be necessary within the coming year.

 

 

NOTE 8  STOCK-BASED COMPENSATION EXPENSE

 

Incentive Compensation Plan

 

In  June 2021, the Company’s shareholders approved an amendment and restatement of the Company’s Incentive Compensation Plan (the “Plan”), that among other things, increases the number of shares of the Company’s common stock reserved for issuance under the Plan to 2,580,000 and extends the term of the Plan by five years to  February 22, 2027. The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. No further grants or share issuances will be made under the previous plans. As of December 31, 2023, approximately 935,000 shares remain available for grant under the Plan.

 

Under the Plan, a total of 898,000 restricted stock units have been granted, consisting of 53,000 of annual automatic grants to non-employee directors, 328,000 of deferred retainer fees to non-employee members of the Board, 57,000 grants issued in lieu of commission or bonus to employees of the Company, and 460,000 restricted stock units issued to the Executive Chairman of the Board, see further discussion below. Of the total restricted stock units granted under the Plan, 123,000 of them are fully vested but not yet deemed issued and outstanding, 742,000 are fully vested and outstanding, and 33,000 are outstanding as of December 31, 2023.

 

Changes in restricted stock units, consisting primarily of annual automatic grants, deferred compensation to non-employee directors, shares issued to employees as part of the Company’s bonus plan, and restricted stock units awards to the Executive Chairman of the Board, under the Incentive Compensation Plans during 2023 and 2022 are as follows:

 

  

Restricted Stock Units

  

Grant Date Weighted- Average Fair Value

 

Outstanding at January 1, 2022

  

10,000

   

$ 2.57

 

Granted

  

131,000

   

$ 2.40

 

Vested

  

(132,000)

   

$ 2.40

 

Forfeited

  

(3,000)

   

$ 2.92

 
         

Outstanding at December 31, 2022

  

6,000

   

$ 2.33

 

Granted

  

146,000

   

$ 2.97

 

Vested

  

(119,000)

   

$ 2.94

 

Outstanding at December 31, 2023

  

33,000

   

$ 2.88

 

 

 

F- 17

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 8  STOCK-BASED COMPENSATION EXPENSE (CONTINUED)

 

Certain Executive Equity Awards

 

Effective May 4, 2020, the Company appointed Raymond C. Stachowiak as Interim President and Chief Executive Officer (“CEO”). Pursuant to his Offer Letter, Mr. Stachowiak was granted 50,000 restricted stock awards that vested in full on August 3, 2020. He was granted additional restricted stock awards totaling 10,000 common shares per month, which vested in full at the end of each 30-day period following issuance. Mr. Stachowiak became CEO of the Company on October 1, 2020 and served in such position until he was appointed Executive Chairman of the Board on March 7, 2023. For the year ended December 31, 2022, 120,000 restricted stock awards were issued to Mr. Stachowiak and became fully vested. Total compensation expense recorded for the year ended December 31, 2022 in the consolidated financial statements of income related to executive equity awards was $288,000.  For the year ended December 31, 2023, 120,000 restricted stock awards were issued to Mr. Stachowiak and 90,000 became fully vested.  Total compensation expense recorded for the year ended December 31, 2023 in the consolidated financial statements of income related to the executive equity awards was $351,000.

 

For the year ended  December 31, 2023, stock compensation expense recorded in the consolidated financial statements is summarized as follows:

 

      

Stock-Based

 
  

Awards Issued

  

Compensation

 
  

and Vested

  

Expense

 

Options

    $34,000 

Management Bonus Program - vested and issued

  26,000    

Board RSU Awards - other

     4,000 

Executive Compensation

  90,000   351,000 
   116,000  $389,000 

 

Total stock-based compensation expense before income tax effect for the Company’s options and restricted stock awards in the amount of $389,000 and $399,000 for the years ended  December 31, 2023 and 2022, is reflected in selling and administrative expense in the consolidated statements of income, respectively.

 

Stock Options

 

Changes in stock options outstanding under the Incentive Compensation Plans during 2023 and 2022 are as follows:

 

Options

 

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average Remaining Contractual Term (Years)

  

Aggregate Intrinsic Value

 

Balance at December 31, 2021

  67,000  $2.72   3.33  $ 

Granted

  50,000  $2.72   7.00  $ 

Exercised

  (4,000) $2.29     $ 

Forfeited

  (18,000) $2.64     $ 
                 

Balance at December 31, 2022

  95,000  $2.76   4.83  $25,000 

Granted

  70,000  $2.89   7.00  $ 

Forfeited

  (19,000) $2.69     $ 
                 

Balance at December 31, 2023

  146,000  $2.83   5.44  $ 
                 

Exercisable at December 31, 2022

  38,000  $2.79   2.38  $ 
                 

Exercisable at December 31, 2023

  31,000  $2.84   3.38  $ 

 

F- 18

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 8  STOCK-BASED COMPENSATION EXPENSE (CONTINUED)

 

The weighted average grant-date fair value of the options granted during the years 2023 and 2022 was $2.89 and $1.49, respectively. There were no options exercised during the year ended December 31, 2023. There were 4,000 options exercised which resulted in 3,000 shares issued, due to cashless exercises, during the year ended December 31, 2022. Total stock-based compensation expense recognized for stock options for the years ended December 2023 and 2022 was $34,000 and $10,000, respectively.

 

The Company received approximately $5,000 from the exercise of 2,000 options under the share-based arrangements during the year ended December 31, 2022. The remaining options exercised during 2022 were cashless exercises. 

 

At December 31, 2023, there was approximately $156,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a period of approximately four years.

 

The Company’s stock option awards to employees are calculated using the Black-Scholes options valuation model. The Black-Scholes model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes model requires the input of highly subjective assumptions including the expected stock price volatility. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. For these reasons, management believes that the existing models do not necessarily provide a reliable single measure of the fair value of its stock-based awards to employees.

 

The fair value of the Company’s option grants issued during 2023 and 2022 were estimated using assumptions for expected life, volatility, dividend yield, forfeiture rate, and risk-free interest rate which are specific to each award as summarized in the following table. The estimated fair value of the Company’s options is amortized over the period during which the optionee is required to provide service in exchange for the award, usually the vesting period.

 

The fair value of the Company’s option grants under the Plan in 2023 and 2022 was estimated using the following assumptions:

  

2023

  

2022

 

Expected life (years)

  7.0   7.0 

Expected forfeiture rate

  0.0%  0.0%

Expected volatility

  50%  50%

Dividend yield

  0%  0%

Risk-free interest rate

  3.6%  3.3%

 

The following summarizes the assumption inputs used for the Company’s Black-Scholes calculation:

 

Expected life (years): The expected term represents the weighted average period that the Company’s stock options are expected to be outstanding.  
 

Expected forfeiture rate: Forfeitures are recognized as they occur.   

 

Expected volatility: The expected volatility was derived from the Company’s historical stock volatility. 

 

Dividend yield: The expected dividend yield was assumed to be zero, as the Company has not previously paid dividends on common stock and has no current plans to do so.  

 

Risk-free interest rate:  The risk-free interest rate is based on the interest yield in effect at the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the option’s expected term.

 

Repurchase of Common Stock, Common Stock Warrants and Stock Options

 

In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in 2008. There were no shares of the Company repurchased during 2023 or 2022. There are approximately 72,000 shares remaining under this repurchase authorization.

 

F- 19

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 9  RETIREMENT PLAN

 

The Company has a defined-contribution retirement plan (the “Retirement Plan”) that allows for a matching safe harbor contribution. For 2023, the Board of Directors elected to match participant deferred salary contributions up to a maximum of 4% of the participant’s annual compensation. Discretionary profit sharing contributions are allowed under the Retirement Plan in years that the Board does not elect a safe harbor match. During 2023, the Company contributed $43,000 to the Retirement Plan for the safe harbor match for the year ended December 31, 2023. The Company has accrued approximately $17,000 for additional safe harbor matching contribution for the year ended December 31, 2023. Also during 2023, the Company contributed $47,000 to the Retirement Plan for the safe harbor match for the year ended December 31, 2022.

 

 

NOTE 10  COMMITMENTS AND CONTINGENCIES

 

On December 20, 2018, the Company signed Second Amendments to two System Build Agreements for the Company’s second and third Mevion PBRT units. These commitments expired in January 2024 and the Company was not able to utilize this equipment. During the year-ended  December 31, 2020, the Company impaired these deposits and wrote-off the deposits and related capitalized interest. 

 

As of December 31, 2023, the Company had commitments to install three Leksell Gamma Knife Esprit Systems (“Esprit”), install one Cobalt-60 reload with software, purchase one Gamma Plan workstation, purchase one Linear Accelerator (“LINAC”) system, and purchase one Magnetic Resonance imaging guided LINAC (“MR LINAC”). The LINAC, MR LINAC and one Esprit will be placed at future customer sites. The remaining Esprit upgrades and Cobalt-60 reload are scheduled to occur during 2024 at existing customer sites. The Company also has one commitment to de-install a Gamma Knife unit at an existing customer site. The Company’s LINAC installation in Puebla was in process at  December 31, 2023 and the Company made substantial payments towards the project during 2023. In January 2024, the Company amended the Credit Agreement to include financing for this project. At  December 31, 2023, the Company had commitments remaining for some of the ancillary equipment in Puebla. Total Gamma Knife and LINAC commitments as of December 31, 2023, were $15,925,000. There are no deposits on the consolidated balance sheets related to these commitments as of December 31, 2023.  It is the Company's intent to finance substantially all of these commitments.  There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company.  However, the Company currently has cash on hand of $13,808,000 and a line of credit of $7,000,000 to fund these projects, if necessary.  The Company borrowed $2,500,000 on the Revolving Line as of December 31, 2023, which was paid off in January 2024. 

 

On September 4, 2022, the Company entered into a Maintenance and Support Agreement with Mevion (the “Mevion Service Agreement”), which provides for maintenance and support of the Company’s PBRT unit at Orlando Health from September 2022 through April 2026.  The agreement requires an annual prepayment of $1,865,000 for the current contractual period (one year). This payment portion was recorded as a prepaid contract and will be amortized over the one-year service period.

 

As of December 31, 2023, the Company had commitments to service and maintain its Gamma Knife and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta and Mobius Imaging, LLC. The Company’s commitments to purchase two LINAC systems also include a 9-year and 5-year agreement to service the equipment, respectively. Total service commitments as of December 31, 2023 were $14,805,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

 

The Company’s customer contracts generally contain mutual indemnification provisions. The Company maintains general and professional liability insurance in the United States. The Company is not involved in the practice of medicine and therefore believes its present insurance coverage and indemnification agreements are adequate for its business. The Company’s Peruvian and Ecuadorian Gamma Knife centers are free-standing facilities operated by GKPeru and GKCE, respectively. The treating physicians and clinical staff at these facilities are independent contractors. The Company maintains general and professional liability insurance consistent with the operations of these facilities and believes its present coverage is adequate for its business.

 

F- 20

 
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 11  RELATED PARTY TRANSACTIONS

 

The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife and other radiation therapy equipment. Since the Company purchases the majority of its equipment from Elekta, there are significant related party transactions with Elekta such as equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment

 

The following summarizes related party activity for the years ended  December 31, 2023 and 2022:

 

  

December 31,

 
  

2023

  

2022

 

Equipment purchases and de-install costs

 $6,918,000  $1,844,000 

Costs incurred to maintain equipment

  851,000   1,094,000 

Total related party transactions

 $7,769,000  $2,938,000 

 

The Company had related party commitments to install three Esprit upgrades, one Cobalt-60 reload, purchase one MR LINAC, purchase one Gamma Plan workstation, and service the related equipment. The Company also has two commitments to de-install Gamma Knife units at existing customer sites. Total related party commitments were $18,968,000 as of  December 31, 2023.

 

Related party liabilities on the consolidated balance sheets consist of the following as of December 31, 2023 and 2022:

 

  

December 31,

 
  

2023

  

2022

 

Accounts payable and other accrued liabilities

 $1,961,000  $497,000 

 

 

NOTE 12  SUBSEQUENT EVENT

 

On January 25, 2024 (the “First Amendment Effective Date”), the Company entered into a First Amendment to Credit Agreement (the “First Amendment”) with Fifth Third which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the “Supplemental Term Loan”). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and will be used for capital expenditures related to the Company’s operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030 (the “Maturity Date’). Interest on the Supplemental Term Loan is payable monthly during the initial twelve month period following the First Amendment Effective Date. Following such twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The First Amendment also replaces the LIBOR-based rates in the Credit Agreement with SOFR-based rates. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

 

 

F- 21
EX-10.2F 2 ex_646059.htm EXHIBIT 10.2F ex_646059.htm
 

Exhibit 10.2f

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

FOURTH AMENDMENT TO

 

LEASE AGREEMENT FOR A GAMMA KNIFE UNIT

 

(ESPRIT UPGRADE)

 

This FOURTH AMENDMENT TO LEASE AGREEMENT FOR A GAMMA KNIFE UNIT (this "Fourth Amendment") is dated effective as of July 28, 2023 (the "Effective Date”) and is entered into by and between GK FINANCING, LLC, a California limited liability company ("GKF"), and METHODIST HEALTHCARE SYSTEM OF SAN ANTONIO, LTD., L.L.P. (formerly known as Methodist Healthcare System of San Antonio, Ltd.), d/b/a Southwest Texas Methodist Hospital, a Texas limited liability partnership (''Hospital”).

 

Recitals:

 

 

A.         On October 29, 1996, GKF and Hospital entered into a certain Lease Agreement For A Gamma Knife Unit, which was amended pursuant to a certain Addendum dated October 31, 1996, Addendum Two dated October 16, 1997, an Amendment To Lease Agreement For A Gamma Knife Unit dated effective December 13, 2003 (the “First Amendment"), Second Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion upgrade) dated effective December 23, 2009 (the “Second Amendment”) and Third Amendment to Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) dated June 1, 2022 (the “Third Amendment”, which together with the First Amendment and the Second Amendment, are collectively referred to herein as the “Lease”).

 

B.         Hospital and GKF desire to further amend the Lease to provide for the replacement and upgrade of the existing Leksell Gamma Knife Perfexion unit (the “Perfexion”) that is currently being leased by GKF to Hospital pursuant to the Lease, with a Leksell Gamma Knife – Elekta Esprit unit (such Esprit unit leased hereunder is referred to herein as the “Esprit” or the “Equipment”), which will be installed at the existing Site at which the Perfexion is currently installed, and contemporaneously with the de-installation of the Perfexion (the “Esprit Upgrade”).

 

Agreement:

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.    Defined Terms. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Lease.

 

2.    Confirmation of Hospital Legal Entity. The parties acknowledge that the Lease incorrectly identifies Hospital as a Texas corporation. To correct this error, Hospital represents and warrants to GKF that (i) Hospital’s former legal name was “Methodist Healthcare System of San Antonio, Ltd.” which was then organized as a Texas limited partnership, (ii) Hospital’s current legal name is “Methodist Healthcare System of San Antonio, Ltd., L.L.P.” and is currently organized as a Texas limited liability partnership; and (iii) all references to Hospital in the Lease and in this Fourth Amendment are to one and the same entity.

 

- 1 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

3.    Upgrade of the Perfexion to the Esprit. In accordance with Section 14 of the Lease and subject to the terms and conditions set forth herein, GKF shall acquire and hold title to the Esprit, and install the Esprit with new cobalt-60 sources at the Site.

 

3.1    New LGK Agreement. Concurrently with the execution of this Fourth Amendment, Hospital shall enter into a new LGK Agreement with Elekta, Inc., a Georgia corporation (“Elekta”), which shall supersede and replace the previous LGK Agreement attached as Exhibit A to the Lease (such new LGK Agreement shall hereinafter be referred to as the "LGK Agreement," and shall be deemed attached as Exhibit A to the Lease). Hospital shall operate and maintain a fully functional radiation therapy department at the Site which shall include the Esprit. Use of the Esprit shall be made available to all neurosurgeons and radiation oncologists with Hospital privileges.

 

3.2    User License. Hospital shall apply for and obtain in a timely manner a User License from the Nuclear Regulatory Commission and, if necessary, from the applicable state agency authorizing it to install and operate the Esprit and to take possession of and maintain the Cobalt supply required in connection with the use of the Esprit during the term of the Lease. Hospital also shall apply for and obtain in a timely manner all other licenses, permits, approvals, consents and authorizations which may be required by state or local governmental or other regulatory agencies for the development, construction and preparation of the Site, the charging of the Equipment with its Cobalt supply, the conduct of acceptance tests with respect to the Equipment, and the use of the Equipment during the Term. Upon request, Hospital shall provide GKF with true and correct copies of any and all such licenses, permits, approvals, consents and authorizations.

 

3.3    Delivery of Equipment; Site. GKF shall coordinate with Elekta and Hospital to have the Perfexion de-installed and the Esprit delivered to Hospital at 7700 Floyd Curl Drive, San Antonio, TX 78229 (the “Site”) on a delivery date agreed upon in writing by GKF, Hospital and Elekta. The location of the Site shall be the current Perfexion suite. Subject to availability of the Esprit from the equipment manufacturer, issuance of all regulatory approvals, permits and/or waivers in a timely manner, and completion of construction of the Site, the estimated delivery date is on or around September/October 2023 (provided that this Fourth Amendment is executed by the parties on or before January 25, 2023). GKF makes no representations or warranties concerning delivery of the Equipment to the Site or the actual date thereof. The parties acknowledge that Hospital may not be able to perform Procedures for approximately one (1) month during the Esprit Upgrade and the deinstallation of the Perfexion.

 

3.4    Site Preparation and Installation of Equipment.

 

(a)    GKF, in coordination with Elekta, and at its cost and expense, shall prepare all plans, specifications and site planning criteria (collectively the “Site Planning Criteria”) required to prepare, construct and improve the Site for the installation, use and operation of the Equipment during the Term. The plans and specifications (i) shall be approved by Hospital, which approval shall not be unreasonably withheld or delayed; (ii) shall comply in all respects with the Site Planning Criteria; and (iii) to the extent required by applicable law, shall be submitted to all state and federal agencies for their review and approval. GKF, at its cost and expense, shall obtain all permits, certifications, approvals or authorizations required by applicable federal, state or local laws, rules or regulations necessary to prepare, construct and improve the Site as provided above.

 

(b)    GKF, at its cost and expense, shall de-install the Perfexion and prepare, construct and improve the Site as necessary for the installation, use and operation of the Esprit during the Term (as extended herein), including, without limitation, providing all temporary or permanent shielding required for the charging of the Equipment with the Cobalt supply and for its subsequent use, aligning the Site for the Equipment, and installing all electrical systems and other wiring required for the Equipment. In connection with the construction of the Site, Hospital, at its cost and expense, shall select, purchase and install all radiation monitoring equipment, devices, safety circuits and radiation warning signs required at the Site in connection with the use and operation of the Equipment.

 

- 2 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

(c)    In addition to construction and improvement of the Site, GKF, at its cost and expense, shall be responsible for the installation of the Equipment at the Site, including the positioning of the Equipment on its foundation at the Site in compliance with the Site Planning Criteria.

 

(d)    During the Term (as extended herein), Hospital, at its cost and expense, shall maintain the Site in a good working order, condition and repair, reasonable wear and tear expected.

 

(e)    Upon request by GKF and at GKF’s reasonable expense, Hospital shall execute and deliver a commercially reasonable form of subordination, attornment and non-disturbance or other documentation if such a document is reasonably requested by the third party financing company which holds a security interest in the Esprit.

 

3.5    Hospital Personnel and Services. Upon request and as required by GKF, Hospital, at Hospital’s cost and expense, shall provide GKF with Hospital personnel (including Hospital’s physicists) and services, including security, in connection with the Esprit installation, among other things, to oversee, supervise and assist with construction and compliance with local, state and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the Esprit. Hospital shall not be entitled to reimbursement for its personnel costs, internal costs or overhead in connection with the Esprit Upgrade. Notwithstanding anything to the contrary set forth herein, the Esprit Upgrade shall be performed by GKF only after all necessary and appropriate licenses, permits, approvals, waivers, and consents and authorizations, (collectively, the “Permits”), have been obtained by Hospital at Hospital’s sole cost and expense. The actual purchase of the Esprit from third parties shall be the responsibility of GKF.

 

3.6    Training. GKF, at its cost and expense, shall cover the Esprit training tuition costs for those Hospital-credentialed physicians and physicists who will be using the Esprit. Any travel and entertainment associated with training shall not be the responsibility of GKF.

 

3.7    Acceptance Tests. Upon receipt of Elekta’s report on the results of the Acceptance Tests, Hospital shall have five (5) business days to review and validate the results of the Acceptance Tests to confirm that the Esprit meets the manufacturer’s specifications and documentation. If Hospital fails to respond within such five (5) business day period, Hospital may request a five (5) business day extension to validate and confirm the results of the Acceptance Tests. At the expiration of the five (5) business day period, plus any extension, if applicable, the Hospital’s failure to respond shall constitute Hospital’s validation and confirmation of the Acceptance Tests.

 

4.    De-Installation of the Perfexion; No Ownership Interests. Promptly following the Esprit Upgrade, GKF shall de-install, remove and retain all ownership rights and title to the existing Perfexion. Notwithstanding anything to the contrary set forth in the Lease or herein, Hospital shall have no ownership interest (or option to purchase any ownership interest) in the Perfexion and/or the Esprit, and Hospital hereby waives any ownership interest (or option to purchase any ownership interest) in the Perfexion and/or the Esprit.

 

- 3 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

5.    Extension of Lease Term. In consideration of GKF’s agreement to perform the Esprit Upgrade, the Gamma Knife Service Term (or “Term”) is hereby extended to the date that is ten (10) years following the First Esprit Procedure Date.

 

6.    Compensation.

 

6.1    Commencing from the first procedure performed using the Esprit at the Site (the “First Esprit Procedure Date”) and continuing through the duration of the Term (as extended hereby), Hospital shall pay to GKF on a monthly basis, the applicable payments for each and every “Procedure” (as defined below) as set forth in Exhibit “A” attached hereto (“Per Procedure Payments”). For the avoidance of doubt, Per Procedure Payments shall be due and owing to GKF for each and every Procedure that is performed by Hospital, its representatives, affiliates, joint ventures and/or partnerships, on an inpatient or outpatient basis, and/or “under arrangement,” and irrespective of (i) whether the Procedure is performed on the Esprit or using any other equipment or devices, or (ii) the actual amounts billed or collected, if any, pertaining to such Procedures. The parties acknowledge that the Per Procedure Payments represent fair market value for the use of the Esprit as described herein. As used herein, "Procedure" means any treatment that involves stereotactic, external, single fraction and/or multiple fractions (up to and including 5 fractions), conformal radiation, commonly called radiosurgery, that may include one or more isocenters during the patient treatment session, delivered to any site(s) superior to the foramen magnum.

 

6.2    The procedures relating to payment to GKF of the Per Procedure Payments for Procedures performed from and after the First Esprit Procedure Date shall be in accordance with the same procedures set forth in Sections 3.b, 3.c and 3.d of the Third Amendment except that all references to the Perfexion in connection with such procedures shall be deemed to refer to the Esprit; provided that, notwithstanding anything to the contrary set forth in this Fourth Amendment, the compensation payable to GKF pertaining to Procedures performed prior to the First Esprit Procedure Date shall continue to be calculated and paid by Hospital in accordance with the Third Amendment.

 

6.3    The parties acknowledge that the compensation payable to GKF for the Esprit as set forth in this Fourth Amendment has been negotiated by the parties at arm’s length based upon reasonable and jointly derived assumptions regarding the capacity for clinical services available from the Esprit, Hospital’s capabilities in providing high quality radiation oncology services, market dynamics, GKF’s risk in providing the Esprit, and the provision to GKF of a reasonable rate of return on its investment in support of the Esprit. Based thereon, the parties believe that the Per Procedure Payments represent fair market value for the use of the Esprit, the de-installation and removal of the Perfexion, the Esprit Upgrade, marketing support, maintenance and service, personal property taxes, cost of insurance coverage for the Esprit, and the other additional services and costs to be provided or paid for by GKF pursuant to this Fourth Amendment, and taking into account the Hospital’s payment pursuant to Section 2.f above. Hospital undertakes no obligation to perform any minimum number of procedures on the Esprit, and the use of the Esprit for the performance of procedures is wholly based upon the independent judgment of physicians who order such procedures to meet the medical needs of their patients.

 

- 4 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

7.    Marketing Support. Section 8(e) of the Lease is hereby deleted in its entirety and replaced with the following:

 

“GKF shall coordinate its Gamma Knife marketing plan with Hospital, which marketing plan shall be subject to the approval of Hospital. Hospital shall participate in meetings with GKF to jointly develop a marketing plan annually. The Hospital, with the support of GKF, shall implement the Gamma Knife marketing plan based on the approved budget and timeline. Hospital’s and any Hospital subsidiary’s or related corporation’s name, trademarks, service marks, or other identifying names, marks, images or designations shall be and remain the sole and exclusive property of Hospital, but which may be used in any approved marketing materials without payment of any license or royalty fee. During the first twelve (12) months following the deinstallation of the Perfexion, GKF shall be solely responsible for up to [*****] of out-of-pocket marketing expenses paid to unrelated third parties that are included in the marketing plan budget. Any marketing efforts conducted independently by Hospital shall be at Hospital's expense, and subject to coordination with GKF. Hospital shall use its best efforts to market the Gamma Knife and to educate the public and the medical community as to the benefits of the Gamma Knife. It is acknowledged by the parties that such expenses to be reimbursed by GKF as provided above have been included in GKF’s calculation of Hospital’s Per Procedure Payments so as to allow GKF to recover such GKF expenses during the Term of this Agreement; provided that the foregoing shall not be deemed to limit or otherwise affect Hospital’s obligation to pay the Per Procedure Payments as set forth herein.”

 

8.    Alterations and Upgrades to Equipment.

 

8.1     Hospital shall not make any modifications, alterations or additions to the Equipment (other than normal operating accessories or controls) without the prior written consent of GKF. Hospital shall not, and shall not permit any person other than representatives of Elekta or any other person authorized by GKF to, effect any inspection, adjustment, preventative or remedial maintenance, or repair to the Equipment without the prior written consent of GKF. All modifications, alterations, additions, accessories or operating controls incorporated in or affixed to the Equipment (herein collectively called “additions” and included in the definition of “Equipment”) shall become the property of the GKF upon termination of this Agreement.

 

9.    Option to Reload.

 

9.1    The necessity and financial responsibility for modifications, additions or upgrades to the Equipment, including the reloading of the Cobalt-60 source, shall be mutually agreed upon in writing by GKF and Hospital. If GKF and Hospital agree to reload the Cobalt-60 source (i.e., on or around the 72nd month of the Term), then, notwithstanding any provisions to the contrary herein, (i) the Term shall be automatically extended for an additional two (2) years, plus the period of time that the Equipment is unavailable to perform procedures due to the reload, and (ii) commencing from the first day of the sixth (6th) anniversary the First Esprit Procedure Date (i.e., the first day of the seventy-third (73rd) month after the First Esprit Procedure Date, the “Sixth Anniversary Date”) through the remainder of the Term as extended (the “Revised Per Procedure Payment Period”), the Per Procedure Payments shall be increased to [*****] per Procedure; provided that, if during the twelve (12) month period immediately preceding the Sixth Anniversary Date or each anniversary date thereafter, the number of Procedures performed on the Esprit or using any other equipment or devices equals or exceeds [*****] Procedures (the “Threshold”), then, the Per Procedure Payments shall not be increased to [*****] per Procedure, but instead, shall remain at [*****] per Procedure for the immediately succeeding twelve (12) month period only. In furtherance of the foregoing, (a) the number of annual Procedures performed on the Esprit or using any other equipment or devices shall be reset to zero (0) at the commencement of each anniversary of the Sixth Anniversary Date; (b) any patient treatment provided on a fractionated basis shall count as one (1) Procedure; (c) charity cases shall not be counted towards annual Procedures performed; and (d) during the Revised Per Procedure Payment Period, there shall be no retroactive adjustment of the Per Procedure Payments irrespective of whether the number of Procedures performed reaches the Threshold.

 

- 5 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

9.2    For example, assuming:

 

(a)    [*****] Procedures were performed during the 12 months immediately prior to the Sixth Anniversary Date, then, the Per Procedure Payments during the 12 months immediately following the Sixth Anniversary Date would be [*****] per Procedure;

 

(b)    [*****] Procedures were performed during the 12 months immediately prior to the seventh (7th) anniversary the First Esprit Procedure Date (the “Seventh Anniversary Date”), then, the Per Procedure Payments during the 12 months immediately following the Seventh Anniversary Date would be [*****] per Procedure; and

 

(c)    [*****] Procedures were performed during the 12 months immediately prior to the eighth (8th) anniversary the First Esprit Procedure Date (the “Eighth Anniversary Date”), then, the Per Procedure Payments during the 12 months immediately following the Eighth Anniversary Date would be [*****] per Procedure.

 

(d)    The foregoing methodology would be applied to the entirety of the Revised Per Procedure Payment Period. There are no minimum volume requirements.

 

10.    Options to Extend Lease. Section 17 of the Lease is hereby deleted in its entirety and replaced with the following:

 

“17.         Options.

 

“(a)         At the end of the Gamma Knife Service Term, Hospital shall have the option to either:

 

“(i)         Extend the term of this Agreement for a specified period of time and upon such other terms and conditions as may be agreed upon by GKF and Hospital; or

 

“(ii)          Terminate this Agreement as of the expiration of the Gamma Knife Service Term. Upon the expiration of the Gamma Knife Service Term and within a reasonable time thereafter, GKF, at its cost and expense, may enter upon the Site under Hospital supervision and remove the Equipment.

 

“(b)         Hospital shall exercise one (1) of the two (2) options referred to above by giving an irrevocable written notice thereof to GKF at least one (1) year prior to the expiration of the Term. Any such notice shall be sufficient if it states in substance that Hospital elects to exercise its option and states which of the two (2) options referred to above Hospital is exercising. If Hospital fails to exercise the option granted herein at least one (1) year prior to the expiration of the Term, the option shall lapse and this Agreement shall expire as of the end of the Term. Further, if Hospital exercises the option specified in Section 17(a)(i) above and the parties are unable to mutually agree upon the length of the extension of the Term or any other terms or conditions applicable to such extension prior to the expiration of the Term, this Agreement shall expire as of the end of the Term.”

 

- 6 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

11.    Termination for Economic Justification. Notwithstanding anything to the contrary contained in the Lease or herein, if, at any time after the initial twelve (12) months following the First Esprit Procedure Date, based upon the utilization of the Esprit and other factors considered relevant by GKF in the exercise of its reasonable discretion, within a reasonable period of time after GKF’s written request, Hospital does not provide GKF with a reasonable economic justification to continue the Agreement and the utilization of the Esprit at the Hospital, then and in that event, but without waiving any or all of GKF’s rights or remedies under the Agreement, GKF shall have the option to terminate the Agreement by giving a written notice thereof to Hospital not less than ninety (90) days prior to the effective date of the termination designated in GKF’s written notice. Without limiting the generality of the foregoing, for purposes of this Section, “reasonable economic justification to continue the Agreement” shall not be deemed to exist (and GKF shall have the option to terminate the Agreement) if, during the twelve (12) month period immediately preceding the issuance of GKF’s written notice of termination, the “Net Cash Flow” is negative. As used herein, “Net Cash Flow” shall mean, for the applicable period, (a) the aggregate Per Procedure Payments actually received by GKF during such period, minus (b) the sum of the aggregate (i) debt service on the Esprit, (ii) maintenance expenses, and (iii) Esprit-related personal property taxes and insurance during such period.

 

12.    Supplier and Owner of Esprit. The parties hereto agree that, notwithstanding anything to the contrary set forth herein, the Lease and this Fourth Amendment is and shall be treated and interpreted as a "finance lease," as such term is defined in Article 2A of the Uniform Commercial Code and Section 2A.103(a)(7) of the Business and Commerce Code (Vernon's Texas Statutes and Codes), that GKF shall be treated as a finance lessor who is entitled to the benefits and releases from liability accorded to a finance lessor under Article 2A of the Uniform Commercial Code and Section 2A.103(a)(7) of the Business and Commerce Code (Vernon's Texas Statutes and Codes). In furtherance of the foregoing, Hospital acknowledges that, before signing this Fourth Amendment, GKF has informed Hospital in writing (a) that Elekta is the entity supplying the Esprit to GKF, (b) that Hospital is entitled (under Section 2A of the Uniform Commercial Code and Section 2A.103(a)(7) of the Business and Commerce Code (Vernon's Texas Statutes and Codes)) to the promises and warranties, including those of any third party, provided to GKF by Elekta which is the entity supplying the goods in connection with or as part of the contract by which GKF acquired the Esprit or the right to possession and use of the Esprit, and (c) that Hospital may communicate with Elekta and receive an accurate and complete statement of those promises and warranties, including any disclaimers and limitations of them or of remedies. Hospital also acknowledges that Hospital has selected Elekta to supply the Esprit and has directed GKF to acquire the Esprit or the right to possession and use of the Esprit from Elekta.

 

13.    Miscellaneous. This Fourth Amendment (a) shall be governed by and construed under the laws of the State of Texas, without reference to its principles of conflicts of law; and (b) may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all of which counterparts shall together constitute the same instrument. The captions and paragraph headings used herein are for convenience only and shall not be used in construing or interpreting this Fourth Amendment. This Fourth Amendment together with the Exhibits attached hereto constitutes the full and complete agreement and understanding between the parties hereto concerning the subject matter hereof and shall supersede any and all prior written and oral agreements with regard to such subject matter.

 

- 7 -

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

14.    Full Force and Effect. Except as amended by this Fourth Amendment, all of the terms and provisions of the Lease shall remain unchanged and in full force and effect and, together with this Fourth Amendment, represent the entire agreement of the parties with respect to the Esprit and its use by Hospital. Unless the context requires otherwise, with respect to the Esprit, all references in the Lease to (i) the “Agreement” shall be deemed to refer to the Lease, as amended by this Fourth Amendment; (ii) the “Equipment” shall be deemed to mean the Esprit; (iii) “Installation” shall be deemed to refer to the Esprit Upgrade; (iv) the “Agreement” shall be deemed to refer to the Lease as amended by this Fourth Amendment; (v) the “Site” shall be deemed to refer to the Site; and (vi) the “Gamma Knife Service Term” or “Term” shall be deemed to refer to the Term, as extended pursuant to this Fourth Amendment. To the extent any of the terms of the Lease conflict with the terms of this Fourth Amendment, the terms and provisions of this Fourth Amendment shall prevail and control. Where not different or in conflict with the terms and provisions of this Fourth Amendment, all applicable terms and provisions set forth in the Lease are incorporated within this Fourth Amendment as is if set forth herein and shall apply with equal force and effect to the Esprit. Nothing set forth in this Fourth Amendment shall relieve either party from any or all of its obligations under the Lease with respect to the Perfexion, including, without limitation, the obligation to pay per procedure payments and the service, insurance and property tax expenses associated with the Perfexion.

 

[Signatures continued on next page]

 

- 8 -

 

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

IN WITNESS WHEREOF, the undersigned have executed this Fourth Amendment as of the day first written above.

 

GKF:

GK FINANCING, LLC

By:         /s/ Craig K. Tagawa

Name:    Craig K. Tagawa

Title:      CEO

Dated:    7/28/2023

Hospital:

METHODIST HEALTHCARE SYSTEM OF SAN

ANTONIO, LTD., L.L.P. d/b/a Southwest Texas

Methodist Hospital

By:         /s/ John Armour

Name:    John Armour

Title:      CFO

Dated:    7/26/ 2023

 

 

- 9 -

 

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

Exhibit A

 

PER PROCEDURE PAYMENTS

 

The Per Procedure Payment shall be [*****] [*****]) per Procedure, commencing from the First Esprit Procedure Date and continuing through the duration of the Term (as extended hereby).

 

- 10 -
EX-10.13D 3 ex_643820.htm EXHIBIT 10.13D ex_643820.htm

Exhibit 10.13d

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

AMENDMENT THREE TO EQUIPMENT LEASE AGREEMENT

 

This AMENDMENT THREE TO EQUIPMENT LEASE AGREEMENT (this “Amendment Three”) is dated effective as of _________, 2023 (the “Effective Date”), and is entered into by and between (i) GK FINANCING, LLC, a California limited liability company (“GKF”), whose address is 601 Montgomery Street, Suite 1112, San Francisco, CA 94111, and (ii) LOVELACE HEALTH SYSTEM, LLC d/b/a Lovelace Medical Center, a New Mexico limited liability company (“Hospital”) whose address is 4101 Indian School Road NE, Albuquerque, NM 87110.

 

Recitals:

 

A. GKF and AHS Albuquerque Medical Center, LLC (“AHS”) entered into a certain Equipment Lease Agreement dated February 13, 2003 (the “Lease Agreement”), pursuant to which GKF agreed to lease to AHS a Leksell Stereotactic Gamma Knife unit, Model C with Automatic Positioning System (the “Model C”).

 

B. AHS (also known as CNT-AHS Albuquerque Medical Center, LLC) was merged into Hospital, effective October 1, 2003, pursuant to which Hospital assumed all of AHS’s rights and obligations under the Lease Agreement by operation of law.

 

C. Hospital and GKF amended the Lease Agreement to provide for the replacement and upgrade of the Model C that was being leased by GKF to Hospital pursuant to the Lease Agreement, effective April 8, 2011 (the “First Amendment”), as amended by that certain First Amendment to Consent to Sublease Agreement effective February 19, 2018, with a Leksell Gamma Knife Perfexion unit including the LOP Software (such Perfexion unit leased hereunder is referred to as the “Perfexion”), which was installed at the existing Site (as defined in the Lease) at which the Model C was installed, and contemporaneously with the de-installation of the Model C (the “Perfexion Upgrade”).

 

D. Hospital and GKF further amended the Lease Agreement to upgrade the Perfexion that was being leased by GKF to Hospital pursuant to the Lease Agreement, effective October 15, 2019 (the “Second Amendment,” and together with the Lease Agreement and First Amendment, the “Lease”) to a Leksell Gamma Knife Icon.

 

E. GKF and Hospital desire to further amend the Lease to provide for the Cobalt-60 reload and lightning software upgrade of the Leksell Gamma Knife Icon unit (“Icon”) currently being provided by GKF to Hospital pursuant to the Lease, which will be performed on the existing Icon at the existing Site.

 

Agreement:

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.           Defined Terms. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Lease.

 

1

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

2.           Cobalt-60 Reload and Lightning Software Upgrade.

 

a.    Scheduling and Process for the Reload Lightning Software Upgrade. Subject to the terms and conditions set forth herein, GKF shall reload the existing Icon with new Cobalt-60 that meets the manufacturer’s radioactivity level specifications (the “Reload”) and upgrade the software to include lightning software (“Upgrade”). GKF shall use best efforts to perform the Reload and Upgrade in the first calendar quarter of 2024, subject to execution of this amendment no later than November 10, 2023, or such other time as mutually agreed to in writing by authorized representatives of Hospital and GKF, subject to issuance of all regulatory approvals, permits, licenses, consents, authorizations, and/or waivers in a timely manner (collectively, “Permits”), and completion of construction, if any, of the Site. GKF warrants that all such installations and services provided by GKF shall meet all specifications and other criteria required by applicable law or other documentation as necessary in order to support the Hospital’s ability to perform Procedures using the Equipment. The parties acknowledge that Hospital may not be able to perform Procedures for approximately three (3) weeks during the Reload and Upgrade. Notwithstanding anything to the contrary contained in this Amendment Three, GKF shall have no obligation or liability to pay any damages to Hospital directly resulting from the Hospital’s inability to perform Procedures during the time required for the Reload and Upgrade, provided the time required for such Reload and Upgrade does not exceed three (3) weeks, including, without limitation, any lost revenues or profits during the period of time that the Equipment is unavailable to perform Procedures during the Reload and Upgrade.

 

b.    Site Preparation and Rigging. Without limiting GKF’s obligation or Hospital’s rights under Section 6 of the Lease Agreement, GKF, at its sole cost and expense, shall be solely responsible for the preparation of the Site and the rigging and installation required for the Reload. GKF shall, and shall require its personnel to, comply with all relevant policies, rules, and guidelines of Hospital while onsite or accessing Hospital’s systems or network. GKF takes full responsibility for the acts and omissions of its personnel while at the Site or accessing Hospital’s systems or network.

 

c.    Hospital Personnel and Services. Upon reasonable request and as reasonably required by GKF solely to perform its obligations under this Amendment Three, Hospital shall provide GKF with Hospital personnel (including Hospital’s physicists) and services, including security, in connection with Reload, among other things, to oversee, supervise, and assist with compliance with local, state, and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the Icon. Hospital shall not be entitled to reimbursement for its personnel costs, internal costs, or overhead in connection with the Reload and Upgrade. Notwithstanding anything to the contrary set forth herein, the Reload shall be performed by GKF only after all necessary and appropriate Site modifications (if any) and Permits concerning the proper handling of the Cobalt-60 for use in Procedures by Hospital, have been obtained by Hospital at Hospital’s sole cost and expense. Subject to Sections 2.a and 2.b above and this Section 2.c, the actual costs of the Reload and Upgrade paid or payable to third parties shall be the responsibility of GKF.

 

d.    Lender Documentation. Upon reasonable request by GKF and at GKF’s reasonable expense, Hospital shall execute and deliver a commercially reasonable form of subordination, attornment, and non-disturbance or other documentation if such a document is reasonably requested by the third party financing company which holds a security interest in the Icon.

 

e.    Acceptance Tests. Upon receipt of Elekta’s report on the results of the Acceptance Tests (as defined in the Leksell Gamma Knife End User Agreement dated March 7, 2011 (“LGK Agreement”), by and between Hospital and Elekta, Inc. (“Elekta”)), Hospital shall have five (5) business days to review and validate the results of the Acceptance Tests to confirm that the Icon meets the manufacturer’s specifications and documentation. If Hospital fails to respond within such five (5) business day period, Hospital shall be granted a one-time five (5) business day extension to validate and confirm the results of the Acceptance Tests. If Hospital fails to respond within such review period, as extended, Hospital shall be deemed to have validated and confirmed the results of the Acceptance Tests.

 

3.           No Ownership Interests. Notwithstanding anything to the contrary set forth in the Lease or this Amendment Three, GKF shall retain all ownership rights and title to the Icon, and Hospital shall have no ownership interest therein.

 

4.           Extension of Lease Term. The Term of the Lease is hereby extended for a period of sixty-six (66) months following the termination date contemplated in the Second Amendment, unless earlier terminated, and shall continue through November 22, 2029. All references in the Lease to the “Term” shall refer to the term as extended hereby,

 

5.           Lease Payments.

 

a.    It is understood and agreed that Section 8 of the Lease (Per Procedure Payments) shall remain in full force and effect with respect to all Procedures performed prior to January 1, 2024, and that all rent or lease payments pertaining to Procedures performed prior to January 1, 2024 shall continue to be calculated in accordance with the current Section 8 of the Lease in place prior to this Amendment Three and shall be paid by Hospital to, and retained solely by, GKF. Effective as of and after January 1, 2024, the first paragraph only of Section 8 of the Lease shall be deleted in its entirety and replaced with the following:

 

“8. Per Procedure Payments. As rent for the lease of the Equipment to Hospital pursuant to this Lease, commencing from and after January 1, 2024, Hospital shall pay to GKF pursuant to Exhibit A attached for each Procedure (as defined below) that is performed by Hospital or its representatives or affiliates at the Site or within the State of New Mexico at the direction of Hospital or any of its affiliates, whether on an inpatient or outpatient basis, or “under arrangement” (as used in the Medicare billing context), and irrespective of whether the Procedure is performed on the Equipment or using any other equipment or devices; provided that the Icon was available and fully operational at the time the Procedure was performed. As used herein, a “Procedure” means any treatment that involves stereotactic, external, single or up to and including five (5) fraction(s), conformal radiation, commonly called radiosurgery, that may include one or more isocenters during the patient treatment session, delivered to any site(s) superior to the foramen magnum. “Procedure” shall expressly exclude any procedures which the Equipment is unable to perform or which, in the opinion of Elekta, the Equipment is not designed or reasonably suitable to perform.”

 

2

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

6.           Notices. As of the Effective Date, Hospital’s notice address as set forth in Section 24.14 of the Lease shall be deleted in its entirety and replaced with the following:

 

“To Hospital: Lovelace Medical Center
  Attention: Chief Executive Officer
  4101 Indian School Road NE
  Albuquerque, NM 87110
   
With a copy to: Lovelace Medical Center
  Attention: General Counsel
  340 Seven Springs Way, Suite 100
  Brentwood, TN 37027”

 

7.           Full Force and Effect. Except as amended by this Amendment Three, all of the terms and provisions of the Lease shall remain unchanged and in full force and effect and, together with this Amendment Three, represent the entire agreement of the parties with respect to the Reload and Upgrade and its use by Hospital. Unless the context requires otherwise, with respect to the Cobalt reload and Lightning software upgrade, all references in the Lease to (i) the “Agreement” shall be deemed to mean the Lease as amended; (ii) the “Equipment” shall be deemed to mean the Icon; (iii) the “LGK Agreement” shall be deemed to refer to the LGK Agreement executed by Hospital relating to the Perfexion; and (iv) the “Term” shall be deemed to refer to the Term, as extended pursuant to this Amendment Three. To the extent any of the terms of the Lease as amended conflict with the terms of this Amendment Three as it pertains to the Reload and Upgrade, the terms and provisions of this Amendment Three shall prevail and control. Where not different or in conflict with the terms and provisions of this Amendment Three, all applicable terms and provisions set forth in the Lease as amended are incorporated within this Amendment Three as is if set forth herein and shall apply with equal force and effect to the Reload and Upgrade. Notwithstanding anything to the contrary set forth herein, no term or condition of this Amendment Three shall be effective to the extent it causes Hospital to breach the LGK Agreement or otherwise violate or infringe upon the rights of Elekta. Nothing set forth in this Amendment Three shall relieve either party from any or all of its obligations under the Lease as amended. Hospital shall have no further obligations with respect thereto other than making payments for Procedures performed.

 

[The remainder of this page intentionally left blank; signature page(s) follow.]

 

3

 

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

IN WITNESS WHEREOF, the parties have executed this Amendment Three effective as of the Effective Date.

 

 

GKF:   Hospital:  
           
GK FINANCING, LLC   LOVELACE HEALTH SYSTEM, LLC,  
      d/b/a Lovelace Medical Center  
           
By: /s/ Craig K. Tagawa   By: /s/ Brian Miller  
Name: Craig K. Tagawa   Name: Brian Miller  
Title: Chief Executive Officer   Title: Chief Operating Officer  
Date: 11/6/23   Date: 11/9/23  
           
      Internal Review Only:  
           
      By: /s/ Richard Hann  
      Name:  Richard Hann  
      Title: Div VIP/CFO  
      Date: 11/9/23  

 

4

 

 

[*****] Text Omitted for Confidential Treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

Exhibit A

 

PER PROCEDURE PAYMENTS

 

Annual Paid Procedures Performed

Fee Per Use

1-100

$ [*****] per Procedure

101+

$[*****] per Procedure

 

Notwithstanding anything to the contrary set forth herein, for purposes of determining the Per Procedure Payments, the number of annual Procedures performed on the Icon or using any other equipment or devices shall be reset to zero (0) at the commencement of each annual anniversary after January 1, 2024.

 

For Per Procedure count purposes any patient treatment provided on a fractionated basis shall count as one (1) Procedure.

 

5
EX-10.20B 4 ex_643819.htm EXHIBIT 10.20B ex_643819.htm

Exhibit 10.20b

 

AMENDMENT TWO TO LEKSELL GAMMA KNIFE PERFEXION

PURCHASED SERVICES AGREEMENT

 

This AMENDMENT TWO TO LEKSELL GAMMA KNIFE PERFEXION PURCHASED SERVICES AGREEMENT (this “Amendment”) is made and entered into as of the date of the last party to sign below, by and between GK FINANCING, LLC, a California limited liability company (“GKF”), and PEACEHEALTH, a Washington non-profit corporation, doing business through its operating division PEACEHEALTH SACRED HEART MEDICAL CENTER AT RIVERBEND (“Medical Center”), with reference to the following recitals:

 

RECI TA LS

 

WHEREAS, GKF and Medical Center entered into that Purchased Services Agreement dated March 27, 2014, pursuant to which GKF agreed to provide Medical Center with a Leksell Gamma Knife Perfexion (“Equipment”) and on January 20, 2021, as amended GKF and Medical Center agreed to a Cobalt-60 reload and software upgrade of the Equipment.

 

WHEREAS, GKF and Medical Center desire to further amend the Purchased Services Agreement on the terms set forth herein to provide for the upgrade of the existing Perfexion with an Esprit upgrade package and for the Cobalt-60 reload of the Esprit (Exhibit A) being provided by GKF to Medical Center pursuant to the PSA.

 

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

AGREEMENT

 

1.    Defined Terms. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Agreement.

 

2.    Upgrade of the Perfexion to the Esprit and Cobalt-60 Reload. In accordance with Section 9.2 of the Purchased Service Agreement (“PSA”) and subject to the terms and conditions set forth herein, GKF shall acquire and hold title to the Esprit.

 

2.1 User License. Medical Center shall apply for and obtain in a timely manner a User License from the Nuclear Regulatory Commission and, if necessary, from the applicable state agency authorizing it to install and operate the Esprit and to take possession of and maintain the Cobalt supply required in connection with the use of the Esprit during the term of the PSA. Medical Center also shall apply for and obtain in a timely manner all other licenses, permits, approvals, consents and authorizations which may be required by state or local governmental or other regulatory agencies for the development, construction and preparation of the Site, the charging of the Equipment with its Cobalt supply, the conduct of acceptance tests with respect to the Equipment, and the use of the Equipment during the Term. Upon request, Medical Center shall provide GKF with true and correct copies of any and all such licenses, permits, approvals, consents and authorizations.

 

2.2  Delivery of Equipment; Site. GKF shall coordinate with Elekta and Medical Center to have the Esprit upgrade package and Cobalt-60 delivered to (the “Site”) on a delivery date agreed upon in writing by GKF, Medical Center and Elekta. The location of the Site shall be the current Perfexion suite. Subject to availability of the Esprit and Cobalt-60 from the equipment manufacturer, issuance of all regulatory approvals, permits and/or waivers in a timely manner, and completion of construction of the Site, the estimated delivery date is on or around March 2024, subject to execution of this Amendment Two on/or before January 8, 2024 GKF makes no representations or warranties concerning delivery of the Equipment. The parties acknowledge that Medical Center may not be able to perform Procedures for approximately 6-7 weeks during the Esprit Upgrade and Cobalt-60 reload. GKF and Medical Center agree that the cost of the Esprit Upgrade and Cobalt-60 reload shall be the sole responsibility of GKF.

 

2.3         Site Preparation and Installation of Equipment

 

(a) GKF in coordination with Elekta, shall prepare all plans, specifications and site planning criteria (collectively the “Site Planning Criteria”) required to prepare, construct and improve the Site for the installation, use and operation of the Equipment during the Term. The plans and specifications (i) shall be approved by Medical Center, which approval shall not be unreasonably withheld or delayed; (ii) shall comply in all respects with the Site Planning Criteria; and (iii) to the extent required by applicable law, shall be submitted to all state and federal agencies for their review and approval. Medical Center, shall obtain all permits, certifications, approvals or authorizations required by applicable federal, state or local laws, rules or regulations necessary to prepare, construct and improve the Site as provided above.

 

(b) GKF shall prepare, construct and improve the Site as necessary for the installation, use and operation of the Esprit during the Term (as extended herein), including, without limitation, aligning the Site for the Equipment, and installing all electrical systems and other wiring required for the Equipment. In connection with the construction of the Site, Medical Center, shall select, purchase and install all radiation monitoring equipment, devices, safety circuits and radiation warning signs required at the Site in connection with the use and operation of the Equipment.

 

(c) In addition to construction and improvement of the Site, GKF, shall be responsible for the installation of the Esprit upgrade package, in compliance with the Site Planning Criteria.

 

(d) All costs incurred to fulfill the obligation enumerated in Section 2.3 (a), (b) and (c), shall be the sole responsibility of GKF, except for those Medical Center responsibilities enumerated in Section 2.3 (a) and (b). For the avoidance of doubt, GKF shall bear the cost of all drawings as well as rigging, unloading and loading of Cobalt-60. Medical Center shall be responsible for permit applicable costs and GKF Esprit fees.

 

(e) During the Term (as extended herein), Medical Center, at its cost and expense, shall maintain the Site in a good working order, condition and repair, reasonable wear and tear expected.

 

(f) Lender Documentation. GKF, in its sole discretion, may finance its portion of the Esprit Upgrade and Cobalt-60 Reload costs in which event, the terms and provisions set forth in Section 14 of the Agreement (Financing of Equipment by GKF) shall apply to the Esprit Upgrade and Cobalt-60 Reload. In furtherance of the foregoing, and upon request by GKF, Medical Center shall execute and deliver a commercially reasonable form of subordination, attornment and non-disturbance or other documentation if such a document is reasonably requested by the third party financing company which holds a security interest in the Equipment.

 

2.4 Medical Center Personnel and Services. Upon request and as required by GKF, Medical Center, at Medical Center’s cost and expense, shall provide GKF with Medical Center personnel (including Medical Center’s physicists) and services, including security, in connection with the Esprit installation and Cobalt-60 reload, among other things, to oversee, supervise and assist with construction and compliance with local, state and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the Esprit. Medical Center shall not be entitled to reimbursement for its personnel costs, internal costs or overhead in connection with the Esprit Upgrade and Cobalt-60 reload. Notwithstanding anything to the contrary set forth herein, the Esprit Upgrade and Cobalt-60 reload shall be performed by GKF only after all necessary and appropriate licenses, permits, approvals, waivers, and consents and authorizations, (collectively, the “Permits”), have been obtained by Medical Center at Medical Center’s sole cost and expense.

 

2.5 Training. GKF, at its cost and expense, shall cover the Esprit training tuition costs for those Medical Center-credentialed physicians and physicists who will be using the Esprit as stated in Attachment A. Any travel and entertainment associated with training shall not be the responsibility of GKF.

 

2.6 Acceptance Tests. Upon receipt of Elekta’s report on the results of the Acceptance Tests (as defined in the LGK Agreement), Medical Center shall have seven (7) business days to review and validate the results of the Acceptance Tests to confirm that the Equipment meets the manufacturer’s specifications and documentation. If Medical Center fails to respond within such seven (7) business day period, Medical Center may request in writing a one-time seven (7) business days extension from GKF. If Medical Center fails to respond within such seven (7) business day period (as may be so extended), Medical Center shall be deemed to have validated and confirmed the results of the Acceptance Tests.

 

2.7 Warranty. Upon completion of the Esprit package upgrade and Cobalt-60 reload, a full twelve (12) month warranty for the complete system at the Site will follow.

 

2.8 New LGK End User License Agreement. Concurrently with the execution of this Amendment Two, Medical Center shall enter into a new LGK End User License Agreement with Elekta, Inc., a Georgia corporation (“Elekta”), which shall supersede and replace the previous LGK End User Agreement attached as Exhibit 1 to the PSA (such new LGK End User License Agreement shall hereinafter be referred to as the "LGK EULA ," and shall be deemed attached as Exhibit 1 to the PSA). Use of the Esprit shall be made available to all neurosurgeons and radiation oncologists with Medical Center privileges.

 

3.         Extension of Term of the Agreement. The Term of the Agreement is hereby extended for a period of ten (10) years from the first Esprit clinical procedure. All references in the Agreement Two to the “Term” or “Initial Term” shall be deemed to refer to the Term, as extended hereby. Any subsequent reload of the Cobalt-60 source prior to the expiration of the Term as extended hereby shall be on such terms as specified in Section 13.2 of the PSA. End of Life and End of Guaranteed Support shall be November 1, 2034, for the field upgraded Gamma Knife Esprit.

 

4.          Miscellaneous. This Amendment Two may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all of which counterparts shall together constitute the same instrument. The captions and paragraph headings used herein are for convenience only and shall not be used in construing or interpreting this Amendment Two. This Amendment Two constitutes the full and complete agreement and understanding between the parties hereto concerning the subject matter hereof and shall supersede any and all prior written and oral agreements with regard to such subject matter.

 

5.         Full Force and Effect. Except as amended by this Amendment Two, all of the terms and provisions of the PSA shall remain unchanged and in full force and effect and, together with this Amendment Two, represent the entire agreement of the parties with respect to the Esprit and its use by Medical Center. Unless the context requires otherwise, with respect to the Esprit, all references in the PSA to (i) the “Agreement” shall be deemed to refer to the PSA, as amended by this Amendment Two; (ii) the “Equipment” shall be deemed to mean the Esprit and where appropriate, Perfexion; (iii) “Installation” shall be deemed to refer to the Esprit Upgrade and Cobalt-60 reload; (iv) the “Agreement” shall be deemed to refer to the PSA as amended by this Amendment Two; (v) the “Site” shall be deemed to refer to the Site; and (vi) the “Term” shall be deemed to refer to the Term, as extended pursuant to this Amendment Two. To the extent any of the terms of the PSA conflict with the terms of this Amendment Two, the terms and provisions of this Amendment Two shall prevail and control. Where not different or in conflict with the terms and provisions of this Amendment Two, all applicable terms and provisions set forth in the PSA are incorporated within this Amendment Two as if set forth herein and shall apply with equal force and effect to the Esprit. Nothing set forth in this Amendment Two shall relieve either party from any or all of its obligations under the PSA with respect to the Perfexion, including, without limitation, the obligation to pay Purchased Services Payments and the service, insurance and property tax expenses associated with the Perfexion.

 

 

 

 

 

 

[Signatures continued on next page]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date of the last party to sign below:

 

 

“GKF”                                    GK FINANCING, LLC

 

 

By: /s/ Craig K. Tagawa

 

Title: CEO

 

Date: 12/29/23

 

 

 

 

 

“MEDICAL CENTER”         PEACEHEALTH, dba

PEACEHEALTH SACRED HEART

MEDICAL CENTER AT RIVERBEND                                             

 

By: /s/ Darrin Montalvo

 

Title: EVP Chief Financial Growth Officer

 

Date: 1/19/24_

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit A

ESPRIT UPGRADE PACKAGE AND COBALT-60 RELOAD

 

See Attached PDFs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 1

LGK END USER LICENSE AGREEMENT

 

To be provided by Elekta

 
EX-10.23B 5 ex_643778.htm EXHIBIT 10.23B ex_643778.htm

Exhibit 10.23b

 

FIRST AMENDMENT TO

 

LEASE AGREEMENT FOR A GAMMA KNIFE UNIT

 

(Perfexion on site upgrade to ELEKTA ESPRIT)

 

This FIRST AMENDMENT TO LEASE AGREEMENT FOR A GAMMA KNIFE UNIT (this "First Amendment") is dated effective as of April 18, 2023 (the "Effective Date”) and is entered into by and between GK FINANCING, LLC, a California limited liability company ("GKF"), and THE METHODIST HOSPITALS, INC, an Indiana non-profit corporation (''Hospital”) at 600 Grant Street, Gary, Indiana 46402.

 

Recitals:

 

 

A.         On May 8, 2018, GKF and Hospital entered into a certain equipment Lease Agreement for A Gamma Knife PERFEXION (“Lease”).

 

B.         Hospital, and Elekta, Inc. entered into a Leksell Gamma Knife End User Agreement last executed on May 8, 2018 (“End User Agreement”), as attached in Exhibit B.

 

C.         Hospital and GKF desire to amend the Lease to provide for the upgrade of the existing Leksell Gamma Knife Perfexion unit (the “Perfexion”) that is currently being leased by GKF to Hospital pursuant to the Lease, with a Leksell Gamma Knife – Esprit upgrade package (Exhibit A), (such Esprit unit leased hereunder is referred to herein as the “Esprit” or the “Equipment”), which will be upgraded at the existing Site at which the Perfexion is currently installed.

 

Agreement:

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.    Defined Terms. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Lease.

 

2.    Upgrade of the Perfexion to the Esprit. Elekta, Inc. has agreed to sell the Esprit onsite upgrade package as defined on Exhibit A to GKF to be leased to Hospital pursuant to the Lease, as amended. In accordance with Section 9 of the Lease and subject to the terms and conditions set forth herein, GKF shall acquire and hold title to the Esprit, which shall be used by Hospital at the Site.

 

2.1         The existing End User Agreement shall remain in full force, provided however, the End User Agreement shall be modified as follows: (a) the definition of LGK is modified so that Exhibit A shall be the same as Exhibit A attached to this First Amendment; (b) LGP Software shall mean the dose planning software described in the Specifications for the Esprit, with a copy of such Specifications provided to Hospital prior to installation of the Esprit; (c) the term provided in Section 8.5 shall match the Lease, as extended by this First Amendment; and (d) the Software License described in Exhibit D shall be applicable to the Esprit upgrade software requirements. The current Elekta End User Agreement is attached for the Hospital to suggest changes directly with Elekta.

 

2.1    User License. The following shall replace subparagraph 4.1 of the Lease: Hospital shall apply for and obtain in a timely manner a User License from the Nuclear Regulatory Commission and, if necessary, from the applicable state agency authorizing it to install and operate the Esprit and to take possession of and maintain the Cobalt supply required in connection with the use of the Esprit during the term of the Lease. It is anticipated by Hospital that no additional fee shall be assessed against Hospital for the User License, Cobalt or Cobalt source as a result of the Esprit upgrade. Hospital also shall apply for and obtain in a timely manner all other licenses, permits, approvals, consents, and authorizations which may be required by state or local governmental or other regulatory agencies for the development, construction and preparation of the Site, the charging of the Equipment with its Cobalt supply, the conduct of acceptance tests with respect to the Equipment, and the use of the Equipment during the Term. Upon request, the Hospital shall provide GKF with true and correct copies of any and all such licenses, permits, approvals, consents and authorizations.

 

2.2    Delivery of Equipment; Site. The following shall replace subparagraph 5.1 of the Lease: GKF shall coordinate with Elekta and Hospital to have the Esprit upgrade package delivered to Methodist Merrillville South Lake Campus, 8701 Broadway, Merrillville, IN 46410 (the “Site”) on a delivery date agreed upon in writing by GKF, Hospital and Elekta. The location of the Site shall be the current Perfexion suite. Subject to availability of the Esprit from the equipment manufacturer, issuance of all regulatory approvals, permits and/or waivers in a timely manner, and completion of construction of the Site, the estimated delivery date is on or around September/October 2023, subject to execution of this Amendment on/or before April 15, 2023. GKF makes no representations or warranties concerning delivery of the Equipment to the Site or the actual date thereof. The parties acknowledge that the Hospital may not be able to perform Procedures for approximately 3 - 4 weeks during the Esprit Upgrade.

 

2.3    Site Preparation and Installation of Equipment. The following shall replace Paragraph 6 of the Lease:

 

(a)    GKF, in coordination with Elekta and/or its turnkey solutions provider, H&H Design Build, and at its cost and expense, shall prepare all plans, specifications and site planning criteria (collectively the “Site Planning Criteria”) required to prepare, construct, and improve the Site for the installation, use and operation of the Equipment during the Term. The plans and specifications (i) shall be approved by Hospital, which approval shall not be unreasonably withheld or delayed; (ii) shall comply in all respects with the Site Planning Criteria; and (iii) to the extent required by applicable law, shall be submitted to all state and federal agencies for their review and approval. GKF, at its cost and expense, shall obtain all permits, certifications, approvals, or authorizations required by applicable federal, state or local laws, rules or regulations necessary to prepare, construct and improve the Site as provided above.

 

(b)    GKF, at its cost and expense, prepare, construct, and improve the Site as necessary for the installation, use and operation of the Esprit during the Term (as extended herein), including, without limitation, aligning the Site for the Equipment, and installing all electrical systems and other wiring required for the Equipment. In connection with the construction of the Site, Hospital, at its cost and expense, shall select, purchase and install all radiation monitoring equipment, devices, safety circuits and radiation warning signs required at the Site in connection with the use and operation of the Equipment.

 

(c)    In addition to construction and improvement of the Site, GKF, at its cost and expense, shall be responsible for the installation of the Esprit upgrade package, in compliance with the Site Planning Criteria.

 

(d)    During the Term (as extended herein), the Hospital, at its cost and expense, shall maintain the Site in a good working order, condition and repair, reasonable wear and tear expected.

 

(e)    Upon request by GKF and at GKF’s reasonable expense, Hospital shall execute and deliver a commercially reasonable form of subordination, attornment and non-disturbance or other documentation if such a document is reasonably requested by the third-party financing company which holds a security interest in the Esprit.

 

2.4    Hospital Personnel and Services. Upon request and as required by GKF, Hospital, at Hospital’s cost and expense, shall provide GKF with Hospital personnel (including Hospital’s physicists) and services, including security, in connection with the Esprit installation, among other things, to oversee, supervise and assist with construction and compliance with local, state, and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the Esprit. The hospital shall not be entitled to reimbursement for its personnel costs, internal costs or overhead in connection with the Esprit Upgrade. Notwithstanding anything to the contrary set forth herein, the Esprit Upgrade shall be performed by GKF only after all necessary and appropriate licenses, permits, approvals, waivers, and consents and authorizations, (collectively, the “Permits”), have been obtained by Hospital at Hospital’s sole cost and expense. The actual purchase of the Esprit from third parties shall be the responsibility of GKF.

 

2.5    Training. GKF, at its cost and expense, shall cover the Esprit training tuition costs for those Hospital-credentialed physicians and physicists who will be using the Esprit. Any travel and entertainment associated with training shall not be the responsibility of GKF.

 

2.6    Acceptance Tests. Upon receipt of Elekta’s report on the results of the Acceptance Tests, Hospital shall have five (5) business days to review and validate the results of the Acceptance Tests to confirm that the Esprit meets the manufacturer’s specifications and documentation. If the Hospital fails to respond within such five (5) business day period, Hospital may request a five (5) business day extension to validate and confirm the results of the Acceptance Tests. At the expiration of the five (5) business day period, plus any extension, if applicable, the Hospital’s failure to respond shall constitute Hospital’s validation and confirmation of the Acceptance Tests.

 

2.7    Warranty. Upon completion of the Esprit package upgrade, a full twelve (12) month warranty, starting from signed acceptance test or first clinical use, whichever occurs first, for the complete Esprit system at the Site. This shall include all parts and labor but not include any new function or feature not included as part of this Esprit on upgrade as describes in attached A.

 

3.    No Ownership Interests. Hospital shall have no ownership interest (or option to purchase any ownership interest) in the Esprit, and Hospital hereby waives any ownership interest (or option to purchase any ownership interest) in the Esprit.

 

4.    Extension of Lease Term. In consideration of GKF’s agreement to perform the Esprit Upgrade, the Gamma Knife Service Term (or “Term”) is hereby extended five (5) years to end on January 15, 2034.

 

5.    Compensation.

 

5.1    The parties acknowledge that the compensation payable to GKF for the Esprit shall remain as set forth in Paragraph 8 of the Lease. Such compensation as incorporated into this First Amendment has been negotiated by the parties at arm’s length based upon reasonable and jointly derived assumptions regarding the capacity for clinical services available from the Esprit, Hospital’s capabilities in providing high quality radiation oncology services, market dynamics, GKF’s risk in providing the Esprit, and the provision to GKF of a reasonable rate of return on its investment in support of the Esprit. Based thereon, the parties believe that the Lease Payments represent fair market value for the use of the Esprit, the Esprit Upgrade, maintenance and service, personal property taxes, cost of insurance coverage for the Esprit, and the other additional services and costs to be provided or paid for by GKF pursuant to this First Amendment and taking into account the Hospital’s payment pursuant to Section 8 in the Lease. Hospital undertakes no obligation to perform any minimum number of procedures on the Esprit, and the use of the Esprit for the performance of procedures is wholly based upon the independent judgment of physicians who order such procedures to meet the medical needs of their patients.

 

5.2    As part of the cost reporting process or otherwise, Hospital may be obligated to report and provide information concerning any discounts, rebates, or other price reductions provided under this Agreement pursuant to 42 U.S.C. § 1320a-7b(b)(3)(A) (the discount exception to the Anti-Kickback Law) and/or 42 C.F.R. § 1001.952(h)(the discount safe harbor to the Anti- kickback Law), or other federal or state laws. Hospital hereby acknowledges its legal obligations to fully and accurately report the discounts, rebates and/or other price reductions it receives under this Agreement per these authorities. GKF agrees to fully and accurately report any discounts on the relevant invoice, coupon or statement submitted to Customer, as applicable.  Each party shall retain this Agreement and any other documentation of discounts, rebates, or other price reductions and shall make such information available to federal or state health care programs as required by law.

 

6.    Full Force and Effect. Except as amended by this First Amendment, all of the terms and provisions of the Lease shall remain unchanged and in full force and effect and, together with this First Amendment, represent the entire agreement of the parties with respect to the Esprit and its use by Hospital. Unless the context requires otherwise, with respect to the Esprit, all references in the Lease to (i) the “Agreement” shall be deemed to refer to the Lease, as amended by this First Amendment; (ii) the “Equipment” shall be deemed to mean the Esprit and where appropriate, Perfexion; (iii) “Installation” shall be deemed to refer to the Esprit Upgrade; (iv) the “Agreement” shall be deemed to refer to the Lease as amended by this First Amendment; (v) the “Site” shall be deemed to refer to the Site; and (vi) the “Term” shall be deemed to refer to the Term, as extended pursuant to this First Amendment. To the extent any of the terms of the Lease conflict with the terms of this First Amendment, the terms and provisions of this First Amendment shall prevail and control. Where not different or in conflict with the terms and provisions of this First Amendment, all applicable terms and provisions set forth in the Lease are incorporated within this First Amendment as is if set forth herein and shall apply with equal force and effect to the Esprit. Nothing set forth in this First Amendment shall relieve either party from any or all of its obligations under the Lease and incurred prior to the start of installation of the Esprit with respect to the Perfexion, including, without limitation, the obligation to pay Lease Payments and the service, insurance and property tax expenses associated with the Perfexion.

 

[Signatures continued on next page]

 

 

 

 

 

IN WITNESS WHEREOF, the undersigned have executed this Fourth Amendment as of the day first written above.

 

GKF:

GK FINANCING, LLC

By:          /s/Craig K. Tagawa

Name:         Craig K. Tagawa

Title:           CEO

Dated:         April 18, 2023

Hospital:

THE METHODIST HOSPITALS, INC

By:         /s/ Matthew Doyle

Name:         Matthew Doyle

Title:           President and CEO

Dated:         April 18, 2023

 

 

 

 

 

 

Exhibit A

 

ESPRIT UPGRADE PACKAGE

 

See attachment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attachment B

 

Elekta Perfexion End User Agreement currently in place

 
EX-10.23C 6 ex_643783.htm EXHIBIT 10.23C ex_643783.htm

Exhibit 10.23c

 

SECOND AMENDMENT TO

 

LEASE AGREEMENT FOR A GAMMA KNIFE UNIT

 

(COBALT-60 RELOAD)

 

This SECOND AMENDMENT TO LEASE AGREEMENT FOR A GAMMA KNIFE UNIT (this "Second Amendment") is dated effective as of the last date signed by the parties (the "Effective Date”) and is entered into by and between GK FINANCING, LLC, a California limited liability company ("GKF"), and THE METHODIST HOSPITALS, INC, and Indiana non-profit corporation (''Hospital”) at 600 Grant Street, Gary, Indiana 46402.

 

Recitals:

 

 

A.         On May 8, 2018, GKF and Hospital entered into a certain equipment Lease Agreement for A Gamma Knife PERFEXION (“Lease”).

 

B.         Hospital and GKF entered into a First Amendment to the Lease, effective April 18, 2023, to provide for the upgrade of the existing Leksell Gamma Knife unit (the “Perfexion”) that is currently being leased by GKF to Hospital pursuant to the Lease, with a Leksell Gamma Knife – Esprit upgrade package (such Esprit unit leased hereunder is referred to herein as the “Esprit” or the “Equipment”), which will be upgraded at the existing Site at which the Perfexion is currently installed.

 

C.         Hospital, GKF and Elekta, Inc. entered into a Leksell Gamma Knife End User Agreement contemporaneously with this Lease Agreement (“End User Agreement”).

 

D.         GKF and Hospital desire to further amend the Lease to provide for the Cobalt-60 reload of the Equipment.

 

 

Agreement:

 

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

 

1.    Defined Terms. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Lease.

 

 

2.    Cobalt-60 Reload.

 

 

a.         Scheduling and Process for the Reload. Subject to the terms and conditions set forth herein, GKF shall reload the existing Equipment with new Cobalt-60 that meets the manufacturer’s radioactivity level specifications (the “Reload”). GKF shall use its commercially reasonable best efforts to perform the Reload on or about September 2023, or such other time as mutually agreed to in writing by Hospital and GKF, subject to availability of the Cobalt-60, issuance of all regulatory approvals, permits and/or waivers in a timely manner, and completion of construction, if any, of the Site. The parties acknowledge that Hospital may not be able to perform Procedures for approximately three weeks during the Reload. Notwithstanding anything to the contrary contained in this Second Amendment, GKF makes no representation or warranty to Hospital concerning the Reload and GKF shall have no obligation or liability to pay any damages to Hospital resulting from the Hospital’s inability to perform Procedures during the time required for the Reload.  In the event the Cobalt-60 for Reload is not shipped prior to December 31, 2024, then either party may terminate this Second Amendment, which shall then become null and void.

 

 

b.         Site Preparation and Rigging. GKF, at its sole cost and expense, shall be solely responsible for the preparation of the Site and the rigging and installation required for the Reload.

 

 

c.         Hospital Personnel and Services. Upon request and as required by GKF, Hospital, at Hospital’s cost and expense, shall provide GKF with Hospital personnel (including Hospital’s physicists) and services, including security, in connection with Reload, among other things, to oversee, supervise and assist with compliance with local, state and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the Equipment. Hospital shall not be entitled to reimbursement for its personnel costs, internal costs or overhead in connection with the Reload. Notwithstanding anything to the contrary set forth herein, the Reload shall be performed by GKF only after all necessary and appropriate Site modifications (if any), licenses, permits, approvals, waivers, consents and authorizations, and the proper handling of the Cobalt-60 (collectively, the “Permits”), have been obtained by Hospital at Hospital’s sole cost and expense. Subject to Sections 2.a and 2.b above and this Section 2.c, the actual costs of the Reload paid or payable to third parties shall be the responsibility of GKF.

 

d.         Lender Documentation. Upon request by GKF and at GKF’s reasonable expense, Hospital shall execute and deliver a commercially reasonable form of subordination, attornment and non-disturbance or other documentation if such a document is reasonably requested by the third party financing company which holds a security interest in the Equipment.

 

 

e.         Acceptance Tests. Upon receipt of Elekta’s report on the results of the Acceptance Tests (as defined in the Leksell Gamma Knife End User Agreement (“LGK Agreement”), Hospital shall have five (5) business days to review and validate the results of the Acceptance Tests to confirm that the Icon meets the manufacturer’s specifications and documentation. If Hospital fails to respond within such five (5) business day period, Hospital shall be granted a one-time five (5) business day extension to validate and confirm the results of the Acceptance Tests. If Hospital fails to respond within such review period, as extended, Hospital shall be deemed to have validated and confirmed the results of the Acceptance Tests.

 

f.         Future Reload.  Section 13.2 of the Agreement is amended so that any future reloading of the Cobalt-60 shall only be by mutual Agreement of the parties and no longer in the sole discretion of GKF.

 

 

3.    Insurance.  For clarification purposes, the insurance provisions of Section 23.1 and 23.3 of the Lease shall be applicable to GKF for all purposes of the Reload.

 

 

4.    Extension of Lease Term. The Term of the Lease as amended is hereby extended for a period of three (3) years to January 15, 2037. All references in the Lease to the “Term” shall refer to the term as extended hereby,

 

 

5.    Compensation.

 

 

a.         The parties acknowledge that the compensation payable to GKF for the Esprit shall remain as set forth in Paragraph 8 of the Lease. Such compensation as incorporated into this Second Amendment has been negotiated by the parties at arm’s length based upon reasonable and jointly derived assumptions regarding the capacity for clinical services available from the Esprit, Hospital’s capabilities in providing high quality radiation oncology services, market dynamics, GKF’s risk in providing the Esprit, and the provision to GKF of a reasonable rate of return on its investment in support of the Cobalt-60 reload of the Esprit. Based thereon, the parties believe that the Lease Payments represent fair market value for the Use of the Esprit, the Esprit Cobalt-60 reload, maintenance and service, personal property taxes, cost of insurance coverage for the Esprit, and the other additional services and costs to be provided or paid for by GKF pursuant to this Second Amendment and taking into account the Hospital’s payment pursuant to Section 8 in the Lease. Hospital undertakes no obligation to perform any minimum number of procedures on the Esprit, and the use of the Esprit for the performance of procedures is wholly based upon to independent judgement of physicians who order such procedures to meet the medical needs of their patients.

 

 

b.         As part of the cost reporting process or otherwise, Hospital may be obligated to report and provide information concerning any discounts, rebates, or other price reductions provided under this Agreement pursuant to 42 U.S.C. § 1320a-7b(b)(3)(A) (the discount exception to the Anti-Kickback Law) and/or 42 C.F.R. § 1001.952(h)(the discount safe harbor to the Anti- kickback Law), or other federal or state laws. Hospital hereby acknowledges its legal obligations to fully and accurately report the discounts, rebates and/or other price reductions it receives under this Agreement per these authorities. GKF agrees to fully and accurately report any discounts on the relevant invoice, coupon or statement submitted to Customer, as applicable. Each party shall retain this Agreement and any other documentation of discounts, rebates, or other price reductions and shall make such information available to federal or state health care programs as required by law.

 

 

6.    Full Force and Effect. Except as amended by this Second Amendment, all of the terms and provisions of the Lease as amended shall remain unchanged and in full force and effect and, together with this Second Amendment, represent the entire agreement of the parties with respect to the Esprit and its use by Hospital. Unless the context requires otherwise, with respect to the Esprit, all references in the Lease to (i) the “Agreement” shall be deemed to refer to the Lease, as amended by this Second Amendment; (ii) the “Equipment” shall be deemed to mean the Esprit; (iii) “Installation” shall be deemed to refer to the Esprit Upgrade; (iv) the “Agreement” shall be deemed to refer to the Lease as amended by this Second Amendment; (v) the “Site” shall be deemed to refer to the Site; and (vi) the “Gamma Knife Service Term” or “Term” shall be deemed to refer to the Term, as extended pursuant to this Second Amendment. To the extent any of the terms of the Lease conflict with the terms of this Second Amendment, the terms and provisions of this Second Amendment shall prevail and control. Where not different or in conflict with the terms and provisions of this Second Amendment, all applicable terms and provisions set forth in the Lease are incorporated within this Second Amendment as is if set forth herein and shall apply with equal force and effect to the Esprit. Nothing set forth in this Second Amendment shall relieve either party from any or all of its obligations under the Lease with respect to the Perfexion, including, without limitation, the obligation to pay Lease Payments and the service, insurance and property tax expenses associated with the Perfexion.

 

[Signatures continued next page]

 

 

 

 

 

IN WITNESS WHEREOF, the undersigned have executed this Second Amendment as of the date last written below.

 

 

GKF:

GK FINANCING, LLC

By:         /s/Craig K. Tagawa

Name:       Craig K. Tagawa

Title:         CEO

Dated:       6/13/2023

Hospital:

THE METHODIST HOSPITALS, INC

By:         /s/Matthew Doyle

Name:        Matthew Doyle

Title:          President and CEO

Dated:        6/13/2023

 

 

 
EX-10.33B 7 ex_643794.htm EXHIBIT 10.33B ex_643794.htm

Exhibit 10.33b

 

 

FIRST AMENDMENT TO INVESTMENT AGREEMENT

 

This First Amendment to Investment Agreement dated as of March 1, 2024 (this “Amendment”), is made by and among (a) American Shared Hospital Services, a California corporation (“Purchaser”), (b) GenesisCare USA, Inc., a Florida corporation (as in existence on the date hereof, as a debtor-in-possession and a reorganized debtor, as applicable, “Seller”), and (c) GenesisCare USA Holdings, Inc., a Delaware corporation (as in existence on the date hereof, as a debtor-in-possession and a reorganized debtor, as applicable, “Topco”). Purchaser, Seller, and Topco are referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Investment Agreement (as defined below).

 

RECITALS:

 

WHEREAS, the Parties are parties to that certain Investment Agreement dated as of November 10, 2023 (the “Investment Agreement”);

 

 

WHEREAS, the Parties desire to amend the Investment Agreement pursuant to Section 9.5 of the Investment Agreement.

 

NOW THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth in this Amendment and the Investment Agreement, as applicable, the Parties hereby agree as follows:

 

 

AGREEMENT:

 

 

1.    Section 8.1(c) of the Investment Agreement is hereby amended by replacing “(i) March 10, 2024”, with “(i) April 30, 2024”, in the second and third lines of that section.

 

2.    Except as expressly modified by this Amendment, all other terms of the Investment Agreement shall remain unchanged and in full force and effect.

 

 

 

[Remainder of Page Intentionally Left Blank. Signature Pages Follow.]

 

IN WITNESS WHEREOF, this First Amendment to Investment Agreement has been duly executed as of the date set forth above.

 

 

 

 

PURCHASER:

 

AMERICAN SHARED HOSPITAL SERVICES

 

 

 

By: /s/ Ray Stachowiak

 

Name: Ray Stachowiak

Title: Executive Chairman

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4857-8346-9994, V. 3

 

SELLER:

 

 

GENESISCARE USA, INC.

 

 

 

ex_643794img002.jpg

 

By:           Name: Shaden Marzouk, MD, MBA

Title:         Director and Authorized Signatory

 

 

TOPCO:

 

GENESISCARE USA HOLDINGS, INC.

 

 

 

ex_643794img003.jpg

 

By:                   Name: Shaden Marzouk, MD, MBA

Title: Director and Authorized Signatory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4857-8346-9994, v. 3

 
EX-21.1 8 ex_584852.htm EXHIBIT 21.1 ex_584852.htm

Exhibit 21.1

 

The subsidiaries of American Shared Hospital Services are:

 

MedLeader.com, Inc.

A California corporation

 

OR21, Inc.

A California corporation

 

OR21, LLC

A Washington limited liability company

 

Long Beach Equipment, LLC

A Delaware limited liability company

 

American Shared Radiosurgery Services

A California corporation

 

PBRT Orlando LLC

A Delaware limited liability company

 

ASHS-Rhode Island Proton Beam Radiation Therapy, LLC

A Rhode Island limited liability company

 

ASHS-Bristol Radiation Therapy, LLC

A Rhode Island limited liability company

 

ASHS-Mexico, S.A. de C.V.

A Mexican company

 

Subsidiaries of ASHS-Mexico, S.A. de C.V.

 

AB Radiocirugia Y Radioterapia de Puebla, S.A.P.I. de C.V.

A Mexican company

 

Subsidiaries of American Shared Radiosurgery Services

 

GK Financing, LLC

A California limited liability company

 

Subsidiaries of GK Financing, LLC

 

Albuquerque GK Equipment, LLC

A Delaware limited liability company

 

Jacksonville GK Equipment, LLC

A Delaware limited liability company

 

Instituto de Gamma Knife del Pacifico S.A.C.

A Peruvian company

 

HoldCo GKC S.A.

A Ecuadorian company

 

Subsidiaries of HoldCo GKC S. A.

 

Gamma Knife Center Ecuador S.A.

A Ecuadorian company

 

 
EX-23.1 9 ex_584853.htm EXHIBIT 23.1 ex_584853.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-204593) and Form S-8 (No. 333-276440, No. 333-170650, No. 333-139446, No. 333-81138, No. 333-73172, and No. 333-08009) of American Shared Hospital Services (the “Company”), of our report dated April 1, 2024, relating to the consolidated financial statements of the Company appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2023.

 

/s/ Moss Adams LLP

 

San Francisco, California

April 1, 2024

 

 
EX-31.1 10 ex_584854.htm EXHIBIT 31.1 ex_584854.htm

Exhibit 31.1

 

CERTIFICATION

 

I, Raymond C. Stachowiak., as executive chairman of the board of American Shared Hospital Services, certify that:

 

1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2023 of American Shared Hospital Services;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

April 1, 2024

/s/ Raymond C. Stachowiak

Raymond C. Stachowiak
Executive Chairman of the Board

 

 
EX-31.2 11 ex_584855.htm EXHIBIT 31.2 ex_584855.htm

Exhibit 31.2

 

CERTIFICATION

 

I, Robert L. Hiatt, as chief financial officer of American Shared Hospital Services, certify that:

 

1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2023 of American Shared Hospital Services;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting

 

April 1, 2024

/s/ Robert L. Hiatt

Robert L. Hiatt
Chief Financial Officer

 

 
EX-32.1 12 ex_584856.htm EXHIBIT 32.1 ex_584856.htm

Exhibit 32.1

 

April 1, 2024

 

Securities and Exchange Commission

450 Fifth Street, N.W.

Washington, D.C. 20549

 

Ladies and Gentlemen:

 

The certification set forth below is being submitted to the Securities and Exchange Commission solely for the purpose of complying with Rule 13a-14(b) and Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. This certification is not to be deemed filed pursuant to the Exchange Act and does not constitute a part of the Annual Report on Form 10-K (the “Report”) accompanying this letter.

 

Raymond C. Stachowiak., the Executive Chairman of the Board and Robert L. Hiatt, the Chief Financial Officer of American Shared Hospital Services, each certifies that, to the best of his knowledge:

 

 

1.

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

2.

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Shared Hospital Services.

 

 

/s/ Raymond C. Stachowiak

 

Raymond C. Stachowiak
Executive Chairman of the Board

   
 

/s/ Robert L. Hiatt

 

Robert L. Hiatt
Chief Financial Officer

 

 
EX-97 13 ex_643795.htm EXHIBIT 97 ex_643795.htm

Exhibit 97

 

American Shared Hospital Services

Compensation Recoupment Policy

 

November 2023

 

This Compensation Recoupment Policy (this “Policy”) is the compensation-recovery policy of American Shared Hospital Services (the “Company”), adopted by the Company in accordance with the provisions of Rule 10D-1 promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 811 of the Company Guide of NYSE American LLC (the “NYSEAMER Exchange”; such section, “NYSEAMER Section 811”). This Policy shall be effective as of October 2, 2023, the effective date of NYSEAMER Section 811 (the “Effective Date”).

 

Recoverable Compensation Upon an Accounting Restatement.  If the Company is required to prepare an accounting restatement of all or any portion of its financial statements due to the Company’s material noncompliance with any financial-reporting requirement under applicable U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if either corrected or left uncorrected in the current period (such restatement, an “Accounting Restatement”), the Compensation Committee of the Company’s board of directors (the “Board”; such committee, the “Compensation Committee”) will review any incentive-based compensation received by an executive officer of the Company: (i) during the three completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement, which is the earlier to occur of: (1) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (2) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement (such date, the “Restatement Trigger Date”), and (ii) during any transition period within or immediately following that three-year period preceding the Restatement Trigger Date that results from a change in the Company’s fiscal year (such period of three fiscal years and any transition period, the “Recoverability Period”).

 

Scope of Policy.  This Policy applies to all incentive-based compensation received on or after the Effective Date of this Policy by a person: (i) after becoming an executive officer of the Company; (ii) who served as an executive officer at any time during the performance period for the incentive‑based compensation under review; (iii) while the Company had a class of securities listed on a national securities exchange or association; and (iv) during the Recoverability Period immediately preceding the Restatement Trigger Date (such incentive-based compensation, “Recoverable Incentive-Based Compensation”).

 

Calculating Erroneously Awarded Compensation.  If the Compensation Committee determines, in its sole and absolute discretion, that an executive officer of the Company received any Recoverable Incentive-Based Compensation in excess of the amount of Recoverable Incentive-Based Compensation that would have been received had it been calculated based on the restated financial amounts in an Accounting Restatement, disregarding any taxes paid (such excess incentive-based compensation, “Erroneously Awarded Compensation”), the Company must recover such Erroneously Awarded Compensation. If the Company awarded Recoverable Incentive-Based Compensation based on stock price or total shareholder return, the amount of Erroneously Awarded Compensation will not be subject to mathematical recalculation from the information in an Accounting Restatement, so the Compensation Committee must: (i) determine the amount of Erroneously Awarded Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return, as applicable, upon which the Recoverable Incentive-Based Compensation was received; (ii) maintain documentation of the determination of that reasonable estimate; and (iii) provide such documentation to the NYSEAMER Exchange. For purposes of this Policy, Recoverable Incentive-Based Compensation will be deemed to be received in the fiscal period during which the financial reporting measure specified in the applicable incentive-based compensation award is attained, even if the payment or grant of the award occurs after the end of that period.

 

Reimbursement of Overpayment Amount.  Upon determining that an executive officer received Erroneously Awarded Compensation, the Compensation Committee shall, to the fullest extent permitted by governing law and as it deems appropriate, require such executive officer to reimburse the Company in the amount of the Erroneously Awarded Compensation (such amount to be reimbursed, the “Overpayment Amount”). Promptly after making the determination that an executive officer received Erroneously Awarded Compensation, the Compensation Committee shall send such executive officer a notice of recovery, specifying the Overpayment Amount to be paid to the Company and the terms for prompt repayment thereof.

 

No Indemnification.  The Company is prohibited from indemnifying any executive officer or former executive officer against the loss of Erroneously Awarded Compensation and from paying or reimbursing any current or former executive officer for the premium of any third-party insurance policy purchased by such executive officer to fund potential recovery obligations. This Policy is in addition to (and not in lieu of) any right of repayment, forfeiture, or right of offset against any employee that is required pursuant to any statutory repayment requirements (regardless of whether such requirement was implemented prior to or following the adoption or amendment of this Policy), including Section 304 of the Sarbanes-Oxley Act of 2002. Any amounts paid to the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 shall be considered in calculating any amounts recovered under this Policy.

 

Exceptions to Recovery of Erroneously Awarded Compensation.  Notwithstanding the foregoing, the Company will not be required to recover Erroneously Awarded Compensation in compliance with this Policy to the extent that the Compensation Committee determines that recovery would be impracticable, and the conditions of one of the following three recovery scenarios are met:

 

(1)         The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable recovery attempt(s), and provide that documentation to the NYSEAMER Exchange.

 

(2)         Recovery would violate home country law where that law was adopted prior to November 28, 2022 (the date the SEC published Rule 10D-1 under the Exchange Act). Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to the NYSEAMER Exchange, that recovery would result in such a violation, and must provide such opinion to the NYSEAMER Exchange.

 

(3)         Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to the Company’s employees, to fail to meet the requirements of 26 U.S.C. § 401(a)(13) or 26 U.S.C. § 411(a) and regulations thereunder.

 

Additional Remedies and Means of Recoupment.  The application and enforcement of this Policy does not preclude the Company from taking any other action to enforce an executive officer’s obligations to the Company, including termination of employment or institution of legal proceedings. Nothing in this Policy restricts the Company from seeking recoupment under any other compensation recoupment Policy or any applicable provisions in plans, agreements, awards, or other arrangements that contemplate the recoupment of compensation from an executive officer. If an executive officer fails to repay Erroneously Awarded Compensation that is owed to the Company under this Policy, the Company shall take all appropriate action to recover such Erroneously Awarded Compensation from the executive officer, and the executive officer shall be required to reimburse the Company for all expenses (including legal expenses) incurred by the Company in recovering such Erroneously Awarded Compensation.

 

Binding Policy; Enforceability.  The terms of this Policy shall be binding and enforceable against all executive officers subject to this Policy and their beneficiaries, heirs, executors, administrators, or other legal representatives. If any provision of this Policy or the application of such provision to any executive officer shall be adjudicated to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal, or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision (or the application of such provision) valid, legal, or enforceable.

 

Interpretation.  This Policy shall be interpreted in a manner that is consistent with Rule 10D-1 under the Exchange Act, NYSEAMER Section 811, and any related rules or regulations adopted by the SEC or the NYSEAMER Exchange (the “Applicable Rules”) as well as any other applicable law. To the extent the Applicable Rules require recovery of incentive-based compensation in additional circumstances beyond those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover incentive-based compensation to the fullest extent required by the Applicable Rules.

 

Definitions.  For purposes of this Policy:

 

(i) “executive officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice‑president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a significant policy-making function, any other person who performs similar significant policy-making functions for the Company, any executive officer of the Company’s parent(s) or subsidiaries that performs significant policy-making functions for the Company, and any other person identified by the Company as an executive officer for purposes of Item 401(b) of Regulation S-K (17 CFR § 229.401(b)), as designated from time to time by the Board;

 

(ii) “financial reporting measures” means (1) the measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, (2) any measures that are derived wholly or in part from such measures, and (3) stock price and total shareholder return, regardless of whether any of the financial reporting measures described in clauses (1) through (3) are presented with the Company’s financial statements or included in a filing with the SEC; and

 

(iii) “incentive-based compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure.

 

Acknowledgment.  Each executive officer subject to this Policy shall sign and return to the Company, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which the executive officer agrees to be bound by, and to comply with, the terms and conditions of this Policy (i) within 60 calendars days of the Effective Date of this Policy, or (ii) within 30 calendar days after the date the individual becomes an executive officer, whichever is later.

 

 

Reviewed: November 2023

 

 

 

Exhibit A

 

American Shared Hospital Services

Compensation Recoupment Policy

Acknowledgment Form

 

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Compensation Recoupment Policy (the “Policy”) of American Shared Hospital Services (the “Company”).

 

The undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.

 

 

Executive Officer:

 

 

Signature

 

 

Printed Name

 

 

Title or Position

 

 

Date

 

 

 

 

 

 
EX-101.SCH 14 ams-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statement of Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 995452 - Disclosure - Note 1 - Business and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 995453 - Disclosure - Note 2 - Accounting Policies link:calculationLink link:definitionLink link:presentationLink 995454 - Disclosure - Note 3 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 995455 - Disclosure - Note 4 - Other Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 995456 - Disclosure - Note 5 - Long Term Debt link:calculationLink link:definitionLink link:presentationLink 995457 - Disclosure - Note 6 - Leases link:calculationLink link:definitionLink link:presentationLink 995458 - Disclosure - Note 7 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 995459 - Disclosure - Note 8 - Stock-based Compensation Expense link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Note 9 - Retirement Plan link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 10 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 11 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 12 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 2 - Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 3 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 4 - Other Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 5 - Long Term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 6 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 7 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 8 - Stock-based Compensation Expense (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 11 - Related Party Transactions (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 1 - Business and Basis of Presentation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 2 - Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 3 - Accounting Policies - Allocations to Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 3 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 3 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 5 - Long Term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 5 - Long Term Debt - Long-term Debt Maturities (Details) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 6 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 6 - Leases - Lease Cost and Information (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 7 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 7 - Income Taxes - Components of Income Before Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 8 - Stock-based Compensation Expense (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 8 - Stock-based Compensation Expense - Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 9 - Retirement Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 11 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 12 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 15 ams-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 16 ams-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 17 ams-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information The Credit Agreement, First Loan and Second Loan Facility [Member] Represents credit agreement, first loan and second loan facility. Dividend yield Note To Financial Statement Details Textual Sublease Office in San Francisco, California [Member] Represents sublease office in San Francisco, California. us-gaap_LongtermPurchaseCommitmentPeriod Long-term Purchase Commitment, Period (Year) Significant Accounting Policies Note 2 - Accounting Policies Computed expected federal income tax Note 3 - Property and Equipment Risk-free interest rate Note 4 - Other Accrued Liabilities Note 5 - Long Term Debt Note 6 - Leases Lease Agreement for New Corporate Office [Member] Represents Lease Agreement for New Corporate Office. Note 7 - Income Taxes Note 8 - Stock-based Compensation Expense Note 11 - Related Party Transactions Income Tax Disclosure [Text Block] Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) ams_LesseeOperatingSubleaseMonthlyIncome Lessee, Operating Sublease, Monthly Income monthly amount of sublease income for operating lease. Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details) Note 3 - Accounting Policies - Allocations to Reportable Segments (Details) Expected volatility Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details) Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details) us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 3 - Property and Equipment - Summary of Property and Equipment (Details) Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details) Note 5 - Long Term Debt - Long-term Debt Maturities (Details) Loss on write down of impaired assets Amount of write down of impaired assets and associated removal costs. Expected life (years) (Year) Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details) Asser retirement obligations, non-related party Note 6 - Leases - Lease Cost and Information (Details) Note 7 - Income Taxes - Components of Income Before Income Taxes (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details) Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details) Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details) Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details) Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details) Lease liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing arrangement. Note 8 - Stock-based Compensation Expense - Assumptions (Details) us-gaap_IndefinitelivedIntangibleAssetsAcquired Indefinite-lived Intangible Assets Acquired Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details) Notes To Financial Statements Granted, grant date weighted average fair value (in dollars per share) Notes To Financial Statements [Abstract] us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Vested, grant date weighted average fair value (in dollars per share) Forfeited, grant date weighted average fair value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding, grant date weighted average fair value (in dollars per share) Outstanding, grant date weighted average fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited (in shares) Guadalupe [Member] Represents legal entity of Guadalupe. Newco [Member] Represents Newco. us-gaap_GoodwillAndIntangibleAssetImpairment Goodwill and Intangible Asset Impairment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Awards issued and vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) Vested (in shares) Current portion of long-term debt, net ams_LongtermInstallServiceAndPurchaseCommitmentAmount Long-term Install Service and Purchase Commitment, Amount The minimum amount the entity agreed to spend under the long-term install service and purchase commitment. Leksell Gamma Knife Icon Systems and Linear Accelerator System [Member] Represents Leksell Gamma Knife Icon Systems and Linear Accelerator System. ams_LongtermCommitmentCashOnHandToFund Long-term Commitment, Cash on Hand to Fund The amount of cash on hand to fund long-term commitment. Exercisable, grant date weighted-average exercise price (in dollars per share) Exercisable, weighted average remaining contractual life (Year) ams_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodUsingCash Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Using Cash (in shares) Number of share options (or share units) exercised using cash during the current period. Corporate Office in San Francisco [Member] Represents corporate office in San Francisco. Exercisable (in shares) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total shareholders’ equity Balances Balances ams_LongtermCommitmentLineOfCreditToFund Long-term Commitment, Line of Credit to Fund Amount of line of credit to fund long-term commitment. Balance, weighted average remaining contractual life (Year) Line of credit PBRT Services [Member] Represents PBRT service. Balance, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Land and Parking Spaces for Gamma Knife Facility in Guayaquil, Ecuador [Member] Represents land and parking spaces for Gamma knife facility in Guayaquil, Ecuador. Condominium Space for Gamma Knife Facility in Guayaquil, Ecuador [Member] Represents condominium space for Gamma knife facility in Guayaquil, Ecuador. Alternative minimum tax payable adjustment Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to AMT tax payable adjustments. ams_UnrecognizedTaxBenefitsDecreaseResultingFromForeignTaxes Unrecognized Tax Benefits, Decrease Resulting from Foreign Taxes Amount of decrease in unrecognized tax benefits resulting from foreign taxes. Board Member [Member] Represents board members. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balance, grant date weighted-average exercise price (in dollars per share) Balance, grant date weighted-average exercise price (in dollars per share) ams_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAfterIncomeAttributableToNoncontrollingInterest Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and after deduction of income (loss) attributable to noncontrolling interest. Forfeited, grant date weighted-average exercise price (in dollars per share) Management Bonus Program [Member] Represents management bonus program. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares) Outstanding (in shares) Outstanding (in shares) Granted, grant date weighted-average exercise price (in dollars per share) Exercised, grant date weighted-average exercise price (in dollars per share) Accounts payable and other accrued liabilities Employee compensation and benefits Lessee, Operating Leases [Text Block] Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Balance (in shares) Balance (in shares) Equipment included in accounts payable and accrued liabilities Credit Facility [Axis] Credit Facility [Domain] Other accrued liabilities Total other accrued liabilities us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_AccruedProfessionalFeesCurrent Professional services us-gaap_AccruedInsuranceCurrent Insurance financing Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Effect of dilutive securities employee stock options and restricted stock (in shares) us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Payment for purchases of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Day) Cash paid for income taxes CURRENT LIABILITIES SUPPLEMENTAL CASH FLOW DISCLOSURE us-gaap_Assets TOTAL ASSETS TOTAL ASSETS Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Plan Name [Axis] Plan Name [Domain] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_SubleaseIncome Sublease income Interest income us-gaap_InterestIncomeInterestEarningAsset Share-Based Payment Arrangement [Text Block] Award Type [Domain] us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders Cash distributions to non-controlling interests Other direct operating costs, related party Other costs from related parties incurred during the reporting period related to other revenue generating activities. Asset retirement obligations, related party (includes $250,000 and $120,000 non-related party at December 31, 2023 and 2022, respectively) Current portion of the carrying amount of a liability for related party portion of an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees. Numerator for basic and diluted earnings per share us-gaap_NetIncomeLoss Net Income (Loss) Attributable to Parent Net income attributable to American Shared Hospital Services Award Type [Axis] INTANGIBLE ASSETS Restricted Stock Units (RSUs) [Member] Restricted Stock [Member] us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Less (plus): net loss (income) attributable to non-controlling interests Share-Based Payment Arrangement, Option [Member] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_GoodwillAcquiredDuringPeriod Goodwill, Acquired During Period Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation GOODWILL LAND us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage Net income Net income INVESTING ACTIVITIES Net income per share attributable to American Shared Hospital Services: Income taxes payable us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable us-gaap_DeferredFinanceCostsGross Debt Issuance Costs, Gross us-gaap_RelatedPartyTransactionAmountsOfTransaction Total related party transactions Equipment purchases and de-install costs Related Party Transactions Disclosure [Text Block] Income tax expense Income tax expense Income Tax Expense (Benefit) Income Tax Expense (Benefit) Schedule of Related Party Transactions [Table Text Block] Granted, weighted average remaining contractual life (Year) Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Interest and other income, net The amount of interest income (loss) and other income (loss) recognized during the period. Asset retirement obligations, related party ams_IncreaseDecreaseInAssetRetirementObligationsRelatedParty The amount of increase decrease in asset retirement obligations from related parties. us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) Restricted cash us-gaap_RestrictedCash Restricted cash us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Related party liabilities us-gaap_IncreaseDecreaseInDueToRelatedParties Cash and cash equivalents us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax Share-Based Payment Arrangement, Expense, after Tax Stock-based compensation expense Share-Based Payment Arrangement, Expense Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] Common stock, shares outstanding (in shares) Balances (in shares) Balances (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_LeaseCost Total lease cost us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other assets Capital Loss Carryforward [Member] Weighted-average discount rate - Operating leases Document Fiscal Period Focus Operating lease cost, net of impairment Document Fiscal Year Focus Lease, Cost [Table Text Block] Document Period End Date Weighted-average remaining lease term - Operating leases in years (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_AssetImpairmentCharges Asset Impairment Charges Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_AreaOfRealEstateProperty Area of Real Estate Property (Square Foot) Entity Public Float Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers Entity Well-known Seasoned Issuer Variable Rate [Domain] us-gaap_AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss Variable Rate [Axis] us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Receivables Entity Tax Identification Number Entity Central Index Key Depreciation and amortization Depreciation and amortization Entity Registrant Name Entity [Domain] Legal Entity [Axis] Customer Concentration Risk [Member] Entity Address, Address Line One Costs incurred to maintain equipment ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Axis] Material Terms of Trading Arrangement [Text Block] Concentration Risk Type [Domain] us-gaap_StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares (in shares) Entity Common Stock, Shares Outstanding us-gaap_AdvertisingExpense Advertising Expense Revenue Benchmark [Member] Accounts Receivable [Member] Long-Term Debt [Text Block] Customer One [Member] Represents customer one. Customer Two [Member] Represents customer two. Trading Symbol Customer Three [Member] Represents customer three. Customer Four [Member] Represents customer four. Concentration Risk Benchmark [Axis] ams_NumberOfMajorCustomers Number of Major Customers The number of major customers. Concentration Risk Benchmark [Domain] One Customer [Member] Represents one customer. Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Rental Income from Medical Services [Member] Represents rental income from medical services. GKCE [Member] Represents Gamma Knife Center Ecuador. Proton Beam Radiation Therapy PBRT [Member] Represents proton beam radiation therapy ("PBRT"). Local Phone Number Gamma Knife And Radiation Therapy Equipment [Member] Represents gamma knife and radiation therapy equipment. Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) Exercised (in shares) us-gaap_TableTextBlock Notes Tables Patient Income [Member] Represents patient income. ams_NumberOfCustomerWithIntentToTerminateContract Number of Customer with Intent to Terminate Contract The number of customers with the intent to terminate contract. us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Vested restricted stock awards (in shares) Options exercised Vested restricted stock awards us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Related Party, Type [Axis] Related Party, Type [Domain] Selling and administrative expense us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Stock-based compensation expense Granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited (in shares) Line of Credit Facility, Lender [Domain] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services (in shares) Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Related Party Transaction [Axis] Related Party Transaction [Domain] Retained earnings Interest expense Interest expense Changes in operating assets and liabilities: DETAIL OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD Accretion of deferred issuance costs Amortization of Debt Issuance Costs us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] LONG-TERM LEASE LIABILITIES, less current portion Total us-gaap_OperatingLeaseLiability Operating Lease, Liability us-gaap_DeferredIncomeTaxesAndTaxCredits Total deferred Subsequent Event Type [Axis] Current portion of lease liabilities Subsequent Event Type [Domain] Retirement Benefits [Text Block] Subsequent Events [Text Block] RIGHT OF USE ASSETS, net Operating Lease, Right-of-Use Asset us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less imputed interest Deferred income taxes us-gaap_DeferredIncomeTaxExpenseBenefit us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2024 Segment Reporting, Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Stock-based compensation OTHER ASSETS Earnings Per Share, Policy [Policy Text Block] ams_OperatingLeaseMonthlyExpense Operating Lease, Monthly Expense Amount of operating lease expense per month. Excludes sublease income. Income Tax, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) us-gaap_Depreciation Depreciation us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Gain (Loss) on Sale of Assets and Asset Impairment Charges us-gaap_AssetsCurrent Total current assets Compensation Related Costs, Policy [Policy Text Block] Advertising Cost [Policy Text Block] Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares – 6,300,000 at December 31, 2023 and 6,184,000 at December 31, 2022 Adjustments to reconcile net income to net cash from operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Common stock, no par value (in dollars per share) us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) us-gaap_DeferredTaxAssetsValuationAllowance Valuation allowance Statistical Measurement [Domain] Cash paid for amounts included in the measurement of lease liabilities - Operating leases Maximum [Member] SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES Minimum [Member] Ownership [Domain] Product and Service [Axis] Asset Retirement Obligation [Policy Text Block] Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Deferred tax assets net of valuation allowance Statistical Measurement [Axis] Investment, Name [Domain] Ownership [Axis] Cash paid for interest Investment, Name [Axis] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] us-gaap_DeferredTaxAssetsOther Other Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Goodwill and Intangible Assets, Policy [Policy Text Block] Geographical [Domain] Property, Plant and Equipment [Table Text Block] us-gaap_DeferredTaxAssetsGross Total deferred tax assets us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Revenue Sharing Arrangements [Member] Represents revenue sharing arrangements. us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax DFC Loan [Member] Represents the DFC loan. Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block] Customer [Axis] Customer [Domain] Stand-alone Facility in Lima, Peru [Member] Represents the stand-alone office in Lima, Peru. Reconciliation of Assets from Segment to Consolidated [Table Text Block] Uncertain tax positions Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions. Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Prepaid maintenance The amount of prepaid maintenance classified as current. Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Return to provision true-up Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision true-up. ams_AccruedLiabilitesOtherCurrent Other The amount of accrued liabilities classified as current not specifically disclosed. Employees [Member] Represents employees. ams_OptionsIssuedDuringPeriodCashlessStockOptionsExercised Options Issued During Period, Cashless Stock Options Exercised (in shares) The number of options issued during the period from cashless stock options exercised. us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) us-gaap_PropertyPlantAndEquipmentSalvageValue Property, Plant, and Equipment, Salvage Value Construction in Progress [Member] Non-controlling interests in subsidiaries ams_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest, Outstanding, Number (in shares) Number of fully vested and expected to vest equity instrument other than options outstanding that can be converted into shares under share based compensation plan. Accruals and allowances Non Employee Directors and Corporate Secretary [Member] Represents non employee directors and corporates secretary. OPERATING ACTIVITIES Non Employee Directors [Member] Represents non employee directors. ams_AccruedOperatingCostsCurrent Operating costs The amount of accrued operating costs classified as current. Revenue [Policy Text Block] Expected forfeiture rate The estimated forfeiture rate of award under share-based payment arrangement. Statement [Line Items] Executive Equity Awards [Member] Represents the executive equity awards. Allowance for doubtful accounts Accounts receivable, net of allowance for credit losses of $100,000 At December 31, 2023 and December 31, 2022 us-gaap_NumberOfReportableSegments Number of Reportable Segments Building [Member] Additional paid-in capital Capital loss carryover Mevion Medical Systems Inc [Member] Represents Mevion Medical Systems Inc. Property, Plant and Equipment, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] SHAREHOLDERS’ EQUITY Tax credits ams_LongtermServiceCommitmentAmount Long-Term Service Commitment, Amount The amount of long-term service commitment. Net operating loss carryforwards Chief Executive Officer [Member] Maintenance And Support Agreement, Mevion Service Agreement [Member] Represents the Maintenance And Support Agreement the Mevion Service Agreement. CURRENT ASSETS ams_PurchaseAgreementAnnualPrepayment Purchase Agreement Annual Prepayment The amount of annual prepayments under purchase agreement. ams_LongtermServiceCommitmentPeriod Long-Term Service Commitment, Period (Year) The period of the long-term service commitment. LINAC System [Member] Represents the LINAC system. ams_PercentageOfRevenues Percentage of Revenues The percentage of revenues. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year GKF Subsidiary [Member] Represents the GKF subsidiary. DFC Loan, Tranche Two [Member] Represents tranche two of the DFC loan. US Subsidiary Of Elekta Member Represents the US subsidiary Of Elekta. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents DFC Loan, Tranche One [Member] Represents tranche one of the DFC loan. us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities us-gaap_Liabilities TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES (See Note 10) us-gaap_OperatingIncomeLoss Operating income us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) investing activities Prepaid expenses and other current assets us-gaap_DeferredTaxLiabilities Net deferred tax liabilities Other direct operating costs us-gaap_CostOfRevenue Cost of Revenue us-gaap_GrossProfit Gross margin DEFERRED INCOME TAXES us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent Deferred Compensation Liability, Current and Noncurrent Other Liabilities [Table Text Block] us-gaap_DeferredTaxLiabilitiesLeasingArrangements ROU asset The Credit Agreement, 2024 Supplemental Term Loan [Member] Represents the 2024 supplemental term loan part of the credit agreement. ams_DebtInstrumentVariableRateFloor Debt Instrument, Variable Rate, Floor Represents the variable rate floor for a debt instrument. Income taxes payable Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Property and equipment us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Prepaid expenses Other Liabilities Disclosure [Text Block] Maintenance and supplies us-gaap_CostDepreciationAmortizationAndDepletion Depreciation and amortization Direct Patient Services [Member] Represents direct patient services. Costs of revenue: Medical Equipment Leasing [Member] Represents medical equipment leasing. Noncontrolling Interest [Member] Equipment Sales [Member] Represents equipment sales. Cost of Goods and Service [Policy Text Block] Scenario [Domain] Forecast [Member] Retained Earnings [Member] Proceeds from options exercised Proceeds from Stock Options Exercised Revenues Title of Individual [Domain] us-gaap_CurrentStateAndLocalTaxExpenseBenefit State Title of Individual [Axis] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State Scenario [Axis] us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased (in shares) us-gaap_CurrentForeignTaxExpenseBenefit Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] Parent [Member] Common Stock [Member] us-gaap_CurrentFederalTaxExpenseBenefit Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased (in shares) Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-Term Debt Long-Term Debt us-gaap_CurrentIncomeTaxExpenseBenefit Total current us-gaap_PaymentsToMinorityShareholders Distributions to non-controlling interests Foreign us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes Domestic ICFR Auditor Attestation Flag us-gaap_LineOfCredit Long-Term Line of Credit us-gaap_PaymentsOfDebtIssuanceCosts Debt issuance costs long-term debt State and Local Jurisdiction [Member] us-gaap_DeferredFinanceCostsNet Debt Issuance Costs, Net Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] Office Equipment [Member] us-gaap_RepaymentsOfLongTermDebt Principal payments on long-term debt Document Annual Report Accounts Receivable [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits Balance at beginning of year Balance at end of year Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Document Financial Statement Error Correction [Flag] Selling, General and Administrative Expenses [Member] us-gaap_RepaymentsOfLongTermLinesOfCredit Principal payments on line of credit Entity Interactive Data Current Related Party [Member] Additions based on tax positions of prior years Security Exchange Name us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Additions based on tax positions of prior years Title of 12(b) Security us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued Unrecognized Tax Benefits, Income Tax Penalties Accrued us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued Long-term debt financing on purchase of property and equipment Income Statement Location [Axis] Income Statement Location [Domain] us-gaap_AssetRetirementObligation Asset Retirement Obligation Auditor Name Auditor Firm ID Auditor Location us-gaap_RepaymentsOfShortTermDebt Principal payments on short-term financing prepaid insurance Segments [Axis] Segments [Domain] us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Weighted average common shares for diluted earnings per share (in shares) Denominator for diluted earnings per share – adjusted weighted-average shares (in shares) us-gaap_PurchaseObligation Purchase Obligation Tax Credit Carryforward [Axis] Non-US [Member] Tax Credit Carryforward, Name [Domain] us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Advances on line of credit Statement [Table] us-gaap_MinorityInterestOwnershipPercentageByParent Noncontrolling Interest, Ownership Percentage by Parent Earnings per common share- diluted (in dollars per share) Earnings per common share - diluted (in dollars per share) Earnings Per Share, Diluted (in dollars per share) Statement of Financial Position [Abstract] Denominator for basic earnings per share – weighted-average shares (in shares) Weighted average common shares for basic earnings per share (in shares) Weighted Average Number of Shares Outstanding, Basic, Total (in shares) London Interbank Offered Rate [Member] Interest rate at which a bank borrows funds from other banks in the London interbank market. Business Acquisition [Axis] Earnings per common share- basic (in dollars per share) Earnings per common share - basic (in dollars per share) Business Acquisition, Acquiree [Domain] Statement of Cash Flows [Abstract] Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] Income Statement [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2026 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2027 us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Lessee, Operating Lease, Remaining Lease Term (Year) us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts Business Acquisition, Transaction Costs us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2024 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2025 Property and equipment, gross Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale, excluding land. Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Accounts payable, accrued liabilities and deferred revenue The amount of increase (decrease) in accounts payable, accrued liabilities and deferred revenue. PROPERTY AND EQUIPMENT, net Net property and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, excluding land. Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Non cash lease expense ams_NoncashLeaseExpense The amount of noncash lease expense. ams_NumberOfMedicalCenters Number of Medical Centers The number of medical centers. Asset Acquisition [Axis] Salvage Value [Member] Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC [Member] Related to acquisitions. Other deferred tax adjustments FINANCING ACTIVITIES us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Change in Accounting Estimate by Type [Axis] Asset Acquisition [Domain] Change in Accounting Estimate, Type [Domain] Change in valuation allowance Stock compensation Architectural Design Company [Member] Represents an architectural design company. Gamma Knife Units [Member] Represents Gamma Knife units. Gamma Knife Center Ecuador S.A. (GKCE) [Member] Represents Gamma Knife Center Ecuador S.A. (“GKCE”). OR21, LLC [Member] Represents OR21, LLC (“OR21 LLC”). PBRT Equipment [Member] Represents PBRT equipment. Medical Equipment and Facilities [Member] Represents medical equipment and facilities. Fifth Third Bank, N.A. [Member] Represents Fifth Third Bank, N.A. The Credit Agreement [Member] Represents the Credit Agreement. The Credit Agreement, Second Loan Facility [Member] The second loan facility of the credit agreement. ams_NumberOfDebtInstruments Number of Debt Instruments The number of debt instruments. Incentive Compensation Plan [Member] Represents the incentive compensation plan. DEFERRED REVENUE, less current portion us-gaap_StockholdersEquity Total equity- American Shared Hospital Services us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Non-deductible expenses The Credit Agreement, Third Loan Facility [Member] Represents the third loan facility of the credit agreement. Class of Stock [Axis] ams_DebtInstrumentCovenantMaximumFundedDebtToEditdaRatio Debt Instrument, Covenant, Maximum Funded Debt to EDITDA Ratio The maximum funded debt to EBITDA ratio allowed under the covenant of the debt instrument. ams_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio Requirement for fixed charge coverage ratio under the debt agreement. LONG-TERM DEBT, net, less current portion Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] State income taxes, net of federal benefit Other receivables Foreign rate differential Other Gamma Knife Units [Member] Represents other gamma knife units. EX-101.PRE 18 ams-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 19 ex_643794img002.jpg begin 644 ex_643794img002.jpg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end GRAPHIC 20 ex_643794img003.jpg begin 644 ex_643794img003.jpg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end XML 22 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2023
Mar. 22, 2024
Mar. 30, 2023
Document Information [Line Items]      
Entity Central Index Key 0000744825    
Entity Registrant Name AMERICAN SHARED HOSPITAL SERVICES    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 1-08789    
Entity Incorporation, State or Country Code CA    
Entity Tax Identification Number 94-2918118    
Entity Address, Address Line One 601 Montgomery    
Entity Address, City or Town San Francisco    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94111-2619    
City Area Code 415    
Local Phone Number 788-5300    
Title of 12(b) Security Common Stock No Par Value    
Trading Symbol AMS    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 11,205,000
Entity Common Stock, Shares Outstanding   6,330,000  
Auditor Firm ID 659    
Auditor Name Moss Adams LLP    
Auditor Location Seattle, WA United States    
XML 23 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 13,690,000 $ 12,335,000
Restricted cash 118,000 118,000
Accounts receivable, net of allowance for credit losses of $100,000 At December 31, 2023 and December 31, 2022 4,343,000 3,801,000
Other receivables 504,000 327,000
Prepaid maintenance 1,275,000 1,245,000
Prepaid expenses and other current assets 526,000 897,000
Total current assets 20,456,000 18,723,000
PROPERTY AND EQUIPMENT, net 25,844,000 23,467,000
LAND 19,000 19,000
GOODWILL 1,265,000 1,265,000
INTANGIBLE ASSETS 78,000 78,000
RIGHT OF USE ASSETS, net 57,000 317,000
OTHER ASSETS 443,000 87,000
TOTAL ASSETS 48,162,000 43,956,000
CURRENT LIABILITIES    
Accounts payable 315,000 230,000
Employee compensation and benefits 757,000 735,000
Other accrued liabilities 1,226,000 1,544,000
Asset retirement obligations, related party (includes $250,000 and $120,000 non-related party at December 31, 2023 and 2022, respectively) 650,000 360,000
Income taxes payable 1,229,000 255,000
Current portion of lease liabilities 57,000 292,000
Line of credit 2,500,000 0
Current portion of long-term debt, net 2,084,000 1,262,000
Total current liabilities 10,779,000 5,175,000
LONG-TERM LEASE LIABILITIES, less current portion 0 59,000
LONG-TERM DEBT, net, less current portion 11,041,000 12,205,000
DEFERRED REVENUE, less current portion 0 70,000
DEFERRED INCOME TAXES 63,000 822,000
TOTAL LIABILITIES 21,883,000 18,331,000
COMMITMENTS AND CONTINGENCIES (See Note 10)
SHAREHOLDERS’ EQUITY    
Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares – 6,300,000 at December 31, 2023 and 6,184,000 at December 31, 2022 10,763,000 10,763,000
Additional paid-in capital 8,232,000 7,843,000
Retained earnings 3,629,000 3,019,000
Total equity- American Shared Hospital Services 22,624,000 21,625,000
Non-controlling interests in subsidiaries 3,655,000 4,000,000
Total shareholders’ equity 26,279,000 25,625,000
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 48,162,000 43,956,000
Related Party [Member]    
CURRENT LIABILITIES    
Accounts payable and other accrued liabilities $ 1,961,000 $ 497,000
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ / shares in Thousands
Dec. 31, 2023
Dec. 31, 2022
Allowance for doubtful accounts $ 100,000 $ 100,000
Asser retirement obligations, non-related party $ 250,000 $ 120,000
Common stock, no par value (in dollars per share) $ 0 $ 0
Common stock, shares authorized (in shares) 10,000,000 10,000,000
Common stock, shares issued (in shares) 6,300,000 6,184,000
Common stock, shares outstanding (in shares) 6,300,000 6,184,000
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 21,325,000 $ 19,746,000
Costs of revenue:    
Maintenance and supplies 2,032,000 1,878,000
Depreciation and amortization 5,073,000 4,726,000
Other direct operating costs 4,025,000 3,666,000
Other direct operating costs, related party 851,000 1,094,000
Cost of Revenue 11,981,000 11,364,000
Gross margin 9,344,000 8,382,000
Selling and administrative expense 7,022,000 5,145,000
Interest expense 1,112,000 806,000
Loss on write down of impaired assets 940,000 0
Operating income 270,000 2,431,000
Interest and other income, net 426,000 87,000
Income before income taxes 696,000 2,518,000
Income tax expense 431,000 963,000
Net income 265,000 1,555,000
Less (plus): net loss (income) attributable to non-controlling interests 345,000 (227,000)
Net income attributable to American Shared Hospital Services $ 610,000 $ 1,328,000
Net income per share attributable to American Shared Hospital Services:    
Earnings per common share - basic (in dollars per share) $ 0.1 $ 0.21
Earnings per common share - diluted (in dollars per share) $ 0.1 $ 0.21
Weighted average common shares for basic earnings per share (in shares) 6,358,000 6,297,000
Weighted average common shares for diluted earnings per share (in shares) 6,393,000 6,303,000
Rental Income from Medical Services [Member]    
Revenues $ 17,772,000 $ 16,655,000
Patient Income [Member]    
Revenues 3,353,000 3,091,000
Equipment Sales [Member]    
Revenues $ 200,000 $ 0
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statement of Shareholders' Equity - USD ($)
Restricted Stock [Member]
Common Stock [Member]
Restricted Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total
Balances (in shares) at Dec. 31, 2021     6,049,000          
Balances at Dec. 31, 2021     $ 10,758,000 $ 7,444,000 $ 1,691,000 $ 19,893,000 $ 4,346,000 $ 24,239,000
Stock-based compensation expense       399,000   399,000   $ 399,000
Options exercised (in shares)     3,000         4,000
Options exercised     $ 5,000     5,000   $ 5,000
Vested restricted stock awards (in shares) 132,000              
Vested restricted stock awards   $ 0            
Cash distributions to non-controlling interests             (573,000) (573,000)
Net income         1,328,000 1,328,000 227,000 $ 1,555,000
Balances (in shares) at Dec. 31, 2022     6,184,000         6,184,000
Balances at Dec. 31, 2022     $ 10,763,000 7,843,000 3,019,000 21,625,000 4,000,000 $ 25,625,000
Stock-based compensation expense       389,000   389,000   $ 389,000
Options exercised (in shares)               0
Vested restricted stock awards (in shares)     116,000          
Vested restricted stock awards               $ 0
Net income         610,000 610,000 (345,000) $ 265,000
Balances (in shares) at Dec. 31, 2023     6,300,000         6,300,000
Balances at Dec. 31, 2023     $ 10,763,000 $ 8,232,000 $ 3,629,000 $ 22,624,000 $ 3,655,000 $ 26,279,000
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
OPERATING ACTIVITIES    
Net income $ 265,000 $ 1,555,000
Adjustments to reconcile net income to net cash from operating activities:    
Depreciation and amortization 5,165,000 4,783,000
Non cash lease expense (34,000) (40,000)
Accretion of deferred issuance costs 46,000 84,000
Loss on write down of impaired assets 940,000 0
Deferred income taxes (759,000) 344,000
Stock-based compensation 389,000 399,000
Changes in operating assets and liabilities:    
Receivables (719,000) 696,000
Prepaid expenses and other assets 21,000 (111,000)
Asset retirement obligations, related party 0 (397,000)
Related party liabilities (491,000) (845,000)
Accounts payable, accrued liabilities and deferred revenue (79,000) 608,000
Income taxes payable 974,000 159,000
Net cash provided by operating activities 5,718,000 7,235,000
INVESTING ACTIVITIES    
Payment for purchases of property and equipment (6,273,000) (388,000)
Net cash (used in) investing activities (6,273,000) (388,000)
FINANCING ACTIVITIES    
Principal payments on long-term debt (2,129,000) (2,032,000)
Principal payments on line of credit (1,400,000) 0
Long-term debt financing on purchase of property and equipment 1,750,000 0
Advances on line of credit 3,900,000 0
Distributions to non-controlling interests 0 (573,000)
Debt issuance costs long-term debt (9,000) (9,000)
Proceeds from options exercised 0 5,000
Principal payments on short-term financing prepaid insurance (202,000) (48,000)
Net cash provided by (used in) financing activities 1,910,000 (2,657,000)
Net change in cash and cash equivalents 1,355,000 4,190,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year 12,453,000 8,263,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year 13,808,000 12,453,000
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 1,066,000 722,000
Cash paid for income taxes 297,000 169,000
SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Equipment included in accounts payable and accrued liabilities 1,955,000 0
DETAIL OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD    
Cash and cash equivalents 13,690,000 12,335,000
Restricted cash 118,000 118,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year $ 13,808,000 $ 12,453,000
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
12 Months Ended
Dec. 31, 2023
Insider Trading Arr Line Items  
Material Terms of Trading Arrangement [Text Block]

ITEM 9B. OTHER INFORMATION

 

None.

Rule 10b5-1 Arrangement Terminated [Flag] false
Rule 10b5-1 Arrangement Adopted [Flag] false
Non-Rule 10b5-1 Arrangement Terminated [Flag] false
Non-Rule 10b5-1 Arrangement Adopted [Flag] false
XML 29 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Note 1 - Business and Basis of Presentation
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

NOTE 1 BUSINESS AND BASIS OF PRESENTATION

 

Business – These consolidated financial statements include the accounts of American Shared Hospital Services (“ASHS”) and its subsidiaries (the “Company”) as follows: ASHS wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), ASHS-Mexico, S.A. de C.V. (“ASHS-Mexico”), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC, ASHS-Bristol Radiation Therapy, LLC, OR21, Inc., and MedLeader.com, Inc. (“MedLeader”); ASHS is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and HoldCo GKC S.A. (“HoldCo”). HoldCo wholly owns the subsidiary Gamma Knife Center Ecuador S.A. (“GKCE”). GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). 

 

The Company (through ASRS) and Elekta AG (“Elekta”), the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. During 2023, GKF leased Gamma Knife units to twelve medical centers in the United States in the states of California, Florida, Illinois, Indiana, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, and Texas. GKF also owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States.

 

The Company formed the subsidiary GKPeru and acquired GKCE for the purposes of expanding its business internationally; Orlando and LBE to provide PBRT equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. LBE is not expected to generate revenue within the next two years.

 

On  April 27, 2022, the Company signed a Joint Venture Agreement (the “Agreement”) with the principal owners of Radioterapia Guadalupe Amor y Bien S.A. de C.V. (“Guadalupe”) to establish AB Radiocirugia y Radioterapia de Puebla, S.A.P.I. de C.V. of Puebla (“Puebla”) to treat public- and private-paying cancer patients and provide radiation therapy and radiosurgery services locally in Mexico. The Company and Guadalupe hold 85% and 15% ownership interests, respectively, in Puebla. Under the Agreement, the Company is responsible for providing a linear accelerator and Guadalupe will be accountable for all site modification costs.  The Company formed ASHS-Mexico on October 3, 2022 to establish Puebla.  Puebla was formed on December 15, 2022 and the Company expects Puebla to begin treating patients in June 2024.  Operating costs incurred during the year ended  December 31, 2023 by Puebla, are included in the consolidated statement of operations.

 

The Company continues to develop its design and business model for The Operating Room for the 21st CenturySM through its 50% owned OR21, LLC (“OR21”). The remaining 50% of OR21 is owned by an architectural design company. OR21 is not expected to generate significant revenue within the next two years.

 

MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time.

 

On November 10, 2023, the Company entered into an Investment Purchase Agreement (the “IPA”) with GenesisCare USA, Inc. (the “GenesisCare”) and GenesisCare USA Holdings, Inc. (“GC Holdings”), pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, (collectively, the “RI Target Companies”) together with the assignment of certain payor contacts for a purchase price of $2,850,000 (such transaction, the “RI Acquisition”).  The equity interests to be acquired by the Company under the IPA equates to a 60% interest in each RI Target Company. The RI Target Companies operate three functional radiation therapy cancer centers in Rhode Island. The RI Acquisition is contingent upon certain closing conditions, including GenesisCare and the Company entering into a consent agreement with the Rhode Island Department of Health and approval of all equity holders and managers of each RI Target Company. On March 1, 2024, the Company, GenesisCare and GC Holding entered into a First Amendment to the Investment Agreement pursuant to which the parties agreed to extend the date on which a party could terminate the IPA if the closing conditions had not been met from March 10, 2024 to April 30, 2024. The Company anticipates that these conditions will be met in April 2024.

 

The transaction will be accounted for as a business combination under ASC 805 Business Combinations, which requires, among other things, that purchase consideration, assets acquired, and liabilities assumed be measured at their fair values as of the acquisition date. The initial purchase allocation for the business combination is incomplete at this time, subject to finalizing the IPA. After closing, disclosures regarding amounts recognized for major classes of assets acquired and liabilities assumed will be provided once the initial accounting is completed. 

 

Costs related to legal, financial and due diligence services performed in connection with this transaction recorded in the consolidated statement of operations were $432,000 for the year ended  December 31, 2023.

 

All intercompany accounts and transactions have been eliminated in consolidation.

 

XML 30 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

NOTE 2 ACCOUNTING POLICIES

 

Use of estimates in the preparation of financial statements – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the estimated useful lives of property and equipment and its salvage values, revenues and costs of sales for revenue sharing customers.  Actual results could differ from those estimates.

 

Advertising and marketing – The Company expenses advertising and marketing costs as incurred (collectively, marketing costs”). Marketing costs were $165,000 and $233,000 during the years ended December 31, 2023 and 2022, respectively. Marketing costs include joint marketing with customers and corporate advertising costs. Marketing costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of income. 

 

Sales and Service – The Company markets its financial and turn-key solutions directly to cancer treatment centers, hospitals, and large cancer networks worldwide through its sales staff.  Sales expense includes payroll and travel costs for the Company’s sales staff. The Company also typically provides the equipment, as well as planning, installation, reimbursement and marketing support services to its customers.

 

Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.

 

 

Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement and the minimum cash that must be maintained by GKF per it’s financing agreement with the United States International Development Finance Corporation (“DFC”).  See further discussion at Note 5 - Long Term Debt.

 

Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. The Company monitors the financial condition of the financial institutions it uses on a regular basis.

 

All of the Company’s revenue was provided by 15 locations or 1 PBRT unit and 14 Gamma Knife units in each of 2023 and 2022. One location accounted for approximately 48% and 45% of the Company’s total revenue in 2023 and 2022, respectively. At December 31, 2023, two locations each individually accounted for 30% and 31% of total accounts receivable, respectively. At December 31, 2022, four locations each individually accounted for 12%, 14%, 16% and 22% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.

 

All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.

 

Accounts receivable and allowance for credit losses – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for expected losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are offset against bad debt expense when received.

 

Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. Non-controlling interest is determined by the income (loss) multiplied by the non-controlling interest in subsidiaries, and the income or losses of the non-controlling interests in various subsidiaries controlled by GKF.  The Company also presents the consolidated net income and the portion of the consolidated net income (loss) allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations.

 

Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where applicable. The Company acquired a building as part of the acquisition of GKCE in June 2020. Depreciation for buildings is determined using the straight-line method over 20 years. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. As of October 1, 2022, the Company reduced its estimate for salvage value for one of its domestic Gamma Knife Perfexion units. As of December 31, 2023 and 2022, the Company had seven domestic Gamma Knife units with salvage value ranging from $140,000 to $300,000. 

 

As of January 1, 2023, the Company reduced its estimated useful life for one of its direct patient services Gamma Knife units. The net effect of the change in estimate made January 1, 2023, for the year ended  December 31, 2023, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.

 

Depreciation for PBRT and related equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.

 

The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements accounted for as operating leases. At December 31, 2023, the Company held equipment under operating lease contracts with customers with an original cost of $70,635,000 and accumulated depreciation of $52,302,000. At December 31, 2022, the Company held equipment under operating lease contracts with customers with an original cost of $69,306,000 and accumulated depreciation of $47,992,000. 

 

As of December 31, 2023 and 2022, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. During the year ended December 31, 2023, the Company recorded an asset removal obligation (“ARO”) for one of the customer contracts that expired during 2023.  An ARO for the second contract that expired during 2023 was recorded and impaired in a prior period. For the ARO recorded during 2023, the Company concluded the related increase to the underlying assets could not be supported by the cash flows of the equipment and therefore the Company recorded a loss on the write-down of the ARO in June 2023. The Company’s estimate for the ARO liability was subsequently adjusted during the fourth quarter of 2023 based on new information. Total ARO impairment for the year ended  December 31, 2023 was $290,000. The Company also reviewed its long-lived assets during the fourth quarter of 2023 and concluded events and circumstances existed that indicated additional impairment existed at a third Gamma Knife site related to the existing equipment.  Total equipment impairment for the year ended  December 31, 2023 was $650,000. See further discussion under Note 2 - Long-lived asset impairment and Note 3 - Property and Equipment.

 

 

Revenue recognition - The Company recognizes revenues under ASC 842 Leases (“ASC 842”) and ASC 606 Revenue from Contracts with Customers (“ASC 606”).

 

Rental income from medical equipment leasing (leasing) – The Company recognizes leasing revenue under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s lease contracts are typically for a ten-year term and are classified as either fee per use or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s lease agreement with the Company. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from third party payors, and the Company is responsible for paying operating costs of the equipment determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the years ended,  December 31, 2023 and 2022, the Company recognized leasing revenue of approximately $17,772,000 and $16,655,000 under ASC 842, respectively, of which approximately $10,133,000 and $8,952,000 were for PBRT services, respectively.

 

Revenue sharing arrangements amounted to approximately 70 % and 67% of total revenue for the years ended December 31, 2023 and 2022, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.  Payor mix is a significant variable in the Company’s estimate for revenue sharing revenues.  

 

Direct patient services income (retail) – The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid between three and six months, following issuance of invoice. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. Accounts receivable under ASC 606 at December 31, 2023 was $1,626,000. Accounts receivable under ASC 606 at January 1, 2022 and  December 31, 2022 was $668,000 and $1,119,000. For the years ended  December 31, 2023 and 2022, the Company recognized retail revenues of approximately $3,553,000 and $3,091,000 under ASC 606, respectively.

 

Equipment sales – During the year-ended December 31, 2023, the Company completed a sale of equipment to a new customer.  The Company assessed this transaction under ASC 606 and concluded the Company acted as the agent in this transaction and provided, at a point in time, two performance obligations, in the form of an equipment sale of an Icon and Cobalt-60 reload.  The performance obligation to sell, assign, transfer and deliver the equipment to the customer was carried out via Elekta.  Revenue related to the equipment sale is recognized on a net basis when the sale is complete.  The Company recognized net revenue of $200,000 on the sale of equipment for the year-ended December 31, 2023.

 

Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 8 - Stock-Based Compensation Expense for additional information on the Company’s stock-based compensation programs.

 

Costs of revenue – The Company’s costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s revenue sharing and retail sites). Costs of revenue are recognized as incurred.

 

Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

 

The Company accounts for uncertainty in income taxes as required by the provisions of ASC 740 Income taxes (“ASC 740”), which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires the Company to determine the probability of various possible outcomes. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.

 

See Note 7 - Income Taxes for further discussion on income taxes.

 

Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will reassess its accounting for the operation to the local currency from the U.S. dollar. The Company analyzed it’s Gamma Knife site in Peru and its startup operations in Mexico for Puebla under ASC 830 as of December 31, 2023 and 2022 and concluded the functional currency was the U.S. dollar. As facts and circumstances change, the Company will revisit this conclusion.  The functional currency of the Company’s Gamma Knife site in Ecuador is the U.S. dollar because that is the local currency of Ecuador. 

 

Asset Retirement Obligations – Based on the guidance provided in ASC 410, Asset Retirement Obligations (“ASC 410”), the Company analyzed its existing lease agreements and determined whether an ARO exists to remove the respective units at the end of the lease terms. As of December 31, 2023, the Company has two AROs recorded for the two customer sites that expired during the year, totaling $650,000.  One ARO was recorded and impaired in a prior period.  The Company recorded and impaired an ARO for the second customer site during 2023. No liability has been recorded as of December 31, 2023 for the remaining Gamma Knife or PBRT locations, because it is uncertain these units will be removed and the Company historically has not removed the equipment at the end of the lease term. The Company will re-evaluate the need to record additional ARO liabilities on a periodic basis when facts and circumstances change that could affect this conclusion.

 

Earnings per share – The Company calculates diluted shares using the treasury stock method. Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding and unvested restricted stock units, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options and from unvested restricted stock units. The computation for the years ended  December 31, 2023 and 2022 excluded approximately 144,000 and 20,000, respectively, of the Company’s stock options because the exercise price of the options was higher than the average market price during the period. The weighted average common shares outstanding for the years ended  December 31, 2023 and 2022, included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance. 


The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2023 and 2022.

 

  

2023

  

2022

 

Numerator for basic and diluted earnings per share

 $610,000  $1,328,000 

Denominator:

        

Denominator for basic earnings per share – weighted-average shares

  6,358,000   6,297,000 

Effect of dilutive securities employee stock options and restricted stock

  35,000   6,000 

Denominator for diluted earnings per share – adjusted weighted-average shares

  6,393,000   6,303,000 

Earnings per common share- basic

 $0.10  $0.21 

Earnings per common share- diluted

 $0.10  $0.21 

 

 

Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting (“ASC 280”), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are two reportable segments, leasing and retail. During 2023, the Company provided Gamma Knife and PBRT equipment to thirteen hospitals in the United States and owns and operates two single-unit facilities in Lima, Peru and Guayaquil, Ecuador as of December 31, 2023. An operating segment is defined by ASC 280 as it engages in business activities in which it may recognize revenues and incur expenses, its operating results are regularly reviewed by the Company’s Chief Operating Decision Maker (“CODM”), and its discrete financial information is available. The Company determined two reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the two reportable segments are reviewed by the Company’s Executive Chairman of the Board, who is also the CODM.

 

For the years ended  December 31, 2023 and 2022, the Company’s PBRT operations represented a significant majority of the net income attributable to American Shared Hospital Services from the leasing segment, disclosed below. The revenues, depreciation, interest expense, interest income, tax expense, and net income attributable to American Shared Hospital Services, and total asset allocations for the Company’s two reportable segments as of December 31, 2023 and 2022 consists of the following:

 

  

2023

  

2022

 

Revenues

        

Leasing

 $17,772,000  $16,655,000 

Retail

  3,553,000   3,091,000 

Total

 $21,325,000  $19,746,000 

 

  

2023

  

2022

 

Depreciation expense

        

Leasing

 $4,429,000  $4,268,000 

Retail

  736,000   515,000 

Total

 $5,165,000  $4,783,000 

 

  

2023

  

2022

 

Interest expense

        

Leasing

 $1,087,000  $806,000 

Retail

  25,000    

Total

 $1,112,000  $806,000 

 

  

2023

  

2022

 

Interest income

        

Leasing

 $458,000  $103,000 

Retail

      

Total

 $458,000  $103,000 

 

  

2023

  

2022

 

Income tax expense

        

Leasing

 $306,000  $753,000 

Retail

  125,000   210,000 

Total

 $431,000  $963,000 

 

  

2023

  

2022

 

Net income attributable to American Shared Hospital Services

        

Leasing

 $518,000  $1,187,000 

Retail

  92,000   141,000 

Total

 $610,000  $1,328,000 

 

  

2023

  

2022

 

Total assets

        

Leasing

 $39,854,000  $37,575,000 

Retail

  8,308,000   6,381,000 

Total

 $48,162,000  $43,956,000 

 

 

Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. As of December 31, 2023, impairment of $650,000 was recorded related to cash flow losses of one of the Company’s Gamma Knife units.  No impairment was recorded as of December 31, 2022. See Note 3 - Property and Equipment for further discussion.

 

Goodwill and intangible assets - The Company recorded goodwill of $1,265,000 and an intangible asset with a fair value of $78,000 as part of the acquisition of GKCE in June 2020. The intangible asset identified was GKCE’s trade name and the Company assigned an indefinite useful life to the asset. Based on the guidance provided in accordance with ASC 350 Intangibles-Goodwill and Other (“ASC 350”), the Company does not amortize the intangible asset because it has an indefinite life. The Company assesses goodwill at the reporting unit level, which has been determined to be GKCE. Each reporting period, the Company assesses whether events or circumstances continue to support an indefinite useful life for the intangible asset. Per ASC 350, the Company tests goodwill and intangibles for impairment annually or as events or circumstances change that indicate the fair value may be below the carrying amount. As of December 31, 2023 and 2022, there has been no change to the Company's assessment of the value of intangible assets or goodwill.

 

Accounting pronouncements issued and not yet adopted - In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses.  The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-07 to determine the impact it may have on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign.  ASU 2023-09 is effective for annual periods beginning after December 31, 2024.  The Company is currently evaluating ASU 2023-09 to determine the impact it may have on its consolidated financial statements. 

 

Reclassifications - Certain comparative balances as of and for the year ended have been reclassified to make them consistent with the current year presentation.

XML 31 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Property and Equipment
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

NOTE 3 PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following:

 

  

December 31,

 
  

2023

  

2022

 

Medical equipment and facilities

 $77,150,000  $73,709,000 

Office equipment

  306,000   422,000 

Construction in progress

  3,771,000   106,000 
   81,227,000   74,237,000 

Accumulated depreciation

  (55,383,000)  (50,770,000)

Net property and equipment

 $25,844,000  $23,467,000 

 

As of December 31, 2023 and 2022, approximately $3,966,000 and $2,201,000, respectively, of the net property and equipment balance is outside of the United States.  Depreciation expense recorded in costs of revenue and selling and administrative expense in the consolidated statements of income for the years ended  December 31, 2023 and 2022, was $5,165,000 and $4,783,000, respectively.

 

As of October 1, 2022, the Company reduced its estimate for salvage value for one of its domestic Gamma Knife Perfexion units.  As of January 1, 2023, the Company reduced its estimated useful life for one of its direct patient services Gamma Knife units. The net effect of the change in estimate made January 1, 2023, for the year ended  December 31, 2023, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.

 

As of December 31, 2023 and 2022, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. The impairment as of  December 31, 2023 was related to cash flow impairment for one of the Company’s Gamma Knife units and estimated removal costs of the two Gamma Knife contracts that expired during the year. The Company reviewed its Gamma Knife equipment, in light of available information as of December 31, 2022 and concluded no impairment existed. The Company reviewed it’s PBRT equipment, in light of available information as of December 31, 2023 and 2022 and concluded no impairment exists.

 

 

XML 32 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Other Accrued Liabilities
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]

NOTE 4 - OTHER ACCRUED LIABILITIES

 

Other accrued liabilities consists of the following:

 

  

December 31,

 
  

2023

  

2022

 

Insurance financing

 $  $591,000 

Professional services

  472,000   92,000 

Operating costs

  450,000   539,000 

Other

  304,000   322,000 

Total other accrued liabilities

 $1,226,000  $1,544,000 

 

XML 33 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Long Term Debt
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Long-Term Debt [Text Block]

NOTE 5 - LONG TERM DEBT

 

On  April 9, 2021 the Company along with certain of its domestic subsidiaries (collectively, the “Loan Parties”) entered into a five year $22,000,000 credit agreement with Fifth Third Bank, N.A. (“the Credit Agreement”). The Credit Agreement includes three loan facilities. The first loan facility is a $9,500,000 term loan (the “Term Loan”) which was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs. The second loan facility is a $5,500,000 delayed draw term loan (the “DDTL”) which was used to refinance the Company’s PBRT finance leases and associated closing costs, as well as to provide additional working capital. The third loan facility provides for a $7,000,000 revolving line of credit (the “Revolving Line”) available for future projects and general corporate purposes. The Company borrowed $2,500,000 on the Revolving Line as of  December 31, 2023, which was paid off in January 2024.  The facilities have a five-year maturity, carry a floating interest of LIBOR plus 3.0% and are secured by a lien on substantially all of the assets of the Loan Parties and guaranteed by ASHS.  The long-term debt on the consolidated balance sheets related to the Term Loan and DDTL was $10,825,000 and $12,624,000 as of December 31, 2023 and 2022, respectively.

 

The Revolving Line is charged an unused line fee of 0.25% per annum. The Term Loan and DDTL have interest and principal payments due quarterly. Principal amortization on an annual basis for the Term Loan and DDTL equates to 48% of the original principal loan commitments in years one through five and an end of term payment of the remaining principal balance.

 

The Credit Agreement contains customary covenants and representations, including without limitation, a minimum fixed charge coverage ratio of 1.25 and maximum funded debt to EBITDA ratio of 3.0 to 1.0 (tested on a trailing twelve-month basis at the end of each fiscal quarter), reporting obligations, limitations on dispositions, changes in ownership, mergers and acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and capital expenditures.  The Loan Parties are in compliance with the Credit Agreement covenants as of  December 31, 2023On January 25, 2024, the Company amended its Credit Agreement to include financing for the equipment in Puebla, see Note 12 - Subsequent Event for further information.

 

The loan entered into with DFC in connection with the acquisition of GKCE in  June 2020 (the “DFC Loan”) was obtained through the Company’s wholly-owned subsidiary, HoldCo, and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE’s assets. The first tranche of the DFC Loan was funded in June 2020. During the fourth quarter of 2023, the second tranche of the DFC loan was funded to finance the equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%.  The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The long-term debt on the consolidated balance sheets related to the DFC loan was $2,464,000 and $1,041,000 as of  December 31, 2023 and 2022, respectively.  The Company capitalized debt issuance costs of $9,000 and $9,000 as of  December 31, 2023 and 2022, respectively, related to maintenance and administrative fees on the DFC Loan.  

 

The DFC Loan contains customary covenants among other covenants and obligations, requirements that the Company maintain certain financial ratios related to liquidity and cash flow as well as depository requirements.  On March 28, 2024 the Company received a waiver and amendment from DFC for certain covenants as of December 31, 2023 and through December 31, 2024 and amended other covenants and definitions permanently. The Company expects to be in compliance with all debt covenants pursuant to the DFC Loan as amended and waived at  March 31, 2024.

 

The accretion of debt issuance costs for the years ended  December 31, 2023 and 2022, was $46,000 and $84,000, respectively. As of  December 31, 2023 and 2022, the unamortized debt issuance costs on the consolidated balances sheets were $164,000 and $198,000.  

 

The following are contractual maturities of long-term debt by year at December 31, 2023, excluding debt issuance costs of $164,000:

 

Year ending December 31,

 

Principal

 

2024

 $2,157,000 

2025

  2,907,000 

2026

  7,732,000 

2027

  493,000 
  $13,289,000 

 

 

XML 34 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Leases
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

NOTE 6 - LEASES

 

The Company determines if a contract is a lease at inception. Under ASC 842, the Company is a lessor of equipment to various customers. Leases that commenced prior to ASC 842 adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. All of the Company’s lessor arrangements entered into after ASC 842 adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do not contain the option to terminate early or purchase the asset at the end of the term. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset.

 

The Company’s Gamma Knife and PBRT contracts with hospitals are classified as operating leases under ASC 842. The related equipment is included in medical equipment and facilities on the Company’s consolidated balance sheets (see further discussion at Note 2). As all income from the Company’s lessor arrangements is solely based on procedure volume, all income is considered variable payments not dependent on an index or a rate. As such, the Company does not measure future operating lease receivables.

 

On November 3, 2021, the Company entered into an agreement to sublease (the “Sublease”) its corporate office located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month. The lease expired in August 2023. The Sublease was for $16,195 per month through the existing contract expiration date. The Company also entered into a lease (the “Lease”) agreement for new corporate office space at 601 Montgomery, Suite 1112, San Francisco, CA for approximately 900 square feet for $4,500 per month with a lease expiration date in November 2024.  The Company assessed the Lease under ASC 842 and concluded the Lease should be classified as an operating lease. 

 

The Company’s lessee operating leases are accounted for as ROU assets, current portion of lease liabilities, and lease liabilities on the consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s operating lease contracts do not provide an implicit rate for calculating the present value of future lease payments, so the Company determined its incremental borrowing rate to be in the range of approximately 4.0% and 6.0% by using available market rates and expected lease terms. The operating lease ROU assets and liabilities also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company’s lessee operating lease agreements are for administrative office space and related equipment, and the agreement to lease clinic space for its stand-alone facility in Lima, Peru. These leases have remaining lease terms of approximately 1 year, some of which include options to renew or extend the lease. As of December 31, 2023, operating ROU assets and lease liabilities were $57,000.

 

The following table summarizes maturities of lessee operating lease liabilities as of December 31, 2023:

 

Year ending December 31,

 

Operating Leases

 
     

2024

 $58,000 

Total lease payments

  58,000 

Less imputed interest

  (1,000)

Total

 $57,000 

 

  

Year Ended December 31,

 
  

2023

  

2022

 

Lease cost

        

Operating lease cost, net of impairment

 $302,000  $406,000 

Sublease income

  (129,000)  (174,000)

Total lease cost

 $173,000  $232,000 
         

Other information

        

Cash paid for amounts included in the measurement of lease liabilities - Operating leases

 $302,000  $406,000 

Weighted-average remaining lease term - Operating leases in years

  0.80   1.11 

Weighted-average discount rate - Operating leases

  4.65%  5.65%

 

The Company’s corporate offices are located at 601 Montgomery Street, Suite 1112, San Francisco, California, where it leases approximately 900 square feet for $4,500 per month with a lease expiration date in November 2024. The Company subleased its existing corporate offices located at Two Embarcadero Center, Suite 410, San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month.  This lease expired in August 2023. The monthly lease expense was offset by sublease income of $16,195. The sublease term was consistent with the existing lease term. The Company owns and operates a stand-alone Gamma Knife facility in Lima, Peru where it leases approximately 1,600 square feet for approximately $8,850 per month with a lease expiration date in January 2024. The lease in Peru is currently on a month-to-month basis. The Company also owns and operates a stand-alone Gamma Knife facility in Guayaquil, Ecuador where it owns 864 square feet of condominium space in an office building and approximately 10,135 of related land and parking spaces.

 

Net rent expense was $234,000 and $290,000 for the years ended December 31, 2023 and 2022, respectively, and includes the above operating leases as well as month-to-month rental and certain executory costs. 

 

 

XML 35 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE 7  INCOME TAXES

 

The components of income before income taxes for the years ended  December 31, 2023 and 2022 are as follows:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 
         

Domestic

 $666,000  $2,350,000 

Foreign

  30,000   168,000 

Income before income taxes

 $696,000  $2,518,000 

 

For the year ended  December 31, 2023 and 2022, the Company recorded an income tax expense of $431,000 and $963,000, respectively. 

 

The components of the provision for income taxes for the years ended  December 31, 2023 and 2022 consists of the following:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Current:

        

Federal

 $940,000  $355,000 

State

  115,000   60,000 

Foreign

  135,000   204,000 

Total current

  1,190,000   619,000 
         

Deferred:

        

Federal

  (672,000)  290,000 

State

  (77,000)  48,000 

Foreign

  (10,000)  6,000 

Total deferred

  (759,000)  344,000 
  $431,000  $963,000 

 

Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2023 and 2022 are as follows:

 

  

December 31,

 
  

2023

  

2022

 

Deferred tax liabilities:

        

Property and equipment

 $(323,000) $(708,000)

Prepaid expenses

  (409,000)  (493,000)

ROU asset

  (12,000)  (54,000)
         

Total deferred tax liabilities

  (744,000)  (1,255,000)
         

Deferred tax assets:

        

Net operating loss carryforwards

  155,000   139,000 

Accruals and allowances

  438,000   167,000 

Lease liabilities

  12,000   61,000 

Tax credits

  4,000   3,000 

Other

  140,000   114,000 

Capital loss carryover

  646,000   646,000 
         

Total deferred tax assets

  1,395,000   1,130,000 
         

Valuation allowance

  (714,000)  (697,000)
         

Deferred tax assets net of valuation allowance

  681,000   433,000 
         

Net deferred tax liabilities

 $(63,000) $(822,000)

 

 

NOTE 7  INCOME TAXES (CONTINUED)

 

The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in 2023 and 2022) to income before taxes as follows:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Computed expected federal income tax

 $218,000  $477,000 

State income taxes, net of federal benefit

  12,000   100,000 

Foreign rate differential

  38,000    

Stock compensation

  7,000    

Non-deductible expenses

  6,000   (25,000)

Return to provision true-up

  18,000   52,000 

Uncertain tax positions

  9,000   (17,000)

Alternative minimum tax payable adjustment

     208,000 

Change in valuation allowance

  17,000    

Other deferred tax adjustments

  106,000   168,000 
         
  $431,000  $963,000 

 

As of  December 31, 2023, the Company has net operating loss carryforwards for federal and state income tax return purposes of approximately $0 and $2,586,000 that begin to expire in 2029. 

 

Utilization of the net operating loss and credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended (the “Code”), and similar state provisions. Any annual limitation may result in the expiration of net operating losses and credits before utilization.

 

At December 31, 2023, the Company has a capital loss carryforward for federal income tax return purposes of approximately $2,679,000,which start to expire in 2024. The Company has capital loss carryforwards for state income tax purposes of approximately $129,000, which starts to expire in 2024.

 

Due to uncertainty surrounding the realization of impairment losses, capital losses and foreign operating losses in future years, the Company has placed a valuation allowance against a portion of its net domestic and foreign deferred tax assets. The net valuation allowance increased by $17,000 and $0 for the years ended December 31, 2023 and 2022, respectively.

 

The tax return years 2019 through 2022 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for calendar years 1999 through 2004, 2009, 2010, 2012, 2014, 2015, 2016, 2017 and 2018 remain open to examination by the major domestic taxing jurisdictions.

 

 

NOTE 7  INCOME TAXES (CONTINUED)

 

The Company has adopted accounting standards which prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a companys income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Additionally, these accounting standards specify that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company has made no reclassifications between current taxes payable and long term taxes payable under this guidance.

 

As of December 31, 2023, the unrecognized tax benefit was $287,000 which, if recognized, will not affect the annual effective tax rate as these unrecognized tax benefits would increase deferred tax assets, which would be subject to a full valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:

 

  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Balance at beginning of year

 $278,000  $295,000 

Additions based on tax positions of prior years

  9,000   (17,000)
         

Balance at end of year

 $287,000  $278,000 

 

The Company’s policy for deducting interest and penalties is to treat interest as interest expense and penalties as income taxes. As of December 31, 2023, the Company had $58,000 accrued for the payment of penalties and zero interest related to unrecognized tax benefits. The Company does not expect any material changes to our uncertain tax positions within the next 12 months. The Company believes that it is reasonably possible that a decrease of up to $100,000 in unrecognized tax benefits related to foreign taxes may be necessary within the coming year.

XML 36 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

NOTE 8  STOCK-BASED COMPENSATION EXPENSE

 

Incentive Compensation Plan

 

In  June 2021, the Company’s shareholders approved an amendment and restatement of the Company’s Incentive Compensation Plan (the “Plan”), that among other things, increases the number of shares of the Company’s common stock reserved for issuance under the Plan to 2,580,000 and extends the term of the Plan by five years to  February 22, 2027. The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. No further grants or share issuances will be made under the previous plans. As of December 31, 2023, approximately 935,000 shares remain available for grant under the Plan.

 

Under the Plan, a total of 898,000 restricted stock units have been granted, consisting of 53,000 of annual automatic grants to non-employee directors, 328,000 of deferred retainer fees to non-employee members of the Board, 57,000 grants issued in lieu of commission or bonus to employees of the Company, and 460,000 restricted stock units issued to the Executive Chairman of the Board, see further discussion below. Of the total restricted stock units granted under the Plan, 123,000 of them are fully vested but not yet deemed issued and outstanding, 742,000 are fully vested and outstanding, and 33,000 are outstanding as of December 31, 2023.

 

Changes in restricted stock units, consisting primarily of annual automatic grants, deferred compensation to non-employee directors, shares issued to employees as part of the Company’s bonus plan, and restricted stock units awards to the Executive Chairman of the Board, under the Incentive Compensation Plans during 2023 and 2022 are as follows:

 

  

Restricted Stock Units

  

Grant Date Weighted- Average Fair Value

 

Outstanding at January 1, 2022

  

10,000

   

$ 2.57

 

Granted

  

131,000

   

$ 2.40

 

Vested

  

(132,000)

   

$ 2.40

 

Forfeited

  

(3,000)

   

$ 2.92

 
         

Outstanding at December 31, 2022

  

6,000

   

$ 2.33

 

Granted

  

146,000

   

$ 2.97

 

Vested

  

(119,000)

   

$ 2.94

 

Outstanding at December 31, 2023

  

33,000

   

$ 2.88

 

 

 

 

NOTE 8  STOCK-BASED COMPENSATION EXPENSE (CONTINUED)

 

Certain Executive Equity Awards

 

Effective May 4, 2020, the Company appointed Raymond C. Stachowiak as Interim President and Chief Executive Officer (“CEO”). Pursuant to his Offer Letter, Mr. Stachowiak was granted 50,000 restricted stock awards that vested in full on August 3, 2020. He was granted additional restricted stock awards totaling 10,000 common shares per month, which vested in full at the end of each 30-day period following issuance. Mr. Stachowiak became CEO of the Company on October 1, 2020 and served in such position until he was appointed Executive Chairman of the Board on March 7, 2023. For the year ended December 31, 2022, 120,000 restricted stock awards were issued to Mr. Stachowiak and became fully vested. Total compensation expense recorded for the year ended December 31, 2022 in the consolidated financial statements of income related to executive equity awards was $288,000.  For the year ended December 31, 2023, 120,000 restricted stock awards were issued to Mr. Stachowiak and 90,000 became fully vested.  Total compensation expense recorded for the year ended December 31, 2023 in the consolidated financial statements of income related to the executive equity awards was $351,000.

 

For the year ended  December 31, 2023, stock compensation expense recorded in the consolidated financial statements is summarized as follows:

 

      

Stock-Based

 
  

Awards Issued

  

Compensation

 
  

and Vested

  

Expense

 

Options

    $34,000 

Management Bonus Program - vested and issued

  26,000    

Board RSU Awards - other

     4,000 

Executive Compensation

  90,000   351,000 
   116,000  $389,000 

 

Total stock-based compensation expense before income tax effect for the Company’s options and restricted stock awards in the amount of $389,000 and $399,000 for the years ended  December 31, 2023 and 2022, is reflected in selling and administrative expense in the consolidated statements of income, respectively.

 

Stock Options

 

Changes in stock options outstanding under the Incentive Compensation Plans during 2023 and 2022 are as follows:

 

Options

 

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average Remaining Contractual Term (Years)

  

Aggregate Intrinsic Value

 

Balance at December 31, 2021

  67,000  $2.72   3.33  $ 

Granted

  50,000  $2.72   7.00  $ 

Exercised

  (4,000) $2.29     $ 

Forfeited

  (18,000) $2.64     $ 
                 

Balance at December 31, 2022

  95,000  $2.76   4.83  $25,000 

Granted

  70,000  $2.89   7.00  $ 

Forfeited

  (19,000) $2.69     $ 
                 

Balance at December 31, 2023

  146,000  $2.83   5.44  $ 
                 

Exercisable at December 31, 2022

  38,000  $2.79   2.38  $ 
                 

Exercisable at December 31, 2023

  31,000  $2.84   3.38  $ 

 

 

NOTE 8  STOCK-BASED COMPENSATION EXPENSE (CONTINUED)

 

The weighted average grant-date fair value of the options granted during the years 2023 and 2022 was $2.89 and $1.49, respectively. There were no options exercised during the year ended December 31, 2023. There were 4,000 options exercised which resulted in 3,000 shares issued, due to cashless exercises, during the year ended December 31, 2022. Total stock-based compensation expense recognized for stock options for the years ended December 2023 and 2022 was $34,000 and $10,000, respectively.

 

The Company received approximately $5,000 from the exercise of 2,000 options under the share-based arrangements during the year ended December 31, 2022. The remaining options exercised during 2022 were cashless exercises. 

 

At December 31, 2023, there was approximately $156,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a period of approximately four years.

 

The Company’s stock option awards to employees are calculated using the Black-Scholes options valuation model. The Black-Scholes model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes model requires the input of highly subjective assumptions including the expected stock price volatility. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. For these reasons, management believes that the existing models do not necessarily provide a reliable single measure of the fair value of its stock-based awards to employees.

 

The fair value of the Company’s option grants issued during 2023 and 2022 were estimated using assumptions for expected life, volatility, dividend yield, forfeiture rate, and risk-free interest rate which are specific to each award as summarized in the following table. The estimated fair value of the Company’s options is amortized over the period during which the optionee is required to provide service in exchange for the award, usually the vesting period.

 

The fair value of the Company’s option grants under the Plan in 2023 and 2022 was estimated using the following assumptions:

  

2023

  

2022

 

Expected life (years)

  7.0   7.0 

Expected forfeiture rate

  0.0%  0.0%

Expected volatility

  50%  50%

Dividend yield

  0%  0%

Risk-free interest rate

  3.6%  3.3%

 

The following summarizes the assumption inputs used for the Company’s Black-Scholes calculation:

 

Expected life (years): The expected term represents the weighted average period that the Company’s stock options are expected to be outstanding.  
 

Expected forfeiture rate: Forfeitures are recognized as they occur.   

 

Expected volatility: The expected volatility was derived from the Company’s historical stock volatility. 

 

Dividend yield: The expected dividend yield was assumed to be zero, as the Company has not previously paid dividends on common stock and has no current plans to do so.  

 

Risk-free interest rate:  The risk-free interest rate is based on the interest yield in effect at the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the option’s expected term.

 

Repurchase of Common Stock, Common Stock Warrants and Stock Options

 

In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in 2008. There were no shares of the Company repurchased during 2023 or 2022. There are approximately 72,000 shares remaining under this repurchase authorization.

 

 

XML 37 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Retirement Plan
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Retirement Benefits [Text Block]

NOTE 9  RETIREMENT PLAN

 

The Company has a defined-contribution retirement plan (the “Retirement Plan”) that allows for a matching safe harbor contribution. For 2023, the Board of Directors elected to match participant deferred salary contributions up to a maximum of 4% of the participant’s annual compensation. Discretionary profit sharing contributions are allowed under the Retirement Plan in years that the Board does not elect a safe harbor match. During 2023, the Company contributed $43,000 to the Retirement Plan for the safe harbor match for the year ended December 31, 2023. The Company has accrued approximately $17,000 for additional safe harbor matching contribution for the year ended December 31, 2023. Also during 2023, the Company contributed $47,000 to the Retirement Plan for the safe harbor match for the year ended December 31, 2022.

 

XML 38 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Commitments and Contingencies
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

NOTE 10  COMMITMENTS AND CONTINGENCIES

 

On December 20, 2018, the Company signed Second Amendments to two System Build Agreements for the Company’s second and third Mevion PBRT units. These commitments expired in January 2024 and the Company was not able to utilize this equipment. During the year-ended  December 31, 2020, the Company impaired these deposits and wrote-off the deposits and related capitalized interest. 

 

As of December 31, 2023, the Company had commitments to install three Leksell Gamma Knife Esprit Systems (“Esprit”), install one Cobalt-60 reload with software, purchase one Gamma Plan workstation, purchase one Linear Accelerator (“LINAC”) system, and purchase one Magnetic Resonance imaging guided LINAC (“MR LINAC”). The LINAC, MR LINAC and one Esprit will be placed at future customer sites. The remaining Esprit upgrades and Cobalt-60 reload are scheduled to occur during 2024 at existing customer sites. The Company also has one commitment to de-install a Gamma Knife unit at an existing customer site. The Company’s LINAC installation in Puebla was in process at  December 31, 2023 and the Company made substantial payments towards the project during 2023. In January 2024, the Company amended the Credit Agreement to include financing for this project. At  December 31, 2023, the Company had commitments remaining for some of the ancillary equipment in Puebla. Total Gamma Knife and LINAC commitments as of December 31, 2023, were $15,925,000. There are no deposits on the consolidated balance sheets related to these commitments as of December 31, 2023.  It is the Company's intent to finance substantially all of these commitments.  There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company.  However, the Company currently has cash on hand of $13,808,000 and a line of credit of $7,000,000 to fund these projects, if necessary.  The Company borrowed $2,500,000 on the Revolving Line as of December 31, 2023, which was paid off in January 2024. 

 

On September 4, 2022, the Company entered into a Maintenance and Support Agreement with Mevion (the “Mevion Service Agreement”), which provides for maintenance and support of the Company’s PBRT unit at Orlando Health from September 2022 through April 2026.  The agreement requires an annual prepayment of $1,865,000 for the current contractual period (one year). This payment portion was recorded as a prepaid contract and will be amortized over the one-year service period.

 

As of December 31, 2023, the Company had commitments to service and maintain its Gamma Knife and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta and Mobius Imaging, LLC. The Company’s commitments to purchase two LINAC systems also include a 9-year and 5-year agreement to service the equipment, respectively. Total service commitments as of December 31, 2023 were $14,805,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

 

The Company’s customer contracts generally contain mutual indemnification provisions. The Company maintains general and professional liability insurance in the United States. The Company is not involved in the practice of medicine and therefore believes its present insurance coverage and indemnification agreements are adequate for its business. The Company’s Peruvian and Ecuadorian Gamma Knife centers are free-standing facilities operated by GKPeru and GKCE, respectively. The treating physicians and clinical staff at these facilities are independent contractors. The Company maintains general and professional liability insurance consistent with the operations of these facilities and believes its present coverage is adequate for its business.

 

 

XML 39 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Related Party Transactions
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

NOTE 11  RELATED PARTY TRANSACTIONS

 

The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife and other radiation therapy equipment. Since the Company purchases the majority of its equipment from Elekta, there are significant related party transactions with Elekta such as equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment

 

The following summarizes related party activity for the years ended  December 31, 2023 and 2022:

 

  

December 31,

 
  

2023

  

2022

 

Equipment purchases and de-install costs

 $6,918,000  $1,844,000 

Costs incurred to maintain equipment

  851,000   1,094,000 

Total related party transactions

 $7,769,000  $2,938,000 

 

The Company had related party commitments to install three Esprit upgrades, one Cobalt-60 reload, purchase one MR LINAC, purchase one Gamma Plan workstation, and service the related equipment. The Company also has two commitments to de-install Gamma Knife units at existing customer sites. Total related party commitments were $18,968,000 as of  December 31, 2023.

 

Related party liabilities on the consolidated balance sheets consist of the following as of December 31, 2023 and 2022:

 

  

December 31,

 
  

2023

  

2022

 

Accounts payable and other accrued liabilities

 $1,961,000  $497,000 

 

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Subsequent Events
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Subsequent Events [Text Block]

NOTE 12  SUBSEQUENT EVENT

 

On January 25, 2024 (the “First Amendment Effective Date”), the Company entered into a First Amendment to Credit Agreement (the “First Amendment”) with Fifth Third which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the “Supplemental Term Loan”). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and will be used for capital expenditures related to the Company’s operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030 (the “Maturity Date’). Interest on the Supplemental Term Loan is payable monthly during the initial twelve month period following the First Amendment Effective Date. Following such twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The First Amendment also replaces the LIBOR-based rates in the Credit Agreement with SOFR-based rates. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

 

XML 41 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]

Use of estimates in the preparation of financial statements – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the estimated useful lives of property and equipment and its salvage values, revenues and costs of sales for revenue sharing customers.  Actual results could differ from those estimates.

 

Advertising Cost [Policy Text Block]

Advertising and marketing – The Company expenses advertising and marketing costs as incurred (collectively, marketing costs”). Marketing costs were $165,000 and $233,000 during the years ended December 31, 2023 and 2022, respectively. Marketing costs include joint marketing with customers and corporate advertising costs. Marketing costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of income. 

 

Sales and Service – The Company markets its financial and turn-key solutions directly to cancer treatment centers, hospitals, and large cancer networks worldwide through its sales staff.  Sales expense includes payroll and travel costs for the Company’s sales staff. The Company also typically provides the equipment, as well as planning, installation, reimbursement and marketing support services to its customers.

 

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.

 

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement and the minimum cash that must be maintained by GKF per it’s financing agreement with the United States International Development Finance Corporation (“DFC”).  See further discussion at Note 5 - Long Term Debt.

 

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. The Company monitors the financial condition of the financial institutions it uses on a regular basis.

 

All of the Company’s revenue was provided by 15 locations or 1 PBRT unit and 14 Gamma Knife units in each of 2023 and 2022. One location accounted for approximately 48% and 45% of the Company’s total revenue in 2023 and 2022, respectively. At December 31, 2023, two locations each individually accounted for 30% and 31% of total accounts receivable, respectively. At December 31, 2022, four locations each individually accounted for 12%, 14%, 16% and 22% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.

 

All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.

 

Accounts Receivable [Policy Text Block]

Accounts receivable and allowance for credit losses – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for expected losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are offset against bad debt expense when received.

 

Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]

Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. Non-controlling interest is determined by the income (loss) multiplied by the non-controlling interest in subsidiaries, and the income or losses of the non-controlling interests in various subsidiaries controlled by GKF.  The Company also presents the consolidated net income and the portion of the consolidated net income (loss) allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations.

 

Property, Plant and Equipment, Policy [Policy Text Block]

Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where applicable. The Company acquired a building as part of the acquisition of GKCE in June 2020. Depreciation for buildings is determined using the straight-line method over 20 years. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. As of October 1, 2022, the Company reduced its estimate for salvage value for one of its domestic Gamma Knife Perfexion units. As of December 31, 2023 and 2022, the Company had seven domestic Gamma Knife units with salvage value ranging from $140,000 to $300,000. 

 

As of January 1, 2023, the Company reduced its estimated useful life for one of its direct patient services Gamma Knife units. The net effect of the change in estimate made January 1, 2023, for the year ended  December 31, 2023, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.

 

Depreciation for PBRT and related equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.

 

The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements accounted for as operating leases. At December 31, 2023, the Company held equipment under operating lease contracts with customers with an original cost of $70,635,000 and accumulated depreciation of $52,302,000. At December 31, 2022, the Company held equipment under operating lease contracts with customers with an original cost of $69,306,000 and accumulated depreciation of $47,992,000. 

 

As of December 31, 2023 and 2022, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. During the year ended December 31, 2023, the Company recorded an asset removal obligation (“ARO”) for one of the customer contracts that expired during 2023.  An ARO for the second contract that expired during 2023 was recorded and impaired in a prior period. For the ARO recorded during 2023, the Company concluded the related increase to the underlying assets could not be supported by the cash flows of the equipment and therefore the Company recorded a loss on the write-down of the ARO in June 2023. The Company’s estimate for the ARO liability was subsequently adjusted during the fourth quarter of 2023 based on new information. Total ARO impairment for the year ended  December 31, 2023 was $290,000. The Company also reviewed its long-lived assets during the fourth quarter of 2023 and concluded events and circumstances existed that indicated additional impairment existed at a third Gamma Knife site related to the existing equipment.  Total equipment impairment for the year ended  December 31, 2023 was $650,000. See further discussion under Note 2 - Long-lived asset impairment and Note 3 - Property and Equipment.

 

Revenue [Policy Text Block]

Revenue recognition - The Company recognizes revenues under ASC 842 Leases (“ASC 842”) and ASC 606 Revenue from Contracts with Customers (“ASC 606”).

 

Rental income from medical equipment leasing (leasing) – The Company recognizes leasing revenue under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company’s lease contracts are typically for a ten-year term and are classified as either fee per use or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s lease agreement with the Company. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from third party payors, and the Company is responsible for paying operating costs of the equipment determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the years ended,  December 31, 2023 and 2022, the Company recognized leasing revenue of approximately $17,772,000 and $16,655,000 under ASC 842, respectively, of which approximately $10,133,000 and $8,952,000 were for PBRT services, respectively.

 

Revenue sharing arrangements amounted to approximately 70 % and 67% of total revenue for the years ended December 31, 2023 and 2022, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.  Payor mix is a significant variable in the Company’s estimate for revenue sharing revenues.  

 

Direct patient services income (retail) – The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC 606, the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE’s patient population is primarily covered by a government payor and payments are paid between three and six months, following issuance of invoice. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. Accounts receivable under ASC 606 at December 31, 2023 was $1,626,000. Accounts receivable under ASC 606 at January 1, 2022 and  December 31, 2022 was $668,000 and $1,119,000. For the years ended  December 31, 2023 and 2022, the Company recognized retail revenues of approximately $3,553,000 and $3,091,000 under ASC 606, respectively.

 

Equipment sales – During the year-ended December 31, 2023, the Company completed a sale of equipment to a new customer.  The Company assessed this transaction under ASC 606 and concluded the Company acted as the agent in this transaction and provided, at a point in time, two performance obligations, in the form of an equipment sale of an Icon and Cobalt-60 reload.  The performance obligation to sell, assign, transfer and deliver the equipment to the customer was carried out via Elekta.  Revenue related to the equipment sale is recognized on a net basis when the sale is complete.  The Company recognized net revenue of $200,000 on the sale of equipment for the year-ended December 31, 2023.

 

Compensation Related Costs, Policy [Policy Text Block]

Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 8 - Stock-Based Compensation Expense for additional information on the Company’s stock-based compensation programs.

 

Cost of Goods and Service [Policy Text Block]

Costs of revenue – The Company’s costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s revenue sharing and retail sites). Costs of revenue are recognized as incurred.

 

Income Tax, Policy [Policy Text Block]

Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

 

The Company accounts for uncertainty in income taxes as required by the provisions of ASC 740 Income taxes (“ASC 740”), which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires the Company to determine the probability of various possible outcomes. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.

 

See Note 7 - Income Taxes for further discussion on income taxes.

 

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will reassess its accounting for the operation to the local currency from the U.S. dollar. The Company analyzed it’s Gamma Knife site in Peru and its startup operations in Mexico for Puebla under ASC 830 as of December 31, 2023 and 2022 and concluded the functional currency was the U.S. dollar. As facts and circumstances change, the Company will revisit this conclusion.  The functional currency of the Company’s Gamma Knife site in Ecuador is the U.S. dollar because that is the local currency of Ecuador. 

 

Asset Retirement Obligation [Policy Text Block]

Asset Retirement Obligations – Based on the guidance provided in ASC 410, Asset Retirement Obligations (“ASC 410”), the Company analyzed its existing lease agreements and determined whether an ARO exists to remove the respective units at the end of the lease terms. As of December 31, 2023, the Company has two AROs recorded for the two customer sites that expired during the year, totaling $650,000.  One ARO was recorded and impaired in a prior period.  The Company recorded and impaired an ARO for the second customer site during 2023. No liability has been recorded as of December 31, 2023 for the remaining Gamma Knife or PBRT locations, because it is uncertain these units will be removed and the Company historically has not removed the equipment at the end of the lease term. The Company will re-evaluate the need to record additional ARO liabilities on a periodic basis when facts and circumstances change that could affect this conclusion.

 

Earnings Per Share, Policy [Policy Text Block]

Earnings per share – The Company calculates diluted shares using the treasury stock method. Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding and unvested restricted stock units, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options and from unvested restricted stock units. The computation for the years ended  December 31, 2023 and 2022 excluded approximately 144,000 and 20,000, respectively, of the Company’s stock options because the exercise price of the options was higher than the average market price during the period. The weighted average common shares outstanding for the years ended  December 31, 2023 and 2022, included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance. 


The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2023 and 2022.

 

  

2023

  

2022

 

Numerator for basic and diluted earnings per share

 $610,000  $1,328,000 

Denominator:

        

Denominator for basic earnings per share – weighted-average shares

  6,358,000   6,297,000 

Effect of dilutive securities employee stock options and restricted stock

  35,000   6,000 

Denominator for diluted earnings per share – adjusted weighted-average shares

  6,393,000   6,303,000 

Earnings per common share- basic

 $0.10  $0.21 

Earnings per common share- diluted

 $0.10  $0.21 

 

Segment Reporting, Policy [Policy Text Block]

Business segment information - Based on the guidance provided in accordance with ASC 280 Segment Reporting (“ASC 280”), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are two reportable segments, leasing and retail. During 2023, the Company provided Gamma Knife and PBRT equipment to thirteen hospitals in the United States and owns and operates two single-unit facilities in Lima, Peru and Guayaquil, Ecuador as of December 31, 2023. An operating segment is defined by ASC 280 as it engages in business activities in which it may recognize revenues and incur expenses, its operating results are regularly reviewed by the Company’s Chief Operating Decision Maker (“CODM”), and its discrete financial information is available. The Company determined two reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the two reportable segments are reviewed by the Company’s Executive Chairman of the Board, who is also the CODM.

 

For the years ended  December 31, 2023 and 2022, the Company’s PBRT operations represented a significant majority of the net income attributable to American Shared Hospital Services from the leasing segment, disclosed below. The revenues, depreciation, interest expense, interest income, tax expense, and net income attributable to American Shared Hospital Services, and total asset allocations for the Company’s two reportable segments as of December 31, 2023 and 2022 consists of the following:

 

  

2023

  

2022

 

Revenues

        

Leasing

 $17,772,000  $16,655,000 

Retail

  3,553,000   3,091,000 

Total

 $21,325,000  $19,746,000 

 

  

2023

  

2022

 

Depreciation expense

        

Leasing

 $4,429,000  $4,268,000 

Retail

  736,000   515,000 

Total

 $5,165,000  $4,783,000 

 

  

2023

  

2022

 

Interest expense

        

Leasing

 $1,087,000  $806,000 

Retail

  25,000    

Total

 $1,112,000  $806,000 

 

  

2023

  

2022

 

Interest income

        

Leasing

 $458,000  $103,000 

Retail

      

Total

 $458,000  $103,000 

 

  

2023

  

2022

 

Income tax expense

        

Leasing

 $306,000  $753,000 

Retail

  125,000   210,000 

Total

 $431,000  $963,000 

 

  

2023

  

2022

 

Net income attributable to American Shared Hospital Services

        

Leasing

 $518,000  $1,187,000 

Retail

  92,000   141,000 

Total

 $610,000  $1,328,000 

 

  

2023

  

2022

 

Total assets

        

Leasing

 $39,854,000  $37,575,000 

Retail

  8,308,000   6,381,000 

Total

 $48,162,000  $43,956,000 

 

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. As of December 31, 2023, impairment of $650,000 was recorded related to cash flow losses of one of the Company’s Gamma Knife units.  No impairment was recorded as of December 31, 2022. See Note 3 - Property and Equipment for further discussion.

 

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and intangible assets - The Company recorded goodwill of $1,265,000 and an intangible asset with a fair value of $78,000 as part of the acquisition of GKCE in June 2020. The intangible asset identified was GKCE’s trade name and the Company assigned an indefinite useful life to the asset. Based on the guidance provided in accordance with ASC 350 Intangibles-Goodwill and Other (“ASC 350”), the Company does not amortize the intangible asset because it has an indefinite life. The Company assesses goodwill at the reporting unit level, which has been determined to be GKCE. Each reporting period, the Company assesses whether events or circumstances continue to support an indefinite useful life for the intangible asset. Per ASC 350, the Company tests goodwill and intangibles for impairment annually or as events or circumstances change that indicate the fair value may be below the carrying amount. As of December 31, 2023 and 2022, there has been no change to the Company's assessment of the value of intangible assets or goodwill.

 

New Accounting Pronouncements, Policy [Policy Text Block]

Accounting pronouncements issued and not yet adopted - In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses.  The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance.  ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating ASU 2023-07 to determine the impact it may have on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign.  ASU 2023-09 is effective for annual periods beginning after December 31, 2024.  The Company is currently evaluating ASU 2023-09 to determine the impact it may have on its consolidated financial statements. 

 

Reclassification, Comparability Adjustment [Policy Text Block] Reclassifications - Certain comparative balances as of and for the year ended have been reclassified to make them consistent with the current year presentation.
XML 42 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

2023

  

2022

 

Numerator for basic and diluted earnings per share

 $610,000  $1,328,000 

Denominator:

        

Denominator for basic earnings per share – weighted-average shares

  6,358,000   6,297,000 

Effect of dilutive securities employee stock options and restricted stock

  35,000   6,000 

Denominator for diluted earnings per share – adjusted weighted-average shares

  6,393,000   6,303,000 

Earnings per common share- basic

 $0.10  $0.21 

Earnings per common share- diluted

 $0.10  $0.21 
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]
  

2023

  

2022

 

Revenues

        

Leasing

 $17,772,000  $16,655,000 

Retail

  3,553,000   3,091,000 

Total

 $21,325,000  $19,746,000 
Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]
  

2023

  

2022

 

Depreciation expense

        

Leasing

 $4,429,000  $4,268,000 

Retail

  736,000   515,000 

Total

 $5,165,000  $4,783,000 
  

2023

  

2022

 

Interest expense

        

Leasing

 $1,087,000  $806,000 

Retail

  25,000    

Total

 $1,112,000  $806,000 
  

2023

  

2022

 

Interest income

        

Leasing

 $458,000  $103,000 

Retail

      

Total

 $458,000  $103,000 
  

2023

  

2022

 

Income tax expense

        

Leasing

 $306,000  $753,000 

Retail

  125,000   210,000 

Total

 $431,000  $963,000 
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
  

2023

  

2022

 

Net income attributable to American Shared Hospital Services

        

Leasing

 $518,000  $1,187,000 

Retail

  92,000   141,000 

Total

 $610,000  $1,328,000 
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
  

2023

  

2022

 

Total assets

        

Leasing

 $39,854,000  $37,575,000 

Retail

  8,308,000   6,381,000 

Total

 $48,162,000  $43,956,000 
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

December 31,

 
  

2023

  

2022

 

Medical equipment and facilities

 $77,150,000  $73,709,000 

Office equipment

  306,000   422,000 

Construction in progress

  3,771,000   106,000 
   81,227,000   74,237,000 

Accumulated depreciation

  (55,383,000)  (50,770,000)

Net property and equipment

 $25,844,000  $23,467,000 
XML 44 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Other Accrued Liabilities (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Other Liabilities [Table Text Block]
  

December 31,

 
  

2023

  

2022

 

Insurance financing

 $  $591,000 

Professional services

  472,000   92,000 

Operating costs

  450,000   539,000 

Other

  304,000   322,000 

Total other accrued liabilities

 $1,226,000  $1,544,000 
XML 45 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Long Term Debt (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Maturities of Long-Term Debt [Table Text Block]

Year ending December 31,

 

Principal

 

2024

 $2,157,000 

2025

  2,907,000 

2026

  7,732,000 

2027

  493,000 
  $13,289,000 
XML 46 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Leases (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Year ending December 31,

 

Operating Leases

 
     

2024

 $58,000 

Total lease payments

  58,000 

Less imputed interest

  (1,000)

Total

 $57,000 
Lease, Cost [Table Text Block]
  

Year Ended December 31,

 
  

2023

  

2022

 

Lease cost

        

Operating lease cost, net of impairment

 $302,000  $406,000 

Sublease income

  (129,000)  (174,000)

Total lease cost

 $173,000  $232,000 
         

Other information

        

Cash paid for amounts included in the measurement of lease liabilities - Operating leases

 $302,000  $406,000 

Weighted-average remaining lease term - Operating leases in years

  0.80   1.11 

Weighted-average discount rate - Operating leases

  4.65%  5.65%
XML 47 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

YEARS ENDED December 31,

 
  

2023

  

2022

 
         

Domestic

 $666,000  $2,350,000 

Foreign

  30,000   168,000 

Income before income taxes

 $696,000  $2,518,000 
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Current:

        

Federal

 $940,000  $355,000 

State

  115,000   60,000 

Foreign

  135,000   204,000 

Total current

  1,190,000   619,000 
         

Deferred:

        

Federal

  (672,000)  290,000 

State

  (77,000)  48,000 

Foreign

  (10,000)  6,000 

Total deferred

  (759,000)  344,000 
  $431,000  $963,000 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

December 31,

 
  

2023

  

2022

 

Deferred tax liabilities:

        

Property and equipment

 $(323,000) $(708,000)

Prepaid expenses

  (409,000)  (493,000)

ROU asset

  (12,000)  (54,000)
         

Total deferred tax liabilities

  (744,000)  (1,255,000)
         

Deferred tax assets:

        

Net operating loss carryforwards

  155,000   139,000 

Accruals and allowances

  438,000   167,000 

Lease liabilities

  12,000   61,000 

Tax credits

  4,000   3,000 

Other

  140,000   114,000 

Capital loss carryover

  646,000   646,000 
         

Total deferred tax assets

  1,395,000   1,130,000 
         

Valuation allowance

  (714,000)  (697,000)
         

Deferred tax assets net of valuation allowance

  681,000   433,000 
         

Net deferred tax liabilities

 $(63,000) $(822,000)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Computed expected federal income tax

 $218,000  $477,000 

State income taxes, net of federal benefit

  12,000   100,000 

Foreign rate differential

  38,000    

Stock compensation

  7,000    

Non-deductible expenses

  6,000   (25,000)

Return to provision true-up

  18,000   52,000 

Uncertain tax positions

  9,000   (17,000)

Alternative minimum tax payable adjustment

     208,000 

Change in valuation allowance

  17,000    

Other deferred tax adjustments

  106,000   168,000 
         
  $431,000  $963,000 
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
  

YEARS ENDED December 31,

 
  

2023

  

2022

 

Balance at beginning of year

 $278,000  $295,000 

Additions based on tax positions of prior years

  9,000   (17,000)
         

Balance at end of year

 $287,000  $278,000 
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
  

Restricted Stock Units

  

Grant Date Weighted- Average Fair Value

 

Outstanding at January 1, 2022

  

10,000

   

$ 2.57

 

Granted

  

131,000

   

$ 2.40

 

Vested

  

(132,000)

   

$ 2.40

 

Forfeited

  

(3,000)

   

$ 2.92

 
         

Outstanding at December 31, 2022

  

6,000

   

$ 2.33

 

Granted

  

146,000

   

$ 2.97

 

Vested

  

(119,000)

   

$ 2.94

 

Outstanding at December 31, 2023

  

33,000

   

$ 2.88

 
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
      

Stock-Based

 
  

Awards Issued

  

Compensation

 
  

and Vested

  

Expense

 

Options

    $34,000 

Management Bonus Program - vested and issued

  26,000    

Board RSU Awards - other

     4,000 

Executive Compensation

  90,000   351,000 
   116,000  $389,000 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]

Options

 

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average Remaining Contractual Term (Years)

  

Aggregate Intrinsic Value

 

Balance at December 31, 2021

  67,000  $2.72   3.33  $ 

Granted

  50,000  $2.72   7.00  $ 

Exercised

  (4,000) $2.29     $ 

Forfeited

  (18,000) $2.64     $ 
                 

Balance at December 31, 2022

  95,000  $2.76   4.83  $25,000 

Granted

  70,000  $2.89   7.00  $ 

Forfeited

  (19,000) $2.69     $ 
                 

Balance at December 31, 2023

  146,000  $2.83   5.44  $ 
                 

Exercisable at December 31, 2022

  38,000  $2.79   2.38  $ 
                 

Exercisable at December 31, 2023

  31,000  $2.84   3.38  $ 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

2023

  

2022

 

Expected life (years)

  7.0   7.0 

Expected forfeiture rate

  0.0%  0.0%

Expected volatility

  50%  50%

Dividend yield

  0%  0%

Risk-free interest rate

  3.6%  3.3%
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Related Party Transactions (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Related Party Transactions [Table Text Block]
  

December 31,

 
  

2023

  

2022

 

Equipment purchases and de-install costs

 $6,918,000  $1,844,000 

Costs incurred to maintain equipment

  851,000   1,094,000 

Total related party transactions

 $7,769,000  $2,938,000 
  

December 31,

 
  

2023

  

2022

 

Accounts payable and other accrued liabilities

 $1,961,000  $497,000 
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Note 1 - Business and Basis of Presentation (Details Textual)
Nov. 10, 2023
USD ($)
Dec. 31, 2023
USD ($)
Apr. 27, 2022
Number of Medical Centers   12  
Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC [Member]      
Business Combination, Consideration Transferred $ 2,850,000    
Business Acquisition, Percentage of Voting Interests Acquired 60.00%    
Business Acquisition, Transaction Costs   $ 432,000  
Newco [Member]      
Equity Method Investment, Ownership Percentage     85.00%
Newco [Member] | Guadalupe [Member]      
Equity Method Investment, Ownership Percentage     15.00%
OR21, LLC [Member]      
Equity Method Investment, Ownership Percentage   50.00%  
OR21, LLC [Member] | Architectural Design Company [Member]      
Equity Method Investment, Ownership Percentage   50.00%  
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies (Details Textual)
12 Months Ended
Jun. 12, 2020
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Jan. 01, 2022
USD ($)
Advertising Expense   $ 165,000 $ 233,000  
Net Income (Loss) Attributable to Parent   $ 610,000 $ 1,328,000  
Earnings Per Share, Diluted (in dollars per share) | $ / shares   $ 0.1 $ 0.21  
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization   $ 81,227,000    
Gain (Loss) on Sale of Assets and Asset Impairment Charges   (940,000) $ (0)  
Asset Retirement Obligation   290,000    
Asset Impairment Charges   $ 650,000    
Lessee, Operating Lease, Term of Contract (Year)   10 years    
Weighted Average Number of Shares Outstanding, Basic, Total (in shares) | shares   6,358,000 6,297,000  
Number of Reportable Segments   2 2  
Goodwill and Intangible Asset Impairment   $ 0 $ 0  
Gamma Knife Center Ecuador S.A. (GKCE) [Member]        
Goodwill, Acquired During Period $ 1,265,000      
Gamma Knife Center Ecuador S.A. (GKCE) [Member] | Trade Names [Member]        
Indefinite-lived Intangible Assets Acquired $ 78,000      
Restricted Stock Units (RSUs) [Member]        
Weighted Average Number of Shares Outstanding, Basic, Total (in shares) | shares   123,000 123,000  
Share-Based Payment Arrangement, Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares   144,000 20,000  
GKCE [Member]        
Accounts Receivable, after Allowance for Credit Loss   $ 1,626,000 $ 1,119,000 $ 668,000
Gamma Knife Units [Member]        
Asset Retirement Obligation   $ 650,000    
Number of Customer with Intent to Terminate Contract   2    
Other Gamma Knife Units [Member]        
Asset Retirement Obligation   $ 0    
Rental Income from Medical Services [Member]        
Revenue from Contract with Customer, Including Assessed Tax   17,772,000 16,655,000  
PBRT Services [Member]        
Revenue from Contract with Customer, Including Assessed Tax   $ 10,133,000 $ 8,952,000  
Revenue Sharing Arrangements [Member]        
Percentage of Revenues   70.00% 67.00%  
Patient Income [Member]        
Revenue from Contract with Customer, Including Assessed Tax   $ 3,553,000 $ 3,091,000  
Equipment Sales [Member]        
Revenue from Contract with Customer, Including Assessed Tax   200,000    
Salvage Value [Member]        
Net Income (Loss) Attributable to Parent   $ (207,000)    
Earnings Per Share, Diluted (in dollars per share) | $ / shares   $ 0.03    
Minimum [Member]        
Property, Plant, and Equipment, Salvage Value   $ 140,000 140,000  
Maximum [Member]        
Property, Plant, and Equipment, Salvage Value   $ 300,000 300,000  
Office Equipment [Member] | Minimum [Member]        
Property, Plant and Equipment, Useful Life (Year)   3 years    
Office Equipment [Member] | Maximum [Member]        
Property, Plant and Equipment, Useful Life (Year)   10 years    
Building [Member]        
Property, Plant and Equipment, Useful Life (Year)   20 years    
Proton Beam Radiation Therapy PBRT [Member]        
Property, Plant and Equipment, Useful Life (Year)   20 years    
Gamma Knife And Radiation Therapy Equipment [Member]        
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization   $ 70,635,000 69,306,000  
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization   $ 52,302,000 $ 47,992,000  
Customer Concentration Risk [Member] | Revenue Benchmark [Member]        
Number of Major Customers   15 15  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]        
Concentration Risk, Percentage   48.00% 45.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member]        
Number of Major Customers   2 4  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]        
Concentration Risk, Percentage   30.00% 12.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]        
Concentration Risk, Percentage   31.00% 14.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]        
Concentration Risk, Percentage     16.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Four [Member]        
Concentration Risk, Percentage     22.00%  
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Numerator for basic and diluted earnings per share $ 610,000 $ 1,328,000
Denominator for basic earnings per share – weighted-average shares (in shares) 6,358,000 6,297,000
Effect of dilutive securities employee stock options and restricted stock (in shares) 35,000 6,000
Denominator for diluted earnings per share – adjusted weighted-average shares (in shares) 6,393,000 6,303,000
Earnings per common share- basic (in dollars per share) $ 0.1 $ 0.21
Earnings per common share- diluted (in dollars per share) $ 0.1 $ 0.21
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 21,325,000 $ 19,746,000
Medical Equipment Leasing [Member]    
Revenues 17,772,000 16,655,000
Direct Patient Services [Member]    
Revenues $ 3,553,000 $ 3,091,000
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Accounting Policies - Allocations to Reportable Segments (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Depreciation and amortization $ 5,165,000 $ 4,783,000
Interest expense 1,112,000 806,000
Interest income 458,000 103,000
Income tax expense 431,000 963,000
Medical Equipment Leasing [Member]    
Depreciation and amortization 4,429,000 4,268,000
Interest expense 1,087,000 806,000
Interest income 458,000 103,000
Income tax expense 306,000 753,000
Direct Patient Services [Member]    
Depreciation and amortization 736,000 515,000
Interest expense 25,000 0
Interest income 0 0
Income tax expense $ 125,000 $ 210,000
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Net Income (Loss) Attributable to Parent $ 610,000 $ 1,328,000
Medical Equipment Leasing [Member]    
Net Income (Loss) Attributable to Parent 518,000 1,187,000
Direct Patient Services [Member]    
Net Income (Loss) Attributable to Parent $ 92,000 $ 141,000
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
TOTAL ASSETS $ 48,162,000 $ 43,956,000
Medical Equipment Leasing [Member]    
TOTAL ASSETS 39,854,000 37,575,000
Direct Patient Services [Member]    
TOTAL ASSETS $ 8,308,000 $ 6,381,000
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Property and Equipment (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization $ 81,227,000  
Depreciation 5,165,000 $ 4,783,000
Net Income (Loss) Attributable to Parent $ 610,000 $ 1,328,000
Earnings Per Share, Diluted (in dollars per share) $ 0.1 $ 0.21
Gain (Loss) on Sale of Assets and Asset Impairment Charges $ (940,000) $ (0)
Asset Impairment Charges 650,000  
PBRT Equipment [Member]    
Asset Impairment Charges 0 0
Salvage Value [Member]    
Net Income (Loss) Attributable to Parent $ (207,000)  
Earnings Per Share, Diluted (in dollars per share) $ 0.03  
Non-US [Member]    
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization $ 3,966,000 $ 2,201,000
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property and equipment, gross   $ 74,237,000
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization $ 81,227,000  
Accumulated depreciation (55,383,000) (50,770,000)
Net property and equipment 25,844,000 23,467,000
Medical Equipment and Facilities [Member]    
Property and equipment, gross 77,150,000 73,709,000
Office Equipment [Member]    
Property and equipment, gross 306,000 422,000
Construction in Progress [Member]    
Property and equipment, gross $ 3,771,000 $ 106,000
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Insurance financing $ 0 $ 591,000
Professional services 472,000 92,000
Operating costs 450,000 539,000
Other 304,000 322,000
Total other accrued liabilities $ 1,226,000 $ 1,544,000
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Long Term Debt (Details Textual)
12 Months Ended
Apr. 09, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
Long-Term Debt   $ 13,289,000    
Amortization of Debt Issuance Costs   46,000 $ 84,000  
Debt Issuance Costs, Net   164,000 198,000  
The Credit Agreement [Member] | Fifth Third Bank, N.A. [Member]        
Debt Instrument, Term (Year) 5 years      
Line of Credit Facility, Maximum Borrowing Capacity $ 22,000,000      
Number of Debt Instruments 3      
Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio 1.25      
Debt Instrument, Covenant, Maximum Funded Debt to EDITDA Ratio 3      
The Credit Agreement, First Loan and Second Loan Facility [Member] | Fifth Third Bank, N.A. [Member]        
Debt Instrument, Face Amount $ 9,500,000      
Long-Term Debt   $ 10,825,000 12,624,000  
Debt Instrument, Interest Rate, Stated Percentage   48.00%    
The Credit Agreement, Second Loan Facility [Member] | Fifth Third Bank, N.A. [Member]        
Debt Instrument, Face Amount $ 5,500,000      
The Credit Agreement, Third Loan Facility [Member] | Fifth Third Bank, N.A. [Member] | Revolving Credit Facility [Member]        
Debt Instrument, Term (Year) 5 years      
Line of Credit Facility, Maximum Borrowing Capacity $ 7,000,000      
Long-Term Line of Credit   $ 2,500,000    
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage       0.25%
The Credit Agreement, Third Loan Facility [Member] | Fifth Third Bank, N.A. [Member] | Revolving Credit Facility [Member] | London Interbank Offered Rate [Member]        
Debt Instrument, Basis Spread on Variable Rate 3.00%      
DFC Loan, Tranche One [Member]        
Debt Instrument, Interest Rate, Stated Percentage   3.67%    
DFC Loan, Tranche Two [Member]        
Debt Instrument, Interest Rate, Stated Percentage   7.49%    
DFC Loan [Member]        
Long-Term Debt   $ 2,464,000 $ 1,041,000  
Debt Issuance Costs, Gross   $ 9,000    
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Long Term Debt - Long-term Debt Maturities (Details)
Dec. 31, 2023
USD ($)
2024 $ 2,157,000
2025 2,907,000
2026 7,732,000
2027 493,000
Long-Term Debt $ 13,289,000
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Leases (Details Textual)
12 Months Ended
Nov. 03, 2021
USD ($)
ft²
Dec. 31, 2023
USD ($)
a
Dec. 31, 2022
USD ($)
Lessee, Operating Lease, Remaining Lease Term (Year)   1 year  
Operating Lease, Right-of-Use Asset   $ 57,000 $ 317,000
Operating Lease, Expense   234,000 $ 290,000
Operating Lease, Liability   $ 57,000  
Condominium Space for Gamma Knife Facility in Guayaquil, Ecuador [Member]      
Area of Real Estate Property (Square Foot) | a   864  
Land and Parking Spaces for Gamma Knife Facility in Guayaquil, Ecuador [Member]      
Area of Real Estate Property (Square Foot) | a   10,135  
Minimum [Member]      
Lessee, Operating Lease, Discount Rate   4.00%  
Maximum [Member]      
Lessee, Operating Lease, Discount Rate   6.00%  
Sublease Office in San Francisco, California [Member]      
Area of Real Estate Property (Square Foot) 3,253 3,253  
Operating Lease, Monthly Expense $ 22,011 $ 22,011  
Lessee, Operating Sublease, Monthly Income $ 16,195 $ 16,195  
Lease Agreement for New Corporate Office [Member]      
Area of Real Estate Property (Square Foot) | ft² 900    
Operating Lease, Monthly Expense $ 4,500    
Corporate Office in San Francisco [Member]      
Area of Real Estate Property (Square Foot) | a   900  
Operating Lease, Monthly Expense   $ 4,500  
Stand-alone Facility in Lima, Peru [Member]      
Area of Real Estate Property (Square Foot) | a   1,600  
Operating Lease, Monthly Expense   $ 8,850  
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details)
Dec. 31, 2023
USD ($)
2024 $ 58,000
Total lease payments 58,000
Less imputed interest (1,000)
Total $ 57,000
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Leases - Lease Cost and Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating lease cost, net of impairment $ 302,000 $ 406,000
Sublease income (129,000) (174,000)
Total lease cost 173,000 232,000
Cash paid for amounts included in the measurement of lease liabilities - Operating leases $ 302,000 $ 406,000
Weighted-average remaining lease term - Operating leases in years (Year) 9 months 18 days 1 year 1 month 9 days
Weighted-average discount rate - Operating leases 4.65% 5.65%
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Expense (Benefit)   $ 431,000 $ 963,000  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent   21.00% 21.00%  
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount   $ 17,000 $ 0  
Unrecognized Tax Benefits   287,000 $ 278,000 $ 295,000
Unrecognized Tax Benefits, Income Tax Penalties Accrued   58,000    
Unrecognized Tax Benefits, Interest on Income Taxes Accrued   0    
Forecast [Member] | Maximum [Member]        
Unrecognized Tax Benefits, Decrease Resulting from Foreign Taxes $ 100,000      
Domestic Tax Authority [Member]        
Operating Loss Carryforwards   0    
Domestic Tax Authority [Member] | Capital Loss Carryforward [Member]        
Tax Credit Carryforward, Amount   2,679,000    
State and Local Jurisdiction [Member]        
Operating Loss Carryforwards   2,586,000    
State and Local Jurisdiction [Member] | Capital Loss Carryforward [Member]        
Tax Credit Carryforward, Amount   $ 129,000    
XML 66 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes - Components of Income Before Income Taxes (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Domestic $ 666,000 $ 2,350,000
Foreign 30,000 168,000
Income before income taxes $ 696,000 $ 2,518,000
XML 67 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Federal $ 940,000 $ 355,000
State 115,000 60,000
Foreign 135,000 204,000
Total current 1,190,000 619,000
Federal (672,000) 290,000
State (77,000) 48,000
Foreign (10,000) 6,000
Total deferred (759,000) 344,000
Income Tax Expense (Benefit) $ 431,000 $ 963,000
XML 68 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property and equipment $ (323,000) $ (708,000)
Prepaid expenses (409,000) (493,000)
ROU asset (12,000) (54,000)
Total deferred tax liabilities (744,000) (1,255,000)
Net operating loss carryforwards 155,000 139,000
Accruals and allowances 438,000 167,000
Lease liabilities 12,000 61,000
Tax credits 4,000 3,000
Other 140,000 114,000
Capital loss carryover 646,000 646,000
Total deferred tax assets 1,395,000 1,130,000
Valuation allowance (714,000) (697,000)
Deferred tax assets net of valuation allowance 681,000 433,000
Net deferred tax liabilities $ (63,000) $ (822,000)
XML 69 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Computed expected federal income tax $ 218,000 $ 477,000
State income taxes, net of federal benefit 12,000 100,000
Foreign rate differential 38,000 0
Stock compensation 7,000 0
Non-deductible expenses 6,000 (25,000)
Return to provision true-up 18,000 52,000
Uncertain tax positions 9,000 (17,000)
Alternative minimum tax payable adjustment 0 208,000
Change in valuation allowance 17,000 0
Other deferred tax adjustments 106,000 168,000
Income Tax Expense (Benefit) $ 431,000 $ 963,000
XML 70 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance at beginning of year $ 278,000 $ 295,000
Additions based on tax positions of prior years 9,000  
Additions based on tax positions of prior years   (17,000)
Balance at end of year $ 287,000 $ 278,000
XML 71 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense (Details Textual) - USD ($)
12 Months Ended
Aug. 03, 2020
May 04, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     116,000      
Share-Based Payment Arrangement, Expense     $ 389,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)     $ 2.89 $ 1.49    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)     0 4,000    
Options Issued During Period, Cashless Stock Options Exercised (in shares)       3,000    
Proceeds from Stock Options Exercised     $ 0 $ 5,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Using Cash (in shares)       2,000    
Stock Repurchase Program, Number of Shares Authorized to be Repurchased (in shares)     1,000,000      
Stock Repurchased During Period, Shares (in shares)     0 0    
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased (in shares)     72,000      
Restricted Stock Units (RSUs) [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     146,000 131,000    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     119,000 132,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)     33,000 6,000 10,000  
Restricted Stock Units (RSUs) [Member] | Selling, General and Administrative Expenses [Member]            
Share-Based Payment Arrangement, Expense, after Tax     $ 389,000 $ 399,000    
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     90,000      
Share-Based Payment Arrangement, Expense     $ 351,000      
Share-Based Payment Arrangement, Option [Member]            
Share-Based Payment Arrangement, Expense     34,000 10,000    
Share-Based Payment Arrangement, Expense, after Tax     $ 156,000      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     4 years      
Incentive Compensation Plan [Member]            
Common Stock, Capital Shares Reserved for Future Issuance (in shares)           2,580,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)     935,000      
Incentive Compensation Plan [Member] | Restricted Stock Units (RSUs) [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     898,000      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     123,000      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest, Outstanding, Number (in shares)     742,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)     33,000      
Incentive Compensation Plan [Member] | Restricted Stock Units (RSUs) [Member] | Employees [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     57,000      
Incentive Compensation Plan [Member] | Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     460,000      
Incentive Compensation Plan [Member] | Restricted Stock Units (RSUs) [Member] | Non Employee Directors and Corporate Secretary [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     53,000      
Incentive Compensation Plan [Member] | Restricted Stock Units (RSUs) [Member] | Non Employee Directors [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     328,000      
Executive Equity Awards [Member] | Restricted Stock Units (RSUs) [Member]            
Share-Based Payment Arrangement, Expense     $ 351,000 $ 288,000    
Executive Equity Awards [Member] | Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 10,000 50,000        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     90,000      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Day) 30 days          
Stock Issued During Period, Shares, Issued for Services (in shares)     120,000 120,000    
XML 72 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Vested (in shares) (116,000)  
Restricted Stock Units (RSUs) [Member]    
Outstanding (in shares) 6,000 10,000
Outstanding, grant date weighted average fair value (in dollars per share) $ 2.33 $ 2.57
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 146,000 131,000
Granted, grant date weighted average fair value (in dollars per share) $ 2.97 $ 2.4
Vested (in shares) (119,000) (132,000)
Vested, grant date weighted average fair value (in dollars per share) $ 2.94 $ 2.4
Forfeited (in shares)   (3,000)
Forfeited, grant date weighted average fair value (in dollars per share)   $ 2.92
Outstanding (in shares) 33,000 6,000
Outstanding, grant date weighted average fair value (in dollars per share) $ 2.88 $ 2.33
XML 73 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement, Expense $ 389,000  
Awards issued and vested (in shares) 116,000  
Stock-based compensation expense $ 389,000  
Management Bonus Program [Member]    
Awards issued and vested (in shares) 26,000  
Share-Based Payment Arrangement, Option [Member]    
Share-Based Payment Arrangement, Expense $ 34,000 $ 10,000
Stock-based compensation expense $ 34,000 $ 10,000
Restricted Stock Units (RSUs) [Member]    
Awards issued and vested (in shares) 119,000 132,000
Restricted Stock Units (RSUs) [Member] | Board Member [Member]    
Share-Based Payment Arrangement, Expense $ 4,000  
Stock-based compensation expense 4,000  
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]    
Share-Based Payment Arrangement, Expense $ 351,000  
Awards issued and vested (in shares) 90,000  
Stock-based compensation expense $ 351,000  
XML 74 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 01, 2022
Balance (in shares) 95,000 67,000    
Balance, grant date weighted-average exercise price (in dollars per share) $ 2.76 $ 2.72    
Balance, weighted average remaining contractual life (Year) 5 years 5 months 8 days 4 years 9 months 29 days 3 years 3 months 29 days  
Balance, aggregate intrinsic value $ 0 $ 25,000   $ 0
Granted (in shares) 70,000 50,000    
Granted, grant date weighted-average exercise price (in dollars per share) $ 2.89 $ 2.72    
Granted, weighted average remaining contractual life (Year) 7 years 7 years    
Exercised (in shares) 0 (4,000)    
Exercised, grant date weighted-average exercise price (in dollars per share)   $ 2.29    
Forfeited (in shares) (19,000) (18,000)    
Forfeited, grant date weighted-average exercise price (in dollars per share) $ 2.69 $ 2.64    
Balance (in shares) 146,000 95,000 67,000  
Balance, grant date weighted-average exercise price (in dollars per share) $ 2.83 $ 2.76 $ 2.72  
Exercisable (in shares) 31,000 38,000    
Exercisable, grant date weighted-average exercise price (in dollars per share) $ 2.84 $ 2.79    
Exercisable, weighted average remaining contractual life (Year) 3 years 4 months 17 days      
Minimum [Member]        
Exercisable, weighted average remaining contractual life (Year)   2 years 4 months 17 days    
XML 75 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Stock-based Compensation Expense - Assumptions (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Expected life (years) (Year) 7 years 7 years
Expected forfeiture rate 0.00% 0.00%
Expected volatility 50.00% 50.00%
Dividend yield 0.00% 0.00%
Risk-free interest rate 3.60% 3.30%
XML 76 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Retirement Plan (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 4.00%  
Defined Contribution Plan, Cost $ 43,000 $ 47,000
Deferred Compensation Liability, Current and Noncurrent $ 17,000  
XML 77 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Commitments and Contingencies (Details Textual) - USD ($)
12 Months Ended
Sep. 04, 2022
Dec. 31, 2023
Leksell Gamma Knife Icon Systems and Linear Accelerator System [Member]    
Long-term Install Service and Purchase Commitment, Amount   $ 15,925,000
Long-term Commitment, Cash on Hand to Fund   13,808,000
Long-term Commitment, Line of Credit to Fund   7,000,000
Long-Term Line of Credit   2,500,000
Maintenance And Support Agreement, Mevion Service Agreement [Member] | Mevion Medical Systems Inc [Member]    
Purchase Agreement Annual Prepayment $ 1,865,000  
Long-term Purchase Commitment, Period (Year) 1 year  
LINAC System [Member]    
Long-Term Service Commitment, Amount   $ 14,805,000
LINAC System [Member] | Maximum [Member]    
Long-Term Service Commitment, Period (Year)   9 years
LINAC System [Member] | Minimum [Member]    
Long-Term Service Commitment, Period (Year)   5 years
XML 78 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Related Party Transactions (Details Textual)
Dec. 31, 2023
USD ($)
US Subsidiary Of Elekta Member  
Purchase Obligation $ 18,968,000
GKF Subsidiary [Member]  
Noncontrolling Interest, Ownership Percentage by Parent 81.00%
US Subsidiary Of Elekta Member  
Noncontrolling Interest, Ownership Percentage by Parent 19.00%
XML 79 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details) - Related Party [Member] - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equipment purchases and de-install costs $ 6,918,000 $ 1,844,000
Costs incurred to maintain equipment 851,000 1,094,000
Total related party transactions 7,769,000 2,938,000
Accounts payable and other accrued liabilities $ 1,961,000 $ 497,000
XML 80 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Fifth Third Bank, N.A. [Member] - The Credit Agreement, 2024 Supplemental Term Loan [Member]
Jan. 25, 2024
USD ($)
Debt Instrument, Face Amount $ 2,700,000
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]  
Debt Instrument, Basis Spread on Variable Rate 3.00%
Debt Instrument, Variable Rate, Floor 0.00%
EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 178 361 1 false 85 0 false 9 false false R1.htm 000 - Document - Document And Entity Information Sheet http://ashs.com/20231231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://ashs.com/20231231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://ashs.com/20231231/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Shareholders' Equity Sheet http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity Consolidated Statement of Shareholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 7 false false R8.htm 995452 - Disclosure - Note 1 - Business and Basis of Presentation Sheet http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation Note 1 - Business and Basis of Presentation Notes 8 false false R9.htm 995453 - Disclosure - Note 2 - Accounting Policies Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies Note 2 - Accounting Policies Notes 9 false false R10.htm 995454 - Disclosure - Note 3 - Property and Equipment Sheet http://ashs.com/20231231/role/statement-note-3-property-and-equipment Note 3 - Property and Equipment Notes 10 false false R11.htm 995455 - Disclosure - Note 4 - Other Accrued Liabilities Sheet http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities Note 4 - Other Accrued Liabilities Notes 11 false false R12.htm 995456 - Disclosure - Note 5 - Long Term Debt Sheet http://ashs.com/20231231/role/statement-note-5-long-term-debt Note 5 - Long Term Debt Notes 12 false false R13.htm 995457 - Disclosure - Note 6 - Leases Sheet http://ashs.com/20231231/role/statement-note-6-leases Note 6 - Leases Notes 13 false false R14.htm 995458 - Disclosure - Note 7 - Income Taxes Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes Note 7 - Income Taxes Notes 14 false false R15.htm 995459 - Disclosure - Note 8 - Stock-based Compensation Expense Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense Note 8 - Stock-based Compensation Expense Notes 15 false false R16.htm 995460 - Disclosure - Note 9 - Retirement Plan Sheet http://ashs.com/20231231/role/statement-note-9-retirement-plan Note 9 - Retirement Plan Notes 16 false false R17.htm 995461 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies Note 10 - Commitments and Contingencies Notes 17 false false R18.htm 995462 - Disclosure - Note 11 - Related Party Transactions Sheet http://ashs.com/20231231/role/statement-note-11-related-party-transactions Note 11 - Related Party Transactions Notes 18 false false R19.htm 995463 - Disclosure - Note 12 - Subsequent Events Sheet http://ashs.com/20231231/role/statement-note-12-subsequent-events Note 12 - Subsequent Events Notes 19 false false R20.htm 995464 - Disclosure - Significant Accounting Policies (Policies) Sheet http://ashs.com/20231231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://ashs.com/20231231/role/statement-note-2-accounting-policies 20 false false R21.htm 995465 - Disclosure - Note 2 - Accounting Policies (Tables) Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables Note 2 - Accounting Policies (Tables) Tables http://ashs.com/20231231/role/statement-note-2-accounting-policies 21 false false R22.htm 995466 - Disclosure - Note 3 - Property and Equipment (Tables) Sheet http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables Note 3 - Property and Equipment (Tables) Tables http://ashs.com/20231231/role/statement-note-3-property-and-equipment 22 false false R23.htm 995467 - Disclosure - Note 4 - Other Accrued Liabilities (Tables) Sheet http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables Note 4 - Other Accrued Liabilities (Tables) Tables http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities 23 false false R24.htm 995468 - Disclosure - Note 5 - Long Term Debt (Tables) Sheet http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables Note 5 - Long Term Debt (Tables) Tables http://ashs.com/20231231/role/statement-note-5-long-term-debt 24 false false R25.htm 995469 - Disclosure - Note 6 - Leases (Tables) Sheet http://ashs.com/20231231/role/statement-note-6-leases-tables Note 6 - Leases (Tables) Tables http://ashs.com/20231231/role/statement-note-6-leases 25 false false R26.htm 995470 - Disclosure - Note 7 - Income Taxes (Tables) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-tables Note 7 - Income Taxes (Tables) Tables http://ashs.com/20231231/role/statement-note-7-income-taxes 26 false false R27.htm 995471 - Disclosure - Note 8 - Stock-based Compensation Expense (Tables) Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables Note 8 - Stock-based Compensation Expense (Tables) Tables http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense 27 false false R28.htm 995472 - Disclosure - Note 11 - Related Party Transactions (Tables) Sheet http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables Note 11 - Related Party Transactions (Tables) Tables http://ashs.com/20231231/role/statement-note-11-related-party-transactions 28 false false R29.htm 995473 - Disclosure - Note 1 - Business and Basis of Presentation (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual Note 1 - Business and Basis of Presentation (Details Textual) Details http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation 29 false false R30.htm 995474 - Disclosure - Note 2 - Accounting Policies (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual Note 2 - Accounting Policies (Details Textual) Details http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables 30 false false R31.htm 995475 - Disclosure - Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) Details 31 false false R32.htm 995476 - Disclosure - Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details) Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details) Details 32 false false R33.htm 995477 - Disclosure - Note 3 - Accounting Policies - Allocations to Reportable Segments (Details) Sheet http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details Note 3 - Accounting Policies - Allocations to Reportable Segments (Details) Details 33 false false R34.htm 995478 - Disclosure - Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details) Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details) Details 34 false false R35.htm 995479 - Disclosure - Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details) Sheet http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details) Details 35 false false R36.htm 995480 - Disclosure - Note 3 - Property and Equipment (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual Note 3 - Property and Equipment (Details Textual) Details http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables 36 false false R37.htm 995481 - Disclosure - Note 3 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details Note 3 - Property and Equipment - Summary of Property and Equipment (Details) Details 37 false false R38.htm 995482 - Disclosure - Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details) Sheet http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details) Details 38 false false R39.htm 995483 - Disclosure - Note 5 - Long Term Debt (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual Note 5 - Long Term Debt (Details Textual) Details http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables 39 false false R40.htm 995484 - Disclosure - Note 5 - Long Term Debt - Long-term Debt Maturities (Details) Sheet http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details Note 5 - Long Term Debt - Long-term Debt Maturities (Details) Details 40 false false R41.htm 995485 - Disclosure - Note 6 - Leases (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-6-leases-details-textual Note 6 - Leases (Details Textual) Details http://ashs.com/20231231/role/statement-note-6-leases-tables 41 false false R42.htm 995486 - Disclosure - Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details) Sheet http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details) Details 42 false false R43.htm 995487 - Disclosure - Note 6 - Leases - Lease Cost and Information (Details) Sheet http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details Note 6 - Leases - Lease Cost and Information (Details) Details 43 false false R44.htm 995488 - Disclosure - Note 7 - Income Taxes (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual Note 7 - Income Taxes (Details Textual) Details http://ashs.com/20231231/role/statement-note-7-income-taxes-tables 44 false false R45.htm 995489 - Disclosure - Note 7 - Income Taxes - Components of Income Before Income Taxes (Details) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details Note 7 - Income Taxes - Components of Income Before Income Taxes (Details) Details 45 false false R46.htm 995490 - Disclosure - Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details) Details 46 false false R47.htm 995491 - Disclosure - Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details) Details 47 false false R48.htm 995492 - Disclosure - Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) Details 48 false false R49.htm 995493 - Disclosure - Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) Sheet http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) Details 49 false false R50.htm 995494 - Disclosure - Note 8 - Stock-based Compensation Expense (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual Note 8 - Stock-based Compensation Expense (Details Textual) Details http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables 50 false false R51.htm 995495 - Disclosure - Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details) Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details) Details 51 false false R52.htm 995496 - Disclosure - Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details) Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details) Details 52 false false R53.htm 995497 - Disclosure - Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details) Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details) Details 53 false false R54.htm 995498 - Disclosure - Note 8 - Stock-based Compensation Expense - Assumptions (Details) Sheet http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details Note 8 - Stock-based Compensation Expense - Assumptions (Details) Details 54 false false R55.htm 995499 - Disclosure - Note 9 - Retirement Plan (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual Note 9 - Retirement Plan (Details Textual) Details http://ashs.com/20231231/role/statement-note-9-retirement-plan 55 false false R56.htm 995500 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual Note 10 - Commitments and Contingencies (Details Textual) Details http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies 56 false false R57.htm 995501 - Disclosure - Note 11 - Related Party Transactions (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual Note 11 - Related Party Transactions (Details Textual) Details http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables 57 false false R58.htm 995502 - Disclosure - Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details) Sheet http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details) Details 58 false false R59.htm 995503 - Disclosure - Note 12 - Subsequent Events (Details Textual) Sheet http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual Note 12 - Subsequent Events (Details Textual) Details http://ashs.com/20231231/role/statement-note-12-subsequent-events 59 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 47 fact(s) appearing in ix:hidden were eligible for transformation: ams:NumberOfDebtInstruments, ams:NumberOfMajorCustomers, ams:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber, dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, ecd:NonRule10b51ArrAdoptedFlag, ecd:NonRule10b51ArrTrmntdFlag, ecd:Rule10b51ArrAdoptedFlag, ecd:Rule10b51ArrTrmntdFlag, us-gaap:AllocatedShareBasedCompensationExpense, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount, us-gaap:AssetImpairmentCharges, us-gaap:AssetRetirementObligationCurrent, us-gaap:CommonStockNoParValue, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentTerm, us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate, us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1, us-gaap:GoodwillAndIntangibleAssetImpairment, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:LongtermPurchaseCommitmentPeriod, us-gaap:NumberOfReportableSegments, us-gaap:OperatingLeaseLiability, us-gaap:PropertyPlantAndEquipmentSalvageValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue, us-gaap:StockRepurchasedDuringPeriodShares - asha20231231_10k.htm 8, 10, 13, 14, 15, 16, 17, 18, 19, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 ams-20231231.xsd ams-20231231_cal.xml ams-20231231_def.xml ams-20231231_lab.xml ams-20231231_pre.xml asha20231231_10k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "asha20231231_10k.htm": { "nsprefix": "ams", "nsuri": "http://ashs.com/20231231", "dts": { "schema": { "local": [ "ams-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ams-20231231_cal.xml" ] }, "definitionLink": { "local": [ "ams-20231231_def.xml" ] }, "labelLink": { "local": [ "ams-20231231_lab.xml" ] }, "presentationLink": { "local": [ "ams-20231231_pre.xml" ] }, "inline": { "local": [ "asha20231231_10k.htm" ] } }, "keyStandard": 322, "keyCustom": 39, "axisStandard": 32, "axisCustom": 0, "memberStandard": 29, "memberCustom": 54, "hidden": { "total": 53, "http://fasb.org/us-gaap/2023": 40, "http://xbrl.sec.gov/dei/2023": 6, "http://ashs.com/20231231": 3, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 178, "entityCount": 1, "segmentCount": 85, "elementCount": 565, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 664, "http://xbrl.sec.gov/dei/2023": 37, "http://xbrl.sec.gov/ecd/2023": 5 }, "report": { "R1": { "role": "http://ashs.com/20231231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R3": { "role": "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "longName": "003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DirectOperatingMaintenanceSuppliesCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R5": { "role": "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "longName": "004 - Statement - Consolidated Statement of Shareholders' Equity", "shortName": "Consolidated Statement of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ams:NoncashLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "longName": "995452 - Disclosure - Note 1 - Business and Basis of Presentation", "shortName": "Note 1 - Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "longName": "995453 - Disclosure - Note 2 - Accounting Policies", "shortName": "Note 2 - Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "longName": "995454 - Disclosure - Note 3 - Property and Equipment", "shortName": "Note 3 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities", "longName": "995455 - Disclosure - Note 4 - Other Accrued Liabilities", "shortName": "Note 4 - Other Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "longName": "995456 - Disclosure - Note 5 - Long Term Debt", "shortName": "Note 5 - Long Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://ashs.com/20231231/role/statement-note-6-leases", "longName": "995457 - Disclosure - Note 6 - Leases", "shortName": "Note 6 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes", "longName": "995458 - Disclosure - Note 7 - Income Taxes", "shortName": "Note 7 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "longName": "995459 - Disclosure - Note 8 - Stock-based Compensation Expense", "shortName": "Note 8 - Stock-based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://ashs.com/20231231/role/statement-note-9-retirement-plan", "longName": "995460 - Disclosure - Note 9 - Retirement Plan", "shortName": "Note 9 - Retirement Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "longName": "995461 - Disclosure - Note 10 - Commitments and Contingencies", "shortName": "Note 10 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "longName": "995462 - Disclosure - Note 11 - Related Party Transactions", "shortName": "Note 11 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "longName": "995463 - Disclosure - Note 12 - Subsequent Events", "shortName": "Note 12 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies", "longName": "995464 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables", "longName": "995465 - Disclosure - Note 2 - Accounting Policies (Tables)", "shortName": "Note 2 - Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables", "longName": "995466 - Disclosure - Note 3 - Property and Equipment (Tables)", "shortName": "Note 3 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables", "longName": "995467 - Disclosure - Note 4 - Other Accrued Liabilities (Tables)", "shortName": "Note 4 - Other Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables", "longName": "995468 - Disclosure - Note 5 - Long Term Debt (Tables)", "shortName": "Note 5 - Long Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://ashs.com/20231231/role/statement-note-6-leases-tables", "longName": "995469 - Disclosure - Note 6 - Leases (Tables)", "shortName": "Note 6 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables", "longName": "995470 - Disclosure - Note 7 - Income Taxes (Tables)", "shortName": "Note 7 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables", "longName": "995471 - Disclosure - Note 8 - Stock-based Compensation Expense (Tables)", "shortName": "Note 8 - Stock-based Compensation Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables", "longName": "995472 - Disclosure - Note 11 - Related Party Transactions (Tables)", "shortName": "Note 11 - Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "longName": "995473 - Disclosure - Note 1 - Business and Basis of Presentation (Details Textual)", "shortName": "Note 1 - Business and Basis of Presentation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "ams:NumberOfMedicalCenters", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "ams:NumberOfMedicalCenters", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "longName": "995474 - Disclosure - Note 2 - Accounting Policies (Details Textual)", "shortName": "Note 2 - Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "longName": "995475 - Disclosure - Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)", "shortName": "Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R32": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "longName": "995476 - Disclosure - Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details)", "shortName": "Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-MedicalEquipmentLeasingMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R33": { "role": "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "longName": "995477 - Disclosure - Note 3 - Accounting Policies - Allocations to Reportable Segments (Details)", "shortName": "Note 3 - Accounting Policies - Allocations to Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InterestIncomeInterestEarningAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R34": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "longName": "995478 - Disclosure - Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details)", "shortName": "Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_StatementBusinessSegmentsAxis-MedicalEquipmentLeasingMember", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R35": { "role": "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "longName": "995479 - Disclosure - Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details)", "shortName": "Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_StatementBusinessSegmentsAxis-MedicalEquipmentLeasingMember", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R36": { "role": "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "longName": "995480 - Disclosure - Note 3 - Property and Equipment (Details Textual)", "shortName": "Note 3 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R37": { "role": "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "longName": "995481 - Disclosure - Note 3 - Property and Equipment - Summary of Property and Equipment (Details)", "shortName": "Note 3 - Property and Equipment - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "ams:PropertyPlantAndEquipmentGrossExcludingLand", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31", "name": "ams:PropertyPlantAndEquipmentGrossExcludingLand", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details", "longName": "995482 - Disclosure - Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details)", "shortName": "Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccruedInsuranceCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccruedInsuranceCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual", "longName": "995483 - Disclosure - Note 5 - Long Term Debt (Details Textual)", "shortName": "Note 5 - Long Term Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R40": { "role": "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details", "longName": "995484 - Disclosure - Note 5 - Long Term Debt - Long-term Debt Maturities (Details)", "shortName": "Note 5 - Long Term Debt - Long-term Debt Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "longName": "995485 - Disclosure - Note 6 - Leases (Details Textual)", "shortName": "Note 6 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details", "longName": "995486 - Disclosure - Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details)", "shortName": "Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details", "longName": "995487 - Disclosure - Note 6 - Leases - Lease Cost and Information (Details)", "shortName": "Note 6 - Leases - Lease Cost and Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "longName": "995488 - Disclosure - Note 7 - Income Taxes (Details Textual)", "shortName": "Note 7 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R45": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details", "longName": "995489 - Disclosure - Note 7 - Income Taxes - Components of Income Before Income Taxes (Details)", "shortName": "Note 7 - Income Taxes - Components of Income Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "longName": "995490 - Disclosure - Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)", "shortName": "Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details", "longName": "995491 - Disclosure - Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details)", "shortName": "Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details", "longName": "995492 - Disclosure - Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)", "shortName": "Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details", "longName": "995493 - Disclosure - Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)", "shortName": "Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R50": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "longName": "995494 - Disclosure - Note 8 - Stock-based Compensation Expense (Details Textual)", "shortName": "Note 8 - Stock-based Compensation Expense (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R51": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "longName": "995495 - Disclosure - Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details)", "shortName": "Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details", "longName": "995496 - Disclosure - Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details)", "shortName": "Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_PlanNameAxis-ManagementBonusProgramMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R53": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details", "longName": "995497 - Disclosure - Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details)", "shortName": "Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "unique": true } }, "R54": { "role": "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details", "longName": "995498 - Disclosure - Note 8 - Stock-based Compensation Expense - Assumptions (Details)", "shortName": "Note 8 - Stock-based Compensation Expense - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual", "longName": "995499 - Disclosure - Note 9 - Retirement Plan (Details Textual)", "shortName": "Note 9 - Retirement Plan (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "longName": "995500 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "shortName": "Note 10 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember", "name": "ams:LongtermInstallServiceAndPurchaseCommitmentAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember", "name": "ams:LongtermInstallServiceAndPurchaseCommitmentAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual", "longName": "995501 - Disclosure - Note 11 - Related Party Transactions (Details Textual)", "shortName": "Note 11 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2023-12-31_RelatedPartyTransactionAxis-USSubsidiaryOfElektaMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_RelatedPartyTransactionAxis-USSubsidiaryOfElektaMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R58": { "role": "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "longName": "995502 - Disclosure - Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details)", "shortName": "Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } }, "R59": { "role": "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "longName": "995503 - Disclosure - Note 12 - Subsequent Events (Details Textual)", "shortName": "Note 12 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-01-25_DebtInstrumentAxis-TheCreditAgreement2024SupplementalTermLoanMember_LineOfCreditFacilityAxis-FifthThirdBankNAMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-01-25_DebtInstrumentAxis-TheCreditAgreement2024SupplementalTermLoanMember_LineOfCreditFacilityAxis-FifthThirdBankNAMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asha20231231_10k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r654" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r611" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsReceivableNet", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r558", "r610", "r660", "r781" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses of $100,000 At December 31, 2023 and December 31, 2022", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r254", "r255" ] }, "us-gaap_AccruedIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxes", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Income taxes payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes." } } }, "auth_ref": [ "r90", "r91", "r127", "r134", "r483" ] }, "us-gaap_AccruedInsuranceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedInsuranceCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedInsuranceCurrent", "terseLabel": "Insurance financing", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "ams_AccruedLiabilitesOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "AccruedLiabilitesOtherCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "ams_AccruedLiabilitesOtherCurrent", "terseLabel": "Other", "documentation": "The amount of accrued liabilities classified as current not specifically disclosed." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details" ], "lang": { "en-us": { "role": { "label": "Accounts payable and other accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "ams_AccruedOperatingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "AccruedOperatingCostsCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "ams_AccruedOperatingCostsCurrent", "terseLabel": "Operating costs", "documentation": "The amount of accrued operating costs classified as current." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Professional services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "ams_PropertyPlantAndEquipmentNetExcludingLand", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r63", "r165", "r491" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r96" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r375", "r376", "r377", "r535", "r704", "r705", "r706", "r761", "r786" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash from operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r147" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r379" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r370", "r378" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "terseLabel": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r171", "r258", "r266" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Accretion of deferred issuance costs", "terseLabel": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r103", "r317", "r439", "r699" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r218" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r43" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r43" ] }, "ams_ArchitecturalDesignCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "ArchitecturalDesignCompanyMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Architectural Design Company [Member]", "documentation": "Represents an architectural design company." } } }, "auth_ref": [] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AreaOfRealEstateProperty", "terseLabel": "Area of Real Estate Property (Square Foot)", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r759" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r759" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r7", "r61" ] }, "us-gaap_AssetRetirementObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligation", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetRetirementObligation", "terseLabel": "Asset Retirement Obligation", "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r282", "r283" ] }, "us-gaap_AssetRetirementObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationCurrent", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Asser retirement obligations, non-related party", "documentation": "Current portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r716" ] }, "ams_AssetRetirementObligationRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "AssetRetirementObligationRelatedPartyCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Asset retirement obligations, related party (includes $250,000 and $120,000 non-related party at December 31, 2023 and 2022, respectively)", "documentation": "Current portion of the carrying amount of a liability for related party portion of an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationsPolicy", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Asset Retirement Obligation [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset." } } }, "auth_ref": [ "r281" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "terseLabel": "TOTAL ASSETS", "totalLabel": "TOTAL ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r132", "r168", "r188", "r222", "r242", "r248", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r414", "r418", "r429", "r482", "r563", "r654", "r667", "r721", "r722", "r770" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r162", "r172", "r188", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r414", "r418", "r429", "r654", "r721", "r722", "r770" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r671", "r672", "r673" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r671", "r672", "r673" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r671", "r672", "r673" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ] }, "ams_BoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "BoardMemberMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Board Member [Member]", "documentation": "Represents board members." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r117" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r412", "r645", "r646" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r72", "r74", "r412", "r645", "r646" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "terseLabel": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r73" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r12" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Equipment included in accounts payable and accrued liabilities", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_CapitalLossCarryforwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalLossCarryforwardMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Capital Loss Carryforward [Member]", "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r37", "r164", "r627" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r38", "r131" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "DETAIL OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r110", "r186" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r110" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingEstimateByTypeAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Estimate by Type [Axis]", "documentation": "Information by type of change in accounting estimate." } } }, "auth_ref": [ "r45", "r202" ] }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingEstimateTypeDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Estimate, Type [Domain]", "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities." } } }, "auth_ref": [ "r45", "r202" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r710" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (See Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r29", "r86", "r485", "r549" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r119", "r287", "r288", "r612", "r718" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r30" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r657", "r658", "r659", "r661", "r662", "r663", "r664", "r704", "r705", "r761", "r784", "r786" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNoParValue", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value (in dollars per share)", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r95", "r550" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r95", "r550", "r569", "r786", "r787" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares \u2013 6,300,000 at December 31, 2023 and 6,184,000 at December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r95", "r486", "r654" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r46", "r48", "r80", "r81", "r253", "r611" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r46", "r48", "r80", "r81", "r253", "r521", "r611" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r46", "r48", "r80", "r81", "r253", "r611", "r685" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r87", "r150" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r46", "r48", "r80", "r81", "r253" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r46", "r48", "r80", "r81", "r253", "r611" ] }, "ams_CondominiumSpaceForGammaKnifeFacilityInGuayaquilEcuadorMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "CondominiumSpaceForGammaKnifeFacilityInGuayaquilEcuadorMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Condominium Space for Gamma Knife Facility in Guayaquil, Ecuador [Member]", "documentation": "Represents condominium space for Gamma knife facility in Guayaquil, Ecuador." } } }, "auth_ref": [] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r146" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "DEFERRED REVENUE, less current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r320", "r321", "r324" ] }, "ams_CorporateOfficeInSanFranciscoMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "CorporateOfficeInSanFranciscoMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Corporate Office in San Francisco [Member]", "documentation": "Represents corporate office in San Francisco." } } }, "auth_ref": [] }, "us-gaap_CostDepreciationAmortizationAndDepletion": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostDepreciationAmortizationAndDepletion", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostDepreciationAmortizationAndDepletion", "terseLabel": "Depreciation and amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service." } } }, "auth_ref": [ "r698" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostOfRevenue", "totalLabel": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r107", "r188", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r429", "r721" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Costs of revenue:" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r690" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r689", "r703", "r758" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r689", "r703" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r128", "r400", "r406", "r703" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r689", "r703", "r758" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r47", "r253" ] }, "ams_CustomerFourMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "CustomerFourMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Four [Member]", "documentation": "Represents customer four." } } }, "auth_ref": [] }, "ams_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Represents customer one." } } }, "auth_ref": [] }, "ams_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "CustomerThreeMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "Represents customer three." } } }, "auth_ref": [] }, "ams_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "CustomerTwoMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Represents customer two." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r89", "r90", "r133", "r136", "r193", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r440", "r635", "r636", "r637", "r638", "r639", "r701" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ams_DebtInstrumentCovenantMaximumFundedDebtToEditdaRatio": { "xbrltype": "pureItemType", "nsuri": "http://ashs.com/20231231", "localname": "DebtInstrumentCovenantMaximumFundedDebtToEditdaRatio", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_DebtInstrumentCovenantMaximumFundedDebtToEditdaRatio", "terseLabel": "Debt Instrument, Covenant, Maximum Funded Debt to EDITDA Ratio", "documentation": "The maximum funded debt to EBITDA ratio allowed under the covenant of the debt instrument." } } }, "auth_ref": [] }, "ams_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://ashs.com/20231231", "localname": "DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "terseLabel": "Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio", "documentation": "Requirement for fixed charge coverage ratio under the debt agreement." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r82", "r84", "r302", "r440", "r636", "r637" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r303" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r193", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r440", "r635", "r636", "r637", "r638", "r639", "r701" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ams_DebtInstrumentVariableRateFloor": { "xbrltype": "percentItemType", "nsuri": "http://ashs.com/20231231", "localname": "DebtInstrumentVariableRateFloor", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_DebtInstrumentVariableRateFloor", "terseLabel": "Debt Instrument, Variable Rate, Floor", "documentation": "Represents the variable rate floor for a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent", "terseLabel": "Deferred Compensation Liability, Current and Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r703", "r757", "r758" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsGross", "terseLabel": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r83" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "terseLabel": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r83", "r724" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r128", "r703", "r757" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r128", "r156", "r405", "r406", "r703" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r92", "r93", "r135", "r394" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "DEFERRED INCOME TAXES", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r384", "r385", "r484" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "totalLabel": "Total deferred", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r112" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r703", "r757", "r758" ] }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "Capital loss carryover", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards." } } }, "auth_ref": [ "r71", "r756" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r395" ] }, "ams_DeferredTaxAssetsLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "DeferredTaxAssetsLeasingArrangements", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing arrangement." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred tax assets net of valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r755" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r71", "r756" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsOther", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r71", "r756" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "Tax credits", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r70", "r71", "r756" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "Accruals and allowances", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances." } } }, "auth_ref": [ "r71", "r756" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r396" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r68", "r755" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "negatedLabel": "ROU asset", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r71", "r756" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "negatedLabel": "Prepaid expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Property and equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r71", "r756" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r338" ] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r62" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r7", "r62" ] }, "ams_DfcLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "DfcLoanMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "DFC Loan [Member]", "documentation": "Represents the DFC loan." } } }, "auth_ref": [] }, "ams_DfcLoanTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "DfcLoanTrancheOneMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "DFC Loan, Tranche One [Member]", "documentation": "Represents tranche one of the DFC loan." } } }, "auth_ref": [] }, "ams_DfcLoanTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "DfcLoanTrancheTwoMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "DFC Loan, Tranche Two [Member]", "documentation": "Represents tranche two of the DFC loan." } } }, "auth_ref": [] }, "us-gaap_DirectOperatingMaintenanceSuppliesCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DirectOperatingMaintenanceSuppliesCosts", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Maintenance and supplies", "documentation": "Costs of maintenance supplies used that are directly related to goods produced and sold, or services rendered, during the reporting period." } } }, "auth_ref": [ "r105" ] }, "ams_DirectPatientServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "DirectPatientServicesMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "label": "Direct Patient Services [Member]", "documentation": "Represents direct patient services." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r341", "r343", "r371", "r372", "r374", "r648" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r10", "r64" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-9-retirement-plan" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r671", "r672", "r673" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r671", "r672", "r673", "r675" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r674" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Net income per share attributable to American Shared Hospital Services:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per common share- basic (in dollars per share)", "label": "Earnings per common share - basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r180", "r199", "r200", "r201", "r202", "r203", "r208", "r210", "r215", "r216", "r217", "r219", "r427", "r428", "r480", "r496", "r629" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per common share- diluted (in dollars per share)", "label": "Earnings per common share - diluted (in dollars per share)", "terseLabel": "Earnings Per Share, Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r180", "r199", "r200", "r201", "r202", "r203", "r210", "r215", "r216", "r217", "r219", "r427", "r428", "r480", "r496", "r629" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r43", "r44" ] }, "ams_EffectiveIncomeTaxRateReconciliationAmtTaxPayableAdjustmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationAmtTaxPayableAdjustmentsAmount", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Alternative minimum tax payable adjustment", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to AMT tax payable adjustments." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r190", "r387", "r408" ] }, "ams_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueupAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueupAmount", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Return to provision true-up", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to return to provision true-up." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Stock compensation", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r682", "r752" ] }, "ams_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsAmount", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Uncertain tax positions", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Employee compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r373" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ams_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "EmployeesMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Employees [Member]", "documentation": "Represents employees." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r669" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-document-and-entity-information", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables", "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details", "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details", "http://ashs.com/20231231/role/statement-note-6-leases-tables", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables", "http://ashs.com/20231231/role/statement-note-9-retirement-plan", "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual", "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r669" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r669" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r678" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r669" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r669" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r669" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r669" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r679" ] }, "ams_EquipmentSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "EquipmentSalesMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Equipment Sales [Member]", "documentation": "Represents equipment sales." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r158", "r176", "r177", "r178", "r194", "r195", "r196", "r198", "r204", "r206", "r220", "r264", "r265", "r319", "r375", "r376", "r377", "r401", "r402", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r431", "r432", "r433", "r434", "r435", "r436", "r452", "r516", "r517", "r518", "r535", "r592" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r260", "r261", "r262" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage", "terseLabel": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r260" ] }, "ams_ExecutiveEquityAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "ExecutiveEquityAwardsMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Executive Equity Awards [Member]", "documentation": "Represents the executive equity awards." } } }, "auth_ref": [] }, "ams_FifthThirdBankNAMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "FifthThirdBankNAMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Fifth Third Bank, N.A. [Member]", "documentation": "Represents Fifth Third Bank, N.A." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r430" ] }, "ams_GKCEMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "GKCEMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "GKCE [Member]", "documentation": "Represents Gamma Knife Center Ecuador." } } }, "auth_ref": [] }, "ams_GKFSubsidiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "GKFSubsidiaryMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "GKF Subsidiary [Member]", "documentation": "Represents the GKF subsidiary." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "terseLabel": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": [ "r699" ] }, "ams_GammaKnifeAndRadiationTherapyEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "GammaKnifeAndRadiationTherapyEquipmentMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Gamma Knife And Radiation Therapy Equipment [Member]", "documentation": "Represents gamma knife and radiation therapy equipment." } } }, "auth_ref": [] }, "ams_GammaKnifeCenterEcuadorSAGKCEMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "GammaKnifeCenterEcuadorSAGKCEMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Gamma Knife Center Ecuador S.A. (GKCE) [Member]", "documentation": "Represents Gamma Knife Center Ecuador S.A. (\u201cGKCE\u201d)." } } }, "auth_ref": [] }, "ams_GammaKnifeUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "GammaKnifeUnitsMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Gamma Knife Units [Member]", "documentation": "Represents Gamma Knife units." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "GOODWILL", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r166", "r267", "r479", "r634", "r654", "r712", "r713" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillAcquiredDuringPeriod", "terseLabel": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r270", "r634" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillAndIntangibleAssetImpairment", "terseLabel": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r11", "r57" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross margin", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r104", "r188", "r222", "r241", "r247", "r249", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r429", "r631", "r721" ] }, "ams_GuadalupeMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "GuadalupeMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Guadalupe [Member]", "documentation": "Represents legal entity of Guadalupe." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r671", "r672", "r673" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r118" ] }, "ams_IncentiveCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "IncentiveCompensationPlanMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Incentive Compensation Plan [Member]", "documentation": "Represents the incentive compensation plan." } } }, "auth_ref": [] }, "ams_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAfterIncomeAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesAfterIncomeAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "ams_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAfterIncomeAttributableToNoncontrollingInterest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and after deduction of income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details": { "parentTag": "ams_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAfterIncomeAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r189", "r407" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r101", "r139", "r222", "r241", "r247", "r249", "r481", "r492", "r631" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details": { "parentTag": "ams_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAfterIncomeAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r189", "r407" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r279", "r284", "r576" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r284", "r576" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r190", "r380", "r388", "r391", "r398", "r403", "r409", "r410", "r411", "r529" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "label": "Income tax expense", "terseLabel": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r145", "r157", "r205", "r206", "r230", "r386", "r404", "r497" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r175", "r382", "r383", "r391", "r392", "r397", "r399", "r525" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r752" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Foreign rate differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r752" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Computed expected federal income tax", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r387" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r752" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "Other deferred tax adjustments", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r752" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details" ], "lang": { "en-us": { "role": { "label": "State income taxes, net of federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r752" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "ams_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndDeferredRevenue", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Accounts payable, accrued liabilities and deferred revenue", "documentation": "The amount of increase (decrease) in accounts payable, accrued liabilities and deferred revenue." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Receivables", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes payable", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r6" ] }, "ams_IncreaseDecreaseInAssetRetirementObligationsRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "IncreaseDecreaseInAssetRetirementObligationsRelatedParty", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Asset retirement obligations, related party", "label": "ams_IncreaseDecreaseInAssetRetirementObligationsRelatedParty", "documentation": "The amount of increase decrease in asset retirement obligations from related parties." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Related party liabilities", "label": "us-gaap_IncreaseDecreaseInDueToRelatedParties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Effect of dilutive securities employee stock options and restricted stock (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r211", "r212", "r213", "r217", "r342" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r277", "r278" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r59", "r115" ] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IndefinitelivedIntangibleAssetsAcquired", "terseLabel": "Indefinite-lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r676" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r58", "r60" ] }, "ams_InterestAndOtherIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "InterestAndOtherIncomeLoss", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Interest and other income, net", "documentation": "The amount of interest income (loss) and other income (loss) recognized during the period." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense", "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r83", "r141", "r179", "r226", "r438", "r577", "r665", "r785" ] }, "us-gaap_InterestIncomeInterestEarningAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeInterestEarningAsset", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest income", "label": "us-gaap_InterestIncomeInterestEarningAsset", "documentation": "Amount of interest income from interest-earning asset." } } }, "auth_ref": [ "r691", "r692" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r181", "r184", "r185" ] }, "ams_LINACSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "LINACSystemMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "LINAC System [Member]", "documentation": "Represents the LINAC system." } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "LAND", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r695" ] }, "ams_LandAndParkingSpacesForGammaKnifeFacilityInGuayaquilEcuadorMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "LandAndParkingSpacesForGammaKnifeFacilityInGuayaquilEcuadorMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Land and Parking Spaces for Gamma Knife Facility in Guayaquil, Ecuador [Member]", "documentation": "Represents land and parking spaces for Gamma knife facility in Guayaquil, Ecuador." } } }, "auth_ref": [] }, "ams_LeaseAgreementForNewCorporateOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "LeaseAgreementForNewCorporateOfficeMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Agreement for New Corporate Office [Member]", "documentation": "Represents Lease Agreement for New Corporate Office." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r686" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r686" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r445", "r653" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r766" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-document-and-entity-information", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables", "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details", "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details", "http://ashs.com/20231231/role/statement-note-6-leases-tables", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables", "http://ashs.com/20231231/role/statement-note-9-retirement-plan", "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual", "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ams_LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Leksell Gamma Knife Icon Systems and Linear Accelerator System [Member]", "documentation": "Represents Leksell Gamma Knife Icon Systems and Linear Accelerator System." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r652" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r767" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r451" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r451" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r451" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm", "terseLabel": "Lessee, Operating Lease, Remaining Lease Term (Year)", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r764" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r765" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r441" ] }, "ams_LesseeOperatingSubleaseMonthlyIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "LesseeOperatingSubleaseMonthlyIncome", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_LesseeOperatingSubleaseMonthlyIncome", "terseLabel": "Lessee, Operating Sublease, Monthly Income", "documentation": "monthly amount of sublease income for operating lease." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r23", "r188", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r415", "r418", "r419", "r429", "r548", "r630", "r667", "r721", "r770", "r771" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r100", "r138", "r489", "r654", "r702", "r711", "r762" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r163", "r188", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r415", "r418", "r419", "r429", "r654", "r721", "r770", "r771" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r20", "r136", "r779" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r22", "r701" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r22", "r701" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r22" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r89", "r133" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ams_LondonInterbankOfferedRateMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "LondonInterbankOfferedRateMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "London Interbank Offered Rate [Member]", "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt", "totalLabel": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r136", "r309", "r318", "r636", "r637", "r779" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current portion of long-term debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r169" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r193", "r313" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r193", "r313" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r193", "r313" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r193", "r313" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "LONG-TERM DEBT, net, less current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r170" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r120" ] }, "ams_LongtermCommitmentCashOnHandToFund": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "LongtermCommitmentCashOnHandToFund", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_LongtermCommitmentCashOnHandToFund", "terseLabel": "Long-term Commitment, Cash on Hand to Fund", "documentation": "The amount of cash on hand to fund long-term commitment." } } }, "auth_ref": [] }, "ams_LongtermCommitmentLineOfCreditToFund": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "LongtermCommitmentLineOfCreditToFund", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_LongtermCommitmentLineOfCreditToFund", "terseLabel": "Long-term Commitment, Line of Credit to Fund", "documentation": "Amount of line of credit to fund long-term commitment." } } }, "auth_ref": [] }, "ams_LongtermInstallServiceAndPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "LongtermInstallServiceAndPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_LongtermInstallServiceAndPurchaseCommitmentAmount", "terseLabel": "Long-term Install Service and Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term install service and purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongtermPurchaseCommitmentPeriod", "terseLabel": "Long-term Purchase Commitment, Period (Year)", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ams_LongtermServiceCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "LongtermServiceCommitmentAmount", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_LongtermServiceCommitmentAmount", "terseLabel": "Long-Term Service Commitment, Amount", "documentation": "The amount of long-term service commitment." } } }, "auth_ref": [] }, "ams_LongtermServiceCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://ashs.com/20231231", "localname": "LongtermServiceCommitmentPeriod", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_LongtermServiceCommitmentPeriod", "terseLabel": "Long-Term Service Commitment, Period (Year)", "documentation": "The period of the long-term service commitment." } } }, "auth_ref": [] }, "ams_MaintenanceAndSupportAgreementMevionServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "MaintenanceAndSupportAgreementMevionServiceAgreementMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Maintenance And Support Agreement, Mevion Service Agreement [Member]", "documentation": "Represents the Maintenance And Support Agreement the Mevion Service Agreement." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r253", "r643", "r725", "r782", "r783" ] }, "ams_ManagementBonusProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "ManagementBonusProgramMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Management Bonus Program [Member]", "documentation": "Represents management bonus program." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r339", "r465", "r515", "r540", "r541", "r598", "r600", "r602", "r603", "r605", "r622", "r623", "r633", "r640", "r647", "r656", "r723", "r772", "r773", "r774", "r775", "r776", "r777" ] }, "ams_MedicalEquipmentAndFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "MedicalEquipmentAndFacilitiesMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Medical Equipment and Facilities [Member]", "documentation": "Represents medical equipment and facilities." } } }, "auth_ref": [] }, "ams_MedicalEquipmentLeasingMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "MedicalEquipmentLeasingMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "label": "Medical Equipment Leasing [Member]", "documentation": "Represents medical equipment leasing." } } }, "auth_ref": [] }, "ams_MevionMedicalSystemsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "MevionMedicalSystemsIncMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Mevion Medical Systems Inc [Member]", "documentation": "Represents Mevion Medical Systems Inc." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r339", "r465", "r515", "r540", "r541", "r598", "r600", "r602", "r603", "r605", "r622", "r623", "r633", "r640", "r647", "r656", "r723", "r772", "r773", "r774", "r775", "r776", "r777" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests in subsidiaries", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r32", "r137", "r188", "r263", "r293", "r295", "r296", "r297", "r300", "r301", "r429", "r488", "r552" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "negatedLabel": "Cash distributions to non-controlling interests", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r121" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r677" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r253", "r643", "r725", "r782", "r783" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r183" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r183" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r110", "r111", "r112" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Numerator for basic and diluted earnings per share", "label": "us-gaap_NetIncomeLoss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to American Shared Hospital Services", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r102", "r112", "r140", "r161", "r173", "r174", "r178", "r188", "r197", "r199", "r200", "r201", "r202", "r205", "r206", "r214", "r222", "r241", "r247", "r249", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r428", "r429", "r495", "r571", "r590", "r591", "r631", "r665", "r721" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest", "negatedLabel": "Less (plus): net loss (income) attributable to non-controlling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r130", "r173", "r174", "r205", "r206", "r494", "r697" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ams_NewcoMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "NewcoMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Newco [Member]", "documentation": "Represents Newco." } } }, "auth_ref": [] }, "ams_NonEmployeeDirectorsAndCorporateSecretaryMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "NonEmployeeDirectorsAndCorporateSecretaryMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Non Employee Directors and Corporate Secretary [Member]", "documentation": "Represents non employee directors and corporates secretary." } } }, "auth_ref": [] }, "ams_NonEmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "NonEmployeeDirectorsMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Non Employee Directors [Member]", "documentation": "Represents non employee directors." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r677" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r677" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r788", "r789", "r790", "r791" ] }, "ams_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Non cash lease expense", "label": "ams_NoncashLeaseExpense", "documentation": "The amount of noncash lease expense." } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r76", "r319", "r704", "r705", "r706", "r786" ] }, "ams_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "ams_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ams_NumberOfCustomerWithIntentToTerminateContract": { "xbrltype": "integerItemType", "nsuri": "http://ashs.com/20231231", "localname": "NumberOfCustomerWithIntentToTerminateContract", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_NumberOfCustomerWithIntentToTerminateContract", "terseLabel": "Number of Customer with Intent to Terminate Contract", "documentation": "The number of customers with the intent to terminate contract." } } }, "auth_ref": [] }, "ams_NumberOfDebtInstruments": { "xbrltype": "integerItemType", "nsuri": "http://ashs.com/20231231", "localname": "NumberOfDebtInstruments", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_NumberOfDebtInstruments", "terseLabel": "Number of Debt Instruments", "documentation": "The number of debt instruments." } } }, "auth_ref": [] }, "ams_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://ashs.com/20231231", "localname": "NumberOfMajorCustomers", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "The number of major customers." } } }, "auth_ref": [] }, "ams_NumberOfMedicalCenters": { "xbrltype": "integerItemType", "nsuri": "http://ashs.com/20231231", "localname": "NumberOfMedicalCenters", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_NumberOfMedicalCenters", "terseLabel": "Number of Medical Centers", "documentation": "The number of medical centers." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r709" ] }, "ams_OR21LLCMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "OR21LLCMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "OR21, LLC [Member]", "documentation": "Represents OR21, LLC (\u201cOR21 LLC\u201d)." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "ams_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "OneCustomerMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "One Customer [Member]", "documentation": "Represents one customer." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r222", "r241", "r247", "r249", "r631" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details" ], "lang": { "en-us": { "role": { "label": "Operating lease cost, net of impairment", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r446", "r653" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r763" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r443" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current portion of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r443" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "LONG-TERM LEASE LIABILITIES, less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r443" ] }, "ams_OperatingLeaseMonthlyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "OperatingLeaseMonthlyExpense", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_OperatingLeaseMonthlyExpense", "terseLabel": "Operating Lease, Monthly Expense", "documentation": "Amount of operating lease expense per month. Excludes sublease income." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details" ], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities - Operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r444", "r448" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "RIGHT OF USE ASSETS, net", "terseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r442" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate - Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r450", "r653" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term - Operating leases in years (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r449", "r653" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r70" ] }, "ams_OptionsIssuedDuringPeriodCashlessStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://ashs.com/20231231", "localname": "OptionsIssuedDuringPeriodCashlessStockOptionsExercised", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_OptionsIssuedDuringPeriodCashlessStockOptionsExercised", "terseLabel": "Options Issued During Period, Cashless Stock Options Exercised (in shares)", "documentation": "The number of options issued during the period from cashless stock options exercised." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r88", "r129", "r522", "r523" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "totalLabel": "Total other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r24" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "OTHER ASSETS", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r167" ] }, "us-gaap_OtherCostOfOperatingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCostOfOperatingRevenue", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Other direct operating costs", "documentation": "Other costs incurred during the reporting period related to other revenue generating activities." } } }, "auth_ref": [ "r107" ] }, "ams_OtherCostOfOperatingRevenueRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "OtherCostOfOperatingRevenueRelatedParty", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostOfRevenue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Other direct operating costs, related party", "documentation": "Other costs from related parties incurred during the reporting period related to other revenue generating activities." } } }, "auth_ref": [] }, "ams_OtherGammaKnifeUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "OtherGammaKnifeUnitsMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Gamma Knife Units [Member]", "documentation": "Represents other gamma knife units." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r25" ] }, "us-gaap_OtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ams_PBRTEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "PBRTEquipmentMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "PBRT Equipment [Member]", "documentation": "Represents PBRT equipment." } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ams_PatientIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "PatientIncomeMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Patient Income [Member]", "documentation": "Represents patient income." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Debt issuance costs long-term debt", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r36" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Payment for purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToMinorityShareholders", "negatedLabel": "Distributions to non-controlling interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r34" ] }, "ams_PbrtServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "PbrtServicesMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "PBRT Services [Member]", "documentation": "Represents PBRT service." } } }, "auth_ref": [] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-9-retirement-plan" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r325", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r644" ] }, "ams_PercentageOfRevenues": { "xbrltype": "percentItemType", "nsuri": "http://ashs.com/20231231", "localname": "PercentageOfRevenues", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_PercentageOfRevenues", "terseLabel": "Percentage of Revenues", "documentation": "The percentage of revenues." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r696" ] }, "ams_PrepaidMaintenanceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "PrepaidMaintenanceCurrent", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid maintenance", "documentation": "The amount of prepaid maintenance classified as current." } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r693" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Long-term debt financing on purchase of property and equipment", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r33", "r526" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Advances on line of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r33", "r701" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from options exercised", "terseLabel": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r5", "r19" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r250", "r466", "r509", "r510", "r511", "r512", "r513", "r514", "r625", "r641", "r655", "r688", "r719", "r720", "r725", "r782" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r250", "r466", "r509", "r510", "r511", "r512", "r513", "r514", "r625", "r641", "r655", "r688", "r719", "r720", "r725", "r782" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Net income", "totalLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r161", "r173", "r174", "r182", "r188", "r197", "r205", "r206", "r222", "r241", "r247", "r249", "r263", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r413", "r416", "r417", "r428", "r429", "r481", "r493", "r534", "r571", "r590", "r591", "r631", "r650", "r651", "r666", "r697", "r721" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "terseLabel": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r683", "r687", "r715" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "ams_PropertyPlantAndEquipmentNetExcludingLand", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "terseLabel": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r687", "r714" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r116", "r151", "r154", "r155" ] }, "ams_PropertyPlantAndEquipmentGrossExcludingLand": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "PropertyPlantAndEquipmentGrossExcludingLand", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "ams_PropertyPlantAndEquipmentNetExcludingLand", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale, excluding land." } } }, "auth_ref": [] }, "ams_PropertyPlantAndEquipmentNetExcludingLand": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "PropertyPlantAndEquipmentNetExcludingLand", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT, net", "totalLabel": "Net property and equipment", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, excluding land." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r8", "r151", "r154", "r490" ] }, "us-gaap_PropertyPlantAndEquipmentSalvageValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentSalvageValue", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentSalvageValue", "terseLabel": "Property, Plant, and Equipment, Salvage Value", "documentation": "The estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose)." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r117" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ams_ProtonBeamRadiationTherapyPBRTMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "ProtonBeamRadiationTherapyPBRTMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Proton Beam Radiation Therapy PBRT [Member]", "documentation": "Represents proton beam radiation therapy (\"PBRT\")." } } }, "auth_ref": [] }, "ams_PurchaseAgreementAnnualPrepayment": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "PurchaseAgreementAnnualPrepayment", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_PurchaseAgreementAnnualPrepayment", "terseLabel": "Purchase Agreement Annual Prepayment", "documentation": "The amount of annual prepayments under purchase agreement." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PurchaseObligation", "terseLabel": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r326", "r339", "r366", "r367", "r368", "r464", "r465", "r515", "r540", "r541", "r598", "r600", "r602", "r603", "r605", "r622", "r623", "r633", "r640", "r647", "r656", "r659", "r717", "r723", "r773", "r774", "r775", "r776", "r777" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r326", "r339", "r366", "r367", "r368", "r464", "r465", "r515", "r540", "r541", "r598", "r600", "r602", "r603", "r605", "r622", "r623", "r633", "r640", "r647", "r656", "r659", "r717", "r723", "r773", "r774", "r775", "r776", "r777" ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r54", "r56" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r53", "r56" ] }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets." } } }, "auth_ref": [ "r55", "r56" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r52", "r56" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r330", "r456", "r457", "r543", "r544", "r545", "r546", "r547", "r568", "r570", "r597" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r191", "r192", "r456", "r457", "r458", "r459", "r543", "r544", "r545", "r546", "r547", "r568", "r570", "r597" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "totalLabel": "Total related party transactions", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r85", "r456" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r456", "r457", "r769" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details": { "parentTag": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details" ], "lang": { "en-us": { "role": { "label": "Equipment purchases and de-install costs", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r330", "r456", "r457", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r543", "r544", "r545", "r546", "r547", "r568", "r570", "r597", "r769" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r453", "r454", "r455", "r457", "r460", "r530", "r531", "r532", "r574", "r575", "r576", "r595", "r596" ] }, "ams_RentalIncomeFromMedicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "RentalIncomeFromMedicalServicesMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Rental Income from Medical Services [Member]", "documentation": "Represents rental income from medical services." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Principal payments on long-term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r35", "r527" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermLinesOfCredit", "negatedLabel": "Principal payments on line of credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfShortTermDebt", "negatedLabel": "Principal payments on short-term financing prepaid insurance", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "us-gaap_RestrictedCash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r694", "r700", "r778", "r780" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r164", "r186" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r43" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r97", "r121", "r487", "r519", "r520", "r528", "r551", "r654" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r158", "r194", "r195", "r196", "r198", "r204", "r206", "r264", "r265", "r375", "r376", "r377", "r401", "r402", "r420", "r422", "r423", "r425", "r426", "r516", "r518", "r535", "r786" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r223", "r224", "r240", "r245", "r246", "r250", "r251", "r253", "r322", "r323", "r466" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r223", "r224", "r240", "r245", "r246", "r250", "r251", "r253", "r322", "r323", "r466" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r572", "r624", "r628" ] }, "ams_RevenueSharingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "RevenueSharingArrangementsMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue Sharing Arrangements [Member]", "documentation": "Represents revenue sharing arrangements." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r677" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r677" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r253", "r684" ] }, "us-gaap_SalvageValueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalvageValueMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Salvage Value [Member]", "documentation": "A revision in the estimated value of an asset at the end of its useful life." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": [ "r340", "r707" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r207", "r340", "r680", "r707" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r125" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r708" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r124" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r260", "r261", "r262" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r66" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r649", "r754" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r760" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r668" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r670" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r253", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r285", "r286", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r634", "r688", "r782" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r251", "r252", "r537", "r538", "r539", "r599", "r601", "r604", "r606", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r626", "r642", "r659", "r725", "r782" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r238", "r239", "r251", "r632" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Selling and administrative expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r108" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Day)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r648" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r360" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Forfeited, grant date weighted average fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r360" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r358" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Granted, grant date weighted average fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r358" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Outstanding, grant date weighted average fair value (in dollars per share)", "periodEndLabel": "Outstanding, grant date weighted average fair value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r355", "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Awards issued and vested (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)", "negatedTerseLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details" ], "lang": { "en-us": { "role": { "label": "Vested, grant date weighted average fair value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r367" ] }, "ams_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://ashs.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected forfeiture rate", "documentation": "The estimated forfeiture rate of award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r368" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)", "periodStartLabel": "Outstanding (in shares)", "periodEndLabel": "Outstanding (in shares)", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r15", "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, grant date weighted-average exercise price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r361" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Balance, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Balance, grant date weighted-average exercise price (in dollars per share)", "periodEndLabel": "Balance, grant date weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercised, grant date weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Forfeited, grant date weighted-average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, grant date weighted-average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r351" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected life (years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r365" ] }, "ams_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://ashs.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest, Outstanding, Number (in shares)", "documentation": "Number of fully vested and expected to vest equity instrument other than options outstanding that can be converted into shares under share based compensation plan." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r64" ] }, "ams_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodUsingCash": { "xbrltype": "sharesItemType", "nsuri": "http://ashs.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodUsingCash", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodUsingCash", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Using Cash (in shares)", "documentation": "Number of share options (or share units) exercised using cash during the current period." } } }, "auth_ref": [] }, "ams_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://ashs.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Granted, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Balance, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r122" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r113", "r187" ] }, "ams_SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "lang": { "en-us": { "role": { "label": "Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC [Member]", "documentation": "Related to acquisitions." } } }, "auth_ref": [] }, "ams_StandaloneFacilityInLimaPeruMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "StandaloneFacilityInLimaPeruMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Stand-alone Facility in Lima, Peru [Member]", "documentation": "Represents the stand-alone office in Lima, Peru." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r160", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r253", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r280", "r285", "r286", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r634", "r688", "r782" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r31", "r158", "r176", "r177", "r178", "r194", "r195", "r196", "r198", "r204", "r206", "r220", "r264", "r265", "r319", "r375", "r376", "r377", "r401", "r402", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r431", "r432", "r433", "r434", "r435", "r436", "r452", "r516", "r517", "r518", "r535", "r592" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r251", "r252", "r537", "r538", "r539", "r599", "r601", "r604", "r606", "r609", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r626", "r642", "r659", "r725", "r782" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables", "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details", "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details", "http://ashs.com/20231231/role/statement-note-6-leases-tables", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables", "http://ashs.com/20231231/role/statement-note-9-retirement-plan", "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual", "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r194", "r195", "r196", "r220", "r466", "r524", "r536", "r542", "r543", "r544", "r545", "r546", "r547", "r550", "r553", "r554", "r555", "r556", "r557", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r567", "r568", "r570", "r572", "r573", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r592", "r660" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r207", "r340", "r680", "r681", "r707" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation", "http://ashs.com/20231231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies", "http://ashs.com/20231231/role/statement-note-10-commitments-and-contingencies-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables", "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables", "http://ashs.com/20231231/role/statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-details-textual", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-longterm-debt-maturities-details", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables", "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual", "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details", "http://ashs.com/20231231/role/statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details", "http://ashs.com/20231231/role/statement-note-6-leases-tables", "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-income-before-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details", "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-assumptions-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables", "http://ashs.com/20231231/role/statement-note-9-retirement-plan", "http://ashs.com/20231231/role/statement-note-9-retirement-plan-details-textual", "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r194", "r195", "r196", "r220", "r466", "r524", "r536", "r542", "r543", "r544", "r545", "r546", "r547", "r550", "r553", "r554", "r555", "r556", "r557", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r567", "r568", "r570", "r572", "r573", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r592", "r660" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices", "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Vested restricted stock awards (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r14", "r94", "r95", "r121" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options exercised (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "negatedLabel": "Exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r94", "r95", "r121", "r352" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Vested restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r14", "r121" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation", "terseLabel": "Stock-based compensation expense", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r67", "r94", "r95", "r121" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "Options exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r14", "r31", "r121" ] }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "terseLabel": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased (in shares)", "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "terseLabel": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased (in shares)", "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodShares", "terseLabel": "Stock Repurchased During Period, Shares (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r94", "r95", "r121", "r527", "r592", "r607" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total equity- American Shared Hospital Services", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r95", "r98", "r99", "r114", "r552", "r569", "r593", "r594", "r654", "r667", "r702", "r711", "r762", "r786" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets", "http://ashs.com/20231231/role/statement-consolidated-statement-of-shareholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r76", "r77", "r78", "r158", "r159", "r177", "r194", "r195", "r196", "r198", "r204", "r264", "r265", "r319", "r375", "r376", "r377", "r401", "r402", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r431", "r432", "r436", "r452", "r517", "r518", "r533", "r552", "r569", "r593", "r594", "r608", "r666", "r702", "r711", "r762", "r786" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases-lease-cost-and-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_SubleaseIncome", "negatedLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r447", "r653" ] }, "ams_SubleaseOfficeInSanFranciscoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "SubleaseOfficeInSanFranciscoCaliforniaMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-6-leases", "http://ashs.com/20231231/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Sublease Office in San Francisco, California [Member]", "documentation": "Represents sublease office in San Francisco, California." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r461", "r463" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW DISCLOSURE" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-tables", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-tables", "http://ashs.com/20231231/role/statement-note-3-property-and-equipment-tables", "http://ashs.com/20231231/role/statement-note-4-other-accrued-liabilities-tables", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-tables", "http://ashs.com/20231231/role/statement-note-6-leases-tables", "http://ashs.com/20231231/role/statement-note-7-income-taxes-tables", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r70" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r69" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes", "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r69" ] }, "ams_TheCreditAgreement2024SupplementalTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "TheCreditAgreement2024SupplementalTermLoanMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "The Credit Agreement, 2024 Supplemental Term Loan [Member]", "documentation": "Represents the 2024 supplemental term loan part of the credit agreement." } } }, "auth_ref": [] }, "ams_TheCreditAgreementFirstLoanAndSecondLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "TheCreditAgreementFirstLoanAndSecondLoanFacilityMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The Credit Agreement, First Loan and Second Loan Facility [Member]", "documentation": "Represents credit agreement, first loan and second loan facility." } } }, "auth_ref": [] }, "ams_TheCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "TheCreditAgreementMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The Credit Agreement [Member]", "documentation": "Represents the Credit Agreement." } } }, "auth_ref": [] }, "ams_TheCreditAgreementSecondLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "TheCreditAgreementSecondLoanFacilityMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The Credit Agreement, Second Loan Facility [Member]", "documentation": "The second loan facility of the credit agreement." } } }, "auth_ref": [] }, "ams_TheCreditAgreementThirdLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "TheCreditAgreementThirdLoanFacilityMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The Credit Agreement, Third Loan Facility [Member]", "documentation": "Represents the third loan facility of the credit agreement." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r710", "r768" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-details-textual", "http://ashs.com/20231231/role/statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r142", "r143", "r144", "r256", "r257", "r259" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-2-accounting-policies", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r75" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ashs.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ams_USSubsidiaryOfElektaMember": { "xbrltype": "domainItemType", "nsuri": "http://ashs.com/20231231", "localname": "USSubsidiaryOfElektaMember", "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions", "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "US Subsidiary Of Elekta Member", "documentation": "Represents the US subsidiary Of Elekta." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual", "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Balance at beginning of year", "periodEndLabel": "Balance at end of year", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r381", "r389" ] }, "ams_UnrecognizedTaxBenefitsDecreaseResultingFromForeignTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromForeignTaxes", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "ams_UnrecognizedTaxBenefitsDecreaseResultingFromForeignTaxes", "terseLabel": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Taxes", "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign taxes." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "negatedLabel": "Additions based on tax positions of prior years", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r390" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return." } } }, "auth_ref": [ "r753" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details" ], "lang": { "en-us": { "role": { "label": "Additions based on tax positions of prior years", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r390" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r753" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://ashs.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r49", "r50", "r51", "r148", "r149", "r152", "r153" ] }, "us-gaap_UtilitiesOperatingExpenseMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UtilitiesOperatingExpenseMaintenance", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details": { "parentTag": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details" ], "lang": { "en-us": { "role": { "label": "Costs incurred to maintain equipment", "documentation": "Amount of operating expense for routine plant maintenance and repairs of regulated operation." } } }, "auth_ref": [ "r106" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://ashs.com/20231231/role/statement-note-7-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r393" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://ashs.com/20231231/role/statement-note-12-subsequent-events", "http://ashs.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://ashs.com/20231231/role/statement-note-5-long-term-debt", "http://ashs.com/20231231/role/statement-note-5-long-term-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares for diluted earnings per share (in shares)", "totalLabel": "Denominator for diluted earnings per share \u2013 adjusted weighted-average shares (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r209", "r217" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "http://ashs.com/20231231/role/statement-note-2-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Denominator for basic earnings per share \u2013 weighted-average shares (in shares)", "label": "Weighted average common shares for basic earnings per share (in shares)", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic, Total (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r208", "r217" ] }, "ams_WriteDownOfImpairedAssetsAndAssociatedRemovalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://ashs.com/20231231", "localname": "WriteDownOfImpairedAssetsAndAssociatedRemovalCosts", "crdr": "debit", "calculation": { "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://ashs.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://ashs.com/20231231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Loss on write down of impaired assets", "documentation": "Amount of write down of impaired assets and associated removal costs." } } }, "auth_ref": [] }, "ams_statement-statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-11-related-party-transactions-schedule-of-related-party-transactions-details", "lang": { "en-us": { "role": { "label": "Note 11 - Related Party Transactions - Schedule of Related Party Transactions (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-11-related-party-transactions-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-11-related-party-transactions-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Related Party Transactions" } } }, "auth_ref": [] }, "ams_statement-statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-2-accounting-policies-computation-of-basic-and-diluted-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 2 - Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-2-accounting-policies-profit-loss-allocations-to-reportable-segments-details", "lang": { "en-us": { "role": { "label": "Note 2 - Accounting Policies - Profit (Loss) Allocations to Reportable Segments (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-2-accounting-policies-property-and-equipment-allocations-to-reportable-segments-details", "lang": { "en-us": { "role": { "label": "Note 2 - Accounting Policies - Property and Equipment Allocations to Reportable Segments (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-2-accounting-policies-revenues-allocations-to-reportable-segments-details", "lang": { "en-us": { "role": { "label": "Note 2 - Accounting Policies - Revenues Allocations to Reportable Segments (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-2-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-2-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Accounting Policies" } } }, "auth_ref": [] }, "ams_statement-statement-note-3-accounting-policies-allocations-to-reportable-segments-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-3-accounting-policies-allocations-to-reportable-segments-details", "lang": { "en-us": { "role": { "label": "Note 3 - Accounting Policies - Allocations to Reportable Segments (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-3-property-and-equipment-summary-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-3-property-and-equipment-summary-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 3 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-3-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-3-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Property and Equipment" } } }, "auth_ref": [] }, "ams_statement-statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-4-other-accrued-liabilities-other-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 4 - Other Accrued Liabilities - Other Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-4-other-accrued-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-4-other-accrued-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Other Accrued Liabilities" } } }, "auth_ref": [] }, "ams_statement-statement-note-5-long-term-debt-longterm-debt-maturities-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-5-long-term-debt-longterm-debt-maturities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Long Term Debt - Long-term Debt Maturities (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-5-long-term-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-5-long-term-debt-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Long Term Debt" } } }, "auth_ref": [] }, "ams_statement-statement-note-6-leases-lease-cost-and-information-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-6-leases-lease-cost-and-information-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Cost and Information (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-6-leases-summary-of-maturities-of-lessee-operating-lease-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Summary of Maturities of Lessee Operating Lease Liabilities (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-6-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-6-leases-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Leases" } } }, "auth_ref": [] }, "ams_statement-statement-note-7-income-taxes-components-of-income-before-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-7-income-taxes-components-of-income-before-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Components of Income Before Income Taxes (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-7-income-taxes-components-of-provision-benefit-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Components of Provision (Benefit) for Income Taxes (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-7-income-taxes-reconciliation-of-income-tax-provision-benefit-details", "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-7-income-taxes-reconciliation-of-unrecognized-tax-benefit-details", "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-7-income-taxes-significant-components-of-deferred-tax-liabilities-and-assets-details", "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Significant Components of Deferred Tax Liabilities and Assets (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-7-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-7-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes" } } }, "auth_ref": [] }, "ams_statement-statement-note-8-stockbased-compensation-expense-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-8-stockbased-compensation-expense-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation Expense - Assumptions (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-8-stockbased-compensation-expense-changes-in-restricted-stock-units-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation Expense - Changes in Restricted Stock Units (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-8-stockbased-compensation-expense-stock-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation Expense - Stock Compensation Expense (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-8-stockbased-compensation-expense-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation Expense - Summary of Stock Option Activity (Details)" } } }, "auth_ref": [] }, "ams_statement-statement-note-8-stockbased-compensation-expense-tables": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-note-8-stockbased-compensation-expense-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation Expense" } } }, "auth_ref": [] }, "ams_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://ashs.com/20231231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//410-20/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481999/410-20-25-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r680": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r681": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 89 0001437749-24-010308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-010308-xbrl.zip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�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end XML 91 asha20231231_10k_htm.xml IDEA: XBRL DOCUMENT 0000744825 2023-01-01 2023-12-31 0000744825 2023-03-30 0000744825 2024-03-22 0000744825 2023-12-31 0000744825 2022-12-31 0000744825 us-gaap:RelatedPartyMember 2023-12-31 0000744825 us-gaap:RelatedPartyMember 2022-12-31 0000744825 ams:RentalIncomeFromMedicalServicesMember 2023-01-01 2023-12-31 0000744825 ams:RentalIncomeFromMedicalServicesMember 2022-01-01 2022-12-31 0000744825 ams:PatientIncomeMember 2023-01-01 2023-12-31 0000744825 ams:PatientIncomeMember 2022-01-01 2022-12-31 0000744825 ams:EquipmentSalesMember 2023-01-01 2023-12-31 0000744825 ams:EquipmentSalesMember 2022-01-01 2022-12-31 0000744825 2022-01-01 2022-12-31 0000744825 us-gaap:CommonStockMember 2021-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000744825 us-gaap:RetainedEarningsMember 2021-12-31 0000744825 us-gaap:ParentMember 2021-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2021-12-31 0000744825 2021-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000744825 us-gaap:ParentMember 2022-01-01 2022-12-31 0000744825 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000744825 us-gaap:RestrictedStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000744825 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000744825 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000744825 us-gaap:CommonStockMember 2022-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000744825 us-gaap:RetainedEarningsMember 2022-12-31 0000744825 us-gaap:ParentMember 2022-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2022-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000744825 us-gaap:ParentMember 2023-01-01 2023-12-31 0000744825 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000744825 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000744825 us-gaap:CommonStockMember 2023-12-31 0000744825 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000744825 us-gaap:RetainedEarningsMember 2023-12-31 0000744825 us-gaap:ParentMember 2023-12-31 0000744825 us-gaap:NoncontrollingInterestMember 2023-12-31 0000744825 ams:NewcoMember 2022-04-27 0000744825 ams:NewcoMember ams:GuadalupeMember 2022-04-27 0000744825 ams:OR21LLCMember 2023-12-31 0000744825 ams:OR21LLCMember ams:ArchitecturalDesignCompanyMember 2023-12-31 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2023-11-10 2023-11-10 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2023-11-10 0000744825 ams:SouthernNewEnglandRegionalCancerCenterLLCAndRogerWilliamsRadiationTherapyLLCMember 2023-12-31 0000744825 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000744825 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 ams:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000744825 ams:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000744825 ams:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000744825 ams:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000744825 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 ams:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 ams:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 ams:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 ams:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000744825 srt:MinimumMember us-gaap:OfficeEquipmentMember 2023-12-31 0000744825 srt:MaximumMember us-gaap:OfficeEquipmentMember 2023-12-31 0000744825 us-gaap:BuildingMember 2023-12-31 0000744825 srt:MinimumMember 2023-12-31 0000744825 srt:MinimumMember 2022-12-31 0000744825 srt:MaximumMember 2023-12-31 0000744825 srt:MaximumMember 2022-12-31 0000744825 us-gaap:SalvageValueMember 2023-01-01 2023-12-31 0000744825 ams:ProtonBeamRadiationTherapyPBRTMember 2023-12-31 0000744825 ams:GammaKnifeAndRadiationTherapyEquipmentMember 2023-12-31 0000744825 ams:GammaKnifeAndRadiationTherapyEquipmentMember 2022-12-31 0000744825 ams:PbrtServicesMember 2023-01-01 2023-12-31 0000744825 ams:PbrtServicesMember 2022-01-01 2022-12-31 0000744825 ams:RevenueSharingArrangementsMember 2023-01-01 2023-12-31 0000744825 ams:RevenueSharingArrangementsMember 2022-01-01 2022-12-31 0000744825 ams:GKCEMember 2023-12-31 0000744825 ams:GKCEMember 2022-01-01 0000744825 ams:GKCEMember 2022-12-31 0000744825 ams:GammaKnifeUnitsMember 2023-12-31 0000744825 ams:OtherGammaKnifeUnitsMember 2023-12-31 0000744825 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000744825 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000744825 ams:MedicalEquipmentLeasingMember 2023-01-01 2023-12-31 0000744825 ams:MedicalEquipmentLeasingMember 2022-01-01 2022-12-31 0000744825 ams:DirectPatientServicesMember 2023-01-01 2023-12-31 0000744825 ams:DirectPatientServicesMember 2022-01-01 2022-12-31 0000744825 ams:MedicalEquipmentLeasingMember 2023-12-31 0000744825 ams:MedicalEquipmentLeasingMember 2022-12-31 0000744825 ams:DirectPatientServicesMember 2023-12-31 0000744825 ams:DirectPatientServicesMember 2022-12-31 0000744825 ams:GammaKnifeCenterEcuadorSAGKCEMember 2020-06-12 2020-06-12 0000744825 ams:GammaKnifeCenterEcuadorSAGKCEMember us-gaap:TradeNamesMember 2020-06-12 2020-06-12 0000744825 ams:MedicalEquipmentAndFacilitiesMember 2023-12-31 0000744825 ams:MedicalEquipmentAndFacilitiesMember 2022-12-31 0000744825 us-gaap:OfficeEquipmentMember 2023-12-31 0000744825 us-gaap:OfficeEquipmentMember 2022-12-31 0000744825 us-gaap:ConstructionInProgressMember 2023-12-31 0000744825 us-gaap:ConstructionInProgressMember 2022-12-31 0000744825 us-gaap:NonUsMember 2023-12-31 0000744825 us-gaap:NonUsMember 2022-12-31 0000744825 ams:PBRTEquipmentMember 2023-01-01 2023-12-31 0000744825 ams:PBRTEquipmentMember 2022-01-01 2022-12-31 0000744825 ams:TheCreditAgreementMember ams:FifthThirdBankNAMember 2021-04-09 2021-04-09 0000744825 ams:TheCreditAgreementMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 ams:TheCreditAgreementSecondLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2023-12-31 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2021-04-09 2021-04-09 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember ams:LondonInterbankOfferedRateMember 2021-04-09 2021-04-09 0000744825 ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMember ams:FifthThirdBankNAMember 2023-12-31 0000744825 ams:TheCreditAgreementFirstLoanAndSecondLoanFacilityMember ams:FifthThirdBankNAMember 2022-12-31 0000744825 us-gaap:RevolvingCreditFacilityMember ams:TheCreditAgreementThirdLoanFacilityMember ams:FifthThirdBankNAMember 2021-01-01 2021-12-31 0000744825 ams:DfcLoanTrancheOneMember 2023-12-31 0000744825 ams:DfcLoanTrancheTwoMember 2023-12-31 0000744825 ams:DfcLoanMember 2023-12-31 0000744825 ams:DfcLoanMember 2022-12-31 0000744825 ams:SubleaseOfficeInSanFranciscoCaliforniaMember 2021-11-03 0000744825 ams:SubleaseOfficeInSanFranciscoCaliforniaMember 2021-11-03 2021-11-03 0000744825 ams:LeaseAgreementForNewCorporateOfficeMember 2021-11-03 0000744825 ams:LeaseAgreementForNewCorporateOfficeMember 2021-11-03 2021-11-03 0000744825 ams:CorporateOfficeInSanFranciscoMember 2023-12-31 0000744825 ams:CorporateOfficeInSanFranciscoMember 2023-01-01 2023-12-31 0000744825 ams:SubleaseOfficeInSanFranciscoCaliforniaMember 2023-12-31 0000744825 ams:SubleaseOfficeInSanFranciscoCaliforniaMember 2023-01-01 2023-12-31 0000744825 ams:StandaloneFacilityInLimaPeruMember 2023-12-31 0000744825 ams:StandaloneFacilityInLimaPeruMember 2023-01-01 2023-12-31 0000744825 ams:CondominiumSpaceForGammaKnifeFacilityInGuayaquilEcuadorMember 2023-12-31 0000744825 ams:LandAndParkingSpacesForGammaKnifeFacilityInGuayaquilEcuadorMember 2023-12-31 0000744825 us-gaap:DomesticCountryMember 2023-12-31 0000744825 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000744825 us-gaap:DomesticCountryMember us-gaap:CapitalLossCarryforwardMember 2023-12-31 0000744825 us-gaap:StateAndLocalJurisdictionMember us-gaap:CapitalLossCarryforwardMember 2023-12-31 0000744825 srt:MaximumMember srt:ScenarioForecastMember 2024-01-01 2024-12-31 0000744825 ams:IncentiveCompensationPlanMember 2021-06-30 0000744825 ams:IncentiveCompensationPlanMember 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember ams:IncentiveCompensationPlanMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember ams:IncentiveCompensationPlanMember ams:NonEmployeeDirectorsAndCorporateSecretaryMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember ams:IncentiveCompensationPlanMember ams:NonEmployeeDirectorsMember 2023-01-01 2023-12-31 0000744825 ams:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember ams:IncentiveCompensationPlanMember 2023-01-01 2023-12-31 0000744825 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember ams:IncentiveCompensationPlanMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember ams:IncentiveCompensationPlanMember 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000744825 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember ams:ExecutiveEquityAwardsMember 2020-05-04 2020-05-04 0000744825 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember ams:ExecutiveEquityAwardsMember 2020-08-03 2020-08-03 0000744825 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember ams:ExecutiveEquityAwardsMember 2022-01-01 2022-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember ams:ExecutiveEquityAwardsMember 2022-01-01 2022-12-31 0000744825 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember ams:ExecutiveEquityAwardsMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember ams:ExecutiveEquityAwardsMember 2023-01-01 2023-12-31 0000744825 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000744825 ams:ManagementBonusProgramMember 2023-01-01 2023-12-31 0000744825 ams:BoardMemberMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000744825 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0000744825 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000744825 2021-01-01 2021-12-31 0000744825 2022-01-01 0000744825 srt:MinimumMember 2022-01-01 2022-12-31 0000744825 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000744825 ams:LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember 2023-01-01 2023-12-31 0000744825 ams:LeksellGammaKnifeIconSystemsAndLinearAcceleratorSystemMember 2023-12-31 0000744825 ams:MaintenanceAndSupportAgreementMevionServiceAgreementMember ams:MevionMedicalSystemsIncMember 2022-09-04 0000744825 ams:MaintenanceAndSupportAgreementMevionServiceAgreementMember ams:MevionMedicalSystemsIncMember 2022-09-04 2022-09-04 0000744825 srt:MaximumMember ams:LINACSystemMember 2023-01-01 2023-12-31 0000744825 srt:MinimumMember ams:LINACSystemMember 2023-01-01 2023-12-31 0000744825 ams:LINACSystemMember 2023-12-31 0000744825 ams:GKFSubsidiaryMember 2023-12-31 0000744825 ams:USSubsidiaryOfElektaMember 2023-12-31 0000744825 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000744825 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000744825 ams:USSubsidiaryOfElektaMember 2023-12-31 0000744825 ams:TheCreditAgreement2024SupplementalTermLoanMember ams:FifthThirdBankNAMember us-gaap:SubsequentEventMember 2024-01-25 0000744825 ams:TheCreditAgreement2024SupplementalTermLoanMember ams:FifthThirdBankNAMember us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-25 2024-01-25 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y utr:sqft utr:acre utr:D 0000744825 AMERICAN SHARED HOSPITAL SERVICES false --12-31 FY 2023 false false false false 100000 100000 250000 120000 0 0 10000000 10000000 6300000 6300000 6184000 6184000 15 140000 300000 P10Y 144000 2 0 0 P5Y 3 P5Y 57000 0.21 742000 2.57 2.4 132000 2.4 3000 2.92 2.33 2.97 119000 2.94 2.88 10000 P4Y 0 P1Y 10-K true 2023-12-31 false 1-08789 CA 94-2918118 601 Montgomery San Francisco CA 94111-2619 415 788-5300 Common Stock No Par Value AMS NYSE No No Yes Yes Non-accelerated Filer true false false false false 11205000 6330000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="i9B" title="i9B"></a>ITEM <em style="font: inherit;">9B.</em> OTHER INFORMATION</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="-sec-ix-hidden:c109905269"><span style="-sec-ix-hidden:c109905790"><span style="-sec-ix-hidden:c109905791"><span style="-sec-ix-hidden:c109905792">None</span></span></span>.</span></p> 659 Moss Adams LLP Seattle, WA United States 13690000 12335000 118000 118000 4343000 3801000 504000 327000 1275000 1245000 526000 897000 20456000 18723000 25844000 23467000 19000 19000 1265000 1265000 78000 78000 57000 317000 443000 87000 48162000 43956000 315000 230000 757000 735000 1226000 1544000 1961000 497000 650000 360000 1229000 255000 57000 292000 2500000 0 2084000 1262000 10779000 5175000 0 59000 11041000 12205000 0 70000 63000 822000 21883000 18331000 10763000 10763000 8232000 7843000 3629000 3019000 22624000 21625000 3655000 4000000 26279000 25625000 48162000 43956000 17772000 16655000 3353000 3091000 200000 0 21325000 19746000 2032000 1878000 5073000 4726000 4025000 3666000 851000 1094000 11981000 11364000 9344000 8382000 7022000 5145000 1112000 806000 940000 0 270000 2431000 426000 87000 696000 2518000 431000 963000 265000 1555000 -345000 227000 610000 1328000 0.1 0.21 0.1 0.21 6358000 6297000 6393000 6303000 6049000 10758000 7444000 1691000 19893000 4346000 24239000 399000 399000 399000 3000 5000 5000 5000 132000 0 573000 573000 1328000 1328000 227000 1555000 6184000 10763000 7843000 3019000 21625000 4000000 25625000 389000 389000 389000 116000 0 610000 610000 -345000 265000 6300000 10763000 8232000 3629000 22624000 3655000 26279000 265000 1555000 5165000 4783000 -34000 -40000 46000 84000 940000 0 -759000 344000 389000 399000 719000 -696000 -21000 111000 0 -397000 -491000 -845000 -79000 608000 974000 159000 5718000 7235000 6273000 388000 -6273000 -388000 2129000 2032000 1400000 -0 1750000 0 3900000 0 -0 573000 9000 9000 0 5000 202000 48000 1910000 -2657000 1355000 4190000 12453000 8263000 13808000 12453000 1066000 722000 297000 169000 1955000 0 13690000 12335000 118000 118000 13808000 12453000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="notes" title="notes"></a>NOTE <em style="font: inherit;">1</em> </b>–<b> BUSINESS AND BASIS OF PRESENTATION</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Business</b> – These consolidated financial statements include the accounts of American Shared Hospital Services (“ASHS”) and its subsidiaries (the “Company”) as follows: ASHS wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), ASHS-Mexico, S.A. de C.V. (“ASHS-Mexico”), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC, ASHS-Bristol Radiation Therapy, LLC, <em style="font: inherit;">OR21,</em> Inc., and MedLeader.com, Inc. (“MedLeader”); ASHS is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiary Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and HoldCo GKC S.A. (“HoldCo”). HoldCo wholly owns the subsidiary Gamma Knife Center Ecuador S.A. (“GKCE”). GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company (through ASRS) and Elekta AG (“Elekta”), the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. During <em style="font: inherit;">2023</em>, GKF leased Gamma Knife units to twelve medical centers in the United States in the states of California, Florida, Illinois, Indiana, Mississippi, Nebraska, New Mexico, New York, Ohio, Oregon, and Texas. GKF also owns and operates <em style="font: inherit;">two</em> single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company formed the subsidiary GKPeru and acquired GKCE for the purposes of expanding its business internationally; Orlando and LBE to provide PBRT equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2011</em> and JGKE began operations in the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2011.</em> Orlando treated its <em style="font: inherit;">first</em> patient in <em style="font: inherit;"> April 2016. </em>GKPeru treated its <em style="font: inherit;">first</em> patient in <em style="font: inherit;"> July 2017. </em>LBE is <em style="font: inherit;">not</em> expected to generate revenue within the next <em style="font: inherit;">two</em> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> April 27, 2022</em></span><i><span style="background-color:#ffffff;">,</span></i><span style="background-color:#ffffff;"> the Company signed a Joint Venture Agreement (the “Agreement”) with the principal owners of Radioterapia Guadalupe Amor y Bien S.A. de C.V. (“Guadalupe”) to establish AB </span>Radiocirugia y Radioterapia de Puebla, S.A.P.I. de C.V. <span style="background-color:#ffffff;"> of Puebla (“Puebla”) to treat public- and private-paying cancer patients and provide radiation therapy and radiosurgery services locally in Mexico. The Company and Guadalupe hold 85% and 15% ownership interests, respectively, in Puebla. Under the Agreement, the Company is responsible for providing a linear accelerator and Guadalupe will be accountable for all site modification costs.  The Company formed </span>ASHS-Mexico <span style="background-color:#ffffff;">on <em style="font: inherit;"> October 3, 2022 </em>to establish Puebla.  Puebla was formed on <em style="font: inherit;"> December 15, 2022 </em>and the Company expects Puebla to begin treating patients in <em style="font: inherit;"> June </em><em style="font: inherit;">2024.</em>  Operating costs incurred during the year ended </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;"> by Puebla, are included in the consolidated statement of operations.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company continues to develop its design and business model for The Operating Room for the <em style="font: inherit;">21st</em> CenturySM through its 50% owned <em style="font: inherit;">OR21,</em> LLC (<em style="font: inherit;">“OR21”</em>). The remaining 50% of <em style="font: inherit;">OR21</em> is owned by an architectural design company. <em style="font: inherit;">OR21</em> is <em style="font: inherit;">not</em> expected to generate significant revenue within the next <em style="font: inherit;">two</em> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is <em style="font: inherit;">not</em> operational at this time.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> November 10, 2023, </em>the Company entered into an Investment Purchase Agreement (the “IPA”) with GenesisCare USA, Inc. (the “GenesisCare”) and GenesisCare USA Holdings, Inc. (“GC Holdings”), pursuant to which GenesisCare agreed to sell to the Company its entire equity interest in each of Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, (collectively, the “RI Target Companies”) together with the assignment of certain payor contacts for a purchase price of $2,850,000 (such transaction, the “RI Acquisition”).  The equity interests to be acquired by the Company under the IPA equates to a 60% interest in each RI Target Company. The RI Target Companies operate <em style="font: inherit;">three</em> functional radiation therapy cancer centers in Rhode Island. The RI Acquisition is contingent upon certain closing conditions, including GenesisCare and the Company entering into a consent agreement with the Rhode Island Department of Health and approval of all equity holders and managers of each RI Target Company. On <em style="font: inherit;"> March 1, 2024, </em>the Company, GenesisCare and GC Holding entered into a First Amendment to the Investment Agreement pursuant to which the parties agreed to extend the date on which a party could terminate the IPA if the closing conditions had <em style="font: inherit;">not</em> been met from <em style="font: inherit;"> March 10, 2024 </em>to <em style="font: inherit;"> April 30, 2024. </em>The Company anticipates that these conditions will be met in <em style="font: inherit;"> April 2024.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The transaction will be accounted for as a business combination under ASC <em style="font: inherit;">805</em> Business Combinations, which requires, among other things, that purchase consideration, assets acquired, and liabilities assumed be measured at their fair values as of the acquisition date. The initial purchase allocation for the business combination is incomplete at this time, subject to finalizing the IPA. After closing, disclosures regarding amounts recognized for major classes of assets acquired and liabilities assumed will be provided once the initial accounting is completed. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Costs related to legal, financial and due diligence services performed in connection with this transaction recorded in the consolidated statement of operations were $432,000 for the year ended <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 12 0.85 0.15 0.50 0.50 2850000 0.60 432000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE <em style="font: inherit;">2</em> </b>–<b> ACCOUNTING POLICIES</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of estimates in the preparation of financial statements</b> – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the estimated useful lives of property and equipment and its salvage values, revenues and costs of sales for revenue sharing customers.  Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Advertising and marketing</b> – The Company expenses advertising and marketing costs as incurre<span style="background-color:#ffffff;">d (collectively, </span>“<span style="background-color:#ffffff;">marketing costs”). Marketing costs were </span>$165,000 and $233,000 during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. Marketing costs include joint marketing with customers and corporate advertising costs. Marketing costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of income. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Sales and Service</b> – The Company markets its financial and turn-key solutions directly to cancer treatment centers, hospitals, and large cancer networks worldwide through its sales staff.  Sales expense includes payroll and travel costs for the Company’s sales staff. The Company also typically provides the equipment, as well as planning, installation, reimbursement and marketing support services to its customers.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Cash and cash equivalents</b> – The Company considers all liquid investments with original maturities of <em style="font: inherit;">three</em> months or less at the date of purchase to be cash equivalents. Restricted cash is <em style="font: inherit;">not</em> considered a cash equivalent for purposes of the consolidated statements of cash flows.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Restricted cash</b> – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement and the minimum cash that must be maintained <span style="background-color:#ffffff;">by GKF per it’s financing agreement with the United </span>States International Development Finance Corporation (“D<span style="background-color:#ffffff;">FC”).  </span>See further discussion at Note <em style="font: inherit;">5</em> - Long Term Debt.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Business and credit risk</b> – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. The Company believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk on cash and cash equivalents. The Company monitors the financial condition of the financial institutions it uses on a regular basis.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All of the Company’s revenue was provided by 15 locations or <em style="font: inherit;">1</em> PBRT unit and <em style="font: inherit;">14</em> Gamma Knife units in each of <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em>. One location accounted for approximately 48% and 45% of the Company’s total revenue in <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em>, respectively. At <em style="font: inherit;"> December 31, 2023</em>, two locations each individually accounted for 30% and 31% of total accounts receivable, respectively. At <em style="font: inherit;"> December 31, 2022</em>, four locations each individually accounted for 12%, 14%, 16% and 22% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does <em style="font: inherit;">not</em> require collateral. The Company has <em style="font: inherit;">not</em> experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accounts receivable and allowance for credit losses</b> – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for expected losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are offset against bad debt expense when received.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Non-controlling interests</b> - The Company reports its non-controlling interests as a separate component of shareholders’ equity. Non-controlling interest is determined by the income (loss) multiplied by the non-controlling interest in subsidiaries, and the income or losses of the non-controlling interests in various subsidiaries controlled by GKF.  The Company also presents the consolidated net income and the portion of the consolidated net income (loss) allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Property and equipment</b> – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where applicable. The Company acquired a building as part of the acquisition of GKCE in <em style="font: inherit;"> June 2020. </em>Depreciation for buildings is determined using the straight-line method over 20 years. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. As of <em style="font: inherit;"> October 1, 2022, </em>the Company reduced its estimate for salvage value for <em style="font: inherit;">one</em> of its domestic Gamma Knife Perfexion units. As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company had <em style="font: inherit;">seven</em> domestic Gamma Knife units with salvage value ranging from $140,000 to $300,000. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> January 1, 2023, </em>the Company reduced its estimated useful life for <em style="font: inherit;">one</em> of its direct patient services Gamma Knife units. The net effect of the change in estimate made <em style="font: inherit;"> January 1, 2023, </em>for the year ended <em style="font: inherit;"> December 31, 2023</em>, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Depreciation for PBRT and related equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements accounted for as operating leases. At <em style="font: inherit;"> December 31, 2023</em>, the Company held equipment under operating lease contracts with customers with an original cost of $70,635,000 and accumulated depreciation of $52,302,000. At <em style="font: inherit;"> December 31, 2022</em>, the Company held equipment under operating lease contracts with customers with an original cost of $69,306,000 and accumulated depreciation of $47,992,000. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><span style="background-color:#ffffff;">, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. </span>During the year ended <em style="font: inherit;"> December 31, 2023</em>, the Company recorded an asset removal obligation (“ARO”) for <em style="font: inherit;">one</em> of the customer contracts that expired during <em style="font: inherit;">2023.</em>  An ARO for the <em style="font: inherit;">second</em> contract that expired during <em style="font: inherit;">2023</em> was recorded and impaired in a prior period. For the ARO recorded during <em style="font: inherit;">2023,</em> the Company concluded the related increase to the underlying assets could <em style="font: inherit;">not</em> be supported by the cash flows of the equipment and therefore the Company recorded a loss on the write-down of the ARO in <em style="font: inherit;"> June 2023. </em>The Company’s estimate for the ARO liability was subsequently adjusted during the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2023</em> based on new information. Total ARO impairment for the year ended <em style="font: inherit;"> December 31, 2023</em> was $290,000. The Company also reviewed its long-lived assets during the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2023</em> and concluded events and circumstances existed that indicated additional impairment existed at a <em style="font: inherit;">third</em> Gamma Knife site related to the existing equipment.  Total equipment impairment for the year ended <em style="font: inherit;"> December 31, 2023</em> was $650,000. <span style="background-color:#ffffff;">See further discussion under Note <em style="font: inherit;">2</em> - Long-lived asset impairment and Note <em style="font: inherit;">3</em> - Property and Equipment.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Revenue recognition</b> - The Company recognizes revenues under ASC <em style="font: inherit;">842</em> <i>Leases</i> (“ASC <em style="font: inherit;">842”</em>) and ASC <em style="font: inherit;">606</em> <i>Revenue from Contracts with Customers</i> (“ASC <em style="font: inherit;">606”</em>).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rental income from medical equipment leasing (</i>“<i>leasing</i>”<i>)</i> – The Company recognizes leasing revenue under ASC <em style="font: inherit;">842</em> when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do <em style="font: inherit;">not</em> contain any guaranteed minimum payments. The Company’s lease contracts are typically for a <span style="-sec-ix-hidden:c109905373">ten</span>-year term and are classified as either fee per use or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s lease agreement with the Company. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from <em style="font: inherit;">third</em> party payors, and the Company is responsible for paying operating costs of the equipment determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the years ended, <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company recognized leasing revenue of approximately $17,772,000 and $16,655,000 under ASC <em style="font: inherit;">842,</em> respectively, of which approximately $10,133,000 and $8,952,000 were for PBRT services, respectively.</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-align: justify;"> </p> <div style="font-size:10pt"> <div style="font-family:Times New Roman"> <div style="font-variant: normal; text-align: justify;"> Revenue sharing arrangements amounted to approximately 70 <span style="background-color:#ffffff">%</span> and 67% of total revenue for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.  Payor mix is a significant variable in the Company’s estimate for revenue sharing revenues.   </div> </div> </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Direct patient services income (</i>“<i>retail</i>”<i>)</i> – The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC <em style="font: inherit;">606,</em> the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is <em style="font: inherit;">no</em> variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net <em style="font: inherit;">30</em> days. GKCE’s patient population is primarily covered by a government payor and payments are paid between <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months, following issuance of invoice. The Company did <em style="font: inherit;">not</em> capitalize any incremental costs related to the fulfillment of its customer contracts. Accounts receivable under ASC <em style="font: inherit;">606</em> at <em style="font: inherit;"> December 31, 2023 </em>was $1,626,000. Accounts receivable under ASC <em style="font: inherit;">606</em> at <em style="font: inherit;"> January 1, 2022 </em>and <em style="font: inherit;"> December 31, 2022 </em>was $668,000 and $1,119,000. For the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company recognized retail revenues of approximately $3,553,000 and $3,091,000 under ASC <em style="font: inherit;">606,</em> respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Equipment sales</i> – During the year-ended <em style="font: inherit;"> December 31, 2023</em>, the Company completed a sale of equipment to a new customer.  The Company assessed this transaction under ASC <em style="font: inherit;">606</em> and concluded the Company acted as the agent in this transaction and provided, at a point in time, <em style="font: inherit;">two</em> performance obligations, in the form of an equipment sale of an Icon and Cobalt-<em style="font: inherit;">60</em> reload.  The performance obligation to sell, assign, transfer and deliver the equipment to the customer was carried out via Elekta.  Revenue related to the equipment sale is recognized on a net basis when the sale is complete.  The Company recognized net revenue of $200,000 on the sale of equipment for the year-ended <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Stock-based compensation</b> – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note <em style="font: inherit;">8</em> - Stock-Based Compensation Expense for additional information on the Company’s stock-based compensation programs.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Costs of revenue </b>– The Company’s costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s revenue sharing and retail sites). Costs of revenue are recognized as incurred.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Income taxes</b> – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes as required by the provisions of ASC <em style="font: inherit;">740</em> <i>Income taxes</i> (“ASC <em style="font: inherit;">740”</em>), which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The <em style="font: inherit;">first</em> step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than <em style="font: inherit;">not</em> that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The <em style="font: inherit;">second</em> step is to estimate and measure the tax benefit as the largest amount that is more than <em style="font: inherit;">50%</em> likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires the Company to determine the probability of various possible outcomes. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which <em style="font: inherit;"> may </em>require periodic adjustments and <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> accurately anticipate actual outcomes.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">See Note <em style="font: inherit;">7</em> - Income Taxes for further discussion on income taxes.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Functional currency</b> – Based on guidance provided in accordance with ASC <em style="font: inherit;">830,</em> <i>Foreign Currency Matters</i> (“ASC <em style="font: inherit;">830”</em>), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will reassess its accounting for the operation to the local currency from the U.S. dollar. The Company analyzed it’s Gamma Knife site in Peru and its startup operations in Mexico for Puebla under ASC <em style="font: inherit;">830</em> as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> and concluded the functional currency was the U.S. dollar. As facts and circumstances change, the Company will revisit this conclusion.  The functional currency of the Company’s Gamma Knife site in Ecuador is the U.S. dollar because that is the local currency of Ecuador. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Asset Retirement Obligations </b>– Based on the guidance provided in ASC <em style="font: inherit;">410,</em> <i>Asset Retirement Obligations</i> (“ASC <em style="font: inherit;">410”</em>), the Company analyzed its existing lease agreements and determined whether an <span style="background-color:#ffffff">ARO</span> exists to remove the respective units at the end of the lease terms. As of <em style="font: inherit;"> December 31, 2023</em>, the Company has <em style="font: inherit;">two</em> AROs recorded for the two customer sites that expired during the year, totaling $650,000.  One ARO was recorded and impaired in a prior period.  The Company recorded and impaired an ARO for the <em style="font: inherit;">second</em> customer site during <em style="font: inherit;">2023.</em> No liability has been recorded as of <em style="font: inherit;"> December 31, 2023</em> for the remaining Gamma Knife or PBRT locations, because it is uncertain these units will be removed and the Company historically has <em style="font: inherit;">not</em> removed the equipment at the end of the lease term. The Company will re-evaluate the need to record additional ARO liabilities on a periodic basis when facts and circumstances change that could affect this conclusion.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Earnings per share</b> – The Company calculates diluted shares using the treasury stock method. Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units <em style="font: inherit;">not</em> issued and outstanding and unvested restricted stock units, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options and from unvested restricted stock units. The computation for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> excluded approximately <span style="-sec-ix-hidden:c109905429">144</span><span style="background-color:#ffffff;"><em style="font: inherit;">,000</em> and 20,000</span>, respectively, of the Company’s stock options because the exercise price of the options was higher than the average market price during the period. The weighted average common shares outstanding for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><br/> The following table illustrates the computations of basic and diluted earnings per share for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator for basic and diluted earnings per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">610,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Denominator for basic earnings per share – weighted-average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,358,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,297,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of dilutive securities employee stock options and restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Denominator for diluted earnings per share – adjusted weighted-average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,393,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Earnings per common share- basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Earnings per common share- diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Business segment information</b> - Based on the guidance provided in accordance with ASC <em style="font: inherit;">280</em> <i>Segment Reporting</i> (“ASC <em style="font: inherit;">280”</em>), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are <span style="background-color:#ffffff;">two reportable segments, leasing and retail. During <em style="font: inherit;">2023,</em> t</span>he Company provided Gamma Knife and PBRT equipment to <em style="font: inherit;">thirteen</em> hospitals in the United States and owns and operates <em style="font: inherit;">two</em> single-unit facilities in Lima, Peru and Guayaquil, Ecuador as of <em style="font: inherit;"> December 31, 2023</em>. <span style="background-color:#ffffff">An operating segment is defined by ASC <em style="font: inherit;">280</em> as it engages in business activities in which it <em style="font: inherit;"> may </em>recognize revenues and incur expenses, its operating results are regularly reviewed by the </span>Company’s Chief Operating Decision Maker (“CODM”), and its discrete financial information is available. The Company determined <em style="font: inherit;">two</em> reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the <em style="font: inherit;">two</em> reportable segments are reviewed by the Company’s Executive Chairman of the Board, who is also the CODM.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><span style="background-color:#ffffff;">, the </span>Company’s<span style="background-color:#ffffff;"> PBRT operations represented a significant majority of the net income attributable to American Shared Hospital Services from the leasing segment, disclosed below.</span> The revenues, depreciation, interest expense, interest income, tax expense, and net income attributable to American Shared Hospital Services, and total asset allocations for the Company’s two reportable segments as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em> consists of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,772,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,655,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,553,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,091,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,325,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,746,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,429,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,268,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">736,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">515,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,165,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,783,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,087,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">806,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,112,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">806,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">458,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">458,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">103,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">753,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">125,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income attributable to American Shared Hospital Services</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">518,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,187,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">92,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">610,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39,854,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,575,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,308,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,381,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,162,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,956,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Long lived asset impairment</b> – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Such events or changes in circumstances <em style="font: inherit;"> may </em>include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than <em style="font: inherit;">not,</em> a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. As of <em style="font: inherit;"> December 31, 2023</em>, impairment of $650,000 was recorded related to cash flow losses of <em style="font: inherit;">one</em> of the Company’s Gamma Knife units.  <em style="font: inherit;">No</em> impairment was recorded as of <em style="font: inherit;"> December 31, 2022. </em>See Note <em style="font: inherit;">3</em> - Property and Equipment for further discussion.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Goodwill and intangible assets - </b>The Company recorded goodwill of $1,265,000 and an intangible asset with a fair value of $78,000 as part of the acquisition of GKCE in <em style="font: inherit;"> June 2020. </em>The intangible asset identified was GKCE’s trade name and the Company assigned an indefinite useful life to the asset. Based on the guidance provided in accordance with ASC <em style="font: inherit;">350</em> <i>Intangibles-Goodwill and Other</i> (“ASC <em style="font: inherit;">350”</em>), the Company does <em style="font: inherit;">not</em> amortize the intangible asset because it has an indefinite life. The Company assesses goodwill at the reporting unit level, which has been determined to be GKCE. Each reporting period, the Company assesses whether events or circumstances continue to support an indefinite useful life for the intangible asset. Per ASC <em style="font: inherit;">350,</em> the Company tests goodwill and intangibles for impairment annually or as events or circumstances change that indicate the fair value <em style="font: inherit;"> may </em>be below the carrying amount. As of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em>, there has been no change to the Company's assessment of the value of intangible assets or goodwill.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accounting pronouncements issued and</b> <b><em style="font: inherit;">not</em></b> <b>yet adopted -</b> In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures </i>(“ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07”</em>) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses.  The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance.  ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company is currently evaluating ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> to determine the impact it <em style="font: inherit;"> may </em>have on its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> <i>Income Taxes (Topic <em style="font: inherit;">740</em>) Improvements to Income Tax Disclosures</i> (“ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09”</em>) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign.  ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> is effective for annual periods beginning after <em style="font: inherit;"> December 31, 2024.  </em>The Company is currently evaluating ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> to determine the impact it <em style="font: inherit;"> may </em>have on its consolidated financial statements. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;"><b></b><b>Reclassifications</b> - Certain comparative balances as of and for the year ended have been reclassified to make them consistent with the current year presentation.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of estimates in the preparation of financial statements</b> – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the estimated useful lives of property and equipment and its salvage values, revenues and costs of sales for revenue sharing customers.  Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Advertising and marketing</b> – The Company expenses advertising and marketing costs as incurre<span style="background-color:#ffffff;">d (collectively, </span>“<span style="background-color:#ffffff;">marketing costs”). Marketing costs were </span>$165,000 and $233,000 during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. Marketing costs include joint marketing with customers and corporate advertising costs. Marketing costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of income. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Sales and Service</b> – The Company markets its financial and turn-key solutions directly to cancer treatment centers, hospitals, and large cancer networks worldwide through its sales staff.  Sales expense includes payroll and travel costs for the Company’s sales staff. The Company also typically provides the equipment, as well as planning, installation, reimbursement and marketing support services to its customers.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 165000 233000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Cash and cash equivalents</b> – The Company considers all liquid investments with original maturities of <em style="font: inherit;">three</em> months or less at the date of purchase to be cash equivalents. Restricted cash is <em style="font: inherit;">not</em> considered a cash equivalent for purposes of the consolidated statements of cash flows.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Restricted cash</b> – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement and the minimum cash that must be maintained <span style="background-color:#ffffff;">by GKF per it’s financing agreement with the United </span>States International Development Finance Corporation (“D<span style="background-color:#ffffff;">FC”).  </span>See further discussion at Note <em style="font: inherit;">5</em> - Long Term Debt.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Business and credit risk</b> – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. The Company believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk on cash and cash equivalents. The Company monitors the financial condition of the financial institutions it uses on a regular basis.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All of the Company’s revenue was provided by 15 locations or <em style="font: inherit;">1</em> PBRT unit and <em style="font: inherit;">14</em> Gamma Knife units in each of <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em>. One location accounted for approximately 48% and 45% of the Company’s total revenue in <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em>, respectively. At <em style="font: inherit;"> December 31, 2023</em>, two locations each individually accounted for 30% and 31% of total accounts receivable, respectively. At <em style="font: inherit;"> December 31, 2022</em>, four locations each individually accounted for 12%, 14%, 16% and 22% of total accounts receivable, respectively. The Company performs credit evaluations of its customers and generally does <em style="font: inherit;">not</em> require collateral. The Company has <em style="font: inherit;">not</em> experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All of the Company’s radiosurgery devices have been purchased through Elekta, to date. However, there are other manufacturers that also make radiosurgery devices.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 15 0.48 0.45 2 0.30 0.31 4 0.12 0.14 0.16 0.22 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accounts receivable and allowance for credit losses</b> – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for expected losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are offset against bad debt expense when received.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Non-controlling interests</b> - The Company reports its non-controlling interests as a separate component of shareholders’ equity. Non-controlling interest is determined by the income (loss) multiplied by the non-controlling interest in subsidiaries, and the income or losses of the non-controlling interests in various subsidiaries controlled by GKF.  The Company also presents the consolidated net income and the portion of the consolidated net income (loss) allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Property and equipment</b> – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 10 years, and after accounting for salvage value on the equipment where applicable. The Company acquired a building as part of the acquisition of GKCE in <em style="font: inherit;"> June 2020. </em>Depreciation for buildings is determined using the straight-line method over 20 years. The Company determines salvage value based on the estimated fair value of the equipment at the end of its useful life. As of <em style="font: inherit;"> October 1, 2022, </em>the Company reduced its estimate for salvage value for <em style="font: inherit;">one</em> of its domestic Gamma Knife Perfexion units. As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company had <em style="font: inherit;">seven</em> domestic Gamma Knife units with salvage value ranging from $140,000 to $300,000. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> January 1, 2023, </em>the Company reduced its estimated useful life for <em style="font: inherit;">one</em> of its direct patient services Gamma Knife units. The net effect of the change in estimate made <em style="font: inherit;"> January 1, 2023, </em>for the year ended <em style="font: inherit;"> December 31, 2023</em>, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Depreciation for PBRT and related equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements accounted for as operating leases. At <em style="font: inherit;"> December 31, 2023</em>, the Company held equipment under operating lease contracts with customers with an original cost of $70,635,000 and accumulated depreciation of $52,302,000. At <em style="font: inherit;"> December 31, 2022</em>, the Company held equipment under operating lease contracts with customers with an original cost of $69,306,000 and accumulated depreciation of $47,992,000. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><span style="background-color:#ffffff;">, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. </span>During the year ended <em style="font: inherit;"> December 31, 2023</em>, the Company recorded an asset removal obligation (“ARO”) for <em style="font: inherit;">one</em> of the customer contracts that expired during <em style="font: inherit;">2023.</em>  An ARO for the <em style="font: inherit;">second</em> contract that expired during <em style="font: inherit;">2023</em> was recorded and impaired in a prior period. For the ARO recorded during <em style="font: inherit;">2023,</em> the Company concluded the related increase to the underlying assets could <em style="font: inherit;">not</em> be supported by the cash flows of the equipment and therefore the Company recorded a loss on the write-down of the ARO in <em style="font: inherit;"> June 2023. </em>The Company’s estimate for the ARO liability was subsequently adjusted during the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2023</em> based on new information. Total ARO impairment for the year ended <em style="font: inherit;"> December 31, 2023</em> was $290,000. The Company also reviewed its long-lived assets during the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2023</em> and concluded events and circumstances existed that indicated additional impairment existed at a <em style="font: inherit;">third</em> Gamma Knife site related to the existing equipment.  Total equipment impairment for the year ended <em style="font: inherit;"> December 31, 2023</em> was $650,000. <span style="background-color:#ffffff;">See further discussion under Note <em style="font: inherit;">2</em> - Long-lived asset impairment and Note <em style="font: inherit;">3</em> - Property and Equipment.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> P3Y P10Y P20Y 140000 300000 -207000 0.03 P20Y P20Y 70635000 52302000 69306000 47992000 -940000 -0 290000 650000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Revenue recognition</b> - The Company recognizes revenues under ASC <em style="font: inherit;">842</em> <i>Leases</i> (“ASC <em style="font: inherit;">842”</em>) and ASC <em style="font: inherit;">606</em> <i>Revenue from Contracts with Customers</i> (“ASC <em style="font: inherit;">606”</em>).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Rental income from medical equipment leasing (</i>“<i>leasing</i>”<i>)</i> – The Company recognizes leasing revenue under ASC <em style="font: inherit;">842</em> when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do <em style="font: inherit;">not</em> contain any guaranteed minimum payments. The Company’s lease contracts are typically for a <span style="-sec-ix-hidden:c109905373">ten</span>-year term and are classified as either fee per use or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s lease agreement with the Company. Revenues are recognized at the time the procedures are performed, based on each hospital’s contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company’s revenue sharing arrangements also have a cost sharing component and net profit share for the operating costs of the center. The Company receives payment from the hospital at an agreed upon percentage share of the hospital’s reimbursement from <em style="font: inherit;">third</em> party payors, and the Company is responsible for paying operating costs of the equipment determined primarily based on historical treatment protocols and cost schedules with the hospital. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs and profit. The operating costs and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. For the years ended, <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company recognized leasing revenue of approximately $17,772,000 and $16,655,000 under ASC <em style="font: inherit;">842,</em> respectively, of which approximately $10,133,000 and $8,952,000 were for PBRT services, respectively.</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-align: justify;"> </p> <div style="font-size:10pt"> <div style="font-family:Times New Roman"> <div style="font-variant: normal; text-align: justify;"> Revenue sharing arrangements amounted to approximately 70 <span style="background-color:#ffffff">%</span> and 67% of total revenue for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively. Because the revenue estimates are reviewed on a quarterly basis, any adjustments required for past revenue estimates would result in an increase or reduction in revenue during the current quarterly period.  Payor mix is a significant variable in the Company’s estimate for revenue sharing revenues.   </div> </div> </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Direct patient services income (</i>“<i>retail</i>”<i>)</i> – The Company has stand-alone facilities in Lima, Peru and Guayaquil, Ecuador, where a contract exists between the Company’s facilities and the individual patient treated at the facility. Under ASC <em style="font: inherit;">606,</em> the Company acts as the principal in this transaction and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife treatment. Revenue related to a Gamma Knife treatment is recognized on a gross basis at the time when the patient receives treatment. There is <em style="font: inherit;">no</em> variable consideration present in the Company’s performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net <em style="font: inherit;">30</em> days. GKCE’s patient population is primarily covered by a government payor and payments are paid between <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months, following issuance of invoice. The Company did <em style="font: inherit;">not</em> capitalize any incremental costs related to the fulfillment of its customer contracts. Accounts receivable under ASC <em style="font: inherit;">606</em> at <em style="font: inherit;"> December 31, 2023 </em>was $1,626,000. Accounts receivable under ASC <em style="font: inherit;">606</em> at <em style="font: inherit;"> January 1, 2022 </em>and <em style="font: inherit;"> December 31, 2022 </em>was $668,000 and $1,119,000. For the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company recognized retail revenues of approximately $3,553,000 and $3,091,000 under ASC <em style="font: inherit;">606,</em> respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Equipment sales</i> – During the year-ended <em style="font: inherit;"> December 31, 2023</em>, the Company completed a sale of equipment to a new customer.  The Company assessed this transaction under ASC <em style="font: inherit;">606</em> and concluded the Company acted as the agent in this transaction and provided, at a point in time, <em style="font: inherit;">two</em> performance obligations, in the form of an equipment sale of an Icon and Cobalt-<em style="font: inherit;">60</em> reload.  The performance obligation to sell, assign, transfer and deliver the equipment to the customer was carried out via Elekta.  Revenue related to the equipment sale is recognized on a net basis when the sale is complete.  The Company recognized net revenue of $200,000 on the sale of equipment for the year-ended <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 17772000 16655000 10133000 8952000 0.70 0.67 1626000 668000 1119000 3553000 3091000 200000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Stock-based compensation</b> – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note <em style="font: inherit;">8</em> - Stock-Based Compensation Expense for additional information on the Company’s stock-based compensation programs.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Costs of revenue </b>– The Company’s costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s revenue sharing and retail sites). Costs of revenue are recognized as incurred.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Income taxes</b> – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes as required by the provisions of ASC <em style="font: inherit;">740</em> <i>Income taxes</i> (“ASC <em style="font: inherit;">740”</em>), which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The <em style="font: inherit;">first</em> step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than <em style="font: inherit;">not</em> that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The <em style="font: inherit;">second</em> step is to estimate and measure the tax benefit as the largest amount that is more than <em style="font: inherit;">50%</em> likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires the Company to determine the probability of various possible outcomes. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which <em style="font: inherit;"> may </em>require periodic adjustments and <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> accurately anticipate actual outcomes.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">See Note <em style="font: inherit;">7</em> - Income Taxes for further discussion on income taxes.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Functional currency</b> – Based on guidance provided in accordance with ASC <em style="font: inherit;">830,</em> <i>Foreign Currency Matters</i> (“ASC <em style="font: inherit;">830”</em>), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will reassess its accounting for the operation to the local currency from the U.S. dollar. The Company analyzed it’s Gamma Knife site in Peru and its startup operations in Mexico for Puebla under ASC <em style="font: inherit;">830</em> as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> and concluded the functional currency was the U.S. dollar. As facts and circumstances change, the Company will revisit this conclusion.  The functional currency of the Company’s Gamma Knife site in Ecuador is the U.S. dollar because that is the local currency of Ecuador. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Asset Retirement Obligations </b>– Based on the guidance provided in ASC <em style="font: inherit;">410,</em> <i>Asset Retirement Obligations</i> (“ASC <em style="font: inherit;">410”</em>), the Company analyzed its existing lease agreements and determined whether an <span style="background-color:#ffffff">ARO</span> exists to remove the respective units at the end of the lease terms. As of <em style="font: inherit;"> December 31, 2023</em>, the Company has <em style="font: inherit;">two</em> AROs recorded for the two customer sites that expired during the year, totaling $650,000.  One ARO was recorded and impaired in a prior period.  The Company recorded and impaired an ARO for the <em style="font: inherit;">second</em> customer site during <em style="font: inherit;">2023.</em> No liability has been recorded as of <em style="font: inherit;"> December 31, 2023</em> for the remaining Gamma Knife or PBRT locations, because it is uncertain these units will be removed and the Company historically has <em style="font: inherit;">not</em> removed the equipment at the end of the lease term. The Company will re-evaluate the need to record additional ARO liabilities on a periodic basis when facts and circumstances change that could affect this conclusion.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 2 650000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Earnings per share</b> – The Company calculates diluted shares using the treasury stock method. Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units <em style="font: inherit;">not</em> issued and outstanding and unvested restricted stock units, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options and from unvested restricted stock units. The computation for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> excluded approximately <span style="-sec-ix-hidden:c109905429">144</span><span style="background-color:#ffffff;"><em style="font: inherit;">,000</em> and 20,000</span>, respectively, of the Company’s stock options because the exercise price of the options was higher than the average market price during the period. The weighted average common shares outstanding for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><br/> The following table illustrates the computations of basic and diluted earnings per share for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator for basic and diluted earnings per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">610,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Denominator for basic earnings per share – weighted-average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,358,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,297,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of dilutive securities employee stock options and restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Denominator for diluted earnings per share – adjusted weighted-average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,393,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Earnings per common share- basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Earnings per common share- diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 20000 123000 123000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator for basic and diluted earnings per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">610,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Denominator for basic earnings per share – weighted-average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,358,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,297,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of dilutive securities employee stock options and restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Denominator for diluted earnings per share – adjusted weighted-average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,393,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Earnings per common share- basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Earnings per common share- diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 610000 1328000 6358000 6297000 35000 6000 6393000 6303000 0.1 0.21 0.1 0.21 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Business segment information</b> - Based on the guidance provided in accordance with ASC <em style="font: inherit;">280</em> <i>Segment Reporting</i> (“ASC <em style="font: inherit;">280”</em>), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are <span style="background-color:#ffffff;">two reportable segments, leasing and retail. During <em style="font: inherit;">2023,</em> t</span>he Company provided Gamma Knife and PBRT equipment to <em style="font: inherit;">thirteen</em> hospitals in the United States and owns and operates <em style="font: inherit;">two</em> single-unit facilities in Lima, Peru and Guayaquil, Ecuador as of <em style="font: inherit;"> December 31, 2023</em>. <span style="background-color:#ffffff">An operating segment is defined by ASC <em style="font: inherit;">280</em> as it engages in business activities in which it <em style="font: inherit;"> may </em>recognize revenues and incur expenses, its operating results are regularly reviewed by the </span>Company’s Chief Operating Decision Maker (“CODM”), and its discrete financial information is available. The Company determined <em style="font: inherit;">two</em> reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the <em style="font: inherit;">two</em> reportable segments are reviewed by the Company’s Executive Chairman of the Board, who is also the CODM.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><span style="background-color:#ffffff;">, the </span>Company’s<span style="background-color:#ffffff;"> PBRT operations represented a significant majority of the net income attributable to American Shared Hospital Services from the leasing segment, disclosed below.</span> The revenues, depreciation, interest expense, interest income, tax expense, and net income attributable to American Shared Hospital Services, and total asset allocations for the Company’s two reportable segments as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em> consists of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,772,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,655,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,553,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,091,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,325,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,746,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,429,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,268,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">736,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">515,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,165,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,783,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,087,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">806,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,112,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">806,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">458,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">458,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">103,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">753,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">125,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income attributable to American Shared Hospital Services</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">518,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,187,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">92,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">610,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39,854,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,575,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,308,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,381,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,162,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,956,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2 2 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,772,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,655,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,553,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,091,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,325,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,746,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 17772000 16655000 3553000 3091000 21325000 19746000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,429,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,268,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">736,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">515,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,165,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,783,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,087,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">806,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,112,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">806,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">458,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">458,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">103,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">753,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">125,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 4429000 4268000 736000 515000 5165000 4783000 1087000 806000 25000 0 1112000 806000 458000 103000 0 0 458000 103000 306000 753000 125000 210000 431000 963000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income attributable to American Shared Hospital Services</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">518,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,187,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">92,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">610,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 518000 1187000 92000 141000 610000 1328000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Leasing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">39,854,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,575,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Retail</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,308,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,381,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,162,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,956,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 39854000 37575000 8308000 6381000 48162000 43956000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Long lived asset impairment</b> – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Such events or changes in circumstances <em style="font: inherit;"> may </em>include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than <em style="font: inherit;">not,</em> a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. As of <em style="font: inherit;"> December 31, 2023</em>, impairment of $650,000 was recorded related to cash flow losses of <em style="font: inherit;">one</em> of the Company’s Gamma Knife units.  <em style="font: inherit;">No</em> impairment was recorded as of <em style="font: inherit;"> December 31, 2022. </em>See Note <em style="font: inherit;">3</em> - Property and Equipment for further discussion.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 650000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Goodwill and intangible assets - </b>The Company recorded goodwill of $1,265,000 and an intangible asset with a fair value of $78,000 as part of the acquisition of GKCE in <em style="font: inherit;"> June 2020. </em>The intangible asset identified was GKCE’s trade name and the Company assigned an indefinite useful life to the asset. Based on the guidance provided in accordance with ASC <em style="font: inherit;">350</em> <i>Intangibles-Goodwill and Other</i> (“ASC <em style="font: inherit;">350”</em>), the Company does <em style="font: inherit;">not</em> amortize the intangible asset because it has an indefinite life. The Company assesses goodwill at the reporting unit level, which has been determined to be GKCE. Each reporting period, the Company assesses whether events or circumstances continue to support an indefinite useful life for the intangible asset. Per ASC <em style="font: inherit;">350,</em> the Company tests goodwill and intangibles for impairment annually or as events or circumstances change that indicate the fair value <em style="font: inherit;"> may </em>be below the carrying amount. As of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em>, there has been no change to the Company's assessment of the value of intangible assets or goodwill.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 1265000 78000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accounting pronouncements issued and</b> <b><em style="font: inherit;">not</em></b> <b>yet adopted -</b> In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures </i>(“ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07”</em>) which enhances the disclosure requirements for segment reporting, primarily disclosures around significant segment expenses.  The key provisions of the amendments require disclosure of significant segment expense reviewed by the CODM, require disclosure of an “other” segment category, require disclosure of segment profit or loss and assets for interim periods, clarify and require disclosure of other measurements used by the CODM in assessing segment performance and allocating resources, and require disclosure of the CODM's title and position and explanation of how the CODM assesses segment performance.  ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company is currently evaluating ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> to determine the impact it <em style="font: inherit;"> may </em>have on its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> <i>Income Taxes (Topic <em style="font: inherit;">740</em>) Improvements to Income Tax Disclosures</i> (“ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09”</em>) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign.  ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> is effective for annual periods beginning after <em style="font: inherit;"> December 31, 2024.  </em>The Company is currently evaluating ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> to determine the impact it <em style="font: inherit;"> may </em>have on its consolidated financial statements. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <b>Reclassifications</b> - Certain comparative balances as of and for the year ended have been reclassified to make them consistent with the current year presentation. <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">3</em> </b>–<b> PROPERTY AND EQUIPMENT</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Property and equipment consists of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical equipment and facilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,150,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73,709,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">306,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">422,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in progress</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,771,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,227,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74,237,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55,383,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50,770,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,844,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,467,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em>, approximately $3,966,000 and $2,201,000, respectively, of the net property and equipment balance is outside of the United States.  Depreciation expense recorded in costs of revenue and selling and administrative expense in the consolidated statements of income for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><span style="background-color:#ffffff">, was $5,165,000 and $4,783,000, respectively.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> October 1, 2022, </em>the Company reduced its estimate for salvage value for <em style="font: inherit;">one</em> of its domestic Gamma Knife Perfexion units.  As of <em style="font: inherit;"> January 1, 2023, </em>the Company reduced its estimated useful life for <em style="font: inherit;">one</em> of its direct patient services Gamma Knife units. The net effect of the change in estimate made <em style="font: inherit;"> January 1, 2023, </em>for the year ended <em style="font: inherit;"> December 31, 2023</em>, was a decrease in net income of approximately $207,000 or $0.03 per diluted share. This change in estimate also impacts future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff">As of </span><em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><span style="background-color:#ffffff">, the Company recognized a loss on the write down of impaired assets of $940,000 and $0, respectively. The impairment as of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff"> was </span>related to cash flow impairment for <em style="font: inherit;">one</em> of the Company’s Gamma Knife units and estimated removal costs of the <em style="font: inherit;">two</em> Gamma Knife contracts that expired during the year<span style="background-color:#ffffff">. </span>The Company reviewed its Gamma Knife equipment, in light of available information as of <em style="font: inherit;"> December 31, 2022 </em>and concluded <em style="font: inherit;">no</em> impairment existed. The Company reviewed it’s PBRT equipment, in light of available information as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em> and concluded no impairment exists.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical equipment and facilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,150,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73,709,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">306,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">422,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in progress</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,771,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,227,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74,237,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55,383,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50,770,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,844,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,467,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 77150000 73709000 306000 422000 3771000 106000 81227000 74237000 55383000 50770000 25844000 23467000 3966000 2201000 5165000 4783000 -207000 0.03 -940000 -0 0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>NOTE <em style="font: inherit;">4</em> - OTHER ACCRUED LIABILITIES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Other accrued liabilities consists of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Insurance financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">591,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">472,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">450,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">539,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">322,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,226,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,544,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Insurance financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">591,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">472,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">450,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">539,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">322,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,226,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,544,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 0 591000 472000 92000 450000 539000 304000 322000 1226000 1544000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">5</em> - LONG TERM DEBT</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> April 9, 2021 </em>the Company along with certain of its domestic subsidiaries (collectively, the “Loan Parties”) entered into a <span style="-sec-ix-hidden:c109905507">five</span> year $22,000,000 credit agreement with Fifth Third Bank, N.A. (“the Credit Agreement”). The Credit Agreement includes <span style="-sec-ix-hidden:c109905509">three</span> loan facilities. The <em style="font: inherit;">first</em> loan facility is a $9,500,000 term loan (the “Term Loan”) which was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs. The <em style="font: inherit;">second</em> loan facility is a $5,500,000 delayed draw term loan (the “DDTL”) which was used to refinance the Company’s PBRT finance leases and associated closing costs, as well as to provide additional working capital. The <em style="font: inherit;">third</em> loan facility provides for a $7,000,000 revolving line of credit (the “Revolving Line”) available for future projects and general corporate purposes. The Company borrowed $2,500,000 on the Revolving Line as of <em style="font: inherit;"> December 31, 2023</em>, which was paid off in <em style="font: inherit;"> January 2024.  </em>The facilities have a <span style="-sec-ix-hidden:c109905517">five</span>-year maturity, carry a floating interest of LIBOR plus 3.0% and are secured by a lien on substantially all of the assets of the Loan Parties and guaranteed by ASHS.  The long-term debt on the consolidated balance sheets related to the Term Loan and DDTL was $10,825,000 and $12,624,000 as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Revolving Line is charged an unused line fee of 0.25% per annum. The Term Loan and DDTL have interest and principal payments due quarterly. Principal amortization on an annual basis for the Term Loan and DDTL equates to 48% of the original principal loan commitments in years <em style="font: inherit;">one</em> through <em style="font: inherit;">five</em> and an end of term payment of the remaining principal balance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">The Credit Agreement contains customary covenants and representations, including without limitation, a minimum fixed charge coverage ratio of 1.25 and maximum funded debt to EBITDA ratio of 3.0 to <em style="font: inherit;">1.0</em> (tested on a trailing <em style="font: inherit;">twelve</em>-month basis at the end of each fiscal quarter), reporting obligations, limitations on dispositions, changes in ownership, mergers and acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and capital expenditures.  The Loan Parties are in compliance with the Credit Agreement covenants as of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">. </span>On <em style="font: inherit;"> January 25, 2024, </em>the Company amended its Credit Agreement to include financing for the equipment in Puebla, see Note <em style="font: inherit;">12</em> - Subsequent Event for further information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The loan entered into with DFC in connection with the acquisition of GKCE in <em style="font: inherit;"> June 2020 </em><i>(</i>the “DFC Loan”) was obtained through the Company’s wholly-owned subsidiary, HoldCo, and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE’s assets. The <em style="font: inherit;">first</em> tranche of the DFC Loan was funded in <em style="font: inherit;"> June 2020. </em>During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2023,</em> the <em style="font: inherit;">second</em> tranche of the DFC loan was funded to finance the equipment upgrade in Ecuador. The amount outstanding under the <em style="font: inherit;">first</em> tranche of the DFC Loan is payable in <em style="font: inherit;">29</em> quarterly installments with a fixed interest rate of 3.67%.  The amount outstanding under the <em style="font: inherit;">second</em> tranche of the DFC Loan is payable in <em style="font: inherit;">16</em> quarterly installments with a fixed interest rate of 7.49%. The long-term debt on the consolidated balance sheets related to the DFC loan was $2,464,000 and $1,041,000 as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.  The Company capitalized debt issuance costs of $9,000 and $9,000 as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively, related to maintenance and administrative fees on the DFC Loan.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The DFC Loan contains customary covenants among other covenants and obligations, requirements that the Company maintain certain financial ratios related to liquidity and cash flow as well as depository requirements.  On <em style="font: inherit;"> March 28, 2024 </em>the Company received a waiver and amendment from DFC for certain covenants as of <em style="font: inherit;"> December 31, 2023 </em>and through <em style="font: inherit;"> December 31, 2024 </em>and amended other covenants and definitions permanently. The Company expects to be in compliance with all debt covenants pursuant to the DFC Loan as amended and waived at <em style="font: inherit;"> March 31, 2024.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The accretion of debt issuance costs for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, was $46,000 and $84,000, respectively. As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the unamortized debt issuance costs on the consolidated balances sheets were $164,000 and $198,000.  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The following are contractual maturities of long-term debt by year at <em style="font: inherit;"> December 31, 2023</em>, excluding debt issuance costs of $164,000:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year ending December 31,</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Principal</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,157,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,907,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,732,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">493,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,289,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> 22000000 9500000 5500000 7000000 2500000 0.03 10825000 12624000 0.0025 0.48 1.25 3 0.0367 0.0749 2464000 1041000 9000 9000 46000 84000 164000 198000 164000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year ending December 31,</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Principal</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,157,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,907,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,732,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">493,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,289,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 2157000 2907000 7732000 493000 13289000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">6</em> - LEASES</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company determines if a contract is a lease at inception. Under ASC <em style="font: inherit;">842,</em> the Company is a lessor of equipment to various customers. Leases that commenced prior to ASC <em style="font: inherit;">842</em> adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing it to <em style="font: inherit;">not</em> reassess lease classification, these leases are classified as operating leases under ASC <em style="font: inherit;">842</em> as well. All of the Company’s lessor arrangements entered into after ASC <em style="font: inherit;">842</em> adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do <em style="font: inherit;">not</em> contain the option to terminate early or purchase the asset at the end of the term. The Company has elected <em style="font: inherit;">not</em> to recognize right-of-use (“ROU”) assets and lease liabilities that arise from short-term (<em style="font: inherit;">12</em> months or less) leases for any class of underlying asset.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s Gamma Knife and PBRT contracts with hospitals are classified as operating leases under ASC <em style="font: inherit;">842.</em> The related equipment is included in medical equipment and facilities on the Company’s consolidated balance sheets (see further discussion at Note <em style="font: inherit;">2</em>). As all income from the Company’s lessor arrangements is solely based on procedure volume, all income is considered variable payments <em style="font: inherit;">not</em> dependent on an index or a rate. As such, the Company does <em style="font: inherit;">not</em> measure future operating lease receivables.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> November 3, 2021, </em>the Company entered into an agreement to sublease (the “Sublease”) its corporate office located at Two Embarcadero Center, Suite <em style="font: inherit;">410,</em> San Francisco, California, where it leased approximately 3,253 square feet for $22,011 per month. The lease expired in <em style="font: inherit;"> August 2023. </em>The Sublease was for $16,195 per month through the existing contract expiration date. The Company also entered into a lease (the “Lease”) agreement for new corporate office space at <em style="font: inherit;">601</em> Montgomery, Suite <em style="font: inherit;">1112,</em> San Francisco, CA for approximately 900 square feet for $4,500 per month with a lease expiration date in <em style="font: inherit;"> November 2024.  </em>The Company assessed the Lease under ASC <em style="font: inherit;">842</em> and concluded the Lease should be classified as an operating lease. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s lessee operating leases are accounted for as ROU assets, current portion of lease liabilities, and lease liabilities on the consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company’s operating lease contracts do <em style="font: inherit;">not</em> provide an implicit rate for calculating the present value of future lease payments, so the Company determined its incremental borrowing rate to be in the range of approximately 4.0% and 6.0% by using available market rates and expected lease terms. The operating lease ROU assets and liabilities also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company’s lessee operating lease agreements are for administrative office space and related equipment, and the agreement to lease clinic space for its stand-alone facility in Lima, Peru. These leases have remaining lease terms of approximately 1 year, some of which include options to renew or extend the lease. As of <em style="font: inherit;"> December 31, 2023</em>, operating ROU assets and lease liabilities were $57,000.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes maturities of lessee operating lease liabilities as of <em style="font: inherit;"> December 31, 2023</em>:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ending December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Operating Leases</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">58,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Lease cost</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost, net of impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">302,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">406,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(129,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(174,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other information</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of lease liabilities - Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">302,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">406,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term - Operating leases in years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate - Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div style="font-size:10pt"> <div style="font-family:Times New Roman"> <div style="font-variant: normal; text-align: justify;"> The Company’s corporate offices are located at <em style="font: inherit;">601</em> Montgomery Street, Suite <em style="font: inherit;">1112,</em> San Francisco, California, where it leases approximately 900 square feet for $4,500 per month with a lease expiration date in <em style="font: inherit;"> November 2024. </em>The Company subleased its existing corporate offices located at Two Embarcadero Center, Suite <em style="font: inherit;">410,</em> San Francisco, California, where it leased approximately 3,253 square feet for <span style="background-color:#ffffff">$22,011</span> per month.  This lease expired in <em style="font: inherit;"> August 2023. </em>The monthly lease expense was offset by sublease income of $16,195. The sublease term was consistent with the existing lease term. The Company owns and operates a stand-alone Gamma Knife facility in Lima, Peru where it leases approximately 1,600 square feet for approximately <span style="background-color:#ffffff">$8,850</span> per month with a lease expiration date in <em style="font: inherit;"> January 2024. </em>The lease in Peru is currently on a month-to-month basis. The Company also owns and operates a stand-alone Gamma Knife facility in Guayaquil, Ecuador where it owns 864 square feet of condominium space in an office building and approximately 10,135 of related land and parking spaces. </div> </div> </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"> </p> <div style="font-size:10pt"> <div style="font-family:Times New Roman"> <div style="font-variant:normal"> Net rent expense was $234,000 and $290,000 for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively, and includes the above operating leases as well as month-to-month rental and certain executory costs.  </div> </div> </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> 3253 22011 16195 900 4500 0.04 0.06 P1Y 57000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ending December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Operating Leases</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">58,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 58000 58000 1000 57000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Lease cost</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost, net of impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">302,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">406,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(129,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(174,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">232,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other information</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of lease liabilities - Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">302,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">406,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term - Operating leases in years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate - Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> 302000 406000 129000 174000 173000 232000 302000 406000 P0Y9M18D P1Y1M9D 0.0465 0.0565 900 4500 3253 22011 16195 1600 8850 864 10135 234000 290000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">7</em> </b>–<b> INCOME TAXES</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The components of income before income taxes for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">666,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,350,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">696,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,518,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the year ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, the Company recorded an income tax expense of $431,000 and $963,000, respectively. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The components of the provision for income taxes for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> consists of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">940,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">355,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">135,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">204,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,190,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">619,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(672,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">290,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(77,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(759,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">344,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Significant components of the Company’s deferred tax liabilities and assets as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 0pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(323,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(708,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(409,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(493,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 9pt;">ROU asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(12,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(54,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(744,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,255,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">155,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals and allowances</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">438,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">167,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">12,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">61,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">114,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capital loss carryover</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">646,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">646,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,395,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,130,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(714,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(697,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets net of valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">681,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">433,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(63,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(822,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">7</em> </b>–<b> INCOME TAXES (CONTINUED)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em>) to income before taxes as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computed expected federal income tax</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">218,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">477,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">38,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">7,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-deductible expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Return to provision true-up</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Alternative minimum tax payable adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">208,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other deferred tax adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2023</em>, the Company has net operating loss carryforwards for federal and state income tax return purposes of appr<span style="background-color:#ffffff;">oximately </span>$0<span style="background-color:#ffffff;"> and $2,586,000</span> that begin to expire in <em style="font: inherit;">2029.</em> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Utilization of the net operating loss and credit carryforwards <em style="font: inherit;"> may </em>be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (the “Code”), and similar state provisions. Any annual limitation <em style="font: inherit;"> may </em>result in the expiration of net operating losses and credits before utilization.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">At <em style="font: inherit;"> December 31, 2023</em>, the Company has a capital loss carryforward for federal income tax return purposes of approximately $2,679,000,which start to expire in <em style="font: inherit;">2024.</em> The Company has capital loss carryforwards for state income tax purposes of approximately $129,000, which starts to expire in <em style="font: inherit;">2024.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Due to uncertainty surrounding the realization of impairment losses, capital losses and foreign operating losses in future years, the Company has placed a valuation allowance against a portion of its net domestic and foreign deferred tax assets. The net valuation allowance increased by $17,000 and $0 for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The tax return years <em style="font: inherit;">2019</em> through <em style="font: inherit;">2022</em> remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for calendar years <em style="font: inherit;">1999</em> through <em style="font: inherit;">2004,</em> <em style="font: inherit;">2009,</em> <em style="font: inherit;">2010,</em> <em style="font: inherit;">2012,</em> <em style="font: inherit;">2014,</em> <em style="font: inherit;">2015,</em> <em style="font: inherit;">2016,</em> <em style="font: inherit;">2017</em> and <em style="font: inherit;">2018</em> remain open to examination by the major domestic taxing jurisdictions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">7</em> </b>–<b> INCOME TAXES (CONTINUED)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has adopted accounting standards which prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company<span style="background-color:#ffffff">’</span>s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Additionally, these accounting standards specify that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company has made <em style="font: inherit;">no</em> reclassifications between current taxes payable and long term taxes payable under this guidance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2023</em>, the unrecognized tax benefit was $287,000 which, if recognized, will <em style="font: inherit;">not</em> affect the annual effective tax rate as these unrecognized tax benefits would increase deferred tax assets, which would be subject to a full valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">295,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">287,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The <span style="background-color:#ffffff">Company’s</span> policy for deducting interest and penalties is to treat interest as interest expense and penalties as income taxes. As of <em style="font: inherit;"> December 31, 2023</em>, the Company had $58,000 accrued for the payment of penalties and zero interest related to unrecognized tax benefits. The Company does <em style="font: inherit;">not</em> expect any material changes to our uncertain tax positions within the next <em style="font: inherit;">12</em> months. The Company believes that it is reasonably possible that a decrease of up to $100,000 in unrecognized tax benefits related to foreign taxes <em style="font: inherit;"> may </em>be necessary within the coming year.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">666,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,350,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">696,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,518,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 666000 2350000 30000 168000 696000 2518000 431000 963000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">940,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">355,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">135,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">204,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,190,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">619,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(672,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">290,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(77,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(759,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">344,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 940000 355000 115000 60000 135000 204000 1190000 619000 -672000 290000 -77000 48000 -10000 6000 -759000 344000 431000 963000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 0pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(323,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(708,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(409,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(493,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 9pt;">ROU asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(12,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(54,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(744,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,255,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">155,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals and allowances</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">438,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">167,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">12,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">61,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">114,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capital loss carryover</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">646,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">646,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,395,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,130,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(714,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(697,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets net of valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">681,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">433,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(63,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(822,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 323000 708000 409000 493000 12000 54000 744000 1255000 155000 139000 438000 167000 12000 61000 4000 3000 140000 114000 646000 646000 1395000 1130000 714000 697000 681000 433000 63000 822000 0.21 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computed expected federal income tax</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">218,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">477,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">38,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">7,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-deductible expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Return to provision true-up</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Alternative minimum tax payable adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">208,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other deferred tax adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">431,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">963,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 218000 477000 12000 100000 38000 0 7000 0 6000 -25000 18000 52000 9000 -17000 0 208000 17000 0 106000 168000 431000 963000 0 2586000 2679000 129000 17000 0 287000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">YEARS ENDED December 31,</em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">295,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">287,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 278000 295000 9000 17000 287000 278000 58000 0 100000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">8</em> </b>–<b> STOCK-BASED COMPENSATION EXPENSE</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Incentive Compensation Plan</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">In <em style="font: inherit;"> June 2021, </em>the Company’s shareholders approved an amendment and restatement of the Company’s Incentive Compensation Plan (the “Plan”), that among other things, increases the number of shares of the Company’s common stock reserved for issuance under the Plan to 2,580,000 and extends the term of the Plan by <em style="font: inherit;">five</em> years to <em style="font: inherit;"> February 22, 2027. </em>The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. <em style="font: inherit;">No</em> further grants or share issuances will be made under the previous plans. As of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, approximately 935,000 shares remain available for grant under the Plan.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Under the Plan, a total of 898,000 restricted stock units have been granted, consisting o<span style="background-color:#ffffff;">f 53,000 o</span>f annual automatic grants to non-employee directors, 328,000 of deferred retainer fees to non-employee members of the Board, 57,000 grants issued in lieu of commission or bonus to employees of the Company, and 460,000 restricted stock units issued to the Executive Chairman of the Board, see further discussion below. Of the total restricted stock units granted under the Plan, 123,000 of them are fully vested but <em style="font: inherit;">not</em> yet deemed issued and outstanding, <span style="-sec-ix-hidden:c109905661">742</span><span style="background-color:#ffffff;"><em style="font: inherit;">,000</em></span> are fully vested and outstanding, and 33,000 are outstanding as of <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Changes in restricted stock units, consisting primarily of annual automatic grants, deferred compensation to non-employee directors, shares issued to employees as part of the <span style="background-color:#ffffff">Company’s</span> bonus plan, and restricted stock units awards to the Executive Chairman of the Board, under the Incentive Compensation Plans during <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Restricted Stock Units</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Grant Date Weighted- Average Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at January 1, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905165">$ 2.57</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">131,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905167">$ 2.40</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905168">(132,000)</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905169">$ 2.40</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905170">(3,000)</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905171">$ 2.92</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905173">$ 2.33</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">146,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905175">$ 2.97</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905176">(119,000)</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905177">$ 2.94</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905179">$ 2.88</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE <em style="font: inherit;">8</em> </b>–<b> STOCK-BASED COMPENSATION EXPENSE (CONTINUED)</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Certain Executive Equity Awards</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Effective <em style="font: inherit;"> May 4, 2020, </em>the Company appointed Raymond C. Stachowiak as Interim President and Chief Executive Officer (<span style="background-color:#ffffff">“CEO”</span>). Pursuant to his Offer Letter, Mr. Stachowiak was granted 50,000 restricted stock awards that vested in full on <em style="font: inherit;"> August 3, 2020. </em>He was granted additional restricted stock awards totaling 10,000 common shares per month, which vested in full at the end of each 30-day period following issuance. Mr. Stachowiak became CEO of the Company on <em style="font: inherit;"> October 1, 2020 </em>and served in such position until he was appointed Executive Chairman of the Board on <em style="font: inherit;"> March 7, 2023. </em>For the year ended <em style="font: inherit;"> December 31, 2022</em>, 120,000 restricted stock awards were issued to Mr. Stachowiak and became fully vested. Total compensation expense recorded for the year ended <em style="font: inherit;"> December 31, 2022</em> in the consolidated financial statements of income related to executive equity awards was $288,000.  For the year ended <em style="font: inherit;"> December 31, 2023</em>, 120,000 restricted stock awards were issued to Mr. Stachowiak and 90,000 became fully vested.  Total compensation expense recorded for the year ended <em style="font: inherit;"> December 31, 2023</em> in the consolidated financial statements of income related to the executive equity awards was $351,000.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the year ended <em style="font: inherit;"> December 31, 2023</em>, stock compensation expense recorded in the consolidated financial statements is summarized as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock-Based</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Awards Issued</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Compensation</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">and Vested</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Expense</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">34,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Management Bonus Program - vested and issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Board RSU Awards - other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Executive Compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">351,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">389,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Total stock-based compensation expense before income tax effect for the Company’s options and restricted stock awards in the amount of $389,000 and $399,000 for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em>, is reflected in selling and administrative expense in the consolidated statements of income, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Stock Options</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Changes in stock options outstanding under the Incentive Compensation Plans during <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">67,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE <em style="font: inherit;">8</em> </b>–<b> STOCK-BASED COMPENSATION EXPENSE (CONTINUED)</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The weighted average grant-date fair value of the options granted during the years <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> was <span style="background-color:#ffffff;">$2.89 </span>and <span style="font-size: 10pt; background-color: rgb(255, 255, 255);">$1.49</span>, respectively. There were no options exercised during the year ended <em style="font: inherit;"> December 31, 2023</em>. There were 4,000 options exercised which resulted in 3,000 shares issued, due to cashless exercises, during the year ended <em style="font: inherit;"> December 31, 2022</em>. Total stock-based compensation expense recognized for stock options for the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> was $34,000 and <span style="-sec-ix-hidden:c109905693">$10,000,</span> respectively.</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company received approximately $5,000 from the exercise of 2,000 options under the share-based arrangements during the year ended <em style="font: inherit;"> December 31, 2022</em>. The remaining options exercised during <em style="font: inherit;">2022</em> were cashless exercises. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At <em style="font: inherit;"> December 31, 2023</em>, there was approximately<span style="background-color:#ffffff;"> $156,000 </span>of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a period of approximately <span style="-sec-ix-hidden:c109905698">four</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s stock option awards to employees are calculated using the Black-Scholes options valuation model. The Black-Scholes model was developed for use in estimating the fair value of traded options which have <em style="font: inherit;">no</em> vesting restrictions and are fully transferable. In addition, the Black-Scholes model requires the input of highly subjective assumptions including the expected stock price volatility. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. For these reasons, management believes that the existing models do <em style="font: inherit;">not</em> necessarily provide a reliable single measure of the fair value of its stock-based awards to employees.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of the Company’s option grants issued during <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> were estimated using assumptions for expected life, volatility, dividend yield, forfeiture rate, and risk-free interest rate which are specific to each award as summarized in the following table. The estimated fair value of the Company’s options is amortized over the period during which the optionee is required to provide service in exchange for the award, usually the vesting period.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of the Compan<span style="background-color:#ffffff;">y’s option grants under the Plan in </span><em style="font: inherit;">2023</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;">2022</em><span style="background-color:#ffffff;"> was estimated using the following assumptions:</span></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected forfeiture rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">The following summarizes the assumption inputs used for the Company’s Black-Scholes calculation:</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"> </p> <div style="font-size: 10pt; text-align: justify;"> Expected life (years): The expected term represents the weighted average period that the Company’s stock options are expected to be outstanding.   </div> <div style="font-size: 10pt; text-align: justify;">   </div> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Expected forfeiture rate: Forfeitures are recognized as they occur.   </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Expected volatility: The expected volatility was derived from the Company’s historical stock volatility. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Dividend yield: The expected dividend yield was assumed to be zero, as the Company has <em style="font: inherit;">not</em> previously paid dividends on common stock and has <em style="font: inherit;">no</em> current plans to do so.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Risk-free interest rate:  The risk-free interest rate is based on the interest yield in effect at the date of grant for <em style="font: inherit;">zero</em> coupon U.S. Treasury notes with maturities approximately equal to the option’s expected term.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Repurchase of Common Stock, Common Stock Warrants and Stock Options</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;">1999</em> and <em style="font: inherit;">2001,</em> the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in <em style="font: inherit;">2008.</em> There were no shares of the Company repurchased during <em style="font: inherit;">2023</em> or <em style="font: inherit;">2022</em>. There are approximately 72,000 shares remaining under this repurchase authorization.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2580000 935000 898000 53000 328000 57000 460000 123000 33000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Restricted Stock Units</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Grant Date Weighted- Average Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at January 1, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905165">$ 2.57</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">131,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905167">$ 2.40</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905168">(132,000)</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905169">$ 2.40</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905170">(3,000)</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905171">$ 2.92</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905173">$ 2.33</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">146,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905175">$ 2.97</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905176">(119,000)</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905177">$ 2.94</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33,000</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="-sec-ix-hidden:c109905179">$ 2.88</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 10000 131000 6000 146000 33000 50000 10000 P30D 120000 288000 120000 90000 351000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock-Based</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Awards Issued</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Compensation</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">and Vested</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Expense</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">34,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Management Bonus Program - vested and issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Board RSU Awards - other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Executive Compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">351,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">389,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 34000 26000 4000 90000 351000 116000 389000 389000 399000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">67,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 67000 2.72 P3Y3M29D 0 50000 2.72 P7Y 4000 2.29 18000 2.64 95000 2.76 P4Y9M29D 25000 70000 2.89 P7Y 19000 2.69 146000 2.83 P5Y5M8D 0 38000 2.79 P2Y4M17D 31000 2.84 P3Y4M17D 2.89 1.49 0 4000 3000 34000 5000 2000 156000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected forfeiture rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> P7Y P7Y 0 0 0.50 0.50 0 0 0.036 0.033 1000000 0 72000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">9</em> </b>–<b> RETIREMENT PLAN</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has a defined-contribution retirement plan (the “Retirement Plan”) that allows for a matching safe harbor contribution. For <em style="font: inherit;">2023</em>, the Board of Directors elected to match participant deferred salary contributions up to a maximum of 4% of the participant’s annual compensation. Discretionary profit sharing contributions are allowed under the Retirement Plan in years that the Board does <em style="font: inherit;">not</em> elect a safe harbor match. During <em style="font: inherit;">2023,</em> the Company contributed $43,000 to the Retirement Plan for the safe harbor match for the year ended <em style="font: inherit;"> December 31, 2023</em>. The Company has accrued approximately $17,000 for additional safe harbor matching contribution for the year ended <em style="font: inherit;"> December 31, 2023</em>. Also during <em style="font: inherit;">2023,</em> the Company contributed $47,000 to the Retirement Plan for the safe harbor match for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 0.04 43000 17000 47000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">10</em> </b>–<b> COMMITMENTS AND CONTINGENCIES</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> December 20, 2018, </em>the Company signed Second Amendments to <em style="font: inherit;">two</em> System Build Agreements for the Company’s <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> Mevion PBRT units. These commitments expired in <em style="font: inherit;"> January 2024 </em>and the Company was <em style="font: inherit;">not</em> able to utilize this equipment. During the year-ended <em style="font: inherit;"> December 31, 2020, </em>the Company impaired these deposits and wrote-off the deposits and related capitalized interest. </p> <p style="margin: 0pt; text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2023</em>, the Company had commitments to install <em style="font: inherit;">three</em> Leksell Gamma Knife Esprit Systems (“Esprit”), install <em style="font: inherit;">one</em> Cobalt-<em style="font: inherit;">60</em> reload with software, purchase <em style="font: inherit;">one</em> Gamma Plan workstation, purchase <em style="font: inherit;">one</em> Linear Accelerator (“LINAC”) system, and purchase <em style="font: inherit;">one</em> Magnetic Resonance imaging guided LINAC (“MR LINAC”). The LINAC, MR LINAC and <em style="font: inherit;">one</em> Esprit will be placed at future customer sites. The remaining Esprit upgrades and Cobalt-<em style="font: inherit;">60</em> reload are scheduled to occur during <em style="font: inherit;">2024</em> at existing customer sites. The Company also has <em style="font: inherit;">one</em> commitment to de-install a Gamma Knife unit at an existing customer site. The <span style="background-color:#ffffff">Company’s</span> LINAC installation in Puebla was in process at <em style="font: inherit;"> December 31, 2023</em> and the Company made substantial payments towards the project during <em style="font: inherit;">2023.</em> In <em style="font: inherit;"> January 2024, </em>the Company amended the Credit Agreement to include financing for this project. At <em style="font: inherit;"> December 31, 2023</em>, the Company had commitments remaining for some of the ancillary equipment in Puebla. <span style="background-color:#ffffff;">Total Gamma Knife and LINAC commitments as of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, were $15,925,000. There are <em style="font: inherit;">no</em> deposits on the consolidated balance sheets related to these commitments as of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">.  It is the Company's intent to finance substantially all of these commitments.  There can be <em style="font: inherit;">no</em> assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company.  However, the Company currently has cash on hand of </span>$13,808,000<span style="background-color:#ffffff;"> and a line of credit of $7,000,000 to fund these projects, if necessary.  The Company borrowed $2,500,000 on the Revolving Line as of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, which was paid off in <em style="font: inherit;"> January 2024. </em></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> September 4, 2022, </em>the Company entered into a Maintenance and Support Agreement with Mevion (the “Mevion Service Agreement”), which provides for maintenance and support of the Company’s PBRT unit at Orlando Health from <em style="font: inherit;"> September 2022 </em>through <em style="font: inherit;"> April 2026.  </em>The agreement requires an annual prepayment of $1,865,000 for the current contractual period (<em style="font: inherit;">one</em> year). This payment portion was recorded as a prepaid contract and will be amortized over the <span style="-sec-ix-hidden:c109905750">one</span>-year service period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> December 31, 2023</em><span style="background-color:#ffffff;">, the Company had commitments to service and maintain its Gamma Knife and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta and Mobius Imaging, LLC. The Company’s commitments to purchase t</span>wo LINAC systems also include a 9-year and 5-year agreement to service the equipment, respectively. Total service commitments as of <em style="font: inherit;"> December 31, 2023</em> were $14,805,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s customer contracts generally contain mutual indemnification provisions. The Company maintains general and professional liability insurance in the United States. The Company is <em style="font: inherit;">not</em> involved in the practice of medicine and therefore believes its present insurance coverage and indemnification agreements are adequate for its business. The Company’s Peruvian and Ecuadorian Gamma Knife centers are free-standing facilities operated by GKPeru and GKCE, respectively. The treating physicians and clinical staff at these facilities are independent contractors. The Company maintains general and professional liability insurance consistent with the operations of these facilities and believes its present coverage is adequate for its business.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> 15925000 13808000 7000000 2500000 1865000 P9Y P5Y 14805000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="background-color:#ffffff;">NOTE <em style="font: inherit;">11</em> </span></b><span style="background-color:#ffffff;">–</span><b><span style="background-color:#ffffff;"> RELATED PARTY TRANSACTIONS</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife and other radiation therapy equipment. Since the Company purchases the majority of its equipment from Elekta, there are significant related party transactions with Elekta such as <span style="background-color:#ffffff;">equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment</span>. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following summarizes related party activity for the years ended <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em>:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment purchases and de-install costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,918,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,844,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Costs incurred to maintain equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,094,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total related party transactions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,769,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,938,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company had related party commitments to install <em style="font: inherit;">three</em> Esprit upgrades, <em style="font: inherit;">one</em> Cobalt-<em style="font: inherit;">60</em> reload, purchase <em style="font: inherit;">one</em> MR LINAC, purchase <em style="font: inherit;">one</em> Gamma Plan workstation, and service the related equipment. The Company also has <em style="font: inherit;">two</em> commitments to de-install Gamma Knife units at existing customer sites. Total related party commitments were $18,968,000 as of <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Related party liabilities on the consolidated balance sheets consist of the following as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em>:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable and other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,961,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">497,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> 0.81 0.19 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment purchases and de-install costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,918,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,844,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Costs incurred to maintain equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,094,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total related party transactions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,769,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,938,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable and other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,961,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">497,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 6918000 1844000 851000 1094000 7769000 2938000 18968000 1961000 497000 <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><span style="background-color:#ffffff">NOTE <em style="font: inherit;">12</em> </span></b><span style="background-color:#ffffff">–</span><b><span style="background-color:#ffffff"> SUBSEQUENT EVENT</span></b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 25, 2024 (</em>the “First Amendment Effective Date”), the Company entered into a First Amendment to Credit Agreement (the “First Amendment”) with Fifth Third which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the “Supplemental Term Loan”). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on <em style="font: inherit;"> January 25, 2024, </em>and will be used for capital expenditures related to the Company’s operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on <em style="font: inherit;"> January 25, 2030 (</em>the “Maturity Date’). Interest on the Supplemental Term Loan is payable monthly during the initial <em style="font: inherit;">twelve</em> month period following the First Amendment Effective Date. Following such <em style="font: inherit;">twelve</em> month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. The First Amendment also replaces the LIBOR-based rates in the Credit Agreement with SOFR-based rates. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> 2700000 0.03 0